isr20190630_10k.htm

0001437749-19-019176.txt : 20190927 0001437749-19-019176.hdr.sgml : 20190927 20190927171324 ACCESSION NUMBER: 0001437749-19-019176 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190927 DATE AS OF CHANGE: 20190927 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Isoray, Inc. CENTRAL INDEX KEY: 0000728387 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411458152 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33407 FILM NUMBER: 191122914 BUSINESS ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 BUSINESS PHONE: (509) 375-1202 MAIL ADDRESS: STREET 1: 350 HILLS STREET, STREET 2: SUITE 106 CITY: RICHLAND STATE: WA ZIP: 99354 FORMER COMPANY: FORMER CONFORMED NAME: IsoRay, Inc. DATE OF NAME CHANGE: 20050805 FORMER COMPANY: FORMER CONFORMED NAME: CENTURY PARK PICTURES CORP DATE OF NAME CHANGE: 19920703 10-K 1 isr20190630_10k.htm FORM 10-K isr20190630_10k.htm

Table of Contents

United States Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-K

☒	Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the fiscal year ended June 30, 2019

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from __________ to __________

Commission File No. 001-33407

Isoray, Inc.

(Exact name of registrant as specified in its charter)

Delaware		41-1458152
(State of incorporation)		(I.R.S. Employer Identification No.)

350 Hills St., Suite 106
Richland, Washington		99354
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (509) 375-1202

Securities registered pursuant to Section 12(b) of the Act

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, $0.001 par value	ISR	NYSE American

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Table of Contents

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ☐ No ☒

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter – $20,081,002 as of December 31, 2018.

The number of shares outstanding of the registrant’s common stock, $0.001 par value per share, as of September 24, 2019 was 67,388,047.

Documents incorporated by reference – none.

Table of Contents

ISORAY, INC.

Table of Contents

		Page

ITEM 1 –	BUSINESS	1
ITEM 1A –	RISK FACTORS	25
ITEM 1B –	UNRESOLVED STAFF COMMENTS	40
ITEM 2 –	PROPERTIES	40
ITEM 3 –	LEGAL PROCEEDINGS	40
ITEM 4 –	MINE SAFETY DISCLOSURES	41
ITEM 5 –	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	41
ITEM 6 –	SELECTED FINANCIAL DATA	43
ITEM 7 –	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	44
ITEM 7A –	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	52
ITEM 8 –	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	52
ITEM 9 –	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	52
ITEM 9A –	CONTROLS AND PROCEDURES	52
ITEM 9B –	OTHER INFORMATION	53
ITEM 10 –	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	53
ITEM 11 –	EXECUTIVE COMPENSATION	57
ITEM 12 –	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	61
ITEM 13 –	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	62
ITEM 14 –	PRINCIPAL ACCOUNTANT FEES AND SERVICES	63
ITEM 15 –	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	63
ITEM 16 –	FORM 10-K SUMMARY	92
SIGNATURES		93

Table of Contents

Caution Regarding Forward-Looking Information

In addition to historical information, this Form 10-K contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA.

All statements contained in this Form 10-K, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A – Risk Factors beginning on page 25 below that may cause actual results to differ materially.

Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company’s views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PART I

As used in this Form 10-K, unless the context requires otherwise, “we” or “us” or “Isoray” or the “Company” means Isoray, Inc. and its subsidiaries.

As used in this Form 10-K, unless the context requires otherwise, “fiscal year” or “fiscal” means the Company’s financial year that begins on July 1 and ends on June 30 of the following year (for example: fiscal year 2019 is equivalent to the year ended June 30, 2019).

ITEM 1 – BUSINESS

General

Isoray, Inc. (formerly known as Century Park Pictures Corporation) was incorporated in Minnesota in 1983 and on December 28, 2018, Isoray, Inc. reincorporated to Delaware. On July 28, 2005, Isoray Medical, Inc. (Medical) became a wholly-owned subsidiary of Isoray, Inc. pursuant to a merger. Medical was formed under Delaware law on June 15, 2004 and on October 1, 2004 acquired two affiliated predecessor companies that began operations in 1998. Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.

Isoray International LLC (International), a Washington limited liability company, was formed on November 27, 2007 and is a wholly-owned subsidiary of the Company. International has entered into various international distribution agreements.

Table of Contents

Available Information

Our website address is www.Isoray.com. Information on this website is not a part of this Form 10-K (this “Report”). We make our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, Forms 3, 4, and 5 filed on behalf of directors and executive officers, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (Exchange Act) available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC). You can also read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

Information regarding our corporate governance, including the charters of our audit committee, our nominations and corporate governance committee and our compensation committee, and our Codes of Conduct and Ethics is available on our website (www.Isoray.com). We will provide copies of any of the foregoing information without charge upon request to Mark Austin, Controller, 350 Hills Street, Suite 106, Richland, WA, 99354.

Business Operations

Overview

In 2003, Isoray obtained clearance from the Food and Drug Administration (FDA) for the use of Cesium-131 (Cesium-131) radioisotope in the treatment of all malignant tumors. As of the date of this Report, such applications include prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The brachytherapy seed form (a sealed source) of Cesium-131 may be used in surface, interstitial and intra-cavity applications for tumors with known radio-sensitivity. Management believes the combination of a short half-life and relatively high-energy of Cesium-131 will allow it to become a leader in the brachytherapy market, and Cesium-131 represents the first major advancement in brachytherapy technology in approximately 30 years with attributes that could make it the long-term “seed of choice” for internal radiation therapy procedures.

The Company’s core product is its Cesium-131 sealed source brachytherapy “seed.” These seeds can be inserted individually or in combination into various locations in the body until the physician is satisfied with the radiation dose delivered. The Company also sells seeds in strands to keep them from individually moving and to allow the physician to put multiple seeds in a row as desired. In addition, “pre-loaded” needles may have Cesium-131 brachytherapy seeds inserted in them, or a strand with seeds in the strand, inserted into the needle. Seeds can be sold with our Blu Build™ loading device that allows clinicians to efficiently configure strands in the operating room. Seeds can also be loaded into suture material, which can be sewn by Isoray into a piece of bio-absorbable mesh which can be sewn or stapled into tissue by the physician for use in lung, pelvic floor and other cancer locations. Under a manufacturing agreement for GT Medical Technologies, Inc. (“GT Med Tech”), Isoray inserts Cesium-131 seeds into a collagen matrix which GT Med Tech’s customers place in the brain.

Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The procedure has become one of the primary treatments for prostate cancer. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor (the word “brachytherapy” is derived from Greek and means close therapy). A primary advantage of seed brachytherapy is the ability of the seeds to deliver therapeutic radiation thereby killing the cancerous tumor cells while minimizing exposure (damage) to adjacent healthy tissue. This procedure allows doctors to administer a higher dose of radiation directly to the tumor. A seed contains a radioisotope sealed within a titanium capsule. The number of seeds used varies based on the size of the cancerous area being treated, the isotope used and the activity level specified by the physician. When brachytherapy is combined with another treatment method (dual-therapy), fewer seeds are used in the procedure. The isotope decays over time (half-life) and eventually the seeds become inert (typically over 6 half-lives). The seeds may be used as a primary treatment (monotherapy) or as an adjunct therapy with other treatment modalities, or as treatment for residual disease after excision of primary tumors. The number of seeds for treatment sites vary widely (as few as 8 seeds to more than 100 seeds) depending on the type of cancer, the tumor location, the prescribed activity level and any additional type of therapy being utilized.

Table of Contents

In the cases of lung and brain tumors (and other solid tumors), a surgeon will remove the tumor if it is medically prudent and this offers the patient some benefit in terms of controlling the growth of the cancer or its symptoms. In many cases, radiation therapy is added following the surgery; this is known as “adjuvant” radiation therapy. The Company believes that its form of adjuvant radiation therapy deployable in such cases offers advantages over external beam methods. However, external beam holds the vast majority of the market for adjuvant radiation therapy.

Prostate Cancer

Isoray began the production and sales of Cesium-131 brachytherapy seeds in October 2004 for the treatment of prostate cancer after receiving clearance of its premarket notification (510(k)) by the Food and Drug Administration. Prostate cancer treatment represents over 85% of the business of Isoray today.

When brachytherapy is the only treatment (monotherapy) used in the prostate, approximately 70 to 120 seeds are permanently implanted in the prostate during an outpatient procedure. Typically, physicians use loose seeds in needles or in a cartridge or seeds loaded into strands which can also be loaded into needles for the treatment of prostate cancer. Seeds may be combined with another treatment method (dual therapy) when treating prostate cancer.

In late 2017, the first report with long-term follow-up clinical outcomes for patients treated with Cesium-131 brachytherapy for low-risk patients was presented at the annual meeting of the American Society for Therapeutic Radiation Oncology.

Moran, B. J. and M. H. Braccioforte (2017). Long-term PSA outcomes in a single institution, prospective randomized 131-Cs/125-I permanent prostate brachytherapy trial. Int J Radiat Oncol Biol Phys 99(2 (Suppl)): E255. In this randomized study of 140 patients no statistically significant difference in biochemical failure was seen with long-term follow-up between the Cesium-131 group and the group implanted with I-125.

In addition to the long-term cancer control data mentioned above, a report from 2017 describes favorable long-term quality of life outcomes following Cesium-131 brachytherapy in the treatment of prostate cancer (S.M. Glaser, et al. (2017), Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131, Int J Radiat Oncol Biol Phys. 98(5):1053-1058).

The Company continues to identify and support work that seeks to employ and study Cesium-131 brachytherapy seeds in combination with external beam radiation therapy (“EBRT”). Compelling evidence is emerging supporting the use of such combination brachytherapy and EBRT in intermediate and high-risk prostate cancer cases. (Sylvester J, Braccioforte M.H., Moran B.J. (2019) Intensity modulated radiation therapy (IMRT) followed by cesium-131 brachytherapy for intermediate and high risk localized prostate cancer. Brachytherapy 18(3):S72).

For low-risk prostate cancer, studies are ongoing to evaluate the use of Cesium-131 in “focal,” or sub-total brachytherapy of the prostate. It is hypothesized that low-risk patients using focal brachytherapy may achieve rates of prostate cancer control comparable to that of full gland treatment while significantly reducing side effects. (M.H. Mendez, et al., Current trends and new frontiers in focal therapy for localized prostate cancer, Current Urology Report 16, 35 (June 2015)).

Early results from a series of men treated with Cesium-131 focal therapy were presented at the 2018 Annual Meeting of the American Brachytherapy Society, Kalash, R., et al., (2018), Focal brachytherapy using Cesium-131 in low-risk prostate cancer. Brachytherapy 17 (Suppl):S89. The authors conclude that, while too early to estimate disease specific outcomes, serum PSAs in these men had declined in the short term and there was no residual effect on urinary, bowel or erectile symptoms.

Table of Contents

Gynecologic Cancer

Individual seeds can also be placed via needle into the female reproductive tract for the treatment of various gynecologic cancers. This effort has been led by Dr. Jonathan Feddock, formerly of the University of Kentucky, and currently of Baptist Health Lexington. In June 2016, Dr. Feddock conducted two presentations on gynecological cancer patients who underwent treatment with permanent implantation of Cesium-131 brachytherapy seeds. In the first presentation, it was noted that 21 out of 26 recurrent cancer patients remained visually free of cancer at a median of 14 months after implantation which equates to 80.7% local control (J. Feddock, et al., Permanent interstitial re-irradiation with cesium-131: a highly successful second chance for cure in recurrent pelvic malignancies, Brachytherapy 15 (S1)S78-9 (2016)). In the second presentation, a series of 22 women with pelvic cancer underwent Cesium-131 brachytherapy seed implantation with other forms of radiation therapy treating patients who were recently diagnosed and had not yet undergone any treatment. All these cancers were successfully controlled at a median follow-up of 16 months. Side effects using the Cesium-131 brachytherapy seeds were minor and all treatments were performed as outpatient procedures. (J. Feddock, et al., Outpatient interstitial implants - integrating cesium-131 permanent interstitial brachytherapy into definitive treatment for gynecologic malignancies, Brachytherapy 15 (S1):S93-4 (2016)). Dr. Feddock supplemented his prior publication with a presentation at the American Brachytherapy Society 2018 meeting describing a combination technique of Cesium-131 plus external beam radiation therapy for patients with advanced vaginal melanoma. The group concluded that this small series of five patients demonstrated the treatment to be "effective initial treatment" with a "favorable toxicity profile" (J. Feddock, et al. Permanent interstitial brachytherapy (PIB) using cesium-131 in vaginal melanoma – a new wide-local radiation technique. Int J Radiat Oncol Biol Phys 102(3S); E281 (2016)).

The FDA clearance granted in August 2009 permits loading Cesium-131 seeds into bio-absorbable braided sutures or “braided strands” giving the Company the ability to treat brain, lung, head and neck, colorectal, and chest wall cancers. The Company is currently pursuing the brain, head and neck, and lung cancer applications in addition to its primary focus on prostate cancer.

Brain Cancer

Stranded Cesium-131 Sources

Starting in 2012, multiple institutions began utilizing Cesium-131 brachytherapy seeds loaded in braided strands for treatment of a variety of brain cancers. The application of Cesium-131 brachytherapy seeds loaded in braided strands to date has been primarily in salvage cases as a re-treatment for metastatic brain cancers where aggressive tumors had reoccurred following standard of care treatment.

From 2014 to present there have been numerous published abstracts and society presentations which have been presented and support the effectiveness of treating recurrent metastatic brain cancers with stranded Cesium-131. Dr. Gabriella Wernicke and co-investigators at Weill Cornell Medical College at the NY Presbyterian Hospital have published multiple papers on the efficacy, favorable side-effect profile and cost-effectiveness of Cesium-131 brachytherapy seeds in the treatment of metastatic brain cancer. (A. G. Wernicke, et al., Clinical Outcomes of Large Brain Metastases Treated With Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial, Int J Radiat Oncol Biol Phys. 98 (5):1059-1068 (2017); A. Pham, et al., Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial, J Neurooncol 127(1):63-71 (2016); A.G. Wernicke, et al., Surgical technique and clinically relevant resection cavity dynamics following implantation of cesium-131 brachytherapy in patients with brain metastases, Operative Neurosurgery 12(1):49-60 (2016); A.G. Wernicke, et al., Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease, J Neurosurg DOI: 10.3171/2016.3.JNS152836 (Published online June 3, 2016); A.G. Wernicke, et al., The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors, J Neurooncol 127(1):145-53 (2016)).

GammaTile™ Treatment for Brain Cancer

During fiscal 2013, the Company began providing technical assistance and selling Cesium-131 brachytherapy seeds for embedding in collagen tiles by physicians at Barrow Neurological Institute (Barrow) to treat malignant meningioma, primary brain cancers and metastases of cancers to the brain. These physicians from Barrow formed a company, GammaTile LLC, now GT Medical Technologies, Inc. (“GT Med Tech”), and further refined this technology which integrates Cesium-131 brachytherapy seeds and has resulted in the issuance of multiple patents to GT Med Tech for the treatment of brain cancers.

In fiscal 2019 a paper was published in the Journal of Neurosurgery describing outcomes of patients who had experienced multiple reoccurrences of a tumor type known as meningioma following previous surgeries in conjunction with external beam radiation. Following treatment with Cesium-131, 90% of the treated tumors had no evidence of regrowth at the operative site (local control). The incidence of radiation necrosis, a side effect to the brain from Cesium-131 brachytherapy seeds (a common side effect) occurred in only 2 of the 20 treatments. (D. Brachman, et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: result in 20 recurrent, previously irradiated meningiomas. Journal of Neurosurgery December 2018).

This same group has presented clinical studies of GammaTile™ in the treatment of other brain cancers.

Table of Contents

In June 2019 Dr. David Brachman presented to the American Brachytherapy Society in Miami a series of patients experiencing the recurrence of a variety of brain cancers including meningiomas, high grade gliomas, and brain metastases. (Brachman D., Youssef E., Dardis C., et al. Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial. Brachytherapy 18(S3):S35 (2019.) Dr. Brachman, who was awarded the Judith Stittman Best Abstract Award for this work, described GammaTile™ therapy utilizing Cesium-131 as having an excellent safety profile that “could help expand treatment options for this difficult cohort of patients”. This work is important because recurrence of these hard-to-treat brain cancers leaves patients with very limited options due to their prior radiation treatments.

Earlier, in November of 2016, Dr. Emad Youssef of the Barrow Neurological Institute presented a study conducted on 13 patients with recurrent high grade gliomas (primary brain cancer) at the annual meeting of the Society for Neuro-Oncology meeting. (E. Youssef, et al; Rthp-23. Cs131 Implants For Salvage Therapy Of Recurrent High Grade Gliomas (Hgg), Neuro-Oncology Volume 18, Issue suppl_6, 1 November 2016, Pages vi179). These patients were reported to have achieved a 92% rate of local control of their cancers during the follow-up interval.

The Company collaborated with GT Med Tech to file an application with the U.S. Food and Drug Administration (FDA) to clear GammaTile™ for clinical use and the FDA provided clearance on July 6, 2018. In 2016, the Company, in support of GammaTile™, provided assistance throughout the application process to obtain an ICD-10-PCS code. ICD-10-PCS is a code set designed for use in the hospital inpatient setting in the United States. ICD-10-PCS codes can be used to identify and track differences in resource consumption, quality, and patient outcomes for different inpatient hospital procedures. ICD-10-PCS codes are distinguishable from the MS-DRG (Medicare Severity-Diagnosis Related Group) codes that are commonly used to assign payment levels to inpatient hospital admissions for use by Medicare and other health care insurers.

The Centers for Medicare & Medicaid Services (CMS) established an ICD-10-PCS code for GammaTile™, 00H004Z (insertion of radioactive element, Cesium-131 implant into brain, open approach). CMS also mapped GammaTile™’s ICD-10-PCS code to DRG 023. DRG 023 is the highest paying DRG for craniotomy procedures. Along with Medicare, Commercial Carriers and many Medicaid programs use the ICD-10-PCS and DRG code sets, including DRG 23.

In addition to the traditional coding and reimbursement mechanisms, there is an additional mechanism under Medicare to help ensure that adequate payment is made for new medical services and technologies in the hospital inpatient setting. This mechanism is called “New Technology Add-on Payment” or “NTAP.” CMS may grant NTAP status to technologies that meet a set of criteria, including requirements involving newness, cost, and whether the product results in a substantial clinical improvement in comparison to existing therapies. Under NTAP, hospitals can receive additional reimbursement when treating Medicare beneficiaries with the new technology during the initial two or three years that the product is on the market. The rules governing NTAP eligibility and processes are described in greater detail on the CMS website and in notices that are published from time-to-time in a government publication called the Federal Register.

GT Med Tech applied to CMS for NTAP status for GammaTile™. In August 2019, CMS concluded that the Agency would not approve NTAP status for GammaTile™. We cannot predict the likelihood of whether CMS may make a favorable decision in the future if GT Med Tech decides to continue pursuing NTAP status. Based on the NTAP rules and the initial date of clearance for GammaTile™ by the U.S. Food and Drug Administration, we anticipate that GammaTile™ would remain eligible to re-apply for NTAP status that would take effect during the 2021 federal fiscal year (October 1, 2020 through September 30, 2021).

We are not aware of anything in the CMS notice from August 2019 on NTAP status or otherwise that would suggest any changes are forthcoming for the mapping of the GammaTile™ procedure to DRG 023 for reimbursement purposes. We cannot predict with certainty whether or how the Medicare program may revise its coding or reimbursement policies in the future.

Despite the lack of an NTAP code, GT Med Tech has reimbursement for GammaTile™ under ICD-10PCS-00H004Z and MS-DRG 023 which reimburses hospitals in the inpatient setting and will continue to roll out its sales and marketing strategy for release of GammaTile™. Since January 2019, GammaTile™ Therapy has been in a limited market release and total revenues from sales to GT Med Tech have been nominal. GT Med Tech has indicated it intends to increase sales and marketing efforts during the Company’s fiscal year 2020, but there is no assurance that this will occur.

Head and Neck Cancer

An emerging possible indication for Cesium-131 brachytherapy is the treatment of recurrent head and neck cancers. First reported by Bhupesh Parashar MD from Weill Cornell Medical College (A. Pham, et al. Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes. J Contemp Brachytherapy 7(6):445-52 (2015), the appeal of Cesium-131 brachytherapy in the treatment of these cancers lies in the motivation by the practitioner to avoid delivering dose to critical structures in the head and neck, including the arteries and the spinal cord. Since these patients have already been subjected to external beam radiation therapy and may not tolerate another course, brachytherapy with cesium-131 offers a significant re-treatment option.

In fiscal 2019 a group from Thomas Jefferson University published their initial results from a series of 15 patients with recurrent head and neck cancers treated with surgery and Cesium-131 brachytherapy (V. Bar-Ad, et al. Single institution implementation of permanent (131)Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma. J Contemp Brachytherapy 11(3):227-34 (2019)). The authors of this paper concluded that Cesium-131 brachytherapy is a feasible treatment option for these patients.

Table of Contents

Industry Information

Prostate Cancer Treatment

According to the American Cancer Society, one in seven men will be diagnosed with prostate cancer during his lifetime. It is the most common form of cancer in men after skin cancer, and the second leading cause of cancer deaths in men following lung cancer. The American Cancer Society estimates there will be about 174,650 new cases of prostate cancer diagnosed and an estimated 31,620 deaths associated with the disease in the United States in 2019.

Prostate cancer treatment remains a key focus of the Company. Most doctors use the American Joint Committee on Cancer (AJCC) TNM system to stage prostate cancer. This system is based on three key pieces of information:

■

The extent of the main tumor (T category);

■

Whether the cancer has spread to nearby lymph nodes (N category); and

■

Whether the cancer has metastasized (spread) to other parts of the body (M category).

These factors are combined to determine an overall stage, using Roman numerals I through IV (1-4). The lower the number, the less the cancer has spread. A higher number, such as stage IV, means a more advanced cancer.

Once diagnosed, prostate cancer can generally be divided into either localized or advanced disease. Further, within the localized category the disease can be further categorized to one of the three “risk groups”: low, intermediate and high risk. As the risk increases so does the probability of advanced cancer at diagnosis and the probability of failing treatment with cancer progression or recurrence.

Low Dose Rate Permanent Brachytherapy (LDR). Isoray’s Cesium-131 brachytherapy seeds are an option in the treatment of prostate cancers of all risk levels of localized disease. In this approach, seeds of radioactive material are placed inside thin needles, which are inserted through the skin in the area between the scrotum and anus and into the prostate. The seeds are left in place as the needles are removed and give off low doses of radiation for weeks or months. Radiation from the seeds travels a very short distance, so the seeds can give off a large amount of radiation in a very small area. This limits the amount of damage to nearby healthy tissues.

Isoray’s Cesium-131 brachytherapy seeds are an option in the treatment of prostate cancers of all risk levels of localized disease. The diagnosis of prostate cancer – and especially low risk prostate cancer – has been potentially reduced with the introduction of guidelines dissuading the use of serum PSA screening at the general practitioner level as a means to detect prostate cancer early in men with no symptoms of prostate cancer. Effective July 2012, the U.S. Preventative Services Task Force (USPSTF) recommended against the use of the PSA test as a screening tool. As a result of the recommendation, prostate cancer diagnosis dropped by 12.2% the month after the recommendation and has continued to drop. (D.A. Barocas, et al., Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States, J Urol 194(6) The Journal of Urology (2015)).

In 2018, the USPSTF finalized its recommendation from advising against screening to the position that the decision for men between 55 and 69 to undergo PSA-based screening should be made by a man in consultation with his doctor. This change may contribute to an increased incidence of prostate screening (and therefore more prostate cancer cases) as opposed to an unscreened population – although this conclusion will await future trending information. To the knowledge of management, this is the latest information available.

Furthermore, the deferral of potentially cancer-eradicating (definitive) prostate cancer treatments such as surgery and radiation therapy has become more popular as some men with prostate cancer have decided to “watch” the cancer using a variety of diagnostic tools – a trend known as “active surveillance.”

Table of Contents

As such, the industry has experienced an overall decrease in the number of low risk cases of prostate cancer diagnosed due to reduced PSA screening, as well as a larger number of men who are deferring treatment altogether at a higher rate than seen historically. Intense competition in the space due to numerous established treatment options along with added entrants such as robotic surgery and proton therapy has further eroded the overall brachytherapy market share. The industry continues to focus on the significant data that supports the use of brachytherapy in treating prostate cancer. Management believes the current review of cost effective treatment comparisons with other treatment options, the aging population worldwide and the efficacy of treatment has recently contributed to the revitalization of brachytherapy treatment for prostate cancer.

Minimally invasive brachytherapy such as that provided by the Company’s Cesium-131 brachytherapy seeds provides significant advantages over competing treatments including lower cost, equal or better survival data, fewer side effects, faster recovery time and the convenience of a single outpatient implant procedure that generally lasts less than one hour (Grimm, et al., Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group, British Journal of Urology International, Vol. 109 (Suppl 1), (2012); Merrick, et al., Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation, Techniques in Urology Vol. 7 (2001); Potters, et al., 12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer, Journal of Urology (May 2005); Sharkey, et al., Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer, Current Urology Reports, (2002)).

In addition to permanent, LDR brachytherapy, such as Cesium-131, localized prostate cancer can be treated with prostatectomy surgery (RP for radical prostatectomy), external beam radiation therapy (EBRT), three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), dual or combination therapy, permanent, high dose rate brachytherapy (HDR), cryosurgery, hormone therapy, proton therapy and active surveillance (watchful waiting). The success of any treatment is measured by the feasibility of the procedure for the patient, morbidities associated with the treatment, overall survival, and cost. When the cancerous tissue is not completely eliminated, the cancer typically returns to the primary site, often with metastases to other areas of the body.

Prostatectomy Surgery Options. In the radical prostatectomy operation, a surgeon will remove the entire prostate gland plus some of the tissue around it, including the seminal vesicles. New methods such as laparoscopic and robotic prostatectomy surgeries are currently being used more frequently in order to minimize the damage that leads to impotence and incontinence, but these techniques require a high degree of surgical skill. (American Cancer Society, 2016) Surgical resection accounted for approximately 44% of treatments before the introduction of robotic prostatectomy in the early 2000s and then rose to 60% in 2010. (J.M. Martin, et al. The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base, Cancer 120:2114–2121 (2014); J.M. Martin, et al., Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base, Cancer 120:2114–2121 (2014), Duke University, International Focal Therapy Conference, (June 2016)). To the knowledge of management, this is the latest most relevant information available.

External Radiation Therapy. Primary External Beam Radiation Therapy (EBRT), Three-dimensional Conformal Radiation Therapy (3D-CRT), Stereotactic Radiotherapy (SBRT), Intensity Modulated Radiation Therapy (IMRT) and Proton Therapy all involve directing a beam of radiation from outside the body at the prostate gland to destroy cancerous tissue. Treatments are received on an outpatient basis with the patient usually receiving five treatments per week over a period of several weeks (up to nine). While the treatments each last only a few minutes, getting the patient and equipment in place for each treatment takes longer. The use of EBRT as a whole doubled from 11.6% in 2004 to 24% in 2009. The increase in the number of cases being treated with EBRT during 2004 to 2008 were cases that historically would have been treated with brachytherapy. During that period there was a nearly complete transition to IMRT as the predominant method with IMRT treatment increasing from 0.15% to 95.9% of EBRT treatments from 2000 to 2008. (U. Mahmood, et al., Declining use of brachytherapy for the treatment of prostate cancer, Brachytherapy 13:157–162 (2014). Side effects of these treatments can include bowel problems, bladder problems, urinary incontinence, impotence, fatigue, lymphedema, and urethral stricture. To the knowledge of management, this is the latest most relevant information available.

Table of Contents

Proton beam radiation therapy. Proton beam therapy focuses beams of protons instead of x-rays on the cancer. Unlike x-rays, which release energy both before and after they hit their target, protons cause little damage to tissues they pass through and release their energy only after traveling a certain distance. This means that proton beam radiation can, in theory, deliver more radiation to the prostate while doing less damage to nearby normal tissues. Proton beam radiation can be aimed with techniques similar to 3D-CRT and IMRT.

Although in theory proton beam therapy might be more effective than using x-rays, so far studies have not shown if this is true. As of the filing of this Form 10-K, proton beam therapy is not widely available. The machines needed to make protons are very expensive, and they are not available in many centers in the United States. Management believes proton beam radiation is not covered by all insurance companies as of the filing of this Form 10-K.

Dual or Combination Therapy. Dual therapy is the combination of IMRT or 3-dimensional conformal external beam radiation and seed brachytherapy to treat extra-prostatic disease or high-risk prostate cancers. Combination therapy treats high risk patients with a course of IMRT or EBRT over a period of several weeks. When this initial treatment is completed, the patient must then wait for several more weeks to months to have the prostate seed implant. The process could also involve the seed implant be performed first, followed by the course of external radiation. Management estimates that at least 25% of all U.S. prostate implants are now dual therapy cases.

High Dose Rate Temporary Brachytherapy (HDR). HDR temporary brachytherapy involves placing soft nylon tubes (catheters) into the prostate gland and then giving a series of radiation treatments through these catheters. The catheters are then removed and no radioactive material is left in the prostate gland. A radioactive source typically containing Iridium-192 is placed into the catheters. This procedure is typically repeated multiple times over a period of several days while the patient is hospitalized.

Watchful Waiting and Active Surveillance. Because prostate cancer often grows very slowly, some men (especially those who are older or who have other major health problems) may never need treatment for their cancer. Instead, their doctor may suggest watchful waiting or active surveillance, terms physicians may use differently or interchangeably.

■

Active surveillance is often used to mean watching the cancer closely with PSA blood tests, digital rectal exams (DREs), and ultrasounds at regular intervals to see if the cancer is growing. Prostate biopsies may be done as well to see if the cancer is starting to grow faster. If there is a change in a patient’s test results, the doctor would then talk to the patient about treatment options.

■

Watchful waiting (observation) is sometimes used to describe a less intense type of follow-up that may mean fewer tests and relying more on changes in a man’s symptoms to decide if treatment is needed.

So far, no large randomized studies have compared active surveillance to treatments such as surgery or radiation therapy.

Additional Treatments. Additional, but less frequently used, treatments include cryotherapy, hormone therapy, and chemotherapy.

Table of Contents

Clinical Series for Prostate Low Dose Rate Brachytherapy

Other studies have demonstrated similar, durably high rates of control following brachytherapy for localized prostate cancer out to 15 years post-treatment (J. Sylvester, et al., 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience International Journal of Radiation Oncology Biology Physics, Vol. 67, Issue 1, 57-64 (2007)). The cumulative effect of these studies has been the conclusion by leaders in the field that brachytherapy offers a disease control rate as high as surgery, though with a lesser side-effect profile than surgery (J.P. Ciezki , Prostate brachytherapy for localized prostate cancer, Current Treatment Options in Oncology Volume 6, 389-393 (2005)).

Long-term survival data for brachytherapy with I-125 and Pd-103 supports the efficacy of brachytherapy in the treatment of clinically localized cancer of the prostate gland. Clinical data indicate that brachytherapy offers success rates for early-stage prostate cancer treatment that are equal to or better than those of RP or EBRT. While historically clinical studies of brachytherapy have focused primarily on results from brachytherapy with I-125 and Pd-103, management believes that these data are also relevant for brachytherapy with Cesium-131. In fact, it appears that Cesium-131 offers comparable and potentially improved clinical symptom outcomes over I-125 and Pd-103, perhaps due to its shorter half-life. (A.B. Shah, et al., A comparison of AUA symptom scores following permanent low dose rate prostate brachytherapy with iodine-125 and cesium-131, Brachytherapy 12 (Suppl. 1) S64 (2013)). In addition, a report from 2017 describes favorable long-term quality of life outcomes following Cesium-131 brachytherapy in the treatment of prostate cancer (S.M. Glaser, et al., Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131, Int J Radiat Oncol Biol Phys. 98(5):1053-1058 (2017)).

In May 2017 a collaborative group of Canadian researchers published the results of a study that randomized intermediate- to high-risk localized prostate cancer to an external beam dose escalation and a permanent implant brachytherapy dose escalation (W. J. Morris, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer, International Journal of Radiation Oncology, Biology, Physics Volume 98, 275-285, 2017). These patients all underwent standard external beam radiation therapy and hormonal therapy. This study, known as the “ASCENDE-RT” study, demonstrated a significant therapeutic advantage to the patients who underwent permanent implant brachytherapy boost, reporting a 20% advantage (83% versus 63%) in biochemical relapse-free survival at nine years following treatment.

This study is the first in many years to successfully randomize a group of newly diagnosed, localized prostate cancer patients and demonstrate a statistically significant advantage to one treatment over another – in this case iodine-125 brachytherapy boost over external beam radiation therapy boost. The impact on the number of patients considered for “combination therapy” (external beam and brachytherapy) could be substantial, especially once men are informed of these study results.

Sexual impotence and urinary incontinence are two major concerns men face when choosing among various forms of treatment for prostate cancer. Studies have shown that brachytherapy with existing sources results in lower rates of impotence and incontinence than surgery (C. Buron, et al., Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study, International Journal of Radiation Oncology, Biology, Physics Volume 67, 812-822 (2007)). Combined with the high disease control rates described in many studies, these findings have driven the adoption of brachytherapy as a front-line therapy for localized prostate cancer.

Comparing Cesium-131 to I-125 and Pd-103 Clinical Results

Management believes that the Cesium-131 brachytherapy seed has specific clinical advantages for treating cancer over I-125 and Pd-103, the other isotopes currently used in brachytherapy seeds. The table below highlights the key differences of the three isotopes.

		Isotope Delivery Over Time
Isotope	Half-Life	Energy	90% Dose
Cesium-131	9.7 days	30.4 keV	33 days
Pd-103	17 days	20.8 keV	58 days
I-125	60 days	28.5 keV	204 days

Table of Contents

In June 2019, a study was published on long-term follow-up data collected on Cesium-131 as compared to I-125 (Agarwal M., Braccioforte M.H., Amin N., et al. Long Term Results from a Prospective Randomized Trial of 131Cs vs 125I Permanent Prostate Brachytherapy, Brachytherapy: An International Multidisciplinary Journal, May-June 2019). This long-term data with nine-year median follow-up shows comparable long-term biochemical control (prostate-specific antigen recurrence) results between Cesium-131 and Iodine-125 in these patients. The data supports Cesium-131 as an effective long-term solution for these patients and supports Cesium-131 as a viable choice for prostate cancer patients.

Improved side-effect profile.

In addition to the cancer-related outcomes described for prostate brachytherapy, a significant portion of patients who undergo I-125 or Pd-103 brachytherapy experience acute urinary irritative symptoms following treatment – more so than with surgery or external beam radiation therapy (S.J. Frank, et al., An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy, and brachytherapy Iodine implantation as monotherapies for localized prostate cancer, Journal of Urology Volume 177, 2151-2156 (2007)). These irritative symptoms can range from an increased frequency of urination to significant pain upon urination. Because the portion of the urethra that runs through the prostate takes high doses from the implant, these side effects are fairly common following prostate brachytherapy.

Studies show that Cesium-131, with the shortest available half-life of the commonly used implantable isotopes, results in a quicker resolution of these irritative symptoms based on the shorter time interval over which normal tissue receives radiation from the implanted sources than for longer lived isotopes such as I-125. (A. Shah, et al., A comparison of AUA symptom scores following permanent low-dose-rate prostate brachytherapy with Iodine-125 and Cesium-131, Brachytherapy 12(SI) S64 (2013)). These results are seemingly confirmed with long-term quality of life data as described by a study from UPMC, where it was suggested that patients treated with Cesium-131 prostate brachytherapy were able to recover and maintain their baseline quality of life in the long term. Glaser, S. M., et al. (2017). Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131. Int J Radiat Oncol Biol Phys 98(5): 1053-1058.

Table of Contents

The advantage of the Company’s Cesium-131 brachytherapy seed is the resolution of urinary side effects as pictured in the graphic below has been observed in a second study, presented at the 2013 Annual Meeting of the American Brachytherapy Society (A.B. Shah, et al). The following graph is a comparison of elevated side effect (AUA) symptom scores following permanent low dose rate prostate brachytherapy with Iodine-125 and Cesium-131. (Brachytherapy 12(Suppl. 1) S64 (2013)):

As seen in the plot of these AUA scores, the duration of an elevated side effect score profile resolved to pre-treatment levels more quickly with the Cesium-131 group than with the Iodine-125 group. All patients were treated at the same institution by the same physicians, and the difference in the time to resolution was considered significant.

Further evidence of the favorable side effect profile of Cesium-131 was published by a group from the University of Pittsburgh Medical Center (UPMC) in August 2017 (Glaser 2017). This report concluded that only minimal long-term changes were noted to the urinary and bowel quality of life measures, and that men treated with Cesium-131 for their prostate cancers are able to return to baseline measure of quality of life after treatment.

Brain Cancer Treatment Options

An estimated 23,820 new cases of malignant primary tumors of the brain or spinal cord are expected to be diagnosed in 2019. About 17,760 people are expected to die from brain and spinal cord tumors in 2019. (American Cancer Society, 2019). In addition to primary tumors, metastasis of brain tumors from other body sites are estimated at over 65,000 new cases per year. The chance that a person will develop a malignant tumor of the brain or spinal cord is about 1 in 143 for a man and 1 in 185 for a woman. These numbers would be much higher if benign tumors were also included. (American Cancer Society, 2019).

On July 6, 2018, the Company and GT Med Tech received FDA 510(k) regulatory clearance for the brachytherapy technology, known as GammaTile™ Therapy that incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers for the treatment of recurrent brain tumors. Isoray Medical and GT Medical Technology had previously executed a collaborative development agreement and an exclusive ten-year supply agreement for GammaTile™ Therapy. In fiscal year 2019, the Company and GT Med Tech amended and restated the manufacturing and supply agreement which now expires in April 2029. The amended agreement requires GT Med Tech to provide on a monthly basis a twelve-month rolling forecast. The first calendar month of each rolling forecast becomes a binding purchase order and the remaining eleven months are a non-binding forecast. The amended agreement also adjusted some pricing due to updated procedures, allows GT Med Tech to move the loading of the GammaTile™ to another non-Company facility provided GT Med Tech continues to purchase Cesium-131 seeds exclusively from the Company, and also governs how GammaTile™ process improvement projects will be scoped and billed. GammaTile™ leverages Cesium-131’s unique ability to deliver a highly targeted dose of intense radiation treatment while limiting radiation exposure to surrounding tissue. In 2016, the Company, in support of GammaTile™, provided assistance throughout the application process to obtain an ICD-10-PCS code. ICD-10-PCS is a code set designed for use in the hospital inpatient setting in the United States. ICD-10-PCS codes can be used to identify and track differences in resource consumption, quality, and patient outcomes for different inpatient hospital procedures. ICD-10-PCS codes are distinguishable from the MS-DRG (Medicare Severity-Diagnosis Related Group) codes that are commonly used to assign payment levels to inpatient hospital admissions for use by Medicare and other health care insurers.

In addition to GammaTile™ Therapy, the Company’s customers can also use braided strands containing Cesium-131 brachytherapy seeds for the treatment of brain cancer. Cesium-131 brachytherapy seeds deliver 90% of their dose in 33 days and are therefore well-suited to use with bioabsorbable mesh, single seed applications, implantable strands, and by implantable device.

Table of Contents

Gynecological Cancer Treatment Options (Cervical, Vaginal and Vulvar Cancer)

An estimated 24,590 new cases of cervical (13,170), vaginal (5,350) and vulvar (6,070) cancers are expected to be diagnosed in the United States in 2019. A combined estimate of 6,960 deaths are expected to occur from cervical, vaginal and vulvar cancers in the United States in 2019 (American Cancer Society, 2019). In addition to brachytherapy to treat gynecological cancers such as cervical, vaginal and vulvar cancers, other treatment options include surgery, laser surgery, radiation therapy, chemotherapy, and topical treatments.

During 2016, two abstracts (J. Feddock, et al., Permanent interstitial re-irradiation with cesium-131: a highly successful second chance for cure in recurrent pelvic malignancies, Brachytherapy 15(S1):S78-9 (2016); J. Feddock, et al., Outpatient interstitial implants - integrating cesium-131 permanent interstitial brachytherapy into definitive treatment for gynecologic malignancies, Brachytherapy 15(S1):S93-4 (2016)) and presentations were presented at the World Brachytherapy Conference in San Francisco on the treatment of Re-Irradiation with Cesium-131 in recurrent pelvic malignances in women who have recurrent cancers. Physicians at the University of Kentucky, College of Medicine reported local control in 80.7% after Cesium-131 implantation for the recurrent patients and reported successful control of 22 women with pelvic cancer that had not had previous treatment. Based upon the positive results seen in the Cesium-131 treatment of recurrent gynecological cancers, physicians at the University of Kentucky are currently moving Cesium-131 treatment into the primary treatment of these cancers.

In April 2017, the group from the University of Kentucky published a paper in the journal Brachytherapy that described the early experience with a template-based approach using Cesium-131 in the treatment of gynecologic cancers. Although reporting on only five patients, the University of Kentucky physicians demonstrated the feasibility and safety of replacing a high dose-rate isotope (Iridium-192) with Cesium-131. This report builds on the earlier published and presented work that strongly suggests a role for Cesium-131 in the treatment of gynecologic cancers.

Head and Neck Cancer Treatment Options

An estimated 53,000 new cases of head and neck cancer are expected to be diagnosed in the United States in 2019. (American Cancer Society, 2019).

Surgery is the most common option to treat head and neck cancers. Chemotherapy is often used in conjunction with surgery or radiation therapy depending on the type and stage of the cancer. External beam radiation therapy and brachytherapy have been used together or in combination with surgery or chemotherapy. Immunotherapy is a newer treatment option for advanced or recurrent cancer (American Cancer Society, 2019).

Cesium-131 brachytherapy seeds allow oncologists to add targeted radiation treatment to head and neck cancers after surgical resection. This targeted radiation treatment is especially needed in patients whose neck cancer has recurred following previous radiation therapy. Often these patients cannot tolerate further external beam radiation therapy for fear of over radiating critical head and neck structures.

Management believes Cesium-131 brachytherapy seeds continue to represent an improved approach to brachytherapy treatment of specific head and neck cancers.

Lung Cancer Treatment Options

An estimated 228,150 new cases of lung cancer are expected in 2019, accounting for 13% of all cancer diagnoses in the United States. Approximately 24% of all cancer deaths are from lung cancer and it accounts for the most cancer related deaths in both men and women in the United States. An estimated 142,670 deaths will result from lung cancer in 2019. (American Cancer Society, 2019).

Lung cancer has historically been treated utilizing surgery, radiofrequency ablation (RFA), radiation therapy, chemotherapy, immunotherapy and targeted therapy including LDR brachytherapy. More than one kind of treatment may be used, depending on the stage of the patient’s cancer and other factors. (American Cancer Society, 2018).

The Company believes that Cesium-131, with its shorter half-life (faster rate of decay) and relatively high energy, is better suited for treating lung cancer in Stages I and II than I-125. The bioabsorbable mesh used in this procedure to apply the Cesium-131 brachytherapy seeds generally dissolves after about 45 days. Cesium-131 delivers 90% of its dose in 33 days and is therefore well-suited to use with bioabsorbable mesh. A report was published in May of 2015 describing outcomes from a series of 52 patients treated with a limited surgical resection and Cesium-131 brachytherapy. (B. Parashar, et al., Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer, Brachytherapy 14 (5):648-54 (2015)).

Table of Contents

Our Strategy

The key elements of Isoray’s strategy for fiscal year 2020 includes:

Continue to Invest in Sales and Marketing Development Activities. Prostate cancer treatment represents the original and core business for the Company’s Cesium-131 product. With long-term follow-up data relating to biochemical (PSA) control of prostate cancer now presented to the prostate cancer field, Isoray plans to aggressively increase the number of centers using Cesium-131 through its direct sales force and through its international distributors. Because intermediate- to long-term follow-up data is required to convince clinicians and patients to consider any particular therapy for localized prostate cancer, the availability of long-term data with Cesium-131 in the treatment of prostate cancer represents a significant milestone. Isoray hopes to capture much of the incremental market growth if and when seed implant brachytherapy recovers market share from other treatments, take market share from existing competitors, and expand the use of Cesium-131 as a dual therapy option where it has experienced success. In 2016, the Company started its aggressive sales and marketing approach by hiring industry sales and marketing veterans to assist in this market development effort, including the hire in March 2016 of a Vice-President of Sales and Marketing and Marketing support personnel, who have developed and continue to develop a comprehensive strategy to expand the presence of the Company’s Cesium-131 products in the prostate market. In addition, the Company filled its regional sales positions with experienced sales staff from the prostate brachytherapy industry. A redesigned website for Isoray.com was launched in September 2016 that focused its message to specific decision makers including the physician, patient, family and friends. The new website supports management’s focus on the growth of sales from the treatment of prostate cancer and the Company’s efforts to expand into brain, head and neck, gynecological, and other cancers. The Company has invested in direct to consumer marketing campaigns through social media to target potential patients and their family and friends. These efforts have resulted in significant year over year growth in web traffic (50.1% increase in total visitors), new visitors (48.52% increase) and organic search results (71.5% increase in resulting site traffic). The Company believes that an increased digital presence will result in increased awareness about brachytherapy overall, and specifically increased awareness about Cesium-131. Management believes that this increased awareness will ultimately translate to more patients finding a physician with Cesium-131 experience.

Blu Build™ Loader. The Company believes that customers perform prostate brachytherapy procedures via one of several general procedure techniques, including (but not limited to): Pre-plan techniques, Intra-operative techniques, and Real-time techniques. Further, the Company believes that customers are comfortable with their techniques, and want products to facilitate their preferred methods. All of the Company’s competitors provide a set of standard products (including loose seeds, seeds loaded in cartridges, and seeds pre-loaded in needles) to meet the customer needs. Further Theragenics and BD have products that support intra-operative and real-time techniques that allow for stranding or linking seeds together in custom configurations in the operating room. These products allow physicians to gain the benefits of stranded or linked seeds while still allowing for customization to the patient anatomy, as determined at the time of the procedure. The Company believes that approximately 25% of procedures are performed with some level of customization in the operating room.

It is this segment of the market – customers looking to customize their procedures to the anatomy at the time of the procedure – that the Company expects to address with its new Blu Build™ loading device. The Blu Build™ loading device efficiently configures strands in the operating room, allowing the clinician to make determinations about the product configurations with the most recent picture of the patient’s anatomy. The Company believes that this technique may provide advantages in some brachytherapy products and will provide a better solution for this market segment. The Company also believe the efficiency and ease of use of the Blu Build™ loading device will offer an intriguing opportunity for the other 75% of the market.

During fiscal year 2019, the Company released the Blu Build™ loader in a limited market release. Based on feedback from the limited market release, the Company adjusted certain intricacies of the design. This is the first internally developed proprietary delivery device in the Company's history. The Company expects to have a full market release of the Blu Build™ loader during its second quarter of fiscal year 2020, but there is no assurance that this will occur.

Commercialization of GammaTile™ Therapy for the treatment of recurrent brain metastases. The utilization of the GammaTile™ system over the past five years has developed a product with consistent and repeatable results as evidenced by the June 2016 presentation at the Society of Neurologic Oncologists. Management intends to continue to support and facilitate the commercialization of the GammaTile™ Therapy by GT Medical Technologies product.

In January 2018 the Company entered into a Manufacturing and Supply Agreement with GT Med Tech and in April 2019 the Company entered into an Amended and Restated Manufacturing and Supply Agreement with GT Med Tech (collectively the Manufacturing and Supply Agreement). Pursuant to the Manufacturing and Supply Agreement, the Company has agreed to exclusively supply Cesium-131 seeds to be incorporated into the GammaTile™ Therapy and manufacture the GammaTile™ Therapy product for end users designated by GT Med Tech.

In January 2019, GT Med Tech, which is the sole commercial agent of GammaTile™ Therapy, began a limited market release with plans for a full market release in 2020. The Company continues to provide assistance to GT Med Tech for various process improvement projects on a time and materials basis. To date revenues realized from the process improvement projects have been nominal.

GammaTile™ Therapy has been assigned a new specific ICD-10_PCS code by the CMS for reimbursement purposes in the hospital setting.

Increase utilization of Cesium-131 in treatment of other solid tumor applications such as brain, gynecological, and other cancers. The Company has clearance from the FDA for its premarket notification (510(k)) for Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided sutures and bioabsorbable braided sutures attached to bio absorbable mesh. This FDA clearance allows commercial distribution for treatment of brain, gynecological, head and neck and lung tumors as well as tumors in other organs. The Company continues to sell product to physicians treating brain, gynecological, head and neck and lung cancer while continuing to support the compilation of treatment outcomes for publication. Isoray will continue to explore licenses or joint ventures with other companies to develop the appropriate technologies and therapeutic delivery systems for treatment of other solid tumors.

Early clinical data support management’s initiatives into brain cancers, gynecological, head and neck, and early stage non-small cell lung cancers. Local control – defined as success in preventing the re-growth of cancer in the immediate vicinity of the treatment area – has been excellent to date.

Support Clinical Research and sustained product development. The publication and presentation of speculative and real-world data contribute to the acceptability of Cesium-131 in the oncologic marketplace. Discussion in the medical-scientific community of established and novel Cesium-131 applications is considered a prerequisite to expansion into untapped markets. The Company structures and supports clinical studies on the therapeutic benefits of Cesium-131 for the treatment of solid tumors and other patient benefits. We are and will continue to support clinical studies with several leading radiation oncologists to clinically document patient outcomes, provide support for our product claims, and compare the performance of our seeds to competing seeds. Isoray plans to sustain long-term growth by implementing research and development programs with leading medical institutions in the U.S. and other countries to identify and develop other applications for Isoray’s core radioisotope technology. The Company has deployed a secure, regulatory environment compliant, online information system capable of large usable databases to participating investigators.

Table of Contents

During fiscal year 2019, four presentations were accepted at the annual meeting of the American Society for Radiation Oncology (ASTRO) in October 2018 covering topics related to Cesium-131 treatment of gynecologic cancers, prostate and brain cancers. Four presentations were also made at the 2019 annual meeting of the American Brachytherapy Society in June 2019. The Company will continue to seek to increase the number of reports made to society meetings and the peer reviewed literature in order to seek to enhance the standing of its products in the scientific community.

The Company also continues to consult with noted contributors from the medical physics community and expects that articles for professional journals regarding the benefits of and clinical trials involving Cesium-131 will continue to be submitted.

In addition, the Company continues to support the clinical findings of the various protocols and publications through presentations by respected thought leaders. The Company will continually review and update all marketing materials as more clinical information is gathered from the protocols and studies. Apart from clinical studies and papers sponsored by the Company, several physicians across the country have independently published papers and studies on the benefits of Cesium-131.

Targeted Expansion into International Markets. The Company believes that in addition to a significant domestic market for their products, there exists a potential international demand for Cesium-131. The current global market for permanent prostate brachytherapy is larger than the domestic market. Further, many of the surgical applications the Company is exploring domestically may also have significant international opportunities.

Historically, the Company has placed limited resources towards realizing these international opportunities, instead keeping the focus of expanding our domestic market share. The Company has provided Cesium-131 product, when requested, to certain markets with potential distributors, however, this distribution has been limited. Instead of relying solely on perceived demand by a potential distributor which believes in the viability of the Company’s product in a given country, the Company will continue to consider international markets and only enter those markets based on a potential market meeting some or all of the following criteria:

●

Investigating different geographical markets – In order to maximize return of international investments, the Company will need to understand the regulatory and reimbursement environment, as well as patient and market sizes.

●

Assessing potential physician / patient interest in Cesium-131 – In addition to reviewing the market receptiveness, the Company will work with its existing network of opinion leaders and partners to determine the clinical interest in Cesium-131, and where it may be most appropriate to assess the fit / adoption of Cesium-131.

●

Assessing geographical clinical and capital expense factors – It will be key to understand the alternative therapies available in a given foreign market. For example, in some regions large capital investments are difficult, making the use of permanent brachytherapy more attractive.

●

Identifying potential partners / strategies – The Company will assess if there are strategic partners or other potential strategies for addressing a particular foreign market.

On July 14, 2017, the Company entered into an agreement with a distributor in Russia that provides for the ability to sell the entire product line in the Russian Federation. The agreement has a one-year initial term with two additional one-year terms which automatically renew unless either party invoke their right to terminate earlier under the provisions of the agreement. Although sales have been minimal under this agreement, the two parties elected to have the agreement automatically renew now through July 2020.

On August 1, 2016, the Company entered into an agreement with a distributor in Italy for the territory of Italy and Switzerland, as its prior Italian distribution agreement, with an affiliate of the new distributor, had expired without any sales. The agreement had a one-year initial term with two additional one-year terms which automatically renew unless either party invokes its right to terminate earlier under the provisions of the agreement. The agreement expired August 1, 2019 and was not renewed.

The Company believes that learning more about the different international opportunities will provide a better foundation for its international strategy and potential investments in specific markets.

Cesium-131 Manufacturing Process and Suppliers

Product Overview

Isoray markets the CS-1 Cesium-131 brachytherapy seed for the treatment of prostate cancer, brain cancer, lung cancer, head and neck cancers, gynecological cancer, pelvic/abdominal cancer, and colorectal cancer. The Company intends to market Cesium-131 for the treatment of other malignant diseases as opportunities are identified in the future through the use of existing proven technologies that have received FDA-clearance. The strategy of utilizing existing FDA-cleared technologies reduces the time and cost required to develop new applications of Cesium-131 and deliver them to market.

Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). To produce the Cesium-131 brachytherapy seed, a proprietary chemical separation is performed that results in 99.9% pure Cesium-131 isotope. Purified Cesium-131 is adsorbed onto a ceramic core containing a gold X-ray marker. This internal core assembly is subsequently inserted into a titanium capsule that is then welded shut and becomes a sealed radioactive source and a biocompatible medical device.

Product Offerings

In addition to providing loose seeds to customers, most brachytherapy manufacturers offer their seed product to the end user packaged in various configurations provided in a sterile or non-sterile package depending on the customer’s preference. These include:

■

Pre-loaded needles (loaded typically with three to five seeds and spacers);

Table of Contents

■

Pre-loaded Mick^® cartridges (fits the Mick^® applicator);

■

Strands of seeds (consists of seeds and spacers in a bioabsorbable rigid “carrier sleeve”);

■

Preloaded strands (strands of seeds loaded into a needle);

■

Pre-loaded braided strands (seeds loaded into a flexible bioabsorbable braided suture);

	■	Pre-loaded braided strands attached to bioabsorbable mesh (creates planar implants out of braided sutures and bioabsorbable mesh); and
	■	Intraoperative real-time loading device sold as Blu Build™ (loader that allows custom spacer and seed loading).

In fiscal year 2019, the Company delivered approximately 48% of its Cesium-131 seeds to customers configured in Mick^® cartridges, approximately 37% of its Cesium-131 seeds configured in stranded and pre-loaded in a needle form, 8% of its Cesium-131 seeds configured in a braided strand form, 3% of its Cesium-131 seeds sold in a loose configuration and the remaining 4% configured in either a pre-loaded in a needle, Blu Build™, or stranded form.

In fiscal year 2012, Isoray obtained a CE mark which allows shipment of seeds loaded into flexible braided strands and flexible strands attached to bioabsorbable mesh into the European Union. During fiscal year 2019, the Company elected to not renew its CE Mark due to no sales activity in the European Union, limited interest in Cesium-131 due to the pricing and reimbursement environment, and changing European Union registration requirements that would have required significant investment into additional clinical trials.

Maintain ISO 13485:2016

In August 2008, the Company obtained its initial ISO 13485:2003 certification. This permitted the Company to register its products in Europe in 2008 and in Canada and Russia during fiscal year 2009. The ISO 13485:2003 certification demonstrates that the Company is in compliance with this internationally recognized quality standard and the initial certification was valid for a three-year period. In June 2012, the Company received a recertification to ISO 13485:2003 for an additional three-year period, which was affirmed through a surveillance audit in June 2013. The Company has subsequently maintained timely compliance with ISO 13485:2003.

In March 2017, BSI conducted its full system inspection and recertification and found no nonconformities to ISO 13485:2003 medical device standards. In April 2018, BSI certified the Company’s successful transition to ISO 13485:2016. This transition moved Isoray’s quality system into the current state of the art Quality Management System per the ISO standard. The Company is subject to a recertification audit by BSI every three years, two annual maintenance audits and one additional unannounced audit during each three-year period for a total of four audits during each three-year period. The Company had its first annual surveillance audit in March 2019. The Company successfully passed the audit with only one minor nonconformance found by BSI, which was subsequently resolved. The Company was recommended for continued certification.

Isotope Suppliers

The Company has identified key reactor facilities in Russia, the U.S., Canada, Poland, Belgium, and South Africa, but is currently solely relying on and has a contract with the Russian suppliers. On December 15, 2016, Medical entered into a new supply contract (the INM Agreement) with The Open Joint Stock Company, Isotope, a Russian company (JSC Isotope). On July 30, 2019, Medical entered into a new supply agreement with JSC Isotope. With this Agreement, Medical can purchase Cesium-131 from the Joint Stock Company, within the quality standards and within the time periods specified, through December 31, 2020.

Due to the planned outage at the INM reactor from November 2017 to July 2018, the Company negotiated an agreement in order to receive supply from the Research Institute of Atomic Reactors (RIAR) during the outage. INM began returned from its planned outage in August 2018. INM will again be the 100% supplier of Russian-sourced Cesium-131 beginning in August 2019 when RIAR begins a planned outage until approximately summer 2020 and management believes that INM will reach a supply on a 50/50 basis with RIAR beginning approximately in the summer 2020.

In order to maximize the efficiency of Cesium-131 production from the RIAR reactor, the Company has consigned its supply of “enriched” Barium to the RIAR facility. “Enriched” in this context refers to a Barium Carbonate supply that contains a greater proportion of the non-radioactive isotope Barium-130 than is found in nature. This higher proportion of Barium-130 leads to a greatly increased yield of Cesium-131 when it is placed in a high flux neutron environment such as that available at RIAR and a small number of other reactors worldwide.

The Company also received irradiated barium from the University of Missouri Research Reactor (MURR), located in the United States. For the fiscal year 2018, approximately eighty percent (80%) of our Cesium-131 was supplied by our Russian supplier and approximately twenty percent (20%) of Cesium-131 was generated by the irradiated barium from MURR. Beginning in the first fiscal quarter of 2019, the Company reduced the amount of Cesium-131 provided by the MURR reactor by approximately 35%. After a thorough review of the capacity and quality of production at the MURR facility, the Company decided not to locate a hot cell there to ramp up domestic production. The Company also determined to terminate its supply agreement with MURR thereby eliminating all domestic suppliers of this critical component of its product and the last shipment of isotope from MURR was received in January 2019. This decision means that the Company has no domestic supply capabilities for Cesium-131, however, with sufficient notice it may issue a purchase order as needed from time to time. Even if Cesium-131 was supplied by MURR, MURR cannot manufacture enough supply to meet the Company’s increasing needs and requires additional cost in processing to meet the Company’s isotope specifications.

Table of Contents

Management believes that failure to obtain deliveries of Cesium-131 from its Russian supplier, <<JSC Isotope>> (which provides supply from both the INM and RIAR reactors), would have a material adverse effect on seed production. Over a two-year period of time, the Company has reviewed its isotope strategy and negotiated with both the U.S. and Russian reactors. Management has determined that the U.S. based supply alone would never prove capable of meeting current company requirements and at current quality control and cost measures is no longer a viable supply source. Additionally, expanding on-site chemical processing at the U.S. reactor will not meet company demand and is not cost effective.

As the Company has now determined to rely solely on its Russian suppliers, it is critical to rely on a strategy for outages. Management has developed a three-step process to insulate the Company isotope supply from unplanned outages at the Russian supplier. Step One: the Company has transferred its stock of enriched barium to the Russian RIAR reactor as a contingency in the case of an outage at one or both of its current isotope providers or at a new isotope supplier in Russia. Step Two: identifying close-proximity Russian reactors that could irradiate targets to transfer to INM or RIAR for further processing. This provides the Company additional capacity to meet demand. Step Three: the Company is performing due diligence to identify other reactors that can supply isotope.

Quality Controls

In July 2008, Isoray had its baseline inspection by the FDA at its manufacturing and administrative offices in Richland, WA. This inspection was carried out over a five day period during which the investigator performed a complete inspection following Quality Systems Inspection Techniques (QSIT). At the end of the inspection, no report of deviations from Good Manufacturing Practices or list of observations (FDA Form 483) was issued to Isoray. An additional inspection of Isoray was conducted by FDA in April 2013. Again the FDA reported no deviations from Good Manufacturing Practices and did not list any observations (FDA Form 483). In August 2017, the FDA conducted an announced QSIT inspection of the Richland facility and again, did not find any nonconformance to U.S. medical device regulations and did not issue a Form 483.

In October 2015, Isoray underwent an unannounced inspection by British Standards Institution (BSI), Isoray’s representative to the European Union and designator of Isoray’s CE Marks with no nonconformities found. BSI also conducted a microbiologic audit and a surveillance audit in November 2015 and March 2016 respectively. In March 2017, BSI conducted its full system inspection and recertification and found no nonconformities to ISO 13485:2003 medical device standards. In April 2018, BSI certified the Company’s successful transition to ISO 13485:2016. This transition moved Isoray’s quality system into the current state of the art Quality Management System per the ISO standard. The Company had its first annual surveillance audit in March 2019. The Company successfully passed the audit with only one minor nonconformance found by BSI, which was subsequently resolved. The Company was recommended for continued certification.

The Federal Aviation Administration (FAA) also conducted an unannounced audit in May 2016. Because Isoray ships hazardous materials on flights in the U.S., Isoray is subject to regulation by the FAA. No findings were made in this audit.

Regulatory Developments

In July of 2017, the Company received a five-year renewal from the Washington State Department of Health (WA DOH) in response to its application to renew the Company’s Radioactive Materials License. The WA DOH acts as an agent of the U.S. Nuclear Regulatory Commission and grants the Company its ability to receive, inventory and ship radioactive material.

During fiscal year 2019, the Company elected to not renew its CE Mark due to no sales activity in the European Union, limited interest in Cesium-131 due to the pricing and reimbursement environment, and changing European Union registration requirements that would have required significant investment into additional clinical trials. Therefore, as the Company looks at international opportunities to sell Cesium-131 seeds it will focus on those markets outside of the European Union.

Order Processing

The Company applies a just-in-time production process that is responsive to customer input and orders to ensure that individual customers receive a higher level of customer service than received from our competitors who have the luxury of longer lead times due to longer half-life products. Time from order confirmation to completion of product manufacture can be as soon as two working days, including processing and purification of Cesium-131, attachment of isotope to a core, loading and welding of the core into a titanium casing, testing, quality assurance, assembling seeds into delivery devices (i.e. needles, sutures, strands, cartridges, etc.), sterilization and shipping.

It is up to each physician to determine the dosage necessary for implants and acceptable dosages vary among physicians. Many physicians order more seeds than necessary to assure themselves that they have a sufficient quantity. Upon receipt of an order, the Company either delivers the seeds from its facility directly to the physician in either loose, preloaded, or Blu Build™ form and for a couple customers we send the order to an independent preloading service that delivers the seeds just prior to implant. If the implant is postponed or rescheduled, the short half-life of the seeds makes them unsuitable for use and therefore they must be re-ordered.

Due to the lead time for obtaining and processing the Cesium-131 isotope and its short half-life, the Company relies on sales forecasts and historical knowledge to estimate the proper inventory levels of isotope needed to fulfill all customer orders. Consequently, some portion of the isotope is lost through decay and is not used in an end product. Management continues to reduce the variances between ordered isotope and isotope deliveries and is continually improving its ordering process efficiencies.

Manufacturing Facility

The Company maintains a production facility located at Applied Process Engineering Laboratory (APEL) in Richland, Washington. The APEL facility became operational in September 2007. The production facility has over 15,000 square feet and includes space for isotope separation, seed production, order dispensing, a clean room for assembly of our product offerings, and a dedicated shipping area. In 2015, the Company entered into a modification to the production facility lease that modified the requirement to return the facility to ground at the time of exit at Company discretion, exercised an extension in 2017 to increase the lease term to April 30, 2021, and reduced the required notice to terminate the lease early from twelve months to six months. In July 2019, the Company entered into another modification of the production facility lease that extends the term to April 20, 2026, maintains the current rental rate through April 2020, and provides for an eighteen month termination notice with an early termination penalty of up to $40,000 which decreases each year.

These lease modifications provide the flexibility required for the Company to plan, design and construct its own production facility, which is expected to reduce operational cash flow requirements and provide for long-term security of production capabilities for the Company. The Company has completed the design process for a new facility and has permit ready plans to build when the Company needs to move into a new facility. The Company does not anticipate building a new facility until the Company either obtains financing to pay for the facility or can finance the facility through its own operations. Management believes that construction of a new facility will take 18 to 24 months to complete from the time that ground is broken.

Table of Contents

Sales and Marketing

Marketing Strategy

In fiscal 2019, the Company continued to implement and execute on the established sales and marketing strategy. This strategy involves a more direct focus on the prostate cancer market and existing and new Cesium-131 customers, with a secondary focus on developing opportunities in emerging applications, including brain tumors, gynecological cancers and head and neck tumors. This focus was supported by a complete redesign of the Company brand, website and collateral materials. This effort was initiated in fall 2016. This follows the changes to the sales and marketing team that occurred in 2016, when the Company hired a Vice President of Sales and Marketing, Michael Krachon. Mr. Krachon brought more than twenty years of experience of progressive growth in sales and marketing with the past fifteen years in the brachytherapy market.

Further to support the new marketing strategy, the Company has started the process of reestablishing its medical advisory boards to provide professional input and insight regarding the Company’s current products and research and developments efforts. The boards will vary by cancer type/site and the supporting specialties that treat that cancer. They will include, but not be limited to, radiation oncologists, surgeons, urologists, and physicists. The boards will be a mix of customers and non-customers, which the Company believes will provide increased insight regarding the perception of its products and opportunities to meet the needs of the market. The Company held its first advisory meeting for prostate cancer in September 2016. The Company held its most recent meeting in June 2019 and is planning on continuing this strategy. The Company is looking to continue to build additional advisory boards as the other applications grow in viability.

The market for treatments of localized prostate cancer is very competitive and largely hinges upon two factors: the demonstration of long-term follow-up data that has been presented to the prostate cancer treatment profession and the economic and strategic dynamics of the different therapeutic options. Cesium-131 was introduced to the prostate cancer marketplace more than a decade after Iodine-125 and Palladium-103, and the resulting time for mature clinical data to be developed has proven an obstacle to widespread market acceptance. The time to publish these results is lengthy and includes time to enroll patients in protocols which may take multiple years depending on the size of the enrollment population, time to aggregate the results at five years from the final patient treatment, time to analyze the data and author the article followed by the time for peer review, and publication in a medical journal. The total time for this process may approach a decade from start to publication and these long-term results are just beginning to be published at the end of fiscal year 2019. The first long term data are emerging for Cesium-131 prostate brachytherapy, primarily from The Chicago Prostate Cancer Center.

The prostate brachytherapy market has been pressured by the economic differences and strategic dynamics of competing treatment options such as robotic surgical devices and external beam radiation facilities. These factors have combined to result in the current multi-year contraction of the prostate brachytherapy market. The declining market has impacted the competitive landscape, reducing the number of competitors and their respective investments in sales, marketing and product development efforts. Based upon Company market review and research, there appears to be an opportunity for Isoray to expand its current market opportunity with an investment in sales and marketing efforts. The Company believes its hires of both sales and marketing veterans with regional sales support will lead to growth of their market share in the prostate cancer treatment business. The Company also believes that an increased share of the prostate brachytherapy market share will assist in facilitating Cesium-131 brachytherapy cancer treatment growth in other body sites.

The professional and patient market segments each play a role in the ultimate choice of cancer treatment and the specific isotope chosen for seed brachytherapy treatment. The Company has developed a customized brand message for each audience. The Company’s new website was launched in the fall of 2016 and delivers the message that Cesium-131 is a treatment option for cancers throughout the body. Isoray continues to develop and/or refresh print, visual and digital media (including physician brochures discussing the clinical advantages of Cesium-131, clinical information materials, and digital content for the website and social media awareness efforts). In addition, the Company attends national professional meetings, including:

■

American Brachytherapy Society (ABS);

Table of Contents

■

American Society for Therapeutic Radiation and Oncology (ASTRO);

■

Association of American Physicists in Medicine (AAPM);

■

American Urological Association (AUA);

■

Society for Neuro-Oncology (SNO);

■

American Association of Neurological Surgeons (AANS);

■

American Association for Thoracic Surgery (STS); and

■

various local chapter meetings.

In today’s U.S. health care market, patients are more informed and involved in the management of their health than in the past. Many physicians relate incidents of their patients coming for consultations armed with articles researched on the Internet and other sources describing new treatments and medications. In many cases, these patients are demanding a certain therapy or drug and the physicians are complying when medically appropriate.

Because of this consumer-driven market factor, we also promote our products directly to the general public. We target the prostate cancer patient, his spouse, family, care givers and loved ones. We emphasize to these segments the specific advantages of the Cesium-131 brachytherapy seed through our website (located at www.Isoray.com), patient advocacy efforts, informational patient materials and patient testimonials, other awareness efforts through social media channels, and advertisements in specific markets supporting brachytherapy. None of our websites should be considered a part of this Report. Over the past year, the Company has continued to increase its efforts to raise awareness about Cesium-131 and Isoray Medical. One key method we have pursued for this is to increase our digital footprint, with consistent updates to our website and outreaches through social media, including Twitter, LinkedIn and Facebook. These efforts have resulted in significant year over year growth in web traffic (50.1% increase in total visitors), new visitors (48.52% increase) and organic search results (71.5% increase in resulting site traffic). The Company believes that an increased digital presence will result in increased awareness about brachytherapy overall, and specifically increased awareness about Cesium-131. Management believes this increased awareness should ultimately translate to more patients finding a physician with Cesium-131 experience.

The Company’s marketing plan with regard to non-prostate segments includes identifying and exhibiting at scientific meetings attended by specialty physicians who perform procedures related to Company’s product offerings, direct sales contact with such physicians (for example thoracic surgeons and neuro-surgeons), the development and dissemination of training videos and other media that outline the Company’s products, and the implementation of local training events to provide product and procedure information to potential customers.

Further, the Company is partnering with key clinicians within each application to support early experiences and identify additional facilities that may be interested in the applications. The Company continues to work with its existing radiation oncology physician customers and to educate them as to additional or new Company products and expand utility of Cesium-131 within the facility and across different disease sites. To facilitate this expanded position, the Company’s sales managers call on existing radiation oncology physicians and other key decision makers within an organization to discuss the available clinical results and experiences in coordination with key Company scientific personnel to educate the customer representatives about different Cesium-131 applications and comparisons to competing treatments.

Table of Contents

Sales and Distribution

In the prostate cancer market, the sales organization targets radiation oncologists and medical physicists as well as urologists and facility administrators as key clinical decision-makers in the type of radiation therapy offered to prostate cancer patients.

With respect to non-prostate applications, the Company targets neurosurgeons, thoracic surgeons, gynecologic oncologists and other surgeons in addition to radiation oncologists. After these clinicians identify the value of the Company’s Cesium-131 products, the Company then also needs support for the procedure from the medical physicists on staff and facility administrators. The sales cycle for non-prostate applications has proved to be a longer process than for prostate applications and often takes nine months or longer before the Company is licensed in a new hospital and can make its first sale.

Isoray has a direct sales organization consisting of territory sales managers, and a Vice-President of Sales and Marketing responsible for the development of the team and the execution of the sales plan. The Company’s territory sales managers are responsible for all sales activities in their respective territories and solicit potential specialist physicians in all areas of the body. This approach allows our territory sales managers to call on a single location for all applications of our products, resulting in a more efficient sales approach.

The sales organization is fully committed to and is in the process of executing the commercial plan for the development of new sales materials, training materials, and website assistance. Further, the marketing team supports the development of the company brand. Finally, the sales organization continues to work with the Research and Development team to help in the development of new products and advancements to support customer brachytherapy needs.

The Company expects to continue to explore the opportunity to extend its customer base outside the U.S. market through use of established distributors in target markets of other countries. As of September 2019, the Company had independent distributors in Russia and Peru. The Company’s initial focus on the international markets was for the sale of the GliaSite^® RTS, which was discontinued in March 2016. This has shifted to targeted prostate and gynecological centers in the targeted markets. Although it has international distribution agreements in place, the Company continues to experience difficulties in generating sales of Cesium-131 products through its international distributors. In addition, the Company’s decision to not renew its CE mark during fiscal year 2019 will limit its ability to sell to countries within the European Union.

Reimbursement

Reimbursement by third party payers is the primary means of payment for all Isoray products. The Centers for Medicare and Medicaid Services (CMS) is the primary payer, providing coverage for approximately 65% of all prostate brachytherapy cases and a majority of non-prostate procedures. Well established brachytherapy coverage and payment policies are currently in place by CMS and other non-governmental payers for out-patient procedures. For surgical procedures provided in an in-patient setting, payment is provided as part of a DRG code, which includes the surgical elements of the procedure.

In the hospital outpatient prospective payment system (HOPPS) out-patient setting, brachytherapy sources are legislated to be paid individually. Under this umbrella, in 2003, CMS established a unique HCPCS code for Cesium-131 brachytherapy seeds that permitted providers to report the use of Cesium-131 directly to payers. In July 2007, CMS established two separate Cesium-131 codes for providers to report loose seeds and stranded seeds due to the cost differential of these two products. Reimbursement for prostate brachytherapy services and sources is well established in the U.S. and most providers (hospitals and physicians) are not faced with reimbursement challenges when providing this treatment option to patients.

As noted above, there are currently two different methodologies for CMS payment. The first, the out-patient setting, includes prostate brachytherapy, and a limited range of other procedures, including some gynecological implants, and as such, is covered by the CMS Outpatient Prospective Payment System, which since 2010 has provided a fixed reimbursement per seed for stranded and loose seeds. Iodine, Palladium and Cesium each have their own reimbursement values for stranded and loose seeds. If reported correctly when seeds are submitted for payment to CMS, providers are reimbursed at a flat rate that is determined by median costs of the seeds. CMS has generally continued its historical trend of declining year over year reimbursement with few exceptions. Private insurance companies have historically followed the CMS reimbursement policies. The Company expects that CMS will continue its annual review of payments provided as reimbursement for our various products.

The other payment method is for in-patient procedures, where the patient remains in the hospital for more than 24 hours. Lung, brain and head and neck implant procedures utilizing brachytherapy sources require the patient to be admitted to the hospital. In-patient procedures are covered by CMS which remits a set amount depending on the type of surgery being performed and the complexity of the surgery. Under this Diagnostic Related Group (DRG) system, the hospital pays for all the items involved in the care of the patient excluding physician fees. The brachytherapy seeds in these in-patient cases are not paid for separately by CMS, but rather included as part of the DRG payments from CMS. Because the Company’s seeds may not be reimbursed by CMS, there can be difficulty in convincing hospitals to use the Company’s products. The Company contracted with a reimbursement consultant in April of 2016 to review opportunities to establish incremental reimbursement from CMS for in-patient care for brachytherapy. In September 2019, the Company submitted for an additional ICD-10-PCS code for other surgical procedures and is currently waiting on CMS’s response. The Company plans on considering additional applications for ICD-10-PCS codes for in-patient brachytherapy treatments in the future. Receipt of additional ICD-10-PCS codes in the future for brachytherapy applications will assist in the sales to hospitals and institutions that currently are not reimbursed for brachytherapy radiation for in-patient care. Management believes the lack of incremental reimbursement by CMS and private insurers for brachytherapy placed at the time of surgery rather than delivered at a point in time following surgery may be impeding the faster and broader adoption of in-patient brachytherapy.

Table of Contents

In July 2019, CMS proposed a significant change to the way Medicare currently pays for radiation services in an out-patient setting. If this change proposed by CMS is enacted, the Radiation Oncology Alternative Payment Method (RO APM) would provide for a single, bundled payment for a 90-day episode of radiation therapy including LDR brachytherapy, IMRT, SBRT, proton therapy, and HDR brachytherapy. The RO APM proposal would apply the same payment levels to services provided in physician offices, free-standing centers, and hospital outpatients and would be mandatory for approximately forty percent of the facilities in the United States. In addition, certain surgical codes are included in the bundled payment such as those for gynecological treatments. This CMS proposal for a revised payment includes brachytherapy sources which contradicts the current Congressional mandate to provide separate payment for brachytherapy sources. All comments regarding the RO APM were due to CMS by mid-September 2019 and the Company submitted its comments prior to the deadline. The final rule could become effective for calendar year 2020 if CMS proceeds with little or no changes to the proposed RO APM. Management is currently evaluating the impact that RO APM would have if implemented as currently written.

GT Med Tech filed an application for a New Technology Add-on Payment (NTAP) to the Center for Medicare and Medicaid Services (CMS) seeking reimbursement for the GammaTile™ treatment in the in-patient setting. In August 2019, CMS issued a ruling that GammaTile™ Therapy was not approved for an NTAP. Despite the lack of an NTAP code, GT Med Tech has reimbursement for GammaTile™ under ICD-10PCS-00H004Z and MS-DRG 023 which reimburses hospitals in the inpatient setting and will continue to roll out its sales and marketing strategy for release of GammaTile™.

Financial Information About Segments

The Company has determined that it operates in only one segment, as it only reports profit and loss information on an aggregate basis to its chief operating decision maker.

Financial Information About Geographic Areas

All of the Company’s long-lived assets are located in the United States. Revenue by geographic region is based on the shipping addresses of the Company's customers. The following summarizes revenue by geographic region:

	For the year ended June 30,
	2019			2018			2017
United States		99.36	%		99.33	%		99.94	%
Non – United States		0.64	%		0.67	%		0.06	%
Total		100.00	%		100.00	%		100.00	%

Other Information

Customers

The following are the Company’s top three customers, facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed, which accounted for approximately 35.2% of the total Company sales for the twelve months ended June 30, 2019:

Facility	Location	% of revenue
El Camino, Los Gatos, and other facilities¹	Northern CA		22.1	%
Longview Regional Medical Center, and other facilities	TX		7.4	%
University of Pittsburg Medical Center – Mercy	PA		5.7	%
Total			35.2	%

The head of the single largest physician practice also serves as the Company’s medical director. As the medical director, this physician advises the Company Board of Directors and management, provides technical advice related to product development and research and development, and provides internal training to the Company sales staff and professional training to our sales staff and to other physicians. Revenue from this practice increased by $183,000 in the year ended June 30, 2019 when compared to the year ended June 30, 2018. This increase was due to the addition of new centers located by the regional manager and within the practice range of the medical director.

The loss of either the single largest physician practice or a combination of the other significant facilities and customers could have a material adverse effect on the Company’s revenues, which would continue until the Company located new customers to replace them. There can be no assurance this would occur in a timely manner or at all.

Advanced Radiation Centers of NY was a top three customer in fiscal year 2018. While not a top three customer in fiscal year 2019, Advanced Radiation Centers of NY is still a substantial customer.

Proprietary Rights

The Company relies on a combination of patent, copyright and trademark laws, trade secrets, software security measures, license agreements and nondisclosure agreements to protect its proprietary rights. Some of the Company’s proprietary information may not be patentable.

Table of Contents

Our management believes that certain aspects of the Isoray seed design and construction techniques are patentable innovations. These innovations resulted in a patent granted by the USPTO under Patent Number 7,410,458, in August 2008, with an expiration date of December 5, 2025. Certain methodologies regarding isotope production, separation, and seed manufacture are retained as trade secrets and are embodied in Isoray’s procedures and documentation. Four patents have been granted by the USPTO relating to methods of deriving Cesium-131 developed by Isoray employees: Patent Number 7,479,261, with an expiration date of April 6, 2027; Patent Number 7,531,150, with an expiration date of July 13, 2027; Patent Number 7,316,644, with an expiration date of August 5, 2025; and Patent Number 7,510,691, with an expiration date of July 19, 2027. One patent has been granted by the USPTO relating to a device for loading brachytherapy seeds: Patent Number 10,328,278, with an expiration date in October 2038. The Company has two patents that were issued on April 23, 2014 and are effective in Canada (Canada 2576907 and 2571349). The Company has patents granted in the Russian Federation which expire at various times in 2024 and 2025. The Company has a single patent granted in each of the Netherlands and India that both expire on June 22, 2025. The Company has a single patent pending in the EU and Hong Kong. The Company is continuing its efforts to develop and patent additional methods of deriving Cesium-131 and other isotopes.

There were specific conditions attached to the assignment of the Cesium-131 Trust patent from the late Lane Bray. In particular, the associated Royalty Agreement provided for 1% of gross profit payment from seed sales to Lane Bray and 1% of gross profit from any use of the Cesium-131 process patent for non-seed products. If Isoray reassigned the Royalty Agreement to another company, these royalties increased to 2%. The Royalty Agreement had an anti-shelving clause that required Isoray to return the patent if Isoray permanently abandoned sales of products using the invention. During fiscal years 2019 and 2018, the Company recorded royalty expense of $33,000 and $27,000, respectively, related to this patent. The patent expired in April 2019 and no royalties were paid on sales after the expiration of the patent. The Company has changed and improved its processes over time and was only using a small part of the methodology described in the patent at the time of its expiration. While others can now use the methodologies described in the patent without infringing, management believes that its proprietary processes covered either by other valid patents or by know-how still provide some barriers to entry for anyone wanting to produce a Cesium-131 brachytherapy seed and also allow the Company to more efficiently manufacture Cesium-131 brachytherapy seeds than using the methods listed in the expired patent.

Research and Development

During the two-year period ended June 30, 2019, Isoray and its subsidiaries incurred approximately $3.22 million in costs related to research and development activities. The Company expects to continue ongoing research and development activities for the foreseeable future. Chief among R&D expenditures in fiscal year 2019 were new product development (Blu Build™ loader, GammaTile™ and others) and the support of clinical research studies that are accumulating data on the subjects of prostate, brain and head and neck cancers. Other clinical research, including the study of Cesium-131 in the treatment of gynecological and other cancers, are currently funded by sources other than the Company.

Government Regulation

The Company’s present and future intended activities in the development, manufacture and sale of cancer therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines. Within the United States, the Company’s therapeutic radiological devices must comply with the U.S. Federal Food, Drug and Cosmetic Act, which is enforced by the U.S. Food and Drug Administration (FDA). The Company is also required to adhere to applicable FDA Quality System Regulations, also known as the Good Manufacturing Practices, which include extensive record keeping and periodic inspections of manufacturing facilities. The Company’s predecessor obtained FDA 510(k) clearance in March 2003 to market its Cesium-131 seed for the treatment of localized solid tumors and other malignant disease and Isoray obtained FDA 510(k) clearance in November 2006 to market preloaded brachytherapy seeds and in August 2009 for preloading flexible braided strands and bioabsorbable mesh. In July 2018 the Company obtained 510(k) clearance for the GammaTile™ Therapy which it subsequently transferred to GT Med Tech per the Collaborative Development Agreement executed in March 2017.

In the United States, the FDA regulates, among other things, new product clearances and approvals to establish the safety and efficacy of these products. We are also subject to other federal and state laws and regulations, including the Occupational Safety and Health Act and the Environmental Protection Act.

The Federal Food, Drug, and Cosmetic Act and other federal statutes and regulations govern or influence the research, testing, manufacture, safety, labeling, storage, record keeping, approval, distribution, use, reporting, advertising and promotion of such products. Noncompliance with applicable requirements can result in civil penalties, recall, injunction or seizure of products, refusal of the government to approve or clear product approval applications, disqualification from sponsoring or conducting clinical investigations, preventing us from entering into government supply contracts, withdrawal of previously approved applications, and criminal prosecution.

Table of Contents

In the United States, medical devices are classified into three different categories over which the FDA applies increasing levels of regulation: Class I, Class II, and Class III. Most Class I devices are exempt from premarket notification 510(k); most Class II devices require premarket notification 510(k); and most Class III devices require premarket approval. Our Cesium-131 seed is a Class II device and received 510(k) clearance in March 2003.

Approval of new Class III medical devices is a lengthy procedure and can take a number of years and require the expenditure of significant resources. There is a shorter FDA review and clearance process for Class II medical devices, the premarket notification or 510(k) process, whereby a company can market certain Class II medical devices that can be shown to be substantially equivalent to other legally marketed devices. Since brachytherapy seeds have been classified by the FDA as a Class II device, we have been able to achieve market clearance for our Cesium-131 seed using the 510(k) process.

As a registered medical device manufacturer with the FDA, we are subject to inspection to ensure compliance with FDA’s current Good Manufacturing Practices, or cGMP. These regulations require that we and any of our contract manufacturers design, manufacture and service products, and maintain documents in a prescribed manner with respect to manufacturing, testing, distribution, storage, design control, and service activities. Modifications or enhancements that could significantly affect the safety or effectiveness of a device or that constitute a major change to the intended use of the device require a new 510(k) premarket notification for any significant product modification.

The Medical Device Reporting regulation requires that we provide information to the FDA on deaths or serious injuries alleged to be associated with the use of our devices, as well as product malfunctions that are likely to cause or contribute to death or serious injury if the malfunction were to recur. Labeling and promotional activities are regulated by the FDA and, in some circumstances, by the Federal Trade Commission.

As a medical device manufacturer, we are also subject to laws and regulations administered by governmental entities at the federal, state and local levels. For example, our facility is licensed as a medical device manufacturing facility in the State of Washington and is subject to periodic state regulatory inspections. Our customers are also subject to a wide variety of laws and regulations that could affect the nature and scope of their relationships with us.

In support of the Company’s global strategy to expand marketing to Russia and other strategic countries, the Company determined in FY 2018 it needed to migrate to the ISO 13485:2016 standard. In April 2018, BSI certified the Company’s successful transition to ISO 13485:2016. This transition moved Isoray’s quality system into the current state of the art Quality Management System per the ISO Medical Device Quality Management System standard. It was imperative that the Company complied with ISO 13485:2016 by end of February 2019 in order to maintain its CE Marks. During the fiscal year 2014, the CE Mark was renewed for an additional five years. However, during fiscal year 2019, the Company elected to not to renew its CE Mark due to no sales activity in the European Union, limited interest in Cesium-131 due to the pricing and reimbursement environment, and changing European Union registration requirements that would have required significant investment into additional clinical trials.

Table of Contents

In the United States, as a manufacturer of medical devices and devices utilizing radioactive byproduct material, we are subject to extensive regulation by not only federal governmental authorities, such as the FDA and FAA, but also by state and local governmental authorities, such as the Washington State Department of Health, to ensure such devices are safe and effective. In Washington State, the Department of Health, by agreement with the federal Nuclear Regulatory Commission (NRC), regulates the possession, use, and disposal of radioactive byproduct material as well as the manufacture of radioactive sealed sources to ensure compliance with state and federal laws and regulations. Our Cesium-131 brachytherapy seeds constitute both medical devices and radioactive sealed sources and are subject to these regulations.

Moreover, our use, management, and disposal of certain radioactive substances and wastes are subject to regulation by several federal and state agencies depending on the nature of the substance or waste material. We believe that we are in compliance with all federal and state regulations for this purpose.

The Company believes the costs to comply with various federal, state, and local environmental laws include such costs as radioactive waste disposal, radioactive material licenses, and increased shipping costs related to the radioactivity of our products are less than $100,000 annually.

Seasonality

The Company believes that some seed implantation procedures are deferred around physician vacations (particularly in the summer months), holidays, and medical conventions and conferences resulting in a seasonal influence on the Company’s business. These factors cause a momentary decline in revenue which management believes is ultimately realized in prior or following periods. Because a material portion of the Company’s business is dependent on three customers, physician practices or facilities, simultaneous or extended vacations by the physicians at these facilities or by our single largest physician whose total revenue alone represents a material portion of the Company’s business could cause significant drops in the Company’s productivity during those reporting periods.

Employees

As of September 19, 2019, Isoray employed 43 full-time individuals. The Company’s future success will depend, in part, on its ability to attract, retain, and motivate highly qualified sales, technical and management personnel. From time to time, the Company may employ independent consultants or contractors to support its research and development, marketing, sales, accounting and administrative organizations. None of the Company’s employees are represented by any collective bargaining unit. On September 19, 2019, the Company employed six direct sales people.

Competition

The Company competes in a market characterized by technological innovation, extensive research efforts, and significant competition. In general, the Isoray Cesium-131 brachytherapy seed competes with conventional methods of treating localized cancer, including, but not limited to, all forms of prostatectomy surgery and external beam radiation therapy which includes intensity modulated radiation therapy, stereotactic radiosurgery and proton therapy, as well as competing permanent and temporary brachytherapy devices.

Management believes the Company’s patented Cesium-131 separation process is likely to provide a sustainable competitive advantage and maintain the Company as the sole producer of medical Cesium-131. Production of Cesium-131 also requires specialized facilities that represent high cost and long lead time if not readily available. In addition, a competitor would need to develop a method for isotope attachment and seed assembly, would need to conduct testing to meet NRC and FDA requirements, and would need to obtain regulatory clearances before marketing a competing device. Best Medical received FDA 510(k) clearance to market a Cesium-131 seed on June 6, 1993 but to date, twenty-six years later, have not produced any products for sale.

The permanent brachytherapy seed market includes companies that manufacture and/or distribute Cesium-131, Iodine-125 (I-125) and Palladium-103 (Pd-103). The Company believes the performance characteristics of Cesium-131, specifically the shorter half-life and higher energy than either Pd-103 or I-125, will ultimately prove to be advantageous. Both other permanent brachytherapy isotopes, I-125 and Pd-103 were introduced to the market prior to Cesium-131, allowing many customers to become comfortable with the performance of both isotopes and requiring the Company to overcome these preferences to convert customers to Cesium-131.

Table of Contents

Key competitors who provide permanent prostate brachytherapy products include: Theragenics Corporation, Becton-Dickinson (formerly C. R. Bard), IsoAid, and Best Medical. While none of these companies publicly report specific information about their brachytherapy business, the Company believes the following about their product offerings and market positions:

●

Theragenics Corporation introduced Pd-103 into the market approximately 20 years ago. They are the market leader in Pd-103 production. In the 2000’s, Theragenics introduced their own I-125 product. They deliver product in a variety of configurations, include products that allow for intra-operative needle preparation and stranding. They also provide product (primarily I-125) for international distribution. The majority of their brachytherapy sales are for prostate treatment. They manufacture Pd-103 for Becton Dickinson.

●

Becton-Dickinson (“BD”, Previously C. R. Bard) manufactures their own I-125 and distribute Pd-103 from Theragenics. They are a prior market leader, and historically focused on dedicated delivery devices to support different physician procedure techniques. They continue to distribute I-125 internationally, with the majority of their brachytherapy sales for prostate treatment.

●

IsoAid manufactures both I-125 and Pd-103, with a focus on domestic prostate brachytherapy customers. They have focused on providing seeds to customers in standard configurations. The Company does not believe that IsoAid offers a product for intra-operative needle preparation and stranding.

●

Best Medical manufactures both I-125 and Pd-103, with a focus on domestic prostate brachytherapy customers. They have focused on providing seeds to customers in standard configurations. The Company does not believe that Best Medical offers a product for intra-operative needle preparation and stranding.

The Company believes that customers perform prostate brachytherapy procedures via one of several general procedure techniques, including (but not limited to): Pre-plan techniques, Intra-operative techniques, and Real-time techniques. Further, the Company believes that customers are comfortable with their techniques and want products to facilitate their preferred methods. All of the above competitors provide a set of standard products (including loose seeds, seeds loaded in cartridges, and seeds pre-loaded in needles) to meet the customer needs. Theragenics and BD have products that support intra-operative and real-time techniques that allow for stranding or linking seeds together in custom configurations in the operating room. This allows physicians to gain the benefits of stranded or linked seeds while still allowing for customization to the patient anatomy, as determined at the time of the procedure. The Company believes that approximately 25% of procedures are performed with some level of customization in the operating room.

It is this segment of the market – customer looking to customize their procedures to the anatomy at the time of the procedure – that the Company expects to address with their new Blu Build™ loading device. The Blu Build™ loading device will efficiently configure strands in the operating room, allowing the clinician to make determinations about the product configurations with the most recent picture of the patient’s anatomy. The Company believes that this technique may provide advantages in some brachytherapy products and will provide a better solution for this market segment. The Company also believes the efficiency and ease of use of the Blu Build™ loading device will offer an intriguing opportunity for the other 75% of the market. Blu Build™ was sold in a limited market release during fiscal year 2019 as the Company worked to refine the loader before wide-spread distribution. The Company anticipates a full market release of Blu Build™ in the first half of fiscal year 2020, but there is no assurance this will occur.

The Company’s brachytherapy products used in non-prostate applications typically compete with temporary (high dose-rate, HDR) and external beam radiation therapy (EBRT), which can be provided as conventional or intensity modulated radiation therapy, or as stereotactic radiosurgery, a technique that delivers high doses of radiation to a target in a much lower number of sessions than other forms of EBRT. Manufacturers of EBRT equipment include Varian Medical Systems, Siemens Healthcare, Elekta AB, and Accuray Incorporated, among others.

Table of Contents

ITEM 1A – RISK FACTORS

You should carefully consider the following factors regarding information included in this Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.

Risks Related to Our Industry and Operations

Our Revenues Depend Upon One Product with Multiple Applications. Our revenues depend solely upon the successful production, marketing, and sales of the Cesium-131 brachytherapy seed in its various delivery formats. The rate and level of market acceptance of this product varies depending on the perception by physicians and other members of the healthcare community of its safety and efficacy as compared to that of competing products, if any; the clinical outcomes of the patients treated; the effectiveness of our sales and marketing efforts or those of our distributors in the United States, the Russian Federation, and Peru; any unfavorable publicity concerning our product or similar products; our product’s price relative to other products or competing treatments; any decrease in current reimbursement rates from the Centers for Medicare and Medicaid Services or third-party payers; regulatory developments related to the manufacture or continued use of the product; availability of sufficient supplies of barium for Cesium-131 seed production; ability to produce sufficient quantities of Cesium-131; the ability of physicians to apply the correct dosage of seeds and avoid excessive levels of radiation to patients; and the ability to use this product to treat multiple types of cancers in various organs. Because of our reliance on this product as the sole source of our revenue, any material adverse developments with respect to the commercialization of this product may cause us to continue to incur losses rather than profits in the future.

We Are Subject To Uncertainties Regarding Reimbursement For Use Of Our Product. Hospitals and freestanding clinics may be less likely to purchase our product if they cannot be assured of receiving favorable reimbursement for treatments using our product from third-party payers, such as Medicare and private health insurance plans. Currently, Medicare reimburses hospitals at fixed rates that cover the cost of stranded and loose seeds. Clinics and physicians performing procedures in a free-standing center are reimbursed at the actual cost of the seeds.

In 2019, CMS proposed a significant change to the way Medicare currently pays for radiation services. If this change proposed by CMS is enacted, the Radiation Oncology Alternative Payment Method (RO APM) would provide for a single, bundled payment for a 90-day episode of radiation therapy including LDR brachytherapy, IMRT, SBRT, proton therapy, and HDR brachytherapy. The RO APM proposal would apply the same payment levels to services provided in physician offices, free-standing centers, and hospital outpatients and would be mandatory for approximately forty percent of the facilities in the United States. In addition, certain surgical codes are included in the bundled payment such as those for gynecological treatments. This CMS proposal for a revised payment structure includes brachytherapy sources which contradicts the current Congressional mandate to provide separate payment for these brachytherapy sources. The final rule could become effective for part or all of calendar year 2020. The RO APM could prove beneficial to the Company if clinics and physicians transition to brachytherapy options and away from more expensive IMRT and other non-brachytherapy options. However, if clinics and physicians determine to use less costly iodine brachytherapy this would have a negative impact on the Company as the costs of our Cesium-131 seeds are higher than iodine seeds. Management does not know what effect the RO APM once implemented may have on our business, financial condition, or results of operations as the proposed RO APM reimbursement structure may be revised before it is adopted and if not revised it is difficult to determine the impact on our Company until our customers determine how they intend to proceed.

Brachytherapy seeds have two CMS codes – one code for loose seeds and a second code for stranded seeds. Reimbursement amounts are reviewed and revised annually based upon information submitted to CMS on claims by providers. Changes in reimbursement can positively or negatively affect market demand for our product. We monitor these changes and provide comments, as permitted, when changes are proposed, prior to implementation.

In-patient procedures are covered by CMS and hospitals are paid based on the type and complexity of the surgery. These procedures are done as part of a Diagnostic Related Group or DRG system under which the hospital pays for all items involved in the care of the patient exclusive of the physician fees. Hospitals are less receptive to treatments which require out of pocket costs such as procedures we use for certain non-prostate applications. Certain of our DRG reimbursement amounts coupled with out-of-pocket costs imposed on hospitals make some of our non-prostate procedures not financially viable. We rely on our reimbursement consultant to assist us to improve the rate of reimbursement so that our product reimbursement will create greater incentives to be used. There is no assurance we will obtain the increase necessary to keep certain procedures viable and improve the margins of others.

Historically, private insurers have followed Medicare guidelines in establishing reimbursement rates. However, third-party payers are increasingly challenging the pricing of certain medical services or devices, and we cannot be sure that they will reimburse our customers at levels sufficient for us to maintain favorable sales and price levels for our product. There is no uniform policy on reimbursement among third-party payers, and we can provide no assurance that our product will continue to qualify for reimbursement from all third-party payers or that reimbursement rates will not be reduced. A reduction in or elimination of third-party reimbursement for treatments using our products would have a material adverse effect on our revenues.

Our success in international markets also depends upon the eligibility of our product for coverage and reimbursement through government-sponsored health care payment systems and third-party payors. Reimbursement practices vary significantly by country. Many international markets have government-managed insurance systems that control reimbursement for our new product and procedures. Other foreign markets have both private insurance systems and government-managed systems that control reimbursement for our new product and procedures. Market acceptance of our product may depend on the availability and level of coverage and reimbursement in any country within a particular time. In addition, health care cost containment efforts similar to those we face in the United States are prevalent in many of the other countries in which we intend to sell our product and these efforts are expected to continue.

Furthermore, any federal and state efforts to reform government and private healthcare insurance programs, such as those passed by the federal government in 2010, could significantly affect the purchase of healthcare services and our product in general and demand for our product in particular. Approximately 60% of men diagnosed with prostate cancer are of Medicare age (65+), providing Medicare with a significant influence in the marketplace. We are unable to predict the ultimate impact of current healthcare reform rates, those reforms that may be enacted in the future both in the United States and in other countries, whether other healthcare legislation or regulations affecting the business may be proposed or enacted in the future or what effect any such legislation or regulations would have on our business, financial condition or results of operations.

Although Cleared To Treat Any Malignant Tissue, Our Product Is Primarily Used To Treat A Single Type Of Cancer Which Is In A Flat Market. Currently, the Cesium-131 seed is used almost exclusively for the treatment of prostate cancer (approximately eighty-nine percent of our sales). We have been treating brain cancer which amounted to approximately six percent of our sales, gynecological cancer which amounted to approximately one percent of our sales, head and neck cancer which amounted to approximately one percent of our sales, lung cancer which amounted to approximately one percent of our sales, and other cancers including pelvic cancer and colorectal cancer that combined constituted approximately one percent of our sales in fiscal year 2019. Management believes the Cesium-131 brachytherapy seed will continue to be used to treat other types of cancers as the Company identifies existing delivery systems that can be utilized or develops new delivery methods for the product, however these delivery systems may not prove as effective as anticipated. Management believes that clinical data gathered by select groups of physicians under treatment protocols specific to other organs will be needed prior to widespread acceptance of our product for treating other cancer sites. If our current and future products do not become accepted in treating cancers of other sites, our sales will continue to depend primarily on treatment of prostate cancer, a market with increasing competition and ongoing loss of market share by all brachytherapy products.

Unfavorable Industry Trends In The Prostate Market. In February of 2009, noted urologists announced at a medical conference that prostate specific antigen (PSA) testing was not as necessary as previously believed. Their statements were widely publicized. Even though the past four fiscal years have shown improvements in the Company’s prostate revenues, since the U.S. Preventive Services Task Force (USPSTF) recommendation in 2012 to no longer routinely conduct prostate exams, the market for all prostate procedures has dramatically declined. This recommendation has led to substantial declines in PSA screenings. In addition, there has been an increase in “active surveillance,” a practice where no immediate medical treatment is provided but the physician and patient closely monitor the patient’s cancer for signs that the cancer is growing. We believe that declines in PSA screenings have led to a decline in the number of men diagnosed with prostate cancer, which in turn leads to a decline in the number of procedures to treat prostate cancer, including brachytherapy procedures. An increase in the proportion of men diagnosed with prostate cancer but not seeking immediate medical treatment ultimately also leads to a decline in the number of procedures to treat prostate cancer. In 2017, the USPSTF changed its recommendation from advising against screening to the position that the decision for men between 55 and 69 to undergo PSA-based screening should be made by a man in consultation with his doctor (https://screeningforprostatecancer.org/). This change may have contributed to an increased incidence of screening (and therefore more prostate cancer cases) as opposed to an unscreened population.

Table of Contents

Also, the emergence of IMRT as the preferred treatment alternative as a result of a much higher reimbursement rate to physicians compared to brachytherapy treatments has resulted in declining market share for brachytherapy treatment. In fiscal 2019, each of these factors continued to impact the performance of the Company in the prostate market and the industry as a whole and there is no assurance that they will not continue to impact sales of the Company in the prostate market through fiscal 2020.

We Rely Heavily On Three Customers. Approximately thirty-five percent (35%) of the Company’s revenues are dependent on three customers and approximately twenty-two percent (22%) on one customer. The loss of any of these customers would have a material adverse effect on the Company’s revenues which may not be replaced by other customers particularly as these customers are in the prostate sector which is facing substantial competition from other treatments.

We Rely Heavily On A Limited Number Of Suppliers. Our Most Critical Suppliers Are In Russia And We Periodically Must Rely Solely On One Supplier From Time to Time. Some materials used in our product are currently available only from a limited number of suppliers. Beginning in the third quarter of fiscal year 2019, all of our Cesium-131 was supplied through JSC Isotope from a reactor located in Russia. Our current contract terminates on December 31, 2020. Management will seek to negotiate favorable pricing at each contract extension but there is no assurance as to the outcome of these negotiations. On August 25, 2017, the Company executed a consignment inventory agreement with MedikorPharma-Ural LLC (“Medikor”) to process the Company’s enriched barium at another nuclear reactor in Russia beginning in November 2017. The term of the consignment agreement is 10 years. Our source of supply of Cesium-131 from Russia is historically produced using one of two nuclear reactors which supply the irradiation needed for Cesium-131 production. One of the Russian nuclear reactors was shut down from December 2017 till August 2018, and the other Russian nuclear reactor is scheduled to be shut down for much of 2019 into early 2020. As a result of these scheduled shutdowns, only one of the Company’s historic Russian suppliers of Cesium-131 will be available during these periods. Medikor, located in Russia, is using the barium carbonite consigned by the Company to contract with a third-party manufacturer to produce and supply Cesium-131 to the Company. This arrangement has the effect of minimizing the impact on the Company of the planned temporary shutdown of the nuclear reactors that serve as its sources of Cesium-131 from Russia. Previously, about twenty percent (20%) of our isotope supply came from the domestic MURR facility. In early fiscal 2019, the Company terminated its supply agreement with MURR thereby eliminating all domestic suppliers of this critical component of its product. This decision means that the Company has no domestic supply capabilities for Cesium-131. Management believes that with sufficient notice it may still obtain a supply of Cesium-131 from MURR but there is no assurance as to the availability and timing of fulfillment if needed. Even if Cesium-131 was supplied by MURR, MURR cannot manufacture enough supply to meet the Company’s increasing needs and requires additional cost in processing to meet the Company’s isotope specifications.

Reliance on any single supplier increases the risks associated with concentrating isotope production at a single reactor facility which can be subject to unanticipated shutdowns and political or civil unrest. Failure to obtain deliveries of Cesium-131 from multiple sources could have a material adverse effect on seed production and there may be a delay before we could locate alternative suppliers beyond the two reactors we currently use and one which is currently available.

We may not be able to locate additional suppliers outside of Russia capable of producing the level of output of Cesium at the quality standards we require. Additional factors that could cause interruptions or delays in our source of materials include sanctions placed on financial transactions with Russian banking institutions; limitations on the availability of raw materials or manufacturing performance experienced by our suppliers; or a breakdown in our commercial relations with one or more suppliers. Some of these factors may be completely out of our and our suppliers’ control.

Table of Contents

While we work closely with suppliers to assure continuity of supply and maintain high quality and reliability, these efforts may not be successful. Manufacturing disruptions experienced by our suppliers may jeopardize our supply of components. The loss or disruption of our relationships with outside vendors could subject us to substantial delays in the delivery of our product to customers. Significant delays in the delivery of our product could result in possible cancellation of orders and the loss of customers.

Due to the stringent regulations and requirements of the FDA and similar non-U.S. regulatory agencies regarding the manufacture of our product, we may not be able to quickly establish additional or replacement sources for certain components or materials. A change in suppliers could require significant effort or investment in circumstances where the items supplied are integral to product performance or incorporate unique technology. A reduction or interruption in manufacturing, or an inability to secure alternative sources of raw materials or components, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Any casualty, natural disaster or other significant disruption of any of our suppliers’ operations, or any unexpected loss of any existing exclusive supply contract could have a material adverse effect on our business.

Although we expect our suppliers to comply with our contract terms, we do not have control over these suppliers. Our inability to provide a product that meets delivery schedules could have a material adverse effect on our reputation in the industry, which could have a material adverse effect on our financial condition and results of operations.

Further, any single source suppliers or contract manufacturers may operate through a single facility. If an event occurred that resulted in material damage to this manufacturing facility or our supplier/manufacturing contractor lacked sufficient labor to fully operate the facility, we may be unable to transfer the manufacture of our product or supply of the component to another facility or location in a cost-effective or timely manner, if at all. This potential inability to transfer production could occur for a number of reasons, including but not limited to a lack of necessary relevant manufacturing capability at another facility, or the regulatory requirements of the FDA or other governmental regulatory bodies. Even if there are many qualified suppliers or contract manufacturers available around the country and our product or its components are relatively easy to manufacture, such an event could have a material adverse effect on our financial condition and results of operations.

Doctors And Hospitals May Not Adopt Our Product And Technologies At Levels Sufficient To Sustain Our Business Or To Achieve Our Desired Growth Rate. To date, we have attained very limited penetration of the total potential market for our product, particularly in non-prostate applications. Our future growth and success depends upon creating broad awareness and acceptance of our product by doctors, hospitals and freestanding clinics, as well as patients. This will require substantial marketing and educational efforts, which will be costly and may not be successful. The target customers for our product may not adopt its related technologies or may adopt them at a rate that is slower than desired. We depend extensively on long term protocol results and publications by independent physicians. Unfavorable protocol results or publications would have an impact on the success of our product. In addition, potential customers who decide to utilize any of our devices may later choose to purchase competitors’ products. Important factors that will affect our ability to attain broad market acceptance of our product include:

■

doctor and/or patient awareness and acceptance of our product;

■

the real or perceived effectiveness and safety of our product;

■

the relationship between the cost of our product and the real or perceived medical benefits of our product;

■

the relationship between the cost of our product and the financial benefits to our customers using our product, which will be greatly affected by the coverage of, and reimbursement for, our product by governmental and private third-party payors; and

■

market perception of our ability to continue to grow our business and develop enhancements to our product.

Table of Contents

We must promote our product effectively. Factors that could affect our success in marketing our product include:

■

the adequacy and effectiveness of our sales force and that of any distributor’s sales force;

■

the adequacy and effectiveness of our production, distribution and marketing capabilities and those of our distributors;

■

the success of competing treatments or products; and

■

the availability and extent of reimbursement from third-party payors for our product.

If we fail to maintain our working relationships with health care professionals, many of our products may not be developed and marketed in line with the needs and expectations of the professionals who use and support our products, which could cause a decline in our earnings and profitability. The research, development, marketing, and sales of many of our new and improved products is dependent upon our maintaining working relationships with health care professionals. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing, and sale of our products. Physicians assist us as researchers, marketing and product consultants, inventors, and public speakers. If we are unable to maintain our strong relationships with these professionals and continue to receive their advice and input, the development and marketing of our products could suffer, which could have a material adverse effect on our consolidated earnings, financial condition, and/or cash flows.

If our product fails to achieve market acceptance, we may not be able to market and sell the product successfully, which would limit our ability to generate revenue and could harm our business.

Increased Prices For, Or Unavailability Of, Raw Materials Used In Our Product Could Adversely Affect Our Revenues. Our revenues are affected by the prices of the raw materials and sub-assemblies used in the manufacture of our product. These prices may fluctuate based on a number of factors beyond our control, including changes in supply and demand, general economic conditions, labor costs, fuel related delivery costs, competition, import duties, tariffs, currency exchange rates, and government regulation. Due to the highly competitive nature of the healthcare industry and the cost containment efforts of our customers and third-party payers, we may be unable to pass along cost increases for key components or raw materials through higher prices to our customers. If the cost of key components or raw materials increases, and we are unable fully to recover these increased costs through price increases or offset these increases through other cost reductions, we could experience lower margins and profitability. Significant increases in the prices of raw materials or sub-assemblies that cannot be recovered through productivity gains, price increases or other methods could adversely affect our results of operations.

Table of Contents

Our Operating Results Will Be Subject To Significant Fluctuations. Our quarterly revenues, expenses, and operating results are likely to fluctuate significantly in the future. Fluctuation may result from a variety of factors, which are discussed in detail throughout this “RISK FACTORS” section, including:

■

demand and pricing for the Company’s product;

■

effects of aggressive competitors;

■

hospital, clinic and physician purchasing decisions often impacted by vacation schedules of our primary physician customers;

■

research and development and manufacturing expenses;

■

patient outcomes from our product and unfavorable recommendations related to PSA testing;

■

physician acceptance of our product;

■

government or private healthcare reimbursement policies;

■

healthcare reform;

■

our manufacturing performance and capacity;

■

incidents, if any, that could cause temporary shutdown of our manufacturing facility;

■

the amount and timing of sales orders;

■

rate and success of future product approvals;

■

timing of FDA clearance, if any, of competitive product and the rate of market penetration of competing product;

■

seasonality of purchasing behavior in our market;

■

overall economic conditions;

■

the successful introduction or market penetration of alternative therapies; and

■

the outcome of the FDA’s evaluation of the clearance process for class II devices.

Table of Contents

We Are Subject To The Risk That Certain Third Parties May Mishandle Our Product. We rely on third parties, such as Federal Express, to deliver our Cesium-131 seed, and on other third parties to package our product in certain specialized packaging forms requested by customers. We are subject to the risk that these third parties may mishandle our product, which could result in adverse effects, particularly given the radioactive nature of our product.

We May Encounter Manufacturing Problems Or Delays That Could Result In Lost Revenue. Manufacturing our product is a complex process. We (or our critical suppliers) may encounter difficulties in scaling up or maintaining production of our product, including:

■

problems involving production yields;

■

quality control and assurance;

■

component supply shortages;

■

import or export restrictions on components, materials or technology;

■

shortages of qualified personnel; and

■

compliance with state, federal and foreign regulations.

If demand for our product exceeds our manufacturing capacity, we could develop a substantial backlog of customer orders. If we are unable to maintain larger-scale manufacturing capabilities, our ability to generate revenues will be limited and our reputation in the marketplace could be damaged.

Failure Of Any Clinical Studies Or Third-Party Assessments To Demonstrate Desired Outcomes In Proposed Endpoints May Reduce Physician Usage Or Result In Pricing Pressures That Could Have A Negative Impact On Business Performance. We support third party clinical studies designed to test a variety of endpoints associated with product performance and use across a number of applications. If, as a result of poor design, implementation or otherwise, a clinical study conducted by us or others fails to demonstrate statistically significant results supporting performance or use benefits or comparative cost effectiveness of our product, physicians may elect not to use our product as a treatment for conditions that may benefit from them. Furthermore, in the event of an adverse clinical study outcome, our product may not achieve “standard-of-care” designations, where they exist, for the conditions in question, which could deter the adoption of our product. Also, if serious device-related adverse events are reported during the conduct of a study it could affect continuation of the study, product approval and product adoption. If we are unable to develop a body of statistically significant evidence from our clinical study program, whether due to adverse results or the inability to complete properly designed studies, domestic and international public and private payers could refuse to cover our product, limit the manner in which they cover our product, or reduce the price they are willing to pay or reimburse for our product. In the case of a pre-approval study or a study required by a regulatory body as a condition of clearance or approval, a regulatory body can revoke, modify or deny clearance or approval of the study and/or the product in question.

Other Treatments May Be Deemed Superior To Brachytherapy. Our Cesium-131 seed may face competition not only from companies that sell other radiation therapy products, but also from companies that are developing alternative therapies for the treatment of cancers. It is possible that advances in the pharmaceutical, biomedical, or gene therapy fields could render some or all radiation therapies, whether conventional or brachytherapy, obsolete. If alternative therapies are proven or even perceived to offer treatment options that are superior to brachytherapy, physician adoption of our brachytherapy product could be negatively affected and our revenues from our brachytherapy product could decline.

Table of Contents

Our Industry Is Intensely Competitive. The medical device industry is intensely competitive. We compete with both public and private medical device, biotechnology and pharmaceutical companies that have been in existence longer than we have, have a greater number of products on the market, have greater financial and other resources, and have other technological or competitive advantages. As physicians migrate to medical devices such as external beam radiation and robotic surgery that have a much higher capital cost to repay and higher profit margins, this puts increasing pressure on all brachytherapy products to compete regardless of superior treatment results. The market share for brachytherapy continues to decline as a result of this pressure from increasing usage by oncologists of external beam radiation. In addition, centers that wish to offer the Cesium-131 seed must comply with licensing requirements specific to the state, province, and/or country in which they do business and these licensing requirements may take a considerable amount of time to comply with. Within the brachytherapy industry itself, our Cesium-131 seed is more expensive and receives less favorable reimbursement in many cases than use of iodine. Therefore, when physicians use a brachytherapy product many third party reimbursement plans provide more favorable economic incentives to use an iodine product rather than use our Cesium-131 seed. Certain centers may choose not to offer our Cesium-131 seed due to the time required to obtain necessary license amendments. We also compete with academic institutions, government agencies, and private research organizations in the development of technologies and processes and in acquiring key personnel. Although we have patents granted and patents applied for to protect our isotope separation processes and Cesium-131 seed manufacturing technology, we cannot be certain that one or more of our competitors will not attempt to obtain patent protection that blocks or adversely affects our product development efforts. Radiation therapy is a key element of cancer treatment, and is delivered as external beam radiation therapy (EBRT) in the vast majority of cases. Brachytherapy with Isoray’s Cesium-131 seed competes with EBRT as both primary and adjuvant therapy.

Cost-Containment Efforts Of Our Customers, Purchasing Groups, Third-Party Payers And Governmental Organizations Could Adversely Affect Our Sales And Profitability. The continuing efforts of governments, insurance companies and other payors of healthcare costs to contain or reduce these costs, combined with closer scrutiny of such costs, could lead to patients being unable to obtain approval for payment from these third-party payors. The cost containment measures that healthcare providers are instituting both in the U.S. and internationally could harm our business. Some healthcare providers in the U.S. have adopted or are considering a managed care system in which the providers contract to provide comprehensive healthcare for a fixed cost per person. Healthcare providers may attempt to control costs by authorizing fewer elective surgical procedures or by requiring the use of the least expensive devices possible, which could adversely affect the demand for our product or the price at which we can sell our product. Some healthcare providers have sought to consolidate and create new companies with greater market power, including hospitals. As the healthcare industry consolidates, competition to provide our product has become and will continue to become more intense. This has resulted and likely will continue to result in greater pricing pressures and the exclusion of certain suppliers from important marketing segments.

Outside the United States, we expect to experience pricing pressure from centralized governmental healthcare authorities due to efforts by such authorities to lower healthcare costs. Implementation of healthcare reforms and competitive bidding contract tenders may limit the price or the level at which reimbursement is provided for our product and adversely affect both our pricing flexibility and the demand for our product. Healthcare providers may respond to such cost-containment pressures by substituting lower cost product or other therapies for our product. We may be required to engage in competitive bidding for the sale of our product to governmental purchasing agents and hospital groups. Our failure to offer acceptable prices to these customers could adversely affect our sales and profitability in these markets. Distributors of our product may also negotiate terms of sale more aggressively to increase their profitability. Failure to negotiate distribution arrangements having advantageous pricing and other terms of sale could cause us to lose market share and would adversely affect our business, results of operations, financial condition and cash flows.

If We Fail To Comply With Applicable Healthcare Regulations, We Could Face Substantial Penalties And Our Business, Operations And Financial Condition Could Be Adversely Affected. Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights may be applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business, without limitation. The laws that may affect our ability to operate include, but are not limited to:

■

the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the referral of an individual for the furnishing or arranging for the furnishing of any item or service, or the purchase, lease, order, arrangement for, or recommendation of the purchase, lease, or order of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs;

Table of Contents

■

the civil federal False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the government; conspiring to defraud the government by getting a false or fraudulent claim paid or approved by the government; or knowingly making, using or causing to be made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government;

■

the criminal federal False Claims Act, which imposes criminal fines or imprisonment against individuals or entities who make or present a claim to the government knowing such claim to be false, fictitious or fraudulent;

■

the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent;

■

the Veterans Health Care Act of 1992 which requires manufacturers of “covered drugs” to offer them for sale to certain federal agencies, including but not limited to, the Department of Veterans Affairs, on the Federal Supply Schedule, which requires compliance with applicable federal procurement laws and regulations and subjects manufacturers to contractual remedies as well as administrative, civil and criminal sanctions;

■

the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

■

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates that perform services for them that involve individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization, including mandatory contractual terms as well as directly applicable privacy and security standards and requirements;

■

the federal Physician Payment Sunshine Act, created under the Patient Protection and Affordable Care Act (ACA), and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, with data collection required reporting to CMS by the 90th day following each calendar year;

■

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

■

the Foreign Corrupt Practices Act, a U.S. law that regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals), and state law equivalents of the federal laws, such as anti-kickback, false claims, consumer protection and unfair competition laws which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payors, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances many of which differ from each other in significant ways, with differing effect.

The U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from making improper payments to non-U.S. government officials for the purpose of obtaining or retaining business. Global enforcement of anti-corruption laws has increased substantially in recent years, with more frequent voluntary self-disclosures by companies, aggressive investigations and enforcement proceedings by U.S. and non-U.S. governmental agencies, and assessment of significant fines and penalties against companies and individuals. Our international suppliers create the risk of unauthorized payments or offers of payments by one of our employees, consultants, sales agents, or distributors, because these parties are not always subject to our control. Any alleged or actual violations of these regulations may subject us to government scrutiny, severe criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt our business, and result in a material adverse effect on our reputation, results of operations, financial condition, and cash flows.

Table of Contents

Governmental regulations outside the U.S. have become increasingly stringent and more common, and we may become subject to more rigorous regulation by governmental authorities in the future. In the European Union, for example, a new Medical Device Regulation was approved in 2017 which, when it goes into effect in the spring of 2020, will impose significant additional premarket and post-market requirements. This new EU Medical Device Regulation caused the Company to not renew its CE Mark due to the requirement of additional clinical trials that would have required a significant investment. Penalties for a company’s non-compliance with governmental regulation could be severe, including fines and revocation or suspension of a company’s business license, mandatory price reductions and criminal sanctions. Any governmental law or regulation imposed in the future may have a material adverse effect on us.

Additionally, the compliance environment is changing, with more states, such as California and Massachusetts, mandating implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other states, such as Vermont, Maine, and Minnesota, requiring reporting to state governments of gifts, compensation, and other remuneration to physicians. These laws all provide for penalties for non-compliance. The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may inadvertently run afoul of one or more laws.

If our past or present operations are found to be in violation of any of the laws described above or the other governmental regulations to which we, our distributors or our customers are subject, we may be subject to the applicable penalty associated with the violation, including civil and criminal penalties, damages, fines, exclusion from Medicare, Medicaid and other government programs and the curtailment or restructuring of our operations. If we are required to obtain permits or licensure under these laws that we do not already possess, we may become subject to substantial additional regulation or incur significant expense. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully or clearly interpreted by the regulatory authorities or the courts, and their provisions are subject to a variety of interpretations and additional legal or regulatory change. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business and damage our reputation. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.

Healthcare Reform Measures Could Hinder Our Product’s Commercial Success. In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our product profitably. In the United States, the Patient Protection and Affordable Care Act (the “ACA”) and the Health Care and Education Affordability Reconciliation Act of 2010 (together “the law” or “the legislation”) provide for a number of healthcare policy changes that are or will be applicable to us. However, there are many programs and requirements under the law for which the consequences are not fully understood, and it is unclear what the full impacts will ultimately be from the law. The legislation provides for significant new taxes on medical device makers in the form of a 2.3 percent excise tax on all U.S. medical device sales that commenced in January 2013 which would apply to all of our product sales. Although the excise tax has been suspended by Congress until the end of 2019, its status is unclear for subsequent years. Under the legislation, the total cost to the medical device industry is expected to be approximately $20 billion over 10 years. The law also focuses on a number of Medicare provisions aimed at improving quality and decreasing costs. It is uncertain at this point what negative unintended consequences these provisions will have on patient access to new technologies. The Medicare provisions include value-based payment programs, increased funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and hospital acquired conditions, and pilot programs to evaluate alternative payment methodologies that promote care coordination (such as bundled physician and hospital payments). Additionally, the law includes a reduction in the annual rate of inflation for Medicare payments to hospitals that began in 2011 and the establishment of an independent payment advisory board to recommend ways of reducing the rate of growth in Medicare spending.

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect:

■

our ability to set a price we believe is fair for our product;

■

our ability to generate revenues and achieve or maintain profitability;

■

the availability of capital; and

■

our ability to obtain timely approval of any future product modifications.

Table of Contents

CMS has published final regulations that implement provisions in ACA related to disclosure of payments made by manufacturers to physicians and teaching hospitals, effective April 2013. Because we manufacture devices that are covered by the regulations, all payments that we make to physicians and teaching hospitals are subject to this reporting requirement even if the payment relates to a device that is not considered a covered device. The tracking and reporting of these payments could have an adverse impact on our business and/or consolidated results of operations and financial condition and on our relationships with customers and potential customers.

We May Be Unable To Adequately Protect Or Enforce Our Intellectual Property Rights Or Secure Rights To Third-Party Patents. Our ability and the abilities of our distributors to obtain and maintain patent and other protection for our product will affect our success. We are assigned, have rights to, or have exclusive licenses to patents and patents pending in the U.S. and numerous foreign countries. The patent positions of medical device companies can be highly uncertain and involve complex legal and factual questions. Our patent rights may not be upheld in a court of law if challenged. Our patent rights may not provide competitive advantages for our product and may be challenged, infringed upon or circumvented by our competitors. We cannot patent our product in all countries or afford to litigate every potential violation worldwide. One of the patents that we license expired in fiscal year 2019 and others could now use the methods described in the patent without risk of infringing on our intellectual property. Over the years, the Company has improved and changed our methods and we were only using a small portion of the methods described in the expired patent.

Because of the large number of patent filings in the medical device and biotechnology field, our competitors may have filed applications or been issued patents and may obtain additional patents and proprietary rights relating to our product or processes competitive with or similar to ours. We cannot be certain that U.S. or foreign patents do not exist or will not be issued that would harm our ability to commercialize our product and future product candidates.

Pending And Future Patent Litigation Could Be Costly And Disruptive And May Have An Adverse Effect On Our Financial Condition And Results Of Operations. We operate in an industry characterized by extensive patent litigation. Potential patent claims include challenges to the coverage and validity of the Company’s patents on our product or processes as well as allegations that the Company’s product infringes patents held by competitors or other third parties. A loss in any of these types of cases could result in a loss of patent protection or the ability to market our product, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.

The Company’s commercial success will depend in part on not infringing the patents or violating the other proprietary rights of third parties. Intellectual property litigation is expensive and complex and outcomes are difficult to predict. Any pending or future patent litigation may result in significant damage awards, including treble damages under certain circumstances, and injunctions that could prevent the manufacture and sale of an affected product or force us to make significant royalty payments in order to continue selling the affected product. At any given time, we may be involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time. As a healthcare supplier, we can expect to face claims of patent infringement in the future. A successful claim of patent or other intellectual property infringement against us could adversely affect our results of operations and financial condition.

The Value Of Our Granted Patents, and Our Patents Pending, Is Uncertain. Although our management strongly believes that our patent on the process for producing Cesium-131, our patents on additional methods for producing Cesium-131 and other isotopes, our patent on the manufacture of the brachytherapy seed, and anticipated future patent applications, which have not yet been filed, have significant value, we cannot be certain that other like-kind processes may not exist or be discovered, that any of these patents is enforceable, or that any of our patent applications will result in issued patents.

Failure To Comply With Government Regulations Could Harm Our Business. As a medical device and medical isotope manufacturer, we are subject to extensive, complex, costly, and evolving governmental rules, regulations and restrictions administered by the FDA, the FAA and other federal and state agencies, and by governmental authorities in other countries. Compliance with these laws and regulations is expensive and time-consuming, and changes to or failure to comply with these laws and regulations, or adoption of new laws and regulations, could adversely affect our business.

In the United States, as a manufacturer of medical devices and devices utilizing radioactive by-product material, we are subject to extensive regulation by federal, state, and local governmental authorities, such as the FDA and the Washington State Department of Health, to ensure such devices are safe and effective. Regulations promulgated by the FDA under the U.S. Food, Drug and Cosmetic Act, govern the design, development, testing, manufacturing, packaging, labeling, distribution, marketing and sale, post-market surveillance, repairs, replacements, and recalls of medical devices.

Table of Contents

The FAA has authority to regulate, through its Office of Hazardous Materials Safety, the offering for shipment of hazardous materials, including radioactive materials of the type marketed by the Company. Because we ship hazardous materials on flights in the U.S., the Company is subject to these regulations, including periodic audit and, if applicable, enforcement action by the FAA. As they apply to the Company, the FAA regulations concern the packaging and labeling of hazardous materials. If we fail to comply with these regulations, the Company could face civil or criminal penalties. In Washington State, the Department of Health, by agreement with the federal Nuclear Regulatory Commission (NRC), regulates the possession, use, and disposal of radioactive byproduct material as well as the manufacture of radioactive sealed sources to ensure compliance with state and federal laws and regulations. Our Cesium-131 brachytherapy seeds constitute medical devices and radioactive sealed sources and are subject to these regulations.

Under the FDC Act, medical devices are classified into three different categories, over which the FDA applies increasing levels of regulation: Class I, Class II, and Class III. Our Cesium-131 seed has been classified as a Class II device and has received clearance from the FDA through the 510(k) pre-market notification process. Any modifications to the device that would significantly affect safety or effectiveness, or constitute a major change in intended use, would require a new 510(k) submission. As with any submittal to the FDA, there is no assurance that a 510(k) clearance would be granted to the Company.

The FDA has been considering legislative, regulatory and/or administrative changes to the FDA’s 510(k) program. Various committees of the U.S. Congress have also indicated that they may consider investigating the FDA’s 510(k) process. Under the current 510(k) rules, certain types of medical devices can obtain FDA approval without lengthy and expensive clinical trials. We have received FDA approval under the 510(k) rules for our product as sold in various formats. Our R&D programs and new product programs contemplate obtaining any required FDA approvals under the current 510(k) rules. Any changes to the current 510(k) or related FDA rules that make such rules more stringent or require more clinical data can significantly increase the time and costs associated with bringing new product formats or product modifications to market. This may have a material adverse effect on our business, financial condition and results of operations.

In addition to FDA-required market clearances and approvals for our product formats, our manufacturing operations are required to comply with the FDA's Quality System Regulation (QSR), which addresses requirements for a company’s quality program such as management responsibility, good manufacturing practices, product and process design controls, and quality controls used in manufacturing. Compliance with applicable regulatory requirements is monitored through periodic inspections by the FDA Office of Regulatory Affairs (ORA). We anticipate both announced and unannounced inspections by the FDA. Such inspections could result in non-compliance reports (Form 483) which, if not adequately responded to, could lead to enforcement actions. The FDA can institute a wide variety of enforcement actions ranging from public warning letters to more severe sanctions such as fines; injunctions; civil penalties; recall of our product; operating restrictions; suspension of production; non-approval or withdrawal of pre-market clearances for new products or existing products and criminal prosecution. There can be no assurance that we will not incur significant costs to comply with these regulations in the future or that the regulations will not have a material adverse effect on our business, financial condition and results of operations.

In addition to the ACA, various healthcare reform proposals have also emerged at the state level. Like the ACA, these proposals could reduce medical procedure volumes and impact the demand for our product or the prices at which we sell our product. The impact of these proposals could have a material adverse effect on our business and/or consolidated results of operations and financial condition.

Any cuts to Medicare reimbursement which affect our product could have a material adverse effect on our business and/or our consolidated results of operations and financial condition.

Table of Contents

The marketing of our product in foreign countries will, in general, be regulated by foreign governmental agencies similar to the FDA. Foreign regulatory requirements vary from country to country. The time and cost required to obtain regulatory approvals could be longer than that required for FDA clearance in the United States and the requirements for licensing a product in another country may differ significantly from FDA requirements. We will rely, in part, on foreign distributors to assist us in complying with foreign regulatory requirements. We may not be able to obtain these approvals without incurring significant expenses or at all, and the failure to obtain these approvals would prevent us from selling our product in the applicable countries. This could limit our sales and growth.

Quality Problems With Our Product Could Harm Our Reputation For Producing A High-Quality Product And Erode Our Competitive Advantage, Sales, And Market Share. Quality is extremely important to us and our customers due to the serious and costly consequences of product failure, which can include patient harm. Our operating results depend in part on our ability to sustain an effective quality control system and effectively train and manage our employee base with respect to our quality system. Our quality system plays an essential role in determining and meeting customer requirements, preventing defects and improving our product. While we have a network of quality systems throughout our business lines and facilities, quality and safety issues may occur with respect to any of our product formats. A quality or safety issue may result in a public warning letter from the FDA, product recalls or seizures, monetary sanctions, injunctions to halt manufacturing and distribution of products, civil or criminal sanctions, refusal of a government to grant clearances or approvals or delays in granting such clearances or approvals, import detentions of any future products made outside the United States, restrictions on operations or withdrawal or suspension of existing approvals. Negative publicity regarding a quality issue could damage our reputation, cause us to lose customers, or decrease demand for our product and product formats. Any of the foregoing events could disrupt our business and have an adverse effect on our results of operations and financial condition.

Our Business Exposes Us To Product Liability Claims. Our design, testing, development, manufacture, and marketing of our product involve an inherent risk of exposure to product liability claims and related adverse publicity. Our brachytherapy seed product delivers a highly concentrated and confined dose of radiation directly to the organ in which it is implanted from within the patient’s body. Surrounding tissues and organs are typically spared excessive radiation exposure. It is an inherent risk of the industries in which we operate that we might be sued in a situation where our product results in, or is alleged to result in, a personal injury to a patient, health care provider, or other user. Although we believe that as of the date of this Annual Report, we have adequate insurance to address anticipated potential liabilities associated with product liability, any unforeseen product liability exposure in excess of, or outside the scope of, such insurance coverage could adversely affect our financial condition and operating results. Any such claim brought against us, with or without merit, could result in significant damage to our business. Insurance coverage is expensive and difficult to obtain, and, although we currently have a five million dollar policy, in the future we may be unable to obtain or renew coverage on acceptable terms, if at all. If we are unable to obtain or renew sufficient insurance at an acceptable cost or if a successful product liability claim is made against us, whether fully covered by insurance or not, our business could be harmed. The FDA’s medical device reporting regulations require us to report any incident in which our product may have caused or contributed to a death or serious injury, or in which our product malfunctioned in a way that would be likely to cause or contribute to a death or serious injury if the malfunction reoccurred. Any required filing could result in an investigation of our product and possibly subsequent regulatory action against us if it is found that one of our products caused the death or serious injury of a patient.

Our Business Involves Environmental Risks. Our business involves the controlled use of hazardous materials, chemicals, biologics, and radioactive compounds. Manufacturing is extremely susceptible to product loss due to radioactive, microbial, or viral contamination; material or equipment failure; vendor or operator error; or due to the very nature of the product’s short half-life. Although we believe that our safety procedures for handling and disposing of such materials comply with state and federal standards, there will always be the risk of accidental contamination or injury. In addition, radioactive, microbial, or viral contamination may cause the closure of the manufacturing facility for an extended period of time. By law, radioactive materials may only be disposed of at state-approved facilities. At our leased facility we use commercial disposal contractors. If we obtain sufficient financing to relocate, we intend to shut down our leased manufacturing and office facility, finish the planning and construction of a new manufacturing and office facility to be owned by the Company, and move to the new manufacturing facility. Assuming it is constructed and licensed, we will incur costs related to the clean-up and disposal of hazardous materials, chemicals and radioactive components of the leased facility. While management believes it has reserved a sufficient amount of funds for this process, the Company may need more than the amount of the asset retirement obligation to meet the lease requirements and to receive clearance from the Washington State Department of Health. We may incur substantial costs related to the disposal of these materials. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages, and penalties that could harm our business.

In addition, certain environmental laws assess liability on current or previous owners or operators of real property for the costs of investigation, removal or remediation of hazardous substances or materials at their properties or at properties which they have disposed of hazardous substances. Liability for investigative, removal and remedial costs under certain U.S. federal and state laws are retroactive, strict and joint and several. In addition to cleanup actions brought by governmental authorities, private parties could bring personal injury or other claims due to the presence of, or exposure to, hazardous substances. The ultimate cost of site cleanup and timing of future cash outflows is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

Table of Contents

We Rely Upon Key Personnel. Our success will depend, to a great extent, upon the experience, abilities and continued services of our executive officers, sales staff and key scientific personnel. If we lose the services of several officers, sales personnel, or key scientific personnel, our business could be harmed. Our success also will depend upon our ability to attract and retain other highly qualified scientific, managerial, sales, and manufacturing personnel and their ability to develop and maintain relationships with key individuals in the industry. Competition for these personnel and relationships is intense and we compete with numerous pharmaceutical and biotechnology companies as well as with universities and non-profit research organizations. We are highly dependent on our direct sales organization who promote and support our brachytherapy product. There is intense competition for skilled sales and marketing employees, particularly for people who have experience in the radiation oncology market. Accordingly, we could find it difficult to hire or retain skilled individuals to sell our product. Failure to retain our direct sales force could adversely affect our growth and our ability to meet our revenue goals. There can be no assurance that our direct sales and marketing efforts will be successful. If we are not successful in our direct sales and marketing, our sales revenue and results of operations are likely to be materially adversely affected. We may not be able to continue to attract and retain qualified personnel.

Our Ability To Operate In Foreign Markets Is Uncertain. Our future growth will depend in part on our ability and the ability of our distributors to establish, grow and maintain sales in foreign markets. However, we have limited experience in marketing and distributing our product in other countries. Foreign operations subject us to additional risks and uncertainties, including our customers’ ability to obtain reimbursement for procedures using our product in foreign markets; the burden of complying with complex and changing foreign regulatory requirements; time-sensitive delivery requirements due to the short half-life of our product; language barriers and other difficulties in providing long-distance customer service; potentially increased time to collect accounts receivable; significant currency fluctuations, which could cause third-party distributors to reduce the amount of our product they purchase from us because the cost of our product to them could fluctuate relative to the price they can charge their customers; reduced protection of intellectual property rights in some foreign countries; and the possibility that contractual provisions governed by foreign laws would be interpreted differently than intended in the event of a contract dispute. In addition, the significant appreciation of the U.S. dollar during the past year has made our product much more expensive in overseas markets. Any future foreign sales of our product could also be adversely affected by export license requirements, the imposition of governmental controls, political and economic instability, trade restrictions, changes in tariffs, and difficulties in staffing and managing foreign operations. Many of these factors may also affect our ability to import Cesium-131 from Russia under our contract with JSC Isotope. Sanctions placed on financial transactions with Russian banking institutions may interfere with the Company’s ability to transact business in Russia on a temporary or other basis resulting in an interruption of the Cesium-131 supply which could have a temporary material adverse effect on the Company’s business, operating results and financial condition.

Our Ability To Expand Operations And Manage Growth Is Uncertain. Our efforts to expand our operations will result in new and increased responsibilities for management personnel and will place a strain upon the entire company. To compete effectively and to accommodate growth, if any, we may be required to continue to implement and to improve our management, manufacturing, sales and marketing, operating and financial systems, procedures and controls on a timely basis and to expand, train, motivate and manage our employees. There can be no assurance that our personnel, systems, procedures, and controls will be adequate to support our future operations. If the Cesium-131 seed were to rapidly become the “seed of choice,” it is unlikely that we could immediately meet demand. This could cause customer discontent and invite competition. There can be no assurance that our personnel, systems, procedures, and controls will be adequate to immediately react to that growth.

We Rely On The Performance Of Our Information Technology Systems And Those of Third Parties, The Failure Of Which Could Have An Adverse Effect On Our Business And Performance. Our business requires the continued operation of sophisticated information technology systems and network infrastructure. These systems are vulnerable to interruption by fire, power loss, system malfunction, computer viruses, cyber-attacks and other events, which may be beyond our control. Systems interruptions could reduce our ability to accept customer orders, manufacture our product, or provide service for our customers, and could have an adverse effect on our operations and financial performance. The level of protection and disaster-recovery capability varies from site to site, and there can be no guarantee that any such plans, to the extent they are in place, will be totally effective. In addition, security breaches of our information technology systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us, our employees, partners, customers, or our suppliers, which may result in significant costs and potential government sanctions. In particular, if we are unable to adequately safeguard individually identifiable health information, we may be subject to additional liability under domestic and international laws respecting the privacy and security of health information.

We also rely on third party vendors to supply and/or support certain aspects of our information technology systems. Third party systems may contain defects in design or manufacture or other problems that could result in system disruption or unexpectedly compromise the information security of our own systems, and we are dependent on these third parties to provide reliable systems and software and to deploy appropriate security programs to protect their systems.

If we are unable to maintain reliable information technology systems and prevent disruptions, outages, or data breaches, we may suffer regulatory consequences in addition to business consequences. We have programs to ensure compliance with such laws and regulations. However, there is no guarantee that we will avoid enforcement actions by governmental bodies. Enforcement actions may be costly and interrupt regular operations of our business. In addition, there has been a developing trend of civil lawsuits and class actions relating to breaches of consumer data held by large companies or incidents arising from other cyberattacks.

Our information technology systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving legal and regulatory standards, the increasing need to protect patient and customer information, and the information technology needs associated with our changing products and services. There can be no assurance that our process of consolidating, protecting, upgrading and expanding our systems and capabilities, continuing to build security into the design of our products, and developing new systems to keep pace with continuing changes in information processing technology will be successful or that additional systems issues will not arise in the future. Any significant breakdown, intrusion, interruption, corruption, or destruction of these systems, as well as any data breaches, could have a material adverse effect on our business. If our information technology systems, products or services or sensitive data are compromised, patients or employees could be exposed to financial or medical identity theft, and we could lose existing customers, have difficulty attracting new customers, have difficulty preventing, detecting, and controlling fraud, be exposed to the loss or misuse of confidential information, have disputes with customers, physicians, and other health care professionals, suffer regulatory sanctions or penalties under federal laws, state laws, or the laws of other jurisdictions, experience increases in operating expenses or an impairment in our ability to conduct our operations, incur expenses or lose revenues as a result of a data privacy breach, product failure, information technology outages or disruptions, or suffer other adverse consequences including lawsuits or other legal action and damage to our reputation.

Table of Contents

Fluctuations In Insurance Cost And Availability Could Adversely Affect Our Profitability Or Our Risk Management Profile. We hold a number of insurance policies, including product liability insurance, directors’ and officers’ liability insurance, and workers’ compensation insurance. The costs of our director and officer insurance policy premiums increased nearly 50% for fiscal year 2020. If the costs of maintaining adequate insurance coverage increase significantly in the future, our operating results could be materially adversely affected. Likewise, if any of our current insurance coverage should become unavailable to us or become economically impractical, we would be required to operate our business without indemnity from commercial insurance providers. If we operate our business without insurance, we could be responsible for paying claims or judgments against us that would have otherwise been covered by insurance, which could adversely affect our results of operations or financial condition.

We Have Incurred Significant Losses To Date, And There Is No Guarantee That We Will Ever Become Profitable. We incurred net losses of $5,144,000 and $6,700,000 in the fiscal years ended 2019 and 2018, respectively. In addition, we have accumulated deficit from the inception of business through June 30, 2019 of $84,492,000. The costs for research and product development of our product formats along with marketing and selling expenses and general and administrative expenses have been the principal causes of our losses. We may not ever become profitable.

Risks Related to Our Stock and Reporting Requirements

We May Need Additional Capital In The Future To Maintain Our NYSE American Listing. Our Common Stock is currently listed on the NYSE American stock exchange which will consider delisting a company’s securities if, among other things, the company fails to maintain minimum stockholder’s equity. With our existing cash reserves we believe we will not be able to maintain our listing on the NYSE American unless we raise capital in the next six to nine months assuming we maintain our projected budgeted expenses and contemplated level of revenues. In the event that our common stock is delisted from the NYSE American, trading, if any, in the common stock would be conducted in the over-the-counter market. As a result, our shareholders would likely find it more difficult to dispose of, or to obtain accurate quotations as to the market value of, our common stock.

Our Reporting Obligations As A Public Company Are Costly. Reporting requirements of a public company change depending on the reporting classification in which the Company falls as of the end of its second quarter of each fiscal year. The Company is currently a “smaller reporting company” which falls in the non-accelerated filer category of filer with a public float less than $250 million. If the Company were to be reclassified to the category of “accelerated filer,” the Company would have the additional requirement and cost of a Section 404 audit as part of its Form 10-K filing, as well as other expenses making the public reporting process more costly.

Table of Contents

Our Stock Price Is Likely To Be Volatile. The market price of our common stock has experienced fluctuations and is likely to fluctuate significantly in the future. For example, during fiscal 2019 the closing price of one share of our common stock reached a high of $1.07 and a low of $0.27. There is generally significant volatility in the market prices and limited liquidity of securities of companies which have failed to show profits. Contributing to this volatility are various events that can affect our stock price in a positive or negative manner. These events include, but are not limited to: governmental approvals or refusals to approve of regulations or actions; market acceptance and sales growth of our product; the viability of non-prostate products; litigation involving the Company or our industry; developments or disputes concerning our patents or other proprietary rights; changes in the structure of healthcare payment systems; departure of key personnel; future sales of our securities; fluctuations in our financial results or those of companies that are perceived to be similar to us; swings in seasonal demands of purchasers; investors’ general perception of us; and general economic, industry and market conditions. In addition, the securities of many medical device companies, including us, have historically been subject to extensive price and volume fluctuations that may affect the market price of their common stock. If any of these events occur, it could cause our stock price to fall.

The Price Of Our Common Stock May Be Adversely Affected By The Future Issuance And Sale Of Shares Of Our Common Stock Or Other Equity Securities. We cannot predict the size of future issuances or sales of our common stock or other equity securities for future acquisitions or capital raising activities, or the effect, if any, that such issuances or sales may have on the market price of our common stock. The issuance and sale of substantial amounts of common stock or other equity securities or announcement that such issuances and sales may occur, could adversely affect the market price of our common stock.

We Do Not Expect To Pay Any Dividends For The Foreseeable Future. We do not anticipate paying any dividends to our shareholders for the foreseeable future except for dividends on the Series B Preferred Stock, which we intend to pay on or before December 31, 2019. Shareholders must be prepared to rely on sales of their common stock after price appreciation to earn an investment return, which may never occur. Any determination to pay dividends in the future will be made at the discretion of our Board of Directors and will depend on our results of operations, financial conditions, contractual restrictions, restrictions imposed by applicable laws and other factors that our Board deems relevant.

Table of Contents

ITEM 2 – PROPERTIES

The Company’s executive offices are located at 350 Hills Street, Suite 106, Richland, WA 99354, where it leases approximately 15,300 square feet of office and laboratory space for approximately $24,100 per month plus janitorial expenses of approximately $440 per month from Energy Northwest, the owner of the Applied Process Engineering Laboratory (the APEL facility). The Company executed a modification to the existing lease in October 2015 that stipulates the tenant improvements, machinery, equipment and fixtures (TIs) are permitted to be abandoned at lease termination provided the facility is released by the Washington Department of Health. The modification also reduces the required notice to terminate early from twelve months to six months. In July 2019, the Company entered into another modification of the lease that extends the term to April 30, 2026, maintains the current rental rate through April 2020, and provides for an eighteen month termination notice with an early termination penalty of up to $40,000 which decreases each year. The Company is not affiliated with this lessor.

In the spring of 2017, the Company purchased an adjacent property of approximately 4.2 acres in anticipation of constructing a facility to meet its requirements for production, laboratory, and administrative offices. The new facility is anticipated to be a similar size to the current facility but the final design is dependent on anticipated future requirements. The property also provides for additional future building(s) as needed or subdivision, if required and is located within the Technology and Business Campus of the Port of Benton. While the Company has completed the design of the facility as of the date of this Report, the construction of the facility is subject to acceptable financing and other unanticipated factors which may influence such an operational decision.

The Company’s management believes that the facilities currently occupied by the Company are adequate for present requirements, and that the Company’s current equipment is in good condition and is suitable for the operations involved.

ITEM 3 – LEGAL PROCEEDINGS

Nothing to disclose.

Table of Contents

ITEM 4 –MINE SAFETY DISCLOSURES

Not applicable

PART II

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

The Company’s common stock is listed on the NYSE American under the symbol “ISR” and as of September 24, 2019 there were 67,388,047 shares outstanding.

The high and low sale prices as reported on the NYSE American for each quarter during the last two fiscal years are as follows:

Fiscal 2019	Q1		Q2		Q3		Q4
High	$	1.07	$	0.52	$	0.46	$	0.47
Low	$	0.43	$	0.27	$	0.32	$	0.37

Fiscal 2018	Q1		Q2		Q3		Q4
High	$	0.62	$	0.55	$	0.49	$	0.55
Low	$	0.51	$	0.39	$	0.40	$	0.39

Holders

As of September 24, 2019, there were approximately 230 common stockholders of record. The number of common stockholders was determined from the records of our stock transfer agent and does not reflect persons or entities that hold their shares in nominee or “street” name through various brokerage firms.

Dividends

The Company has never paid cash dividends on its common stock and does not plan to pay cash dividends on its common stock in the foreseeable future. Our Board of Directors anticipates that any earnings that might be available to pay dividends will be retained to finance operations.

Table of Contents

Securities Authorized for Issuance Under Equity Compensation Plans

On June 15, 2017, the Shareholders approved the 2017 Equity Incentive Plan (2017 Incentive Plan). The 2017 Incentive Plan allows the Board of Directors to grant up to 4,000,000 shares of common stock to directors, officers, employees and consultants in a combination of equity incentive forms including incentive stock options (ISO), non-qualified stock options (NQSO), stock appreciation rights (SAR) or restricted shares (RSU) of common stock. Options granted under all of the Plans have a ten year maximum term, an exercise price equal to at least the fair market value of the Company’s common stock (based on the trading price on the NYSE American) on the date of the grant, and varying vesting periods as determined by the Board.

As of June 30, 2019 the following options had been granted under the 2017 Incentive Plan and under prior stock option plans that have now expired.

Plan Category	Number of securities to be issued on exercise of outstanding options, warrants, and rights (a)		Weighted- average exercise price of outstanding options, warrants, and rights (b)		Number of securities remaining available for future issuance under equity compensation Plans (excluding securities in columns (a) and (b)
Equity compensation plans approved by shareholders		3,859,690	$	0.51		38,750
Equity compensation plans not approved by shareholders		785,625	$	1.29		-

Total		4,645,315	$	0.64		38,750

Performance Graph

As a smaller reporting company, the Company is not required to provide a performance graph.

Table of Contents

Sales of Unregistered Securities

Our sales of unregistered securities have been previously reported in our reports on Forms 8-K and 10-Q and filed with the SEC.

Issuer Purchases of Equity Securities

None.

ITEM 6 – SELECTED FINANCIAL DATA

As a smaller reporting company, the Company is not required to provide Item 6 disclosure in this Annual Report.

Table of Contents

ITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Critical Accounting Policies and Estimates

Management’s discussion and analysis of the Company’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent liabilities. On an on-going basis, management evaluates past estimates and judgments, including those related to bad debts, inventories, accrued liabilities, derivative liabilities, and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

Revenue Recognition

Revenue is generally realized or realizable and earned when there is persuasive evidence an arrangement exists, delivery has occurred or services rendered, the price is fixed and determinable, and collection is reasonably assured. The Company records revenue from its sales when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated.

Stock-Based Compensation

The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award.

Research and Development Costs

Research and development costs, including salaries, benefits, and share-based compensation, research materials, facility overhead, lab supplies, depreciation, administrative expenses and contractor fees, are charged to operations as incurred.

Legal Contingencies

The Company may, in the ordinary course of business, be involved in legal proceedings involving securities, contractual and employment relationships, product liability claims, patent rights, environmental matters, and a variety of other matters, the outcomes of which are not within the Company’s complete control and may not be known for extended periods of time. Legal costs associated with defending these matters are expensed as incurred.

The Company records a liability in its consolidated financial statements for damages and/or costs related to claims, settlements, and judgments where the Company has assessed that the loss is probable and an amount can be reasonably estimated.

Table of Contents

Results of Operations

Financial presentation

The following sets forth a discussion and analysis of the Company’s financial condition and results of operations for the fiscal years 2019, 2018, and 2017. This discussion and analysis should be read in conjunction with our consolidated financial statements appearing elsewhere in this Report. The following discussion contains forward-looking statements. Our actual results may differ significantly from the results discussed in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in “Item 1A — Risk Factors,” beginning on page 23 of this Report. (In thousands)

	For the years ended June 30,
	2019						2018						2019 - 2018			2017						2018 - 2017
	Amount			% (a)			Amount			% (a)			% Change			Amount			% (a)			% Change

Sales, net	$	7,314			100		$	5,923			100			23		$	4,761			100			24
Cost of sales		4,267			58			4,081			69			5			3,923			82			4
Gross profit (loss)		3,047			42			1,842			31			65			838			18			121

Operating expenses:
Research and development		1,429			20			1,351			23			6			771			16			75
Collaboration arrangement, net of reimbursement		45			1			395			7			(89	)		194			4			104
Sales and marketing		2,679			37			2,660			45			1			2,310			49			15
General and administrative		4,172			57			4,165			70			0			3,918			82			6
Change in estimate of asset retirement obligation (Note 9)		-			-			-			-						(48	)		(1	)
Gain on equipment disposal		(24	)		-			-			-						-			-
Total operating expenses		8,301			113			8,571			145			(3	)		7,145			150			20
Operating loss		(5,254	)		(72	)		(6,729	)		(114	)		(22	)		(6,307	)		(132	)		6

(a) Expressed as a percentage of sales, net

Sales

Fiscal 2019 sales, net increased 23% compared to fiscal 2018. The Company’s sales personnel continued to bring on new accounts while also working with existing customers to increase their order volumes. The Blu Build™ loader, while in a limited market release, also helped to increase revenues during fiscal 2019.

Fiscal 2018 sales, net increased 24% compared to fiscal 2017. Changes in sales personnel and implementation of a revitalized sales and marketing strategy has resulted in positive sales growth in fiscal 2018 when compared to the prior fiscal year. Ongoing training and support of new sales personnel has led to not only new accounts but also reconnecting with and receiving orders from prior accounts.

	For the years ended June 30,
	2019				2018				2019 - 2018		2017				2018 - 2017
Treatment	Amount		%(a)		Amount		% (a)		% Change		Amount		% (a)		% Change

Prostate Brachytherapy	$	6,488		89	$	5,097		86		27	$	4,173		88		22
Other sales		826		11		826		14		-		588		12		41
Sales, net	$	7,314			$	5,923				23	$	4,761				24

(a) Expressed as a percentage of sales, net

Prostate Brachytherapy.

Prostate sales growth of approximately 27% in fiscal 2019 was achieved due to a sustained focus on acquiring new accounts through physician training programs and marketing campaigns along with continued support of existing customers to help them grow their business. While in a limited market release, the Blu Build™ loader also contributed to prostate revenue growth as it was sold to new customers that desired the intraoperative loader system. The Company continues to update its website and other marketing collateral as well as attending tradeshows to acquire new leads for our sales personnel. Also, the website along with some social media campaigns have been used to educate patients about the availability of Cesium-131 as a treatment option.

Management believes continued growth in prostate brachytherapy revenues will be the result of physicians, payors, and patients increasingly considering overall treatment advantages including costs compared with non-brachytherapy treatments, better treatment outcomes and improvement in the quality of life for patients but there is no assurance as to the timing of a recovery in use of brachytherapy as a whole.

Table of Contents

Management believes increased pressure to deliver effective healthcare in both terms of outcome and cost drove treatment options in fiscal 2019 with prostate brachytherapy receiving more consideration than in previous years.

Other Sales.

Other sales include but is not limited to brain, lung, head/neck, gynecological, pelvic treatments, and services. Other sales remained flat in fiscal 2019. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable.

Other brachytherapy treatments are subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and varies significantly from year to year. Additionally, with other brachytherapy surgical procedures there remains inconsistency and uncertainty regarding reimbursement for the procedures. This unreliable reimbursement for these new procedures will remain until specific coding and coverage policies are established, which could take years. Individual centers weigh the value of the procedure with their other treatment priorities on a patient by patient basis. Isoray believes that additional clinical data will begin to build a compelling argument to support reimbursement and increased adoption of the procedures; however, any growth will be inconsistent in the near term.

GammaTile™

For several years the Company has focused on many different applications of its Cesium-131 brachytherapy seeds in the cranial cavity to target many forms of brain cancer. Most recently, the Company has focused on using braided strand configurations and on a potential collaboration with GammaTile, LLC, now known as GT Medical Technologies, Inc. (GT Med Tech), which has a technology which use biodegradable “tiles” to deliver the Cesium-131 brachytherapy seeds into contact with cancerous tumors in the brain.

Since January 2019, GammaTile™ Therapy has been in a limited market release and total revenues from sales to GT Med Tech have been nominal. While GT Med Tech continues to assure Isoray that its sales and marketing efforts will show steady improvements in sales there is no assurance this will occur.

Table of Contents

Cost of sales

Cost of sales consisted primarily of the costs of manufacturing and distributing the Company’s products. The fiscal 2019 increase was primarily due to higher sales volumes that led to increased labor expenses and non-isotope materials costs offset by decreased isotope costs. Labor expenses increased by $103,000 as the Company had more production volume due to higher sales. Non-isotope materials also increased by $141,000 due to increased sales volume and an increase in the ratio of preloaded seeds (stranded, Blu Build™, etc.) compared to loose seeds sold. Beginning in the first quarter of 2019, the Company reduced the amount of Cesium-131 provided by the MURR reactor by approximately thirty-five percent. After a thorough review of the capacity and quality of production at the MURR facility, the Company determined to terminate its supply agreement with MURR and the last shipment of isotope from MURR was received in January 2019. These changes led to a $98,000 decrease in isotope cost during fiscal 2019 compared to fiscal 2018 despite increased sales volumes. In addition, depreciation increased by $48,000 due to completed automation projects placed into service at the end of fiscal 2018 and for which depreciation expense was recognized throughout fiscal 2019.

The fiscal 2018 increase is primarily the result of increased isotope orders to meet production demand due to improved sales. These cost increases were partially offset by decreases to payroll, benefits, and share-based compensation resulting from a reduction in the number of full time employees as well as a re-allocation of resources to assist in research and development activities.

During both fiscal 2018 and 2019, the Company purchased isotope in excess of known customer orders to provide enough isotope to fill anticipated orders which may or may not materialize. The excess isotope is utilized in the production of upcoming orders where possible considering the decay rates of Cesuim-131. Any loss of isotope to decay is also included as a cost of production during the current period.

Research and development expenses

Research and development consisted primarily of the costs related to employee and third-party research and development activities. The decrease in fiscal 2019 compared to fiscal 2018 was mainly due to reduced expenses related to the Collaborative Development Agreement with GT Med Tech offset by increased spending on the Blu Build™ loader development. Beginning in April 2018 costs were no longer shared equally as had been done historically and GT Med Tech was responsible for more than 50% of the costs. The Company stopped sharing costs with GT Med Tech related to the development of GammaTile™ in December 2018 when the product entered a limited market release. These factors led to a decrease of $350,000 in fiscal 2019. Costs related to the development of the Blu Build™ loader and associated equipment increased by $106,000 during fiscal 2019 as the development continued throughout the limited market release of the product.

Contributing to the fiscal 2018 increase were re-allocating resources from cost of sales to assist with research and development projects, payroll, benefits, and share-based compensation expense, costs associated with the development of Blu-Build™ delivery system for real-time prostate brachytherapy, protocol expense, as well as an increase related to the collaborative agreement with GT Med Tech.

Sales and marketing expenses

Sales and marketing expenses consist primarily of the costs related to the internal and external activities of the Company’s sales, marketing and customer service division. The fiscal 2019 increase was due to increased payroll of $88,000 due to an increase in headcount offset by smaller increases in other categories such as postage and office supplies totaling $13,000. This increase was offset by decreased tradeshow expenses of $43,000 as the Company limited its attendance to those tradeshows that it felt were most advantageous and decreased marketing expenses of $52,000 as the Company spent more in fiscal 2018 to revamp its brand image, website, and marketing materials.

The fiscal 2018 increase is primarily due to increased payroll, benefits, and share-based compensation and travel for sales activities.

Table of Contents

General and administrative expenses

General and administrative expenses consist primarily of the costs related to the executive, quality assurance and regulatory affairs (QA/RA), finance, human resources and information technology functions of the Company. During fiscal 2019 general and administrative expenses increased only slightly over fiscal 2018. Items that increased included QA/RA materials and supplies expense by about $93,000 mainly due to increased production volumes, legal fees by approximately $30,000 primarily related to review of Company agreements, commercial insurance expense by about $38,000 primarily related to increased D&O insurance premiums, other taxes by almost $80,000 from an accrual relating to an audit of the State of Washington Hazardous Substance Tax, other expenses by about $50,000 relating to an accrual based on negotiations with a former consultant, and proxy solicitation fees of about $80,000 associated with redomiciling the Company to Delaware. These increases were offset by decreases in public company expenses of approximately $274,000 (of which $204,000 was non-cash warrant expense) as a result of changing some investor and media relation vendors which lead to significant savings and lower board fees of almost $24,000 due to fewer meetings,

The fiscal 2018 increase is due primarily to investor relations expenses, severance, and payroll, benefits, and share-based compensation partially offset by decreased legal fees.

Liquidity and capital resources

The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During fiscal 2019 the Company used cash raised in July 2018 by selling equity to investors along with existing cash reserves from prior capital raises to fund its operations and capital expenditures. During fiscal 2018 and 2017 the Company used existing cash reserves from prior capital raises to fund its operations and capital expenditures.

Our cash flows for fiscal 2019, 2018, and 2017 respectively, are summarized as follows (in thousands):

	For the years ended June 30,
	2019			2018			2017

Net cash used by operating activities	$	(5,049	)	$	(5,712	)	$	(5,712	)
Net cash provided by investing activities		401			1,859			1,514
Net cash provided by financing activities		7,374			521			(9	)
Net increase (decreases) in cash and cash equivalents	$	2,726		$	(3,332	)	$	(4,207	)

	As of June 30,
	2019		2018		2017

Working Capital	$	6,194	$	3,611	$	9,185
Current Ratio		6.53		2.97		9.30

Cash flows from operating activities

Net cash used by operating activities in fiscal 2019 was primarily due to a net loss of $5.14 million net of approximately $613,000 in adjustments for non-cash activity such as depreciation and amortization expense, the accretion of asset retirement obligation, and share-based compensation. Changes in operating assets and liabilities contributed approximately $518,000 to the cash used by operating activities.

Net cash used by operating activities in fiscal 2018 was primarily due to a net loss of $6.7 million net of approximately $767,000 in adjustments for non-cash activity such as depreciation and amortization expense, the accretion of asset retirement obligation, and share-based compensation. Changes in operating assets and liabilities contributed approximately $221,000 in the cash used by operating activities.

Net cash used by operating activities in fiscal 2017 was primarily due to a net loss of $6.16 million net of approximately $433,000 in adjustments for non-cash activity such as depreciation and amortization expense, the change in estimate of asset retirement obligation, the change in fair value of the warrant derivative liability, and share-based compensation. Changes in operating assets and liabilities contributed approximately $17,000 in the cash used by operating activities.

Also included in operating activities in fiscal 2017 is the one-time payment of $195,000 for settlement of litigation that was not covered by insurance.

Table of Contents

Cash flows from investing activities

Investing activities for all years are presented by primary transaction category. Investing activities consisted of transactions related to the purchase of fixed assets as well as the purchase and subsequent maturity of certificates of deposit. Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest and reinvest maturing certificates of deposit in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.

Included in investing activities in fiscal 2017 is a payment of $197,900 for the default of the development plan for the land purchased from the Port of Benton. See Property Transaction between Medical and The Port of Benton of Note 15 to the consolidated financial statements contained in this Form 10-K.

Cash flows from financing activities

Financing activities for all years are presented by primary transaction category. Financing activities in fiscal 2019, 2018, and 2017 were primarily due to sales of common stock through a registered direct offering, net, an at the market offering, net, and warrant and option exercises net of preferred dividends paid. Financing activities were significantly increased in fiscal 2019 compared to 2018 and 2017 due to the registered direct offering, net.

Projected 2020 Liquidity and Capital Resources

Operating activities

Management forecasts that fiscal 2020 cash requirements will be similar to previous years and that current cash and cash equivalents will be sufficient to meet projected operating cash needs for the next eighteen months. While monthly operating expenses are budgeted to increase for sales and marketing and decrease for general and administrative expenses, management believes the total monthly expense amount will not substantially change. Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy to focus on renewed emphasis to drive the consumer to the prostate market and meets or exceeds its growth targets of twenty percent increase in revenue in fiscal 2020 and this annual growth continues, the Company anticipates reaching cashflow break-even in three to four years. These assumptions do assume that GammaTile™ will contribute to total revenue but do not incorporate any significant growth in the other non-prostate applications as they generate nominal revenues today but if they show significant improvement, cashflow break-even could occur sooner. There is no assurance that the targeted sales growth will materialize but management is encouraged by the depth and experience of its sales team and its track record of growth during the last two fiscal years.

Capital expenditures

Management has completed the design of a future production and administration facility. If financing is obtained and the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility.

Management is reviewing all aspects of production operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive sales.

During fiscal 2019, the Company invested approximately $291,000 in the automation of production processes. Beginning in fiscal 2017 and continuing through fiscal 2019, the Company has invested approximately $840,000 in the automation of five production processes, four of which have been placed in service as of the end of fiscal 2019. Management expects to invest approximately $100,000 more over the next six months on the remaining automation projects, but there is no assurance that this amount will not be revised. This investment is designed to allow the Company to significantly increase the output of Cesium-131 brachytherapy seeds, while allowing the Company to decrease the labor costs related to seed production and also improving the overall safety of our operations.

Financing activities

There was no material change in the use of proceeds from our public offering as described in our final prospectus supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through June 30, 2019, the Company had used the net proceeds raised through the March 2014 offering as described in the public offering. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

Table of Contents

On May 8, 2018, the Company entered into a Sales Agreement with H.C. Wainwright & Co., LLC (“Wainwright”). The common stock sold in the Sales Agreement was distributed at the market prices prevailing at the time of sale. As of June 30, 2018, the Company had sold an aggregate of 980,918 shares under the Sales Agreement at an average price of approximately $0.515 per common share for gross proceeds of approximately $505,000, pursuant to the registration statement on Form S-3 that became effective on November 23, 2015. Net proceeds from this raise totaled approximately $478,000. No additional sales were made in July 2018 and this offering was suspended on July 9, 2018.

On July 11, 2018, the Company sold 11,000,000 shares of its common stock at a price of $0.75 per share, for aggregate gross proceeds of $8.25 million, pursuant to the registration statement on Form S-3 that became effective on November 23, 2015. There was no material change in the use of proceeds from our public offering as described in our prospectus supplement filed with the SEC pursuant to Rule 424(b) on July 11, 2018. Through June 30, 2019, the Company had used the net proceeds raised through the July 11^th offering as described in the prospectus supplement. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

On October 19, 2018, the Company filed a Form S-1 registration statement for the registration of 5,830,000 shares of common stock to be received by the investors and representatives of Wainwright on exercise of warrants issued in connection with the registered direct offering completed on July 11, 2018. The Company may receive up to $4,434,375 in gross proceeds solely to the extent the warrants are exercised for cash. The Form S-1 registration statement became effective on December 14, 2018.

When it does require capital in the future, the Company expects to finance its cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders, Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.

Other Commitments and Contingencies

The Company’s purchase commitments and obligations include all open purchase orders and contractual obligations entered into in the ordinary course of business, including commitments with contract manufacturers and suppliers, for which we have not received the goods or services and acquisition and licensing of intellectual property. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us the option to cancel, reschedule, and/or adjust our requirements based on our business needs prior to the delivery of goods or performance of services. Non-cancellable purchase commitments and obligations that will exist beyond fiscal 2019 and that are not separately presented as a liability on the balance sheet are listed below (in thousands):

			Less than		1 – 3		3 – 5		More than 5
Contractual obligations	Total		1 year		years		years		years
Operating lease obligations	$	531	$	290	$	241	$	-	$	-
Seed core purchase obligation		164		164		-		-		-
Asset retirement obligation		621		-		621		-		-
Total	$	1,316	$	454	$	862	$	-	$	-

Table of Contents

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Impact of Inflation

Inflation had minimal impact on our net sales and revenues or on loss from continuing operations.

New Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 Revenue Recognition, replacing guidance currently codified in Subtopic 605-10 Revenue Recognition-Overall with various SEC Staff Accounting Bulletins providing interpretive guidance. The guidance establishes a new five step principle-based framework in an effort to significantly enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The standard became effective for the Company in the first quarter of its fiscal year 2019. The Company adopted the new standard in the first quarter of fiscal year 2019 and used the modified retrospective method. The adoption of ASU 2014-09 did not have a material impact on the consolidated financial statements of the Company and did not significantly change the timing of revenue recognition compared to the previous methodology.

In February 2016, the FASB issued ASU 2016-02 Leases (Subtopic 842), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The modified retrospective transition approach is required. The ASU will be effective for the Company in the first quarter of fiscal year 2020 and the most significant effects of this ASU relate to the recognition of a new right-of-use asset and corresponding lease liability.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Table of Contents

ITEM 7A – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, the Company is not required to provide Item 7A disclosure in this Annual Report.

ITEM 8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Information required by this Item 8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page 68 of this Report.

ITEM 9 – CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

There were no disagreements or reportable events with DeCoria, Maichel & Teague, P.S.

ITEM 9A – CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and co-principal financial officers, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act), as of June 30, 2019. Based on that evaluation, our principal executive officer and our co-principal financial officers concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met.

Management’s Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance concerning both the reliability of our financial reporting and the preparation of our financial statements in accordance with generally accepted accounting principles. This control includes policies and procedures that obligate us to maintain reasonably detailed records that accurately and fairly reflect our transactions and the disposition of our assets, provide assurance that our transactions are properly recorded, ensure that our receipts and expenditures are authorized by management and, where applicable, our board of directors, and prevent or allow us to timely detect material unauthorized acquisitions, uses or dispositions of our assets.

We have evaluated the effectiveness of our internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control Integrated Framework (2013). This evaluation was performed under the supervision and with the participation of our management, including our chief executive officer and our co-principal financial officers and principal accounting officer, all of whom concluded that our internal control over financial reporting was effective as of June 30, 2019. Our evaluation of the effectiveness of our internal control over financial reporting in future periods may differ due to changing conditions or non-compliance with the policies and procedures we have established.

Table of Contents

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B – OTHER INFORMATION

Not applicable

PART III

ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Board Membership and Board Committees

The directors serving the Company as of June 30, 2019 were as follows:

Audit

Compensation

Nominations

Litigation

Name

Type

Age

Committee

Lori Woods, Chief Executive Officer

Employee

N/A

Philip Vitale, MD

Independent

Member

Chairman

Member

N/A

Alan Hoffmann

Independent

Chairman

Member

Chairman

Michael McCormick, Chairman

Independent

Member

Chairman

Member

Each member of the Board of Directors serves a one-year term and is subject to reelection at the Company’s Annual Meeting of Shareholders held each year.

The Company’s directors, as named above, will serve until the next annual meeting of the Company’s shareholders or until their successors are duly elected and have qualified. Directors will be elected for one-year terms at the annual shareholders meeting. There is no arrangement or understanding between any of the directors or officers of the Company and any other person pursuant to which any director or officer was or is to be selected as a director or officer, and there is no arrangement, plan or understanding as to whether non-management shareholders will exercise their voting rights to continue to elect the current directors to the Company's board. There are also no arrangements, agreements or understandings between non-management shareholders that may directly or indirectly participate in or influence the management of the Company’s affairs.

Table of Contents

Lori Woods – Ms. Woods has been a Director of the Company since June 4, 2018 and brings more than 30 years of experience in the healthcare industry and is particularly well-known and respected in the brachytherapy community. Ms. Woods returns to Isoray after previously serving as Vice President from 2006 to February 2008 at which time she was appointed Acting Chief Operating Officer before her appointment to Chief Operating Officer in February 2009, a position she held until January 2010. Beginning in February 2016, and continuing until her appointment as Interim CEO on June 4, 2018, Ms. Woods served as a senior consultant to Isoray. Ms. Woods was appointed CEO of the Company on December 12, 2018. From February 16, 2016 to June 3, 2018, Ms. Woods was a founder of Medvio, LLC, a medical device consulting company focused on the urology and oncology space. During her time at Medvio she worked with large public and international medical device companies, supporting the approval process and distribution of products in diverse international markets. Further, she worked with various partners to develop proprietary technologies for the colorectal and liver treatment markets. Previously from January 2002 to July 2006, Ms. Woods served as Chief Executive Officer of Pro-Qura, Inc., a privately-owned cancer treatment management company focused on the quality delivery of brachytherapy treatments for prostate cancer. She has also served as the Director of Business Development for the Tumor Institute Radiation Oncology Group and the Seattle Prostate Institute (SPI) in Seattle, WA. SPI was an early innovator in prostate brachytherapy treatments and assisted in the training of more than 2,000 physicians in the use of prostate brachytherapy. Ms. Woods served as a board member of the Northwest division of the Juvenile Diabetes Research Foundation, focusing on their digital awareness programs, including their website and SEO strategy, and their public relations efforts. Ms. Woods earned a Bachelor of Science degree in Business Administration – Marketing and Communications from Loma Linda University, CA. Ms. Woods brings to the Board extensive experience and credibility in the brachytherapy industry and strong relationships with suppliers and distributors of brachytherapy products.

Philip Vitale, MD – Dr. Vitale has been a Director of the Company since 2014 and is a board certified urologist. He practiced Urology from 1978 to 2005 at Lovelace Health Systems in Albuquerque. He also served on the Board of Governors for 9 years and held various administrative positions including Chief Medical Officer and Senior Vice President at Lovelace. He was a staff urologist at Albuquerque VA Medical Center from 2005 until his retirement in November 2014. He served as Chief of the Urology section from 2008 to November 2013. Dr. Vitale was also an Assistant Professor at the University of New Mexico, Division of Urology. He is a member of the American Urological Association and the South Central Section of the American Urological Association. Prior to his retirement, Dr. Vitale’s clinical trials included: chemotherapy after prostatectomy (cap); a phase III randomized study for high risk prostate carcinoma; RTOG 0415 a phase III randomized study of hypofractionated 3d-crt/IMRT versus conventionally fractionated 3d-crt/IMRT in patients with favorable-risk prostate cancer; RTOG 0815 a phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer; and YP19A1 gene and pharmacogenetics of response to testosterone therapy. Dr. Vitale holds a B.A. in Biology from LaSalle College and obtained his M.D. from the New Jersey College of Medicine and Dentistry. He received his M.S. in Health Services Administration from the College of St. Francis. Dr. Vitale brings to the Board medical expertise in the industries the Company is targeting.

Alan Hoffmann – Mr. Hoffmann has been a Director of the Company since January 2016. He is the owner of Alan Hoffmann, CPA, PC, a certified public accounting firm he founded in 1996. The firm performs audits and reviews of private companies. In addition, Mr. Hoffmann currently serves as CFO for Cognitive Research Corporation, a privately-held, full-service contract research organization that specializes in central nervous system product development for pharmaceutical, nutraceutical, biotechnology and medical device companies. In 2011, he served as CFO for an international manufacturing company, Kinematics Manufacturing, Inc. His prior employment included Price Waterhouse from 1985-1989, and local firms in Arizona from 1989 to 1996, where he held multiple positions including Senior Tax Analyst, and Tax Manager. After receiving his undergraduate accounting degree with honors from the University of Wisconsin-Milwaukee in 1985, he became a Certified Public Accountant in 1989. He also served in the United States Marine Corps and was honorably discharged in 1985. He brings over 27 years of public accounting experience to the Company and the Board. Mr. Hoffmann brings to the Board his experience as a public accountant and understanding of oversight and review of financial statements prepared by the Chief Financial Officer.

Michael McCormick – Mr. McCormick has been a Director of the Company since June 2015 and brings over 25 years of senior executive positions in global management, sales, and marketing to the Company. He was appointed Chairman of the Board effective as of June 4, 2018. He serves as a founder and partner of GO Intellectual Capital, which offers marketing services with a focus on the medical and aviation industries, as well as financial services. Previous to his service with GO, Mr. McCormick served as Executive Vice President of Global Sales and Marketing for Columbia Sportswear from 2006-2012, where his team successfully launched several new patented technologies, including Omni-Heat® Reflective and Omni-Freeze® Zero. During Mr. McCormick’s tenure, Columbia built an intellectual property portfolio with over 200 patents. Mr. McCormick started his career with Nike, working in several senior management roles and ultimately becoming the Director of National Sales, U.S., prior to his departure in 1999. He also served as Chief Marketing Officer of Golf Galaxy from 2003-2006 and Executive Vice President of Global Sales and Marketing of Callaway Golf from 2000-2003. Mr. McCormick brings over 26 years of marketing experience in a diverse group of industries to his service on the Company’s Board.

Table of Contents

Executive Officers

The executive officers serving the Company as of September 24, 2019 were as follows:

Name	Age	Position Held
Lori Woods¹	57	Chief Executive Officer, Director
Jonathan Hunt	52	Chief Financial Officer, Co-Principal Financial Officer
Mark Austin	32	Controller, Co-Principal Financial and Principal Accounting Officer
William Cavanagh III	53	Chief Research and Development Officer
Michael Krachon	48	Vice President, Sales and Marketing
Jennifer Streeter²	50	Vice President, Human Resources, Interim Chief Operating Officer
Krista Cline	37	Director of Operations, Corporate Secretary

	1.	The Board of Directors appointed Lori Woods as Interim Chief Executive Officer and Director on June 4, 2018. On December 12, 2018, the Board of Directors appointed Ms. Woods as Chief Executive Officer and Director. Ms. Woods’ biographical information is incorporated by reference in the board membership section of Part III, Item 10.
	2.	Effective July 19, 2019, Mrs. Streeter was appointed Interim Chief Operating Officer.

Jonathan Hunt – Mr. Hunt was appointed as Chief Financial Officer of the Company on December 3, 2018. On February 12, 2019, Mr. Hunt was appointed as Co-Principal Financial Officer. Before joining the Company, Mr. Hunt was Chief Financial Officer at Vivid Learning Systems, an online safety training company, from 2009 to 2018, where he had a central role in its turnaround, including growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the business. Mr. Hunt previously served as Chief Financial Officer of the Company from 2006 to 2009. Prior to that, Mr. Hunt worked at Hypercom Corporation, a global provider of electronic payment solutions and manufacturer of credit card terminals, where he served as Assistant Corporate Controller from 2005 to 2006. Mr. Hunt holds a Bachelor of Science, Accountancy, and a Masters of Accountancy degree from Brigham Young University.

Mark Austin – Mr. Austin has served as Controller, Principal Financial and Accounting Officer, since July 2017 and Co-Principal Financial Officer since February 12, 2019. Prior to joining the Company, Mr. Austin practiced as a Certified Public Accountant with the accounting firm KPMG where he worked from October 2009 to July 2017. At KPMG, Mr. Austin served as a Senior Manager and before that, as a Manager and Senior Associate in Portland, Oregon, where he served as lead for financial statement and internal control audits within the technology industry, including for software and manufacturing companies. While at KPMG, Mr. Austin served as lead manager for a global public company; supervised, coached, and lead teams and team members; and researched technical accounting issues relevant to the technology industry. Mr. Austin holds a Bachelor of Science in Commerce degree in Accounting, from Santa Clara University, in Santa Clara, California.

William Cavanagh III – Mr. Cavanagh joined Isoray Medical, Inc. in January 2010 and served as Vice President, Research and Development until March 3, 2016, other than serving as interim Chief Executive Officer for Isoray from January 7, 2016 to February 14, 2016. He was appointed Chief Operating Officer of Isoray effective March 3, 2016 and Chief Scientific Officer effective August 15, 2016 and served in these positions until February 12, 2019. On February 12, 2019, Mr. Cavanagh was appointed to the position of Chief Research and Development Officer. Immediately prior to joining Isoray Medical, Mr. Cavanagh was engaged in the research and development of dendritic cell therapies for cancer and infectious diseases. He served as Chief Scientific Officer for Sangretech Biomedical, LLC for the six years prior to joining Isoray Medical. At Sangretech, he oversaw the design and implementation of a novel cancer therapy. Mr. Cavanagh began his extensive career in cancer treatment technologies in the early 1990s, when he helped lead research and development of a therapy involving the insertion of radioactive sources directly into the prostate for the treatment of prostate cancer (prostate brachytherapy). He has designed several cancer treatment-related studies, is listed as an author on 34 peer-reviewed publications and is the listed inventor on a U.S. patent application detailing a novel treatment for cancer. Mr. Cavanagh has also served as Director of the Haakon Ragde Foundation for Advanced Cancer Studies in Seattle, Washington, where he led the research foundation in the selection of viable research projects directed at treating advanced cancers. Mr. Cavanagh holds a B.S. in Biology from the University of Portland (Oregon) and attended two years of medical school before beginning his career in research management.

Table of Contents

Michael Krachon – Mr. Krachon brings more than 20 years’ experience of progressive growth in sales and marketing in the medical industry to the Company. He joined Isoray in March 2016 as Vice President, Sales and Marketing. Prior to joining Isoray, Mr. Krachon was employed by C.R. Bard Inc. since 2001, and was a key member of the Bard Urological and Medical Division which developed brachytherapy devices and delivery systems for the U.S. and international markets. He was the leader of the brachytherapy commercial team, which grew to be the global brachytherapy market leader. Mr. Krachon assisted in the business unit’s strategic planning, development of the international business segment and creating and delivering the international product launches which resulted in market leadership across Europe, Japan and Africa. His responsibilities included: the development of strategic brachytherapy sales and marketing programs; the implementation of industry leading national and international training programs; and supporting the product development process. Finally, Mr. Krachon has been instrumental in successfully supporting the industry through congressional lobbying efforts to establish and maintain reimbursement codes for brachytherapy. He served as Chairman of the Coalition for Advancement of Brachytherapy from 2009 to 2016 and has been recognized as a national speaker for brachytherapy by the industry. Mr. Krachon received a B.S.E. in biomedical engineering from Duke University and his M.B.A. from the Goizueta Business School at Emory University.

Jennifer Streeter – Mrs. Streeter brings more than 10 years’ experience of progressive growth in the Human Resources field. She joined Isoray in July 2016 as Vice President of Training. In September 2016, she accepted responsibility as Vice President of Human Resources. Effective July 19, 2019, she was appointed Interim Chief Operating Officer. Prior to joining Isoray, Mrs. Streeter was employed by Supershuttle International as the Vice President of Learning Development, where she led a team of training managers providing overall training and organizational development activities. Mrs. Streeter was employed by Supershuttle International from 2010 to 2016. Previously Mrs. Streeter has facilitated both on ground and online courses at the undergraduate and graduate levels for universities including Grand Canyon University, Ottawa University and Western International University. The courses focused on Human Resource and Organizational Development. Mrs. Streeter received her Bachelor’s Degree in Management/Marketing and her Master’s Degree in Leadership Studies from Baker College, in Michigan.

Krista Cline – Ms. Cline joined Isoray Medical in 2005 and has since held multiple senior management positions. In January 2016, Ms. Cline was appointed Director of Operations and in July 2018, Ms. Cline was appointed Senior Director of Operations. She also functions as Isoray’s corporate secretary. Ms. Cline has guided many of Isoray’s operational improvements and milestones including: automation, 510(k) clearances and CE Marks, and FDA and ISO audits of Isoray’s products. Her strong commitment to fostering innovation, leadership and her understanding of business strategies have propelled her into her current management role. At Isoray, she is responsible for the overall management and execution of the manufacture and distribution of Isoray’s products. Ms. Cline also assists in the coordination of multiple projects for new product development. She holds a Bachelor of Science in Biochemistry from Washington State University.

There are no agreements or understandings for any officer or director to resign at the request of another person, and none of the officers or directors is acting on behalf of, or will act at the direction of, any other person. There are no family relationships among our executive officers and directors.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires the Company’s directors and executive officers, and persons who beneficially own more than ten percent of a registered class of our equity securities, to file with the SEC initial reports of beneficial ownership and reports of changes in beneficial ownership of our Common Stock. The rules promulgated by the SEC under Section 16(a) of the Exchange Act require those persons to furnish us with copies of all reports filed with the SEC pursuant to Section 16(a). The information in this section is based solely upon a review of Forms 3, Forms 4, and Forms 5 received by us.

We believe that Isoray’s executive officers, directors and 10% shareholders timely complied with their filing requirements during the year ended June 30, 2019, except as follows – Jonathan Hunt (one Form 3 and one Form 4 with one transaction each), Krista Cline (one Form 3 and one Form 4). These Form 3s and Form 4s were filed late.

Code of Ethics

We have adopted a Code of Conduct and Ethics that applies to all of our officers, directors and employees and a separate Code of Ethics for Chief Executive Officer and Senior Financial Officers that supplements our Code of Conduct and Ethics.

The Code of Conduct and Ethics was previously filed as Exhibit 14.1 to our Form 10-KSB for the period ended June 30, 2005, and the Code of Ethics for Chief Executive Officer and Senior Financial Officers was previously filed as Exhibit 14.2 to that same report. The Code of Ethics for Chief Executive Officer and Senior Financial Officers is also available to the public on our website at http://www.isoray.com/about/investors/. Each of these policies comprises written standards that are reasonably designed to deter wrongdoing and to promote the behavior described in Item 406 of Regulation S-K promulgated by the Securities and Exchange Commission. Any amendments to or waivers of the Codes will be promptly posted on our website at www.isoray.com or in a Report on Form 8-K, as required by applicable laws.

Table of Contents

Nominating Procedures

There have been no material changes to the procedures by which our shareholders may recommend nominees to the Board of Directors during our last fiscal year.

Audit Committee

The Company has a separately designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Exchange Act. The Audit Committee was established on December 8, 2006, the date on which its Charter was adopted. The Audit Committee Charter lists the purposes of the Audit Committee as overseeing the accounting and financial reporting processes of the Company and audits of the financial statements of the Company and providing assistance to the Board of Directors in monitoring (1) the integrity of the Company’s financial statements, (2) the Company’s compliance with legal and regulatory requirements, (3) the independent auditor’s qualifications and independence, and (4) the performance of the Company’s internal audit function, if any, and independent auditor.

Mr. Vitale, Mr. Hoffman, and Mr. McCormick are each members of the Audit Committee. The Board of Directors has determined that Mr. Hoffmann is an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K promulgated by the SEC, and each Audit Committee member is independent under applicable NYSE American standards. The Board’s conclusions regarding the qualifications of Mr. Hoffmann as an audit committee financial expert were based on his service as a chief financial officer, his experience as a certified public accountant and his degree in accounting.

ITEM 11 – EXECUTIVE COMPENSATION

The following summary compensation table sets forth information concerning compensation for services rendered in all capacities during our past two fiscal years awarded to, earned by or paid to each of the following individuals. Salary and other compensation for these officers are set or recommended to the Board by the Compensation Committee.

Summary Compensation Table


						Non-equity
Name and				Option		incentive plan		All other
principal		Salary³		awards		compensation		compensation		Total
position	Year	($)		($)¹		($)		($)²		($)
Lori Woods	2019		315,612		74,700		15,781		10,431		416,524
CEO and Director	2018		23,064		83,875		971		-		107,911
William Cavanagh	2019		220,256		44,820		11,013		33,617		309,706
CRDO	2018		211,785		50,325		25,414		-		287,524
Michael Krachon	2019		243,338		44,820		12,167		26,508		326,833
VP – S&M	2018		236,250		50,325		28,350		-		314,925

Amounts represent the ASC 718, Compensation – Stock Compensation valuation for the fiscal years 2019 and 2018, respectively. Options awarded vest in three to five equal annual installments and expire ten years after the date of grant. All options were granted at the fair market value of the Company’s stock on the date of grant and the Company used a Black-Scholes methodology as discussed in the footnotes to the financial statements to value the options.

	2.	During fiscal year 2019, the vacation policy was changed for these individuals to an unlimited vacation policy with no accrual. The amounts represent vacation accrued under the prior policy. Mr. Cavanagh’s includes $10,000 to assist with his relocation to Richland, WA.

	3.	In June 2019, the Compensation Committee of the Company set the annual base salary for fiscal 2020 for Lori Woods, our Chief Executive Officer and Director, at $315,612 (no increase), for William Cavanagh, Chief Research and Development Officer, at $220,256 (no increase) and for Michael Krachon, our Vice President Sales and Marketing, at $243,337 (no increase).

Table of Contents

Outstanding Equity Awards at Fiscal Year-End

Option awards

Equity Incentive Plan awards:

Number of

securities

underlying

unexercised

Option

options

exercise

Option

(#)

price

expiration

Name

exercisable

unexercisable

($)

date

Lori Woods

62,500

⁶

187,500

⁶

0.43

06/18/2029

CEO and Director

125,000

⁴

125,000

⁴

0.46

06/13/2028

75,000

25,000

0.605

06/27/2027

William Cavanagh

37,500

⁶

112,500

⁶

0.43

06/18/2029

CRDO

75,000

⁵

75,000

⁵

0.46

06/13/2028

168,750

56,250

0.605

06/27/2027

6,660

0.98

06/27/2022

20,000

2.46

06/17/2024

Michael Krachon

37,500

⁶

112,500

⁶

0.43

06/18/2029

VP – S&M

75,000

⁵

75,000

⁵

0.46

06/13/2028

168,750

56,250

0.605

06/27/2027

	1.	Represents a June 27, 2017, grant, one-fourth of which became exercisable on June 27, 2017, one-fourth of which became exercisable on June 27, 2018, one-fourth of which became exercisable on June 27, 2019, and the final fourth will become exercisable on June 27, 2020.
	2.	Represents a June 27, 2012, grant, all of which were exercisable as of June 27, 2015.

	3.	Represents a June 17, 2014, grant, all of which were exercisable as of June 17, 2017.
	4.	Represents a June 13, 2018, grant, one-fourth of which will become exercisable on December 13, 2018, one-fourth of which became exercisable on June 13, 2019, one-fourth of which will become exercisable on June 13, 2020, and the final fourth will become exercisable on June 13, 2021.
	5.	Represents a June 13, 2018, grant, one-fourth of which became exercisable on June 13, 2018, one-fourth of which became exercisable on June 13, 2019, one-fourth of which will become exercisable on June 13, 2020, and the final fourth will become exercisable on June 13, 2021.
	6.	Represents a June 18, 2019, grant, one-fourth of which became exercisable on June 18, 2019, one-fourth of which will become exercisable on June 18, 2020, one-fourth of which will become exercisable on June 18, 2021, and the final fourth will become exercisable on June 18, 2022.

Table of Contents

The Company has a 401(k) plan that covers all eligible full-time employees of the Company. Contributions to the 401(k) plan are made by participants to their individual accounts through payroll withholding. Additionally, the 401(k) plan provides for the Company to make contributions to the 401(k) plan in amounts at the discretion of management. The Company has not made any contributions to the 401(k) plan and does not maintain any other retirement plans for its executives or employees.

Fiscal Year 2019 Director Compensation

	Fees earned
	or paid in		Option
	cash		awards		Total
Name	($)		($)		($)
Alan Hoffmann		46,000		19,614		65,614
Michael McCormick		46,000		19,614		65,614
Philip Vitale MD		46,000		19,614		65,614

Each non-employee director had stock options to purchase shares of the Company’s common stock outstanding as of June 30, 2019 as follows - Mr. Hoffmann had stock options to purchase 115,000 shares of common stock, Mr. McCormick had stock options to purchase 115,000 shares of common stock, and Dr. Vitale had stock options to purchase 115,000 shares of common stock.

During the fiscal year 2019, the independent directors received $3,000 per month for their service. In addition, each non-employee director received $1,000 per Board meeting attended in person or $500 per Board meeting attended via telephone and $500 per committee meeting attended. Employee directors do not receive any compensation for their service on the Board.

Table of Contents

Performance-Based Annual Bonus

We provide for an annual cash incentive that reinforces our pay-for-performance approach. This incentive compensation is a short-term incentive program that rewards achievement. Annual incentive awards are awarded at the sole determination of the Compensation Committee (on behalf of the Board) based on the actual and measurable performance of the Company based on a set of corporate objectives for the previous year.

For fiscal year 2019, each named officer had an opportunity to earn a bonus of five percent (5%) of his or her annual base salary for a twenty-five percent (25%) or greater increase in revenue from the prior fiscal year’s comparable quarter. Also, effective for fiscal year 2019, each named officer has an opportunity to earn a bonus of five percent (5%) of his or her annual base salary for a twenty-five percent (25%) or greater increase in revenue over the prior fiscal year. For fiscal 2019, the Company achieved 25% revenue growth in one of four fiscal quarters. As a result, the following bonuses were paid to our NEOs who were serving as officers during that quarter and are reported in the non-equity incentive compensation column of the Summary Compensation Table of this Form 10-K. In conjunction with Ms. Woods’ promotion to CEO from Interim CEO and effective January 1, 2019, she had the opportunity to earn a bonus of seven percent (7%) of her annual base salary for a twenty-five percent (25%) or greater increase in revenue from the prior fiscal year’s comparable quarter and an opportunity to earn a bonus of seven percent (7%) of her annual base salary for a twenty-five percent (25%) or greater increase in revenue over the prior fiscal year. No bonuses were earned at this level in fiscal year 2019.

NEO	2019 Bonus ($)
Lori Woods – CEO and Director		15,781
William Cavanagh – CRDO		11,013
Michael Krachon - Vice President Sales and Marketing		12,167

For fiscal year 2020, the bonus plan was revised so that the Chief Executive Officer has an opportunity to earn a bonus of seven percent (7%) of his or her annual base salary and each other named officer has an opportunity to earn a bonus of five percent (5%) of his or her annual base salary by meeting the following parameters: half of the bonus will be paid if the Company has a twenty-five percent (25%) increase in revenue from the prior year’s comparable quarter; one quarter of the bonus will be paid if the Company has a gross margin percentage of fifty percent (50%) or higher in the applicable quarter; and one quarter of the bonus will be paid if the Company has a net loss margin of negative forty percent (-40%) or less in the applicable quarter.

On June 18, 2019, the Committee approved stock option grants to our named executive officers outlined in the table below, at an exercise price of $0.43, our closing stock price on June 18, 2019.

NEO	Option grant (# of shares)
Lori Woods – CEO and Director		250,000
William Cavanagh – CRDO		150,000
Michael Krachon - Vice President Sales and Marketing		150,000

Risks Related to Compensation Policies and Practices

The Compensation Committee has considered whether our overall compensation program for employees in 2019 creates incentives for employees to take excessive or unreasonable risks that could materially harm our Company. We believe that several features of our compensation policies for management employees appropriately mitigate such risks, including a mix of long- and short-term compensation incentives that we believe is properly weighted, our Executive Compensation Clawback Policy and the uniformity of compensation practices across our Company, which the Compensation Committee regards as setting an appropriate level of risk taking for us. We also believe our internal legal and financial controls appropriately mitigate the probability and potential impact of an individual employee committing us to a harmful long-term business transaction in exchange for short-term compensation benefits.

Recoupment Policy

In order to align further management’s interests with the interests of our shareholders and to support good corporate governance practices, the Board has adopted a recoupment policy. Subject to rules of the SEC and NYSE American, in the event that we are required to prepare an accounting restatement due to the material noncompliance with any financial reporting requirement under the federal securities laws, we will form a committee of the independent directors to determine whether we will recover from any of our current or former executive officers, as determined in accordance with such rules, who received performance-based compensation (including stock options awarded as compensation) during the period for which we are required to prepare an accounting restatement, based on the erroneous data, in excess of what would have been paid to the executive officer under the accounting restatement. The committee may also take any other actions authorized by our Executive Compensation Clawback Policy.

Table of Contents

ITEM 12 – SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following tables set forth certain information regarding the beneficial ownership of the Company’s common stock and preferred stock as of September 24, 2019 for (a) each person known by the Company to be a beneficial owner of five percent or more of the outstanding common or preferred stock of the Company, (b) each executive officer, director and nominee for director of the Company, and (c) directors and executive officers of the Company as a group. As of September 24, 2019, the Company had 67,388,047 shares of common stock and 59,065 shares of Series B preferred stock outstanding. Except as otherwise indicated below, the address for each listed beneficial owner is c/o Isoray, Inc., 350 Hills Street, Suite 106, Richland, Washington 99354.

Common Stock Share Ownership

Name of Beneficial Owner	Common Shares Owned		Common Stock Options ¹		Percent of Class²
Lori Woods		130,000		262,500		0.58	%
Alan Hoffmann		45,000		75,000		0.18	%
Michael McCormick		22,000		75,000		0.14	%
Philip Vitale M.D.		110,000		75,000		0.27	%
William Cavanagh III		10,000		307,910		0.47	%
Michael Krachon		55,000		281,250		0.50	%
Jonathan Hunt		-		75,000		0.11	%
Jennifer Streeter		5,440		162,500		0.25	%
Mark Austin		16,000		118,750		0.20	%
Krista Cline		22,933		153,750		0.26	%
Directors and Executive Officers as a group		416,373		1,586,660		2.96	%

	1.	Only includes those common stock options that could be exercised for common stock within 60 days after September 24, 2019.
	2.	Percentage ownership is based on 67,388,047 shares of Common Stock outstanding on September 24, 2019. Shares of Common Stock subject to stock options which are currently exercisable or will become exercisable within 60 days after September 24, 2019 are deemed outstanding for computing the percentage ownership of the person or group holding such options but are not deemed outstanding for computing the percentage ownership of any other person or group.

Table of Contents

Series B Preferred Stock Share Ownership

	Series B
	Preferred
	Shares		Percent of
Name of Beneficial Owner	Owned		Class¹
Aissata Sidibe²		20,000		33.86	%
William and Karen Thompson Trust³		14,218		24.07	%
Jamie Granger⁴ Hostetler Living Trust⁵		9,479		16.05	%
Leslie Fernandez⁶		3,688		6.24	%

Percentage ownership is based on 59,065 shares of Series B Preferred Stock outstanding on September 21, 2019.

The address of Aissata Sidibe is 99302 E Sidibe PR SE, Kennewick, WA 99338.

The address of the William and Karen Thompson Trust is 285 Dondero Way, San Jose, CA 95119.

The address of Jamie Granger is 53709 South Nine Canyon Road, Kennewick, WA 99337.

The address of the Hostetler Living Trust is 9327 NE 175th Street, Bothell, WA 98011.

The address of Leslie Fernandez is 2615 Scottsdale Place, Richland, WA 99352.

No officers or directors beneficially own shares of any class of Preferred Stock.

The “Securities Authorized for Issuance Under Equity Compensation Plans” contained in Item 5 of this Form 10-K is hereby incorporated by reference into this Item 12.

ITEM 13 – CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Transactions with Related Persons

None requiring disclosure under Reg. S-K Item 404.

Review, Approval or Ratification of Transactions with Related Persons

The Company’s Code of Ethics emphasizes the importance of avoiding situations or transactions in which personal interests may interfere with the best interests of the Company or its shareholders. In addition, the Company’s general corporate governance practice includes Board-level discussion and assessment of procedures for discussing and assessing relationships, including business, financial, familial and nonprofit, among the Company and its officers and directors or their immediate family members, to the extent that they may arise. The Board and either the Audit Committee or the Nominations and Corporate Governance Committee review any transaction with an officer or director or their immediate family members to determine, on a case-by-case basis, whether a conflict of interest exists. The Board ensures that all directors voting on such a matter have no interest in the matter and discusses the transaction with counsel as the Board deems necessary. The Board will generally delegate the task of discussing, reviewing and approving transactions between the Company and any related persons to either the Audit Committee or the Nominations and Corporate Governance Committee.

As required under SEC rules, transactions that are determined to be directly or indirectly material to the Company or a related party would be disclosed in our Annual Report; however, during our fiscal year ended June 30, 2019, we did not have any related party transactions requiring disclosure under Reg. S-K Item 404.

Table of Contents

Director Independence

Using the standards of the NYSE American, the Company’s Board has determined that Mr. Hoffmann, Mr. McCormick and Dr. Vitale each qualify under such standards as an independent director. Mr. Hoffmann, Mr. McCormick and Dr. Vitale each meet the NYSE American listing standards for independence both as a director and as a member of both the Audit Committee and the Compensation Committee. No other directors are independent under these standards.

None of our existing directors were disqualified from independent status under the objective standards of the NYSE American other than Ms. Woods, who did not qualify as she is an employee director. In reviewing the subjective criteria of “any relationship that would interfere with the exercise of independent judgment” in carrying out the responsibilities of a director, the Board determined that all directors other than Ms. Woods met this criteria as well.

With respect to Audit Committee independence, the Board determined each member of the Committee qualified as independent for Committee service.

The Company did not consider any other relationship or transaction between itself and these independent directors not already disclosed in this Report in making this independence determination.

ITEM 14 – PRINCIPAL ACCOUNTANT FEES AND SERVICES

The Company paid or accrued the following fees in each of the prior two fiscal years to its principal accountant, DeCoria, Maichel & Teague, P.S. (in thousands):

		For the Year Ended June 30,
		2019		2018

1.	Audit fees	$	47	$	73
3.	Tax fees		9		3
4.	All other fees		14		-
Totals		$	70	$	76

Audit fees include fees for the audit of our annual financial statements, reviews of our quarterly financial statements, and related consents for documents filed with the SEC. Tax fees include fees for the preparation of our federal and state income tax returns. All other fees are from consulting costs created by the review of documents related to equity offerings.

As part of its responsibility for oversight of the independent registered public accountants, the Audit Committee has established a pre-approval policy for engaging audit and permitted non-audit services provided by our independent registered public accountants, DeCoria, Maichel & Teague, P.S. In accordance with this policy, each type of audit, audit-related, tax and other permitted service to be provided by the independent auditors is specifically described and each such service, together with a fee level or budgeted amount for such service, is pre-approved by the Audit Committee. The Audit Committee has delegated authority to its Chairman to pre-approve additional non-audit services (provided such services are not prohibited by applicable law) up to a pre-established aggregate dollar limit. All services pre-approved by the Chairman of the Audit Committee must be presented at the next Audit Committee meeting for review and ratification. All of the services provided by DeCoria, Maichel & Teague, P.S. described above were approved by our Audit Committee.

The Company’s principal accountant, DeCoria, Maichel & Teague, P.S., did not engage any other persons or firms other than the principal accountant’s full-time, permanent employees.

Table of Contents

ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

EXHIBIT INDEX

(Except as otherwise indicated (a) all exhibits were previously filed, (b) all omitted exhibits are intentionally omitted, and (c) all Reports referenced below were filed under SEC file number 001-33407.)

Exhibit #		Description
2.1		Plan of Conversion, incorporated by reference to Appendix A of the Form Def 14A filed on November 9, 2018.
3.1		Certificate of Incorporation, incorporated by reference to Exhibit A of the Form Def 14A filed on November 9, 2018.
3.2		Bylaws, incorporated by reference to Exhibit C of the Form Def 14A filed on November 9, 2018.
4.1		Amendment and Termination of Rights Agreement, dated November 7, 2018, by and between Isoray, Inc. and Computershare Trust Company, N.A., as Rights Agent, incorporated by reference to Exhibit 4.1 of the form 8-K filed on November 8, 2018.
4.2		Warrant to Purchase Common Stock, dated May 20, 2018, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on May 21, 2018.
4.3		Warrant to Purchase Common Stock, dated October 3, 2017, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on October 10, 2017.
4.4		Form of Warrant, dated July 11, 2018, incorporated by reference to Exhibit 10.3 of the Form 8-K filed on July 11, 2018.
10.1		Royalty Agreement of Invention and Patent Application, dated July 12, 1999 between Lane A. Bray and Isoray LLC, incorporated by reference to Exhibit 10.3 of the Form SB-2 filed on November 10, 2005 (Reg. No. 333-129646).
10.2		Section 510(k) Clearance from the Food and Drug Administration to market Lawrence CSERION Model CS-1, dated March 28, 2003, incorporated by reference to Exhibit 10.5 of the Form SB-2 filed on November 10, 2005 (Reg. No. 333-129646).
10.3		Registry of Radioactive Sealed Sources and Devices Safety Evaluation of Sealed Source, dated September 17, 2004, incorporated by reference to Exhibit 10.10 of the Form SB-2/A2 filed on April 27, 2006 (Reg. No. 333-129646).
10.4		State of Washington Radioactive Materials License dated October 6, 2005, incorporated by reference to Exhibit 10.18 of the Form SB-2 filed on November 10, 2005 (Reg. No. 333-129646).
10.5***		Form of Officer and Director Indemnification Agreement, incorporated by reference to Exhibit 10.35 of the Form SB-2 Post-Effective Amendment No. 2 filed on October 13, 2006 (Reg. No. 333-129646).
10.6		Contract, dated December 15, 2015 and effective as of December 7, 2015, by and between Isoray Medical, Inc. and The Open Joint Stock Company ‹‹ Isotope ›› (confidential treatment granted for redacted portions), incorporated by reference to Exhibit 10.85 of the Form 8-K filed on December 21, 2015.
10.7		Stipulation of Settlement, dated September 23, 2016, by and between Isoray, Inc., Dwight Babcock, and the settlement class, incorporated by reference to Exhibit 10.1 of the Form 10-Q filed on November 9, 2016.
10.8		Addendum No. 1 to contract with The Open Joint Stock Company ‹‹ Isotope ››, dated December 22, 2016 and effective as of December 9, 2016, by and between Isoray Medical, Inc. and The Open Joint Stock Company ‹‹ Isotope ›› (confidential treatment granted for redacted portions), incorporated by reference to Exhibit 10.1 of the Form 8-K filed on December 28, 2016.
10.9		Eighth Amendment, dated July 9, 2018, to the Share Rights Agreement, dated as of February 1, 2007, between Isoray, Inc. and Computershare Trust Company, N.A., as Rights Agent, incorporated by reference to Exhibit 4.1 of the form 8-K filed on July 12, 2018.
10.10		Irradiation Services Agreement, dated November 29, 2016, between The Curators of the University of Missouri and Isoray Medical, Inc. (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 10. 1 of the Form 10-Q filed on February 9, 2017.
10.11		Contract Modification, entered into on November 15, 2016 with an effective date of November 1, 2016, to Contract No. X-40403 between Energy Northwest and Isoray Medical, Inc., incorporated by reference to Exhibit 10.2 of the Form 10-Q filed on February 9, 2017.
10.12		Separation Agreement, dated February 28, 2017, between Brien Ragle and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on March 3, 2017.
10.13***		Isoray, Inc. 2017 Equity Incentive Plan (incorporated by reference to Appendix B to Isoray, Inc.'s Definitive Proxy Statement on Schedule 14A, filed on May 17, 2017).

Table of Contents

10.14		Rescission and Release Agreement, dated May 2, 2017, between Isoray Medical, Inc., and the Port of Benton, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on June 8, 2017.
10.15		Separation Agreement, dated May 1, 2017, between Matthew Branson and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on June 23, 2017.
10.16***		Form of Isoray, Inc. Stock Option Agreement and Notice of Grant of Stock Option, by and between each grantee thereunder and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on June 30, 2017.
10.17***		Employment Agreement, dated June 30, 2017, between Mark Austin and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on July 7, 2017.
10.18		Consignment Agreement, dated August 25, 2017, between Isoray Medical, Inc. and MedikorPharma-Ural LLC, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on August 31, 2017.
10.19		Service Agreement, dated August 25, 2017, between Isoray Medical, Inc. and MedikorPharma-Ural LLC, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on August 31, 2017.
10.20		Addendum No. 2 to supply contract by and between Isoray Medical, Inc. and The Open Joint Stock Company «Isotope» (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 10.1 of the Form 8-K filed on October 27, 2017.
10.21		Manufacturing and Supply Agreement, dated January 3, 2018, between Isoray Medical, Inc. and GT Medical Technologies, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on January 8, 2018.
10.22		Collaborative Development Agreement, dated effective as of March 13, 2017, between Isoray Medical, Inc. and GammaTile, LLC, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on January 8, 2018.
10.23		Sales Agreement between Isoray, Inc. and H.C. Wainwright & Co., LLC, dated May 8, 2018, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on May 8, 2018.
10.24		Lease Agreement, dated effective May 2, 2007, between Isoray Medical, Inc. and Energy Northwest, incorporated by reference to Exhibit 10.42 of the Form 8-K filed on May 8, 2007.
10.25***		Employment Agreement, dated effective June 13, 2018, between Lori A. Woods and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on June 19, 2018.
10.26***		Isoray, Inc. Stock Option Agreement and Notice of Grant of Stock Option to Lori A. Woods, dated June 13, 2018, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on June 19, 2018.
10.27		Separation Agreement, dated June 25, 2018, between Thomas C. LaVoy and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on June 29, 2018.
10.28		Letter Agreement, dated July 9, 2018, between H.C. Wainwright & Co. LLC and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on July 11, 2018.
10.29		Form of Securities Purchase Agreement, dated July 9, 2018, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on July 11, 2018.
10.30		Professional Services Agreement, dated August 15, 2018, between Isoray Medical, Inc. and J. Squared Partners, Inc., DBA Global IR Group, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on September 25, 2018.
10.31		Services Agreement, dated August 13, 2018, between Isoray Medical, Inc. and Schultz Public Relations, LLC, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on September 25, 2018.
10.32***		Form of Employment Agreement, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on October 12, 2018.
10.33***		Employment Agreement, dated effective December 3, 2018, between Jonathan Hunt and Isoray, Inc., incorporated by reference to Exhibit 10.1 of the Form 8-K filed on December 3, 2018.
10.34***		Employment Agreement between Isoray, Inc. and Lori A. Woods, dated effective January 1, 2019, incorporated by reference to the Form 8-K filed on December 17, 2018.
10.35		Addendum #8 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, signed December 24, 2018 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 10.4 of the Form 10-Q filed on February 13, 2019.
10.36		Amendment to Exhibit B of Manufacturing and Supply Agreement between Isoray Medical, Inc. and GT Medical Technologies, Inc., dated December 28, 2018 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 10.5 of the Form 10-Q filed on February 13, 2019.

Table of Contents

10.37***		Employment Agreement between Isoray, Inc. and Michael Krachon, dated effective February 6, 2019, incorporated by reference to the Form 8-K filed on February 12, 2019.
10.38		Amended and Restated Manufacturing and Supply Agreement, dated April 26, 2019, between Isoray Medical, Inc. and GT Medical Technologies, Inc., (confidential treatment requested for redacted portions), incorporated by reference to the Form 8-K filed on May 2, 2019.
10.39		Amendment to Exhibit B of Manufacturing and Supply Agreement between Isoray Medical, Inc. and GT Medical Technologies, Inc., dated December 28, 2018 (confidential treatment requested for redacted portions), incorporated by reference to the Form 8-K filed on May 28, 2019.
10.40		Revision to Bonus Plan for fiscal year 2020, dated June 18, 2019, incorporated by reference to Item 5.02 of the Form 8-K filed on June 24, 2019.
10.41*		Addendum #9 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, signed July 11, 2019 (confidential treatment requested for redacted portions), filed herewith.
10.42***		Amended and Restated Employment Agreement between Isoray Inc. and Jennifer Streeter, dated effective July 19, 2019, incorporated by reference to the Form 8-K filed on July 24, 2019.
10.43		Supply Contract, dated July 30, 2019, between Isoray Medical, Inc., and Joint Stock Company «Isotope» (confidential portions of the exhibit have been omitted), incorporated by reference to the Form 8-K filed on August 5, 2019.
10.44		Contract Modification, entered into on November 15, 2016 with an effective date of November 1, 2016, to Contract No. X-40403 between Energy Northwest and Isoray Medical, Inc, incorporated by reference to Exhibit 10.2 of the Form 10-Q filed on February 9, 2017.
10.45*		Contract Modification, entered into on August 19, 2019 with an effective date of July 3, 2019, to Contract No. X-40403 between Energy Northwest and Isoray Medical, Inc.
14.1		Code of Conduct and Ethics, incorporated by reference to Exhibit 14.1 of the Form 10-KSB filed on October 11, 2005. (File No. 000-14247)
14.2		Code of Ethics for Chief Executive Officer & Senior Financial Officers, incorporated by reference to Exhibit 14.2 of the Form 10-KSB filed on October 11, 2005. (File No. 000-14247)
21.1*		Subsidiaries of the Company.
23.1*		Consent of DeCoria, Maichel & Teague, P.S.
31.1*		Rule 13a-14(a)/15d-14(a) Certification - Chief Executive Officer.
31.2*		Rule 13a-14(a)/15d-14(a) Certification of Co-Principal Financial Officer
31.3*		Rule 13a-14(a)/15d-14(a) Certification of Co-Principal Financial Officer
32**		Section 1350 Certifications.
99.1		Addendum #3 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, dated November 30, 2017 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 99.1 of the Form 10-Q filed on February 12, 2019.
99.2		Addendum #4 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, dated March 19, 2018 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 99.2 of the Form 10-Q filed on February 12, 2019.
99.3		Addendum #5 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, dated April 17, 2018 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 99.3 of the Form 10-Q filed on February 12, 2019.
99.4		Addendum #6 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, dated May 3, 2018 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 99.4 of the Form 10-Q filed on February 12, 2019.
99.5		Addendum #7 to Contract between Isoray Medical, Inc. and Joint Stock Company <<Isotope>>, dated May 4, 2018 (confidential treatment requested for redacted portions), incorporated by reference to Exhibit 99.5 of the Form 10-Q filed on February 12, 2019.
101.INS*		XBRL Instance Document.
101.SCH*		XBRL Taxonomy Extension Schema Document.
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document.

*		Filed Herewith
**		Furnished Herewith
***		Denotes Management Contract or Compensatory Plan or Arrangement

Table of Contents

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Isoray, Inc. and Subsidiaries

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Isoray, Inc. and Subsidiaries (the "Company") as of June 30, 2019 and 2018, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the three years in the period ended June 30, 2019, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2019, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ DeCoria, Maichel & Teague, P.S.

We have served as the Company's independent auditor since 2005.

Spokane, Washington

September 27, 2019

Table of Contents

Isoray, Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands, except shares)

	June 30,			June 30,
	2019			2018
ASSETS
Current assets:
Cash and cash equivalents	$	5,326		$	2,600
Short-term investments (Note 3)		-			825
Accounts receivable, net		1,154			1,192
Inventory		530			494
Prepaid expenses and other current assets		305			335

Total current assets		7,315			5,446

Property and equipment, net		1,609			1,311
Restricted cash		181			181
Inventory, non-current		155			319
Other assets, net of accumulated amortization		162			198

Total assets	$	9,422		$	7,455

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued expenses	$	683		$	1,391
Accrued protocol expense		133			77
Accrued radioactive waste disposal		74			37
Accrued payroll and related taxes		89			155
Accrued vacation		142			175

Total current liabilities		1,121			1,835
Non-current liabilities:
Asset retirement obligation		621			590

Total liabilities		1,742			2,425
Commitments and contingencies (Note 15)

Shareholders' equity:
Preferred stock, $.001 par value; 7,000,000 and 7,001,671shares authorized: Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding		-			-
Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 and 56,331,147 shares issued and outstanding		67			56
Additional paid-in capital		92,105			84,322
Accumulated deficit		(84,492	)		(79,348	)

Total shareholders' equity		7,680			5,030

Total liabilities and shareholders' equity	$	9,422		$	7,455

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc. and Subsidiaries

Consolidated Statements of Operations

(Dollars and shares in thousands, except for per-share amounts)

	Year Ended June 30
	2019			2018			2017

Sales, net	$	7,314		$	5,923		$	4,761
Cost of sales		4,267			4,081			3,923
Gross profit		3,047			1,842			838

Operating expenses:
Research and development
Proprietary research and development		1,429			1,351			771
Collaboration arrangement, net of reimbursement (Note 15)		45			395			194
Total research and development		1,474			1,746			965
Sales and marketing		2,679			2,660			2,310
General and administrative		4,172			4,165			3,920
Change in estimate of asset retirement obligation (Note 9)		-			-			(48	)
Gain on equipment disposals		(24	)		-			(2	)
Total operating expenses		8,301			8,571			7,145

Operating loss		(5,254	)		(6,729	)		(6,307	)

Non-operating income:
Interest income		108			29			118
Change in fair value of warrant derivative liability		-			-			27
Other income		2			-			-
Non-operating income, net		110			29			145

Net loss		(5,144	)		(6,700	)		(6,162	)
Preferred stock dividends		(11	)		(11	)		(11	)

Net loss applicable to common shareholders	$	(5,155	)	$	(6,711	)	$	(6,173	)

Basic and diluted loss per share	$	(0.08	)	$	(0.12	)	$	(0.11	)

Weighted average shares used in computing net loss per share:
Basic and diluted		67,042			55,159			55,016

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc. and Subsidiaries
Consolidated Statement of Changes in Shareholders' Equity
(In thousands, except shares)

	Series B Preferred Stock				Common Stock
	Shares		Amount		Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Total

Balances at June 30, 2016		59,065	$	-		55,010,619	$	55	$	82,788		$	(66,442	)	$	16,401

Issuance of common stock pursuant to exercise of options						6,800		-		2						2
Payment of dividend to preferred shareholders										(11	)					(11	)
Share-based compensation										372						372
Net loss		-		-		-		-		-			(6,162	)		(6,162	)

Balances at June 30, 2017		59,065	$	-		55,017,419	$	55	$	83,151		$	(72,604	)	$	10,602

Issuance of common stock pursuant to exercise of options						82,810		-		50						50
Issuance of common stock pursuant to at the market offering, net						980,918		1		478						479
Issuance of common stock pursuant to exercise of warrants						250,000		-		3						3
Payment of dividend to preferred shareholders										(11	)					(11	)
Share-based compensation										404						404
Share-based compensation for third party services										203						203
Adoption of ASU 2016-09										44			(44	)		-
Net loss		-		-		-		-		-			(6,700	)		(6,700	)

Balances at June 30, 2018		59,065		-		56,331,147		56		84,322			(79,348	)		5,030

Issuance of common stock pursuant to exercise of options						56,900		-		15						15
Issuance of common stock, pursuant to registered direct offering, net						11,000,000		11		7,359						7,370
Payment of dividend to preferred shareholders										(11	)					(11	)
Share-based compensation										420						420
Net loss		-		-		-		-		-			(5,144	)		(5,144	)

Balances at June 30, 2019		59,065	$	-		67,388,047	$	67	$	92,105		$	(84,492	)	$	7,680

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(In thousands)

	Year Ended June 30,
	2019			2018			2017

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(5,144	)	$	(6,700	)	$	(6,162	)
Adjustments to reconcile net loss to net cash used by operating activities:
Allowance for doubtful accounts		-			-			(4	)
Depreciation expense		136			80			68
(Gain) loss on equipment disposals		(24	)		-			(2	)
Amortization of other assets		50			50			45
Change in fair value of warrant derivative liability		-			-			(27	)
Accretion of asset retirement obligation		31			29			29
Change in estimate of asset retirement obligation		-			-			(48	)
Share-based compensation		420			404			372
Share-based compensation for third party services		-			203			-
Changes in operating assets and liabilities:
Accounts receivable		38			(466	)		(184	)
Inventory		128			23			89
Prepaid expenses and other current assets		30			(64	)		100
Accounts payable and accrued expenses		(708	)		761			18
Accrued protocol expense		56			2			(47	)
Accrued radioactive waste disposal		37			(88	)		(52	)
Accrued payroll and related taxes		(66	)		17			66
Accrued vacation		(33	)		37			27

Net cash used by operating activities		(5,049	)		(5,712	)		(5,712	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment		(444	)		(337	)		(549	)
Additions to other assets		(14	)		(18	)		(124	)
Proceeds from sale of equipment		34			-			6
Proceeds from maturity of certificates of deposit		5,550			6,268			2,296
Purchases of and interest from certificates of deposit		(4,725	)		(4,054	)		(115	)

Net cash provided by investing activities		401			1,859			1,514

CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid		(11	)		(11	)		(11	)
Proceeds from sales of common stock, pursuant to registered direct offering, net		7,370			-			-
Proceeds from sales of common stock, pursuant to at the market offering, net		-			479			-
Proceeds from sales of common stock, pursuant to exercise of warrants, net		-			3			-
Proceeds from sales of common stock, pursuant to exercise of options		15			50			2

Net cash provided by (used in) financing activities		7,374			521			(9	)

Net increase (decrease) in cash, cash equivalents, and restricted cash		2,726			(3,332	)		(4,207	)
Cash, cash equivalents, and restricted cash beginning of year		2,781			6,113			10,320
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF YEAR	$	5,507		$	2,781		$	6,113

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	$	5,326		$	2,600		$	5,932
Restricted cash	$	181		$	181		$	181
Total cash, cash equivalents, and restricted cash	$	5,507		$	2,781		$	6,113

Non-cash investing and financing activities:
Warrants issued to placement agent of registered direct offering	$	163		$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Isoray, Inc.

Notes to Consolidated Financial Statements

For the years ended June 30, 2019, 2018 and 2017

1.	Organization

Isoray, Inc. was incorporated in Minnesota in 1983. On July 28, 2005, Isoray Medical, Inc. (Medical) became a wholly-owned subsidiary of Isoray, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. In December 2018, upon approval of a majority of shareholders, Isoray, Inc. was redomiciled to Delaware. Medical was formed under Delaware law on June 15, 2004 and on October 1, 2004 acquired two affiliated predecessor companies which began operations in 1998. Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.

Isoray International LLC (International), a Washington limited liability company, was formed on November 27, 2007 and is a wholly-owned subsidiary of Isoray, Inc. International has entered into various international distribution agreements.

2.	Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation.

Cash Equivalents

The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States.

Investments

Investments with original maturities greater than three months and remaining maturities less than one year are classified as “Short-term investments” and included in current assets. Investments with remaining maturities greater than one year are classified as “Investments, non-current” and are included in noncurrent assets. These investments are held to maturity and carried at amortized cost.

Accounts Receivable

Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries.

Table of Contents

Inventory

Inventory is reported at the lower of cost or net realizable value. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a first-in, first-out basis.

The cost of materials and production costs contained in inventory that are not usable due to the passage of time, and resulting loss of bio-effectiveness, are written off to cost of sales at the time it is determined that the product is no longer usable.

Property and Equipment

Fixed assets are capitalized and carried at cost less accumulated depreciation. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations.

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment (in years)	3	to	7
Office equipment (in years)	2	to	5
Furniture and fixtures (in years)	2	to	5

Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.

Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is not recoverable and exceeds its fair value.

Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment.

Prepaid Expenses and Other Assets

Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value.

Asset Retirement Obligation

The estimated fair value of the future retirement costs of the Company’s leased assets and the costs for the decontamination and reclamation of equipment located within the footprint leased asset are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets.

Table of Contents

Financial Instruments

The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and not recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At June 30, 2019 and 2018, the carrying value of financial instruments which include U.S. Treasury Securities, certificates of deposit and restricted cash, approximated fair value.

Fair Value Measurement

When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level 1 uses quoted prices in active markets for identical assets or liabilities, Level 2 uses significant other observable inputs, and Level 3 uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. The Company has no financial assets or liabilities that are adjusted to fair value on a recurring basis.

At June 30, 2019 and 2018, there were no assets or liabilities measured at fair-value on a recurring basis which were measured using Level 3 inputs. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are not measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note 9), the Company had no assets or liabilities measured at fair value on a nonrecurring basis during the two years ended June 30, 2019.

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. (In thousands)

	Fair value at June 30, 2019
	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	5,326	$	5,326	$	-	$	-

	Fair value at June 30, 2018
	Total		Level 1		Level 2		Level 3
Cash and cash equivalents	$	2,600	$	2,600	$	-	$	-

The Company’s cash and cash equivalent instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Table of Contents

Revenue Recognition

The Company recognizes revenue based on the five-step model for revenue recognition as prescribed by ASC 606, Revenue from Contracts with Customers, as follows: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the prices to the performance obligations; and (5) recognize revenue. The Company has some agreements that contain general commercial terms and product prices but do not contain an obligation to provide goods to the customer. Our performance obligation, which is established when the customer submits a purchase order and the Company accepts the order, is to deliver the product based on the purchase order received. The Company typically recognizes revenue at the time of shipment, at which time the title passes to the customer, and there are no further performance obligations. See Note 18.

Shipping and Handling Costs

Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in the transaction price.

Share-Based Compensation

The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options and stock warrants on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Company recognizes forfeitures as they occur.

Research and Development Costs

Research and Development - Proprietary

Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year recognized.

Research and Development - Collaborative Arrangement

Research and development costs incurred and shared in connection with a collaborative research and development project are separately stated in the consolidated statement of operation under “Research and development: Collaboration arrangements, net of reimbursement.”

Advertising and Marketing Costs

Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. (In thousands)

	For the Years Ended June 30,
	2019		2018		2017
Advertising and marketing costs expensed (including tradeshows)	$	210	$	329	$	323

	At June 30,
	2019		2018
Prepaid marketing expenses deferred until event occurs	$	9	$	9

Legal Contingencies

The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does not believe any probable legal proceedings or claims will have a material adverse effect on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company’s recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred.

Table of Contents

Income Taxes

Income taxes are accounted for under the liability method. Under this method, the Company provides deferred income taxes for temporary differences that will result in taxable or deductible amounts in future years based on the reporting of certain costs in different periods for financial statement and income tax purposes. This method also requires the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment of the change. In the event that the Company is assessed penalties and or interest, penalties will be charged to other operating expense and interest will be charged to interest expense in the period that they are assessed.

Income (Loss) Per Common Share

Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company’s net loss position.

Securities that could be dilutive in the future are as follows:

	June 30,
	2019		2018		2017
Preferred stock		59,065		59,065		59,065
Common stock warrants		6,080,000		250,000		-
Common stock options		4,645,315		3,759,840		3,379,191
Total potential dilutive securities		10,784,380		4,068,905		3,438,256

Use of Estimates

The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.

Recent Accounting Pronouncements

Table of Contents

3.	Short-Term Investments

The Company had no short-term investments at June 30, 2019. At June 30, 2018 the Company had short-term investments consisting of Certificate of Deposit Account Registry Service (CDARS) accounts.

CDARS is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). That institution utilizes the CDARS system to purchase certificates of deposit at other financial Institutions while keeping the investment at each institution fully insured by the Federal Deposit Insurance Corporation (FDIC).

Short-term investments held by the Company at June 30, 2018 were as follows (in thousands):

	Under 90		91 days to		Six months to		Greater
	days		six months		1 year		than 1 year
CDARS, as of June 30, 2018	$	825	$	-	$	-	$	-

4.	Inventory

Inventory consisted of the following (in thousands):

	June 30,
	2019		2018
Raw materials	$	333	$	371
Work in process		166		96
Finished goods		31		27
Total inventory	$	530	$	494

	June 30,
	2019		2018
Enriched barium, non-current	$	117	$	276
Raw materials, non-current		38		43
Total inventory, non-current	$	155	$	319

Table of Contents

Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not be consumed within an operating cycle. On August 25, 2017, the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-130 carbonate inventory. The Company anticipates obtaining enough Cesium-131 under this arrangement to obtain over 4,000 curies of Cesium-131. During the year ended June 30, 2019 the Company obtained 1,166 curies under this agreement which has been used in production. At June 30, 2019, the Company estimates that the remaining enriched barium will result in 925 curies; approximately 90 of which will be obtained in the year ended June 30, 2020 and 835 will be obtained after June 30, 2020. There is no assurance as to whether the agreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the third-party Cesium-131 suppliers will be executed.

5.	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	June 30,
	2019		2018
Prepaid insurance	$	38	$	24
Other prepaid expenses		154		241
Other current assets		27		29
Other receivables		86		41
Total prepaid expenses and other current assets	$	305	$	335

6.	Property & Equipment

Property & equipment consisted of the following (in thousands):

	June 30,
	2019			2018
Land	$	366		$	366
Equipment		3,825			4,152
Leasehold improvements		4,143			4,136
Other¹		645			328
Property and equipment		8,979			8,982
Less accumulated depreciation		(7,370	)		(7,671	)
Property and equipment, net	$	1,609		$	1,311

Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at June 30, 2019 and 2018 are costs associated with advance planning and design work on the Company’s new production facility of $207,000.

7.	Restricted Cash

The Washington Department of Health requires the Company to provide collateral for the decommissioning of its facility. To satisfy this requirement, the Company has a bank account with a balance of $181,000. The account is termed restricted cash and classified as a long-term asset as the Company does not anticipate decommissioning the facility until the end of the current lease. The current lease as extended in July 2019 expires April 30, 2026. The cash will become unrestricted following the decommissioning of the facility and the release of the facility by the Washington Department of Health back to the landlord.

Table of Contents

8.	Other Assets, net

Other assets, net of accumulated amortization consisted of the following (in thousands):

	June 30,
	2019			2018
Website development	$	90		$	90
Licenses		516			520
Patents and trademarks		366			366
Total Other Assets		972			976
Less: Accumulated Amortization		(810	)		(778	)
	$	162		$	198

	Year Ended June 30,
	2019		2018		2017
Amortization expense on website development	$	14	$	14	$	12
Amortization expense on licenses		18		18		16
Amortization expense on patents and trademarks		18		18		17
Total amortization expense	$	50	$	50	$	45

Future amortization is expected to be as follows (in thousands):

Year ended June 30, 2020	$	38
2021		23
2022		23
2023		23
2024		23
Thereafter		32
	$	162

9.	Asset Retirement Obligation

The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. The ARO changed as follows (in thousands):

	Year Ended June 30,
	2019		2018
Beginning balance	$	590	$	561
Accretion of discount		31		29
Ending balance	$	621	$	590

Table of Contents

10.

Share-Based Compensation

The Company currently provides share-based compensation under one equity incentive plan approved by the Board of Directors and the shareholders:

■

2017 Equity Incentive Plan (2017 Incentive Plan).

The 2006 Director Plan allowed the Board of Directors to grant options to purchase up to 1,000,000 shares of common stock to directors of the Company. The plan expired on August 16, 2016.

Options granted prior to fiscal 2017 were made pursuant to plans that have expired or were terminated.

The Company’s shareholders approved the 2017 Incentive Plan (“2017 Plan”) in June 2017. The 2017 Plan allows the Board of Directors to grant up to 4,000,000 shares of common stock to directors, officers, employees and consultants in a combination of equity incentive forms including incentive stock options (ISO), non-qualified stock options (NQSO), stock appreciation right (SAR) or restricted shares (RSU) of common stock. Options granted under all of the Plans have a ten year maximum term, an exercise price equal to at least the fair market value of the Company’s common stock (based on the trading price on the NYSE American) on the date of the grant, and with varying vesting periods as determined by the Board.

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. The Company uses the Black-Scholes option valuation model because management believes the model is appropriate for the Company. However, management understands that because changes in the subjective input assumptions can materially affect the fair value estimate, this valuation model does not necessarily provide a reliable single measure of the fair value of its stock options. The risk-free interest rate is based on the U.S. treasury security rate with an equivalent term in effect as of the date of grant. The expected option lives and volatility assumptions are based on historical data of the Company.

The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows:

	For the Year Ended June 30,
	2019			2018			2017
Weighted average fair value		$0.31			$0.34				$0.45
Options issued		1,252,500			1,125,000				2,150,000
Exercise price	$0.37	to	$0.55	$0.44	to	$0.58		$0.55	to	$0.84
Expected term (in years)		5			5			4	to	5
Risk-free rate	1.83%	to	2.91%	1.83%	to	2.85%		1.62%	to	1.83%
Volatility	89%	-	105%	94%	-	101%		101%	-	103%

Table of Contents

The following table presents the share-based compensation expense (in thousands):

	For the Year Ended June 30,
	2019		2018		2017
Cost of sales	$	38	$	62	$	86
Research and development expense		84		92		60
Sales and marketing expense		96		92		86
General and administrative expense		202		158		140
Total share-based compensation	$	420	$	404	$	372

The total value of the stock options awards is expensed ratably over the vesting period of the employees receiving the awards. As of June 30, 2019, total unrecognized compensation cost related to stock-based options and awards was $632,000 and the weighted-average period over which it is expected to be recognized is approximately 1.08 years.

A summary of stock option information within the Company’s share-based compensation plans during the fiscal years is presented below:

	Options
	Outstanding			Price (a)		Life (b)		Value (c)
Balance at June 30, 2016		2,925,059		$	1.21		6.93	$	263
Granted (d)		2,150,000			.61
Expired/Forfeited		(509,904	)		2.55
Voided		(1,179,164	)		.94
Exercised		(6,800	)		.26
Balance at June 30, 2017		3,379,191		$	0.78		7.86	$	151
Granted (d)		1,125,000			.47
Expired		(100,000	)		.75
Forfeited		(561,541	)		.77
Exercised		(82,810	)		.61
Balance at June 30, 2018		3,759,840		$	0.69		7.75	$	49
Granted (d)		1,252,500			.44
Expired		(242,000	)		.41
Forfeited		(68,125	)		.54
Exercised		(56,900	)		.26
Balance at June 30, 2019		4,645,315		$	0.64		7.95	$	1

Vested and expected to vest at June 30, 2019		4,645,315		$	0.64		7.95	$	1

Exercisable at June 30, 2019		2,153,645		$	0.81		6.76	$	-

(a)	Weighted average exercise price per share.

(b)	Weighted average remaining contractual life.

(c)	Aggregate intrinsic value (in thousands).

(d)	All options granted had exercise prices equal to or greater than the ending closing market price of the Company’s common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to five years.

	For the Year Ended June 30,
	2019		2018		2017
Aggregate intrinsic value of options exercised (in thousands)	$	11	$	-	$	3

The Company’s current policy is to issue new shares to satisfy option exercises.

Table of Contents

11.

Shareholders’ Equity

The authorized capital structure of the Company consists of $.001 par value preferred stock and $.001 par value common stock.

Common Stock

On May 8, 2018, the Company entered into a Sales Agreement with H.C. Wainwright & Co., LLC (“Wainwright”). The common stock sold in the Sales Agreement was distributed at the market prices prevailing at the time of sale. As of June 30, 2018, the Company had sold an aggregate of 980,918 shares under the Sales Agreement at an average price of approximately $0.515 per common share for gross proceeds of approximately $505,000. Net proceeds from this raise totaled approximately $478,000. No additional sales were made in July 2018 and this offering was suspended on July 9, 2018.

On July 11, 2018, the Company sold 11,000,000 shares of its common stock at a price of $0.75 per share, for aggregate gross proceeds of $8.25 million.

Additionally, the Company issued to the purchasers unregistered warrants to purchase up to 5,500,000 shares of common stock. The warrants have an exercise price of $0.75 per share common stock, are exercisable commencing six months following the issuance date, and expire five and one-half years from the issuance date. The Company also issued warrants to purchase up to 330,000 shares of common stock of the Company, at an exercise price of $0.9375, to representatives of Wainwright, the placement agent for the registered direct offering, as part of its compensation. If exercised for cash, future exercises of these warrants will provide additional capital to the Company. The Company evaluated the warrants under ASC 815, Derivatives and Hedging, and ASC 480, Distinguishing Liabilities from Equity. Based on the guidance from ASC 815 and ASC 480, the warrants meet the requirement for equity classification as they meet the definition of a derivative, are indexed to the Company's own stock and cannot be net cash settled. The fair value of the warrants with an exercise price of $0.75 was estimated to be $2.8 million and the fair value of the warrants with an exercise price of $0.9375 was estimated to be $0.2 million on the issuance date using a Black-Scholes valuation model. The assumptions used in the Black-Scholes valuation model are in the table below.

Preferred Stock

The Company’s Certificate of Incorporation authorize 7,000,000 shares of $0.001 par value preferred stock available for issuance with such rights and preferences, including liquidation, dividend, conversion, and voting rights, as described below. In connection with redomiciling the Company to Delaware, Preferred Stock Series A, C and D designations were terminated. There were no shares issued under these Series. Series B is the remaining Series authorized at June 30, 2019 and had 59,065 issued and outstanding shares at June 30, 2019.

Series B

Series B preferred shares are entitled to a cumulative 15% dividend annually on the stated par value per share. These shares are convertible into shares of common stock at the rate of one share of common stock for each share of Series B preferred stock, and are subject to automatic conversion into common stock upon the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of common stock in which the gross proceeds to the Company are at least $4,000,000. Series B preferred shareholders have voting rights equal to the voting rights of common stock, except that the vote or written consent of a majority of the outstanding preferred shares is required for any changes to the Company’s Certificate of Incorporation, Bylaws or Certificate of Designation, or for any bankruptcy, insolvency, dissolution or liquidation of the Company. Upon liquidation of the Company, the Company’s assets are first distributed ratably to the Series B preferred shareholders and then to the holders of the Common Stock.

On December 18, 2018, the Board of Directors declared a dividend on the Series B Preferred Stock of all outstanding and cumulative dividends through December 31, 2018. The total dividends of $11,000 were paid as of December 31, 2018. On December 14, 2017, the Board of Directors declared a dividend on the Series B Preferred Stock of all outstanding and cumulative dividends through December 31, 2017. The total dividends of $11,000 were paid as of December 31, 2017. At June 30, 2019 and 2018, there were 59,065 Series B preferred shares outstanding and cumulative dividends in arrears were $5,000.

Table of Contents

Warrants

During the year ended June 30, 2019 the Company issued a total of 5,830,000 warrants in connection with the registered direct offering that was completed on July 11, 2018. The weighted average fair value of warrants issued and the key assumptions used in the Black-Scholes valuation model to calculate the fair value, are as follows:

Weighted average fair value		$0.51
Warrants issued		5,830,000
Exercise price	$0.75	to	$0.9375
Expected term (in years)		5.5
Risk-free rate		2.74%
Volatility		102.73%

During the year ended June 30, 2018, the Company issued warrants as share-based compensation for third party services, principally marketing. The weighted average fair value of warrants issued and the key assumptions used in the Black-Scholes valuation model to calculate the fair value, are as follows:

Weighted average fair value		$0.41
Warrants issued		500,000
Exercise price	$0.01	to	$0.54
Expected term (in years)	2	to	3
Risk-free rate	1.62%	to	2.55%
Volatility	60%	-	82%

The following table summarizes the activity of all stock warrants and weighted average exercise prices.

	Warrants			Price (a)
Balance at June 30, 2016		230,087		$	0.94
Warrants expired		(230,087	)		0.94
Balance at June 30, 2017		-			-
Warrants issued		500,000			0.28
Warrants exercised		(250,000	)		0.01
Balance at June 30, 2018		250,000		$	0.54
Warrants Issued		5,830,000			0.76
Balance at June 30, 2019		6,080,000		$	0.75

(a)

Weighted average exercise price per share.

As of June 30, 2019, the Company had 6,080,000 common warrants outstanding exercisable on or before January 11, 2024.

Table of Contents

12.

Income Taxes

Due to net losses, the Company did not record an income tax provision or benefit for the years ending June 30, 2019, 2018 and 2017.

The significant deferred tax components using a federal income tax rate of 21% for the years ended June 30, 2019 and 2018 are as follows (in thousands):

	As of June 30,
	2019			2018
Fixed assets	$	204		$	197
Share-based compensation		578			480
Other accruals		27			38
Asset retirement obligation		130			124
Research credit carryforwards		96			-
Other		6			10
Net operating loss carryforwards		15,207			14,171
Total deferred tax assets		16,248			15,020
Valuation allowance		(16,248	)		(15,020	)
Total	$	-		$	-

As management of the Company cannot determine that it is more likely than not that the Company will realize the benefit of the net deferred tax asset, a valuation allowance equal to 100% of the net deferred tax asset has been recorded at both June 30, 2019 and 2018.

The Company has federal net operating loss carryforwards of approximately $72.4 million on June 30, 2019 that can be used to offset future regular taxable income. These net operating loss carryforwards expire at various times through the years 2025 to 2038. The current year net operating loss carryforward does not have an expiration date.

The Company has a research credit carryforward of approximately $0.1 million on June 30, 2019 that expire at various times through the years 2037 to 2038.

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the "Act") resulting in significant modifications to existing law. The Company did not incur any income tax benefit or provision for the year ended June 30, 2018 as a result of the changes to tax laws and tax rates under the Act. The Company’s net deferred tax asset was reduced by approximately $9.5 million during the year ended June 30, 2018, which consisted primarily of the remeasurement of federal deferred tax assets and liabilities from 35% to 21%.

The Company’s statutory rate reconciliation is as follows (in thousands):

	For the year ended June 30,
	2019			2018			2017
U.S. federal statutory income tax rate		21	%		28	%		35	%
Expected income tax benefit	$	(1,080	)	$	(1,878	)	$	(2,157	)
Meals and entertainment		12			21			17
Non-deductible penalties		18			4			16
Warrant derivative liability		-			-			(9	)
Share-based compensation		-			-			10
Impact on the change in income tax rate		-			9,556			-
Change in estimate		(178)
Change in valuation allowance		1,228			(7,703	)		2,123
Income tax expense (benefit)	$	-		$	-		$	-

The Company has reviewed the tax positions taken and concluded that it does not have to book a liability for uncertain tax positions.

Currently, tax years 2017-2019 remain open for examination by United States taxing authorities. Net operating losses prior to 2017 could be adjusted during an examination of open years.

13.

401(k) and Profit Sharing Plan

The Company has a 401(k) plan, which commenced in fiscal year 2007, covering all eligible full-time employees of the Company. Contributions to the 401(k) plan are made by the participants to their individual accounts through payroll withholding. The 401(k) plan also allows the Company to make contributions at the discretion of management. To date, the Company has not made any contributions to the 401(k) plan.

Table of Contents

14.

Distribution Agreements

On July 14, 2017, the Company entered into an agreement with a new distributor in Russia that provides for the ability to sell the entire product line in the Russian Federation. The agreement has a one-year initial term with two additional one-year terms which automatically renew unless either party invokes their right to terminate earlier under the provisions of the agreement. The Company and the distributor for Italy and Switzerland executed the distribution agreement on August 1, 2016. The agreement has a one-year initial term with two additional one-year terms which automatically renew unless either party invoke their right to terminate earlier under the provisions of the agreement. The agreement expired on August 1, 2019 and was not renewed. As the Company elected to not renew its CE mark in fiscal 2019, distribution will be limited to those countries outside the European Union.

15.

Commitments and Contingencies

Royalty Agreement for Invention and Patent Application

A former employee and shareholder of the Company previously assigned his rights, title and interest in an invention to Isoray Products LLC (a predecessor company) in exchange for a royalty equal to 1% of the Gross Profit, as defined, from the sale of “seeds” incorporating the technology. The patent and associated royalty obligations were transferred to the Company in connection with the merger transaction.

The Company must also pay a royalty of 2% of Gross Sales, as defined, for any sub-assignments of the aforesaid patented process to any third parties. The royalty agreement remained in force until the expiration of the patents on the assigned technology. The patent expired in April 2019 and no royalties were paid on sales after the expiration of the patent.

During fiscal years 2019, 2018 and 2017, the Company recorded royalty expenses of $33,000, $27,000, and $21,000, respectively.

Patent and Know-How Royalty License Agreement

The Company is the holder of an exclusive license to use certain “know-how” developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed sales. Because the licensor’s patent application was ultimately abandoned, only a 1% “know-how” royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been no sales incorporating the “know-how” and therefore no royalty is due pursuant to the terms of the agreement. Management believes that the possibility of a negative outcome in this matter is remote.

The licensor of the “know-how” has disputed management’s contention that it is not using this “know-how.” On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time.

Irradiation Services Agreement

On November 29, 2016, Medical, a wholly owned subsidiary of IsoRay, entered into an Irradiation Services Agreement (MURR Agreement) with the Curators of the University of Missouri, a public corporation of the State of Missouri, on behalf of its University of Missouri Research Reactor (MURR). The MURR Agreement provides Medical with access to reactor space for the irradiation of natural or enriched barium to produce Ba-131, which is used by Medical to produce Cesium-131 for use in its product. The MURR Agreement has a term of five years concluding November 29, 2021 and will automatically renew for successive twelve-month periods unless terminated by either party, and can be terminated by either party upon three months written notice. The MURR Agreement does not require minimum orders or obligate Medical to future minimum payments. After a thorough review of the capacity and quality of production at the MURR facility, the Company determined to terminate its supply agreement with MURR and the last shipment of isotope from MURR was received in January 2019.

Isotope Purchase Agreement

In December 2015, the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cesium-131 manufactured by the Institute of Nuclear Materials. The purchase agreement provided the Company with one year’s supply of Cesium-131. The original agreement was due to expire on March 31, 2017, but in December 2016 an addendum was signed extending it until December 31, 2017. On October 23, 2017, the Company, together with The Open Joint Stock Company, signed an addendum to the contract to include Cesium-131 manufactured at RIAR and extending it until December 31, 2018. On December 24, 2018, an addendum was signed extending the term of the supply contract through December 31, 2019 and modifying the volume of additional shipments of Cesium-131. Under the addendum, current pricing and volumes for Cesium-131 purchases remained in place until May 31, 2019. On July 11, 2019, another addendum was signed extending the pricing terms until August 4, 2019. On July 30, 2019, a new supply contract was signed with The Open Joint Stock Company for a term of August 2019 to December 2020 as the Company had purchased the maximum amount of Cesium-131 permitted under the prior agreement.

Table of Contents

Operating Lease Agreements

The Company leases office and laboratory space under an operating lease. The lease may be terminated by either party with a six-month written notice. The lease terms require monthly lease payments and include a contractually permitted annual rent increase based on changes in the CPI index. Future minimum lease payments under this operating lease are as follows (in thousands):

Year ending June 30,	Amount
2020		290
2021		241
	$	531

	For the Year Ended June 30,
	2019		2018		2017
Rental expense	$	285	$	285	$	288

In July 2019, the Company entered into another modification of the production facility lease that extends the term to April 20, 2026, maintains the current rental rate through April 2020, and provides for an eighteen-month termination notice with an early termination penalty of up to $40,000 which decreases each year.

Research and Development - Collaborative Arrangement

On March 13, 2017, Medical entered into a Collaborative Development Agreement (CDA) with GammaTile, LLC, now known as GT Medical Technologies, Inc. (GT Med Tech), to further develop a brachytherapy medical device for the treatment of cancerous tumors in the brain and to seek regulatory approval for the new product. As the project manager, Medical incurs all costs in connection with the collaboration project which will be shared equally by both parties as of November 8, 2016 when they informally began the collaboration. The arrangement is accounted for as a collaborative arrangement and related costs are incurred, shared, and separately stated in connection with a collaborative research and development project. These costs are reported on the financial statements under “Research and development: Collaboration arrangements, net of reimbursement.”

Gross costs incurred in connection with the collaboration agreement during fiscal years 2019, 2018 and 2017 were $266,000, $769,000 and $387,000, respectively. As of June 30, 2019 and 2018, the Company had a receivable balance related to this CDA of $0 and $22,000, respectively.

The CDA with GT Med Tech terminated in March 2018 but the Company continued to work collaboratively with GT Med Tech to obtain 510(k) clearance from the FDA and on the design transfer to production without a formal agreement. Beginning in April 2018 costs were no longer shared equally as had been done historically and GT Med Tech was responsible for more than 50% of the costs. The Company stopped sharing costs with GT Med Tech related to the development of GammaTile™ in December 2018 when the product entered a limited market release.

Class Action Lawsuit Related to Press Release

On May 22, 2015, the first of three lawsuits was filed against Isoray, Inc. and two of its officers – Dwight Babcock (the Company’s retired CEO) and Brien Ragle (former CFO who was later dismissed from the lawsuits) – related to a press release on May 20, 2015 regarding a May 19 online publication of the peer-reviewed article in the journal Brachytherapy titled “Analysis of Stereotactic Radiation vs. Wedge Resection vs. Wedge Resection Plus Cesium-131 Brachytherapy in Early-Stage Lung Cancer” by Dr. Bhupesh Parashar, et al. The lawsuits were class actions alleging violations of the federal securities laws. By Order dated August 17, 2015, the three lawsuits were consolidated into one case – In re Isoray, Inc. Securities Litigation; Case No. 4:15-cv-05046-LRS, in the U.S. District Court for the Eastern District of Washington.

Table of Contents

On March 9, 2017, the parties settled this matter and the court entered an order and final judgment that (i) dismissed with prejudice and released the claims asserted in the complaint against the defendants, including Isoray, and (ii) approved the payment of the $3,537,500 settlement fund (paid by Isoray’s insurers), minus the payment of attorneys’ fees and costs to plaintiff’s counsel, to members of the settlement class. This lawsuit is now concluded.

Derivative Complaint related to Shareholder Value

On September 29, 2016, David M. Kitley, purportedly on behalf of Isoray, filed a derivative lawsuit in the United States District Court for the District of Minnesota under the case caption Kitley v. Isoray, Inc., Case No. 0:16-cv-03297-DTS. The complaint named as defendants current and former Isoray directors Dwight Babcock, Thomas LaVoy, Philip J. Vitale and Michael W. McCormick, alleging that they violated their fiduciary duties to Isoray in connection with a press release allegedly containing false and misleading statements concerning the results from a peer reviewed study of its Cesium-131 isotope seeds for the treatment of non-small cell lung cancers, thereby artificially inflating the price of Isoray stock. The complaint sought unspecified damages, in an amount not presently determinable, among other forms of relief.

On November 17, 2016, Isoray moved to dismiss the complaint, arguing that plaintiff was not entitled to pursue his derivative claims due to his failure to serve a pre-suit demand on Isoray’s board. Rather than respond to the motion to dismiss, plaintiff filed an amended complaint on January 23, 2017. The amended complaint alleged the same derivative claims as the original, and added Isoray director Alan Hoffmann as a defendant. Plaintiff sought an award of damages and an order directing Isoray to undertake reforms of its corporate governance and internal procedures. Isoray moved to dismiss the amended complaint on March 9, 2017. Plaintiff responded on April 20, 2017, and Isoray replied on May 17, 2017. The court heard oral argument on the motion on August 22, 2017, and took the matter under advisement at that time. On October 19, 2017, the court granted Isoray’s motion to dismiss. The matter is now resolved.

Class Action Lawsuit re Equity Plans

On January 31, 2017, a putative class action complaint was filed against Isoray and certain current and former directors in the Superior Court of the State of Washington in and for Benton County under the case caption Griffith v. Isoray, Inc., Case No. 17-2-00194-2. The complaint alleged that Isoray’s board permitted certain employee compensation plans to be implemented without receiving the requisite percentage of votes by Isoray shareholders. On May 16, 2017, the parties executed a settlement for $195,000 of the individual Plaintiffs’ claims. The action was dismissed on July 10, 2017.

Table of Contents

16.

Concentrations of Credit and Other Risks

The Company’s financial instruments that were exposed to concentrations of credit risk consist primarily of cash and cash equivalents, U.S. Treasury securities, certificates of deposit, and accounts receivable.

The Company’s cash and cash equivalents were maintained with high-quality financial institutions at June 30, 2019 and 2018, respectively. At June 30, 2019 and 2018, respectively, all cash balances were guaranteed by the Federal Deposit Insurance Corporation (FDIC) and all cash equivalents consisted of U.S. Treasury securities.

The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. At both June 30, 2019 and 2018, the allowance was approximately $26,000.

Table of Contents

Inventories

Most components used in the Company’s product are purchased from outside sources. Certain components are purchased from single suppliers. The failure of any such supplier to meet its commitment on schedule could have a material adverse effect on the Company’s business, operating results and financial condition. If a sole-source supplier were to go out of business or otherwise become unable to meet its supply commitments, the process of locating and qualifying alternate sources could require up to several months, during which time the Company’s production could be delayed. Such delays could have a material adverse effect on the Company’s business, operating results and financial condition. Sanctions placed on financial transactions with Russian banking institutions may interfere with the Company’s ability to transact business in Russia on a temporary or other basis resulting in an interruption of the Cesium-131 supply which could have a temporary material adverse effect on the Company’s business, operating results and financial condition.

17.	Quarterly Financial Data (unaudited)

The following table provides the selected quarterly financial data for fiscal years 2019 and 2018 (dollars and shares in thousands, except for per share amounts):

	Quarters ended
	September 30,			December 31,			March 31,			June 30,
	2018			2018			2019			2019
Net revenue	$	1,562		$	1,904		$	1,924		$	1,924
Gross profit	$	524		$	765		$	879		$	879
Net loss	$	(1,508	)	$	(1,414	)	$	(1,127	)	$	(1,095	)
Net loss per share – basic and diluted	$	(0.02	)	$	(0.02	)	$	(0.02	)	$	(0.02	)
Shares used in basic and diluted per share calculation		66,147			67,331			67,333			67,357

	Quarters ended
	September 30,			December 31,			March 31,			June 30,
	2017			2017			2018			2018
Net revenue	$	1,211		$	1,536		$	1,573		$	1,603
Gross profit/(loss)	$	265		$	531		$	609		$	443
Net loss	$	(1,546	)	$	(1,463	)	$	(1,332	)	$	(2,343	)
Net loss per share – basic and diluted	$	(0.03	)	$	(0.03	)	$	(0.02	)	$	(0.04	)
Shares used in basic and diluted per share calculation		55,017			55,056			55,100			55,463

1.	Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations may be different.

Table of Contents

18.

Contracts with Customers

We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do not obligate us to provide goods to the customer and there is no consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is not controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the sale of our products and services as requested from our customers. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are not affected by contingent events that could impact the transaction price. We do not offer price concessions and do not accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do not have any material performance obligations where we are acting as an agent for another entity.

Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

Sources of Revenue

We have identified the following revenues disaggregated by revenue source:

Domestic – direct sales of products and services.

International – direct sales of products and services.

During the fiscal years 2019, 2018 and 2017, the Company had revenue from both sources. International revenues in all periods was immaterial. For the fiscal year 2019, prostate brachytherapy comprised 89% of our revenue while other revenue comprised 11% compared to 86% and 14%, respectively, in the fiscal year 2018, and 88% and 12%, respectively, in the fiscal year 2017.

Contract Balances

We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.

Warranty

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

Returns

Generally, we allow returns if not implanted and we are notified within a few weeks after satisfying our performance obligations of a return. Returns after shipment may result in a 50% restocking fee.

Significant Judgments in the Application of the Guidance in ASC 606

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Table of Contents

Commissions and Contract Costs

We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.

Practical Expedients

Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Shipping and Handling Charges

Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales.

Taxes Collected from Customers

As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.

Concentration of Customers

One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% of total Company sales. This group of facilities individually do not aggregate to more than 10% of total Company sales. They are serviced by the same physician group, one of whom is our Medical Director:

Year ended June 30,

Facility

2019
% of
total

revenue

2018
% of
total

revenue

2017
% of
total

revenue

El Camino, Los Gatos, & other facilities

22.1

24.2

22.9

19.

Subsequent Events

On July 3, 2019, the Company entered into another modification of the production facility lease that extends the term to April 20, 2026. This lease modification maintains the current rental rate through April 2020, and provides for an eighteen month termination notice with an early termination penalty of up to $40,000 which decreases each year.

Table of Contents

ITEM 16 – FORM 10-K SUMMARY

None

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 27, 2019

	ISORAY, INC., a Delaware corporation

	By /s/ Lori A. Woods
	Lori A. Woods, Chief Executive Officer, Director

	By /s/ Jonathan Hunt
	Jonathan Hunt, Chief Financial Officer,
	Co-Principal Financial Officer

	By /s/ Mark J. Austin
	Mark J. Austin, Controller,
	Co-Principal Financial and Principal Accounting Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Dated: September 27, 2019

	/s/ Lori A. Woods
	Lori A. Woods, Chief Executive Officer, Director

	/s/ Jonathan Hunt
	Jonathan Hunt, Chief Financial Officer,
	Co-Principal Financial Officer

	/s/ Mark J. Austin
	Mark J. Austin, Controller,
	Co-Principal Financial and Principal Accounting Officer

	/s/ Alan Hoffmann
	Alan Hoffmann, Director

	/s/ Michael McCormick
	Michael McCormick, Chairman

	/s/ Philip Vitale
	Philip Vitale, Director

Table of Contents

EX-10.41 2 ex_158570.htm EXHIBIT 10.41 ex_158570.htm

Exhibit 10.41

Addendum No. 9 to

Contract No. 840/08625142/25/158-15 dtd. 2015.12.07

Date of signature: 14.12.2018

THE SELLER

Joint Stock Company «Isotope»,

(JSC «Isotope»)

Pogodinskaya str., 22, Moscow, 119435, Russia.

Phone: +7(499) 245-01-18, 245-13-81.

THE BUYER

The Company IsoRay Medical Inc.

350 Hills Street, Suite 106

Richland, WA 99354-5411 USA

THE BUYER and THE SELLERS have mutually agreed about the following:

1.	Terms of delivery of the Goods under the present Contract is extended for August 4, 2019.

The present addendum is the integral part of contract 840/08625142/25/158-15 and may be signed by E-mail.

All other terms and conditions are in accordance with Contract No. 840/08625142/25/158-15, Appendices 1 and 2, Addenda 1, 2, 3, 4, 5, 7, 8.

THE SELLER		THE BUYER

/s/ Boris Akakiev		/s/ Lori A. Woods
Boris Akakiev		Lori A. Woods
Advisor to Director General		11 Jul 2019
JSC Isotope		Isoray - CEO

EX-10.45 3 ex_158727.htm EXHIBIT 10.45 ex_158727.htm

Exhibit 10.45

Sherri L. Schwartz Contracting Officer

P.O. Box 968 Richland, WA 99352-0968

Ph. 509-372-5072

SLSCHWARTZ@energy-northwest.com

LEASE MODIFICATION

Issued by: S. L. Schwartz, Principal Contracting Officer

LESSEE: ISORAY MEDICAL, INC.

350 Hills Street, Suite 106

Richland, WA 99354

Lease Agreement Number: X-40403

Modification Number: 26

Modification Date: July 3, 2019

DESCRIPTION OF MODIFICATION

The subject Lease Agreement is herein modified to extend the Term of the Lease, adjust Termination notice and document the Consumers Price Index (CPI) increase for year 2019 and future increases, as detailed below.

ARTICLE 2 – TERM

Effective May 1, 2021, the contract term shall extend for an additional 5 year term with a completion date of April 30, 2026.

ARTICLE 4 – RENT

MONTHLY RENT PAYMENTS – The rental rates set forth in Amendment 25 of the Lease Agreement shall not increase by the CPI for the lease period beginning May 1, 2019 to April 30th, 2020. The CPI rental rate increase requirements will resume on May 1st, 2020 and will be capped at 3%. Current total monthly Lease payment is $24,137.36.

ARTICLE 28 – TERMINATION

Both parties hereby agree to modify the advanced written notice of intent to terminate whereas either party shall be required to give the other party eighteen (18) months advanced written notice of its intent to terminate.

In addition to the termination notice of 18 months, both parties hereby agree to an early termination penalty as follows:

4 years or more: $40,000

3 years but less than 4 years:$30,000

2 years but less than 3 years:$20,000

1 year but less than 2 years: $10,000

The completion date, Contract Rent and all other terms, covenants and conditions of the above- referenced Contract, except as duly modified by this and previous amendments, if any, remain in full force and effect.

EXECUTION

LESSOR: ENERGY NORTHWEST	LESSEE: ISORAY MEDICAL, Inc.
Name: /s/ Brad Sawatzke	Name: /s/ Jonathan Hunt
Title: Chief Executive Officer	Title: Chief Financial Officer (CFO)
Date: 8/19/19	Date: 7/17/19

EX-21.1 4 ex_158242.htm EXHIBIT 21.1 ex_158242.htm

Exhibit 21.1

Subsidiaries of the Company

Isoray Medical, Inc.

Isoray International, LLC

EX-23.1 5 ex_158243.htm EXHIBIT 23.1 ex_158243.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-227909) and Form S-8 (Nos. 333-136728, 333-127717 and 333-218853) of Isoray, Inc. and Subsidiaries of our report dated September 27, 2019, relating to the consolidated financial statements which appears in this Form 10-K.

/s/ DeCoria, Maichel & Teague, P.S.

Spokane, Washington
September 27, 2019

EX-31.1 6 ex_158244.htm EXHIBIT 31.1 ex_158244.htm

Exhibit 31.1

CERTIFICATION

I, Lori A. Woods, certify that:

1. I have reviewed this annual report on Form 10-K of Isoray, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 27, 2019

	/s/ Lori A. Woods
	Lori A. Woods
	Chief Executive Officer

EX-31.2 7 ex_158245.htm EXHIBIT 31.2 ex_158245.htm

Exhibit 31.2

CERTIFICATION

I, Jonathan Hunt, certify that:

1. I have reviewed this annual report on Form 10-K of Isoray, Inc.;

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 27, 2019

	/s/ Jonathan Hunt
	Jonathan Hunt
	Chief Financial Officer Co-Principal Financial Officer

EX-31.3 8 ex_158246.htm EXHIBIT 31.3 ex_158246.htm

Exhibit 31.3

CERTIFICATION

I, Mark J. Austin, certify that:

1. I have reviewed this annual report on Form 10-K of Isoray, Inc.;

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 27, 2019

	/s/ Mark J. Austin
	Mark J. Austin
	Controller Co-Principal Financial and Principal Accounting Officer

EX-32 9 ex_158247.htm EXHIBIT 32 ex_158247.htm

Exhibit 32

Section 1350 Certifications

Pursuant to 18 U.S.C. § 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Isoray, Inc., a Delaware corporation (the Company), hereby certify that:

To my knowledge, the Annual Report on Form 10-K of the Company for the annual period ended June 30, 2019 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 27, 2019

	/s/ Lori A. Woods
	Lori A. Woods
	Chief Executive Officer
	(Principal Executive Officer)

Dated: September 27, 2019

	/s/ Jonathan Hunt
	Jonathan Hunt
	Chief Financial Officer
	(Co-Principal Financial Officer)

Dated: September 27, 2019

	/s/ Mark J. Austin
	Mark J. Austin
	Controller
	(Co-Principal Financial and Principal Accounting Officer)

EX-101.INS 10 isr-20190630.xml XBRL INSTANCE DOCUMENT false --06-30 FY 2019 2019-06-30 10-K 0000728387 67388047 Yes false Non-accelerated Filer 20081002 IsoRay, Inc. false true No No Common Stock isr 89000 155000 133000 77000 203000 203000 44000 -44000 207000 207000 2800000 200000 0.01 0.94 0.28 0.76 250000 230087 5830000 500000 500000 5830000 0.51 0.41 4000000 1 1 48000 -178000 -9000 -66000 17000 66000 56000 2000 -47000 -33000 37000 27000 P1Y P5Y 40000 163000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Prepaid Expenses and Other Assets</div> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value.</div></div></div></div></div></div> 0.01 0.02 0.01 478000 P1Y 45000 395000 194000 1429000 1351000 771000 0.5 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt auto 0pt 45pt; min-; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 87%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Production equipment (in years)</div> </td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">3</div></div> </td> <td style="vertical-align: top; width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 87%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Office equipment (in years)</div> </td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">2</div></div> </td> <td style="vertical-align: top; width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 87%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Furniture and fixtures (in years)</div> </td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">2</div></div> </td> <td style="vertical-align: top; width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average fair value</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.51</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,830,000</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;">Exercise price</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.75</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.9375</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.74%</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102.73%</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt auto 0pt 0pt; min-; min-width: 700px;"> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 80%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Weighted average fair value</div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.41</div></td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> </td> <td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 80%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Warrants issued</div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div></td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> </td> <td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 80%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Exercise price</div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">$0.01</div></div> </td> <td style="vertical-align: bottom; width: 6%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$0.54</div></div> </td> <td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 80%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Expected term (in years)</div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">2</div></div> </td> <td style="vertical-align: bottom; width: 6%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">3</div></div> </td> <td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 80%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Risk-free rate</div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">1.62%</div></div> </td> <td style="vertical-align: bottom; width: 6%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">2.55%</div></div> </td> <td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: bottom; width: 80%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Volatility</div> </td> <td style="vertical-align: top; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">60%</div></div> </td> <td style="vertical-align: bottom; width: 6%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="vertical-align: bottom; width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">82%</div></div> </td> <td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> </table></div> 1179164 0.94 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Shipping and Handling Costs</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in the transaction price.</div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Distribution Agreements</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 14, 2017, </div>the Company entered into an agreement with a new distributor in Russia that provides for the ability to sell the entire product line in the Russian Federation. The agreement has a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year initial term with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year terms which automatically renew unless either party invokes their right to terminate earlier under the provisions of the agreement. The Company and the distributor for Italy and Switzerland executed the distribution agreement on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 1, 2016. </div>The agreement has a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year initial term with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year terms which automatically renew unless either party invoke their right to terminate earlier under the provisions of the agreement. The agreement expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 1, 2019 </div>and was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> renewed. As the Company elected to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> renew its CE mark in fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> distribution will be limited to those countries outside the European Union.</div></div>

683000

1391000

142000

175000

7370000

7671000

92105000

84322000

50000

45000

372000

404000

420000

38000

62000

86000

84000

92000

60000

96000

92000

86000

202000

158000

140000

420000

404000

372000

26000

14000

12000

18000

16000

18000

17000

50000

45000

59065

6080000

250000

4645315

3759840

3379191

10784380

4068905

3438256

590000

561000

621000

31000

29000

621000

590000

9422000

7455000

7315000

5446000

5326000

2600000

5932000

5326000

2600000

2781000

6113000

10320000

5507000

2726000

-3332000

-4207000

0.75

0.9375

0.75

0.9375

0.01

0.54

0.94

0.54

0.75

5500000

330000

5830000

6080000

230087

250000

0.001

200000000

67388047

56331147

67388047

56331147

67000

56000

0.89

0.11

0.86

0.14

0.88

0.12

0.221

0.242

0.229

4267000

4081000

3923000

11000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other prepaid expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">154</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">241</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other current assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Total prepaid expenses and other current assets</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">305</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">335</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

16248000

15020000

15207000

14171000

6000

10000

204000

197000

96000

578000

480000

130000

124000

27000

38000

16248000

15020000

136000

80000

68000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div> </div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company currently provides share-based compensation under <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> equity incentive plan approved by the Board of Directors and the shareholders:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <table style="; text-indent: 0px; font-family: "Times New Roman"; font-size: 10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top; font-family: "Times New Roman"; font-size: 10pt;"> <td style="width: 18pt; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 18pt; font-family: "Times New Roman"; font-size: 10pt;">■</td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Equity Incentive Plan (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Incentive Plan).</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-18pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006</div> Director Plan allowed the Board of Directors to grant options to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000,000</div> shares of common stock to directors of the Company. The plan expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 16, 2016.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Options granted prior to fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> were made pursuant to plans that have expired or were terminated.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s shareholders approved the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Incentive Plan (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2017</div> Plan”) in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017. </div>The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan allows the Board of Directors to grant up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000,000</div> shares of common stock to directors, officers, employees and consultants in a combination of equity incentive forms including incentive stock options (ISO), non-qualified stock options (NQSO), stock appreciation right (SAR) or restricted shares (RSU) of common stock. Options granted under all of the Plans have a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> year maximum term, an exercise price equal to at least the fair market value of the Company’s common stock (based on the trading price on the NYSE American) on the date of the grant, and with varying vesting periods as determined by the Board.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. The Company uses the Black-Scholes option valuation model because management believes the model is appropriate for the Company. However, management understands that because changes in the subjective input assumptions can materially affect the fair value estimate, this valuation model does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily provide a reliable single measure of the fair value of its stock options. The risk-free interest rate is based on the U.S. treasury security rate with an equivalent term in effect as of the date of grant. The expected option lives and volatility assumptions are based on historical data of the Company.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="15" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 51%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average fair value</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.31</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.34</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.45</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,252,500</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,125,000</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,150,000</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;">Exercise price</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.37</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.55</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.44</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.58</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.55</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.84</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.83%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.91%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.83%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.85%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.62%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.83%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">105%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94% </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table presents the share-based compensation expense (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">202</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">158</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">372</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The total value of the stock options awards is expensed ratably over the vesting period of the employees receiving the awards. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>total unrecognized compensation cost related to stock-based options and awards was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$632,000</div> and the weighted-average period over which it is expected to be recognized is approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.08</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">A summary of stock option information within the Company’s share-based compensation plans during the fiscal years is presented below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price (a)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (b)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value (c)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2016</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,925,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.21</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.93</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted (d)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,150,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.61</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired/Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(509,904</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.55</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Voided</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,179,164</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.94</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,800</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.26</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2017</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,191</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.78</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.86</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">151</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted (d)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,125,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.47</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.75</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(561,541</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.77</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(82,810</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.61</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2018</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,759,840</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.69</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.75</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted (d)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,252,500</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.44</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(242,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.41</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(68,125</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.54</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(56,900</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.26</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.95</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.95</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,153,645</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.81</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.76</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Weighted average exercise price per share.</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Weighted average remaining contractual life.</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)</div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Aggregate intrinsic value (in thousands).</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">All options granted had exercise prices equal to or greater than the ending closing market price of the Company’s common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Aggregate intrinsic value of options exercised (in thousands)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s current policy is to issue new shares to satisfy option exercises.</div></div>

11000

-0.08

-0.12

-0.11

-0.02

-0.03

-0.02

-0.04

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Income (Loss) Per Common Share</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company’s net loss position.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities that could be dilutive in the future are as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,759,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,191</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total potential dilutive securities</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,784,380</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,068,905</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,438,256</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div></div></div></div></div></div>

0.21

0.28

0.35

632000

P1Y29D

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Fair Value Measurement</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> uses quoted prices in active markets for identical assets or liabilities, Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> uses significant other observable inputs, and Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> financial assets or liabilities that are adjusted to fair value on a recurring basis.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assets or liabilities measured at fair-value on a recurring basis which were measured using Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div>), the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assets or liabilities measured at fair value on a nonrecurring basis during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. (In thousands)</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value at June 30, </div><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value at June 30, </div><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,600</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,600</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s cash and cash equivalent instruments are classified within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> of the fair value hierarchy because they are valued using quoted market prices.</div></div></div></div></div></div>

810000

778000

32000

38000

23000

90000

516000

520000

366000

972000

976000

162000

198000

24000

2000

24000

2000

4172000

4165000

3920000

3047000

1842000

838000

524000

765000

879000

265000

531000

609000

443000

9500000

1228000

-7703000

2123000

9556000

-1080000

-1878000

-2157000

12000

21000

17000

18000

4000

16000

10000

-708000

761000

18000

-38000

466000

184000

-128000

-23000

-89000

37000

-88000

-52000

-30000

64000

-100000

31000

27000

530000

494000

117000

276000

38000

43000

155000

319000

333000

371000

166000

96000

108000

29000

118000

203000

1742000

2425000

9422000

7455000

1121000

1835000

3537500

195000

210000

329000

323000

7374000

521000

-9000

401000

1859000

1514000

-5049000

-5712000

-5144000

-6700000

-6162000

-6700000

-5144000

-1508000

-1414000

-1127000

-1095000

-1546000

-1463000

-1332000

-2343000

-5155000

-6711000

-6173000

110000

29000

145000

2017 2018 2019

8301000

8571000

7145000

-5254000

-6729000

-6307000

531000

241000

290000

72400000

27000

29000

162000

198000

74000

37000

2000

154000

241000

86000

41000

11000

14000

18000

124000

444000

337000

549000

4725000

4054000

115000

5000

0.15

11000

0.001

7000000

7001671

5000000

59065

9000

305000

335000

38000

24000

505000

8250000

7370000

479000

34000

6000

5550000

6268000

2296000

15000

50000

2000

3000

366000

3825000

4152000

4143000

4136000

645000

328000

8979000

8982000

1609000

1311000

P3Y

P7Y

P2Y

P5Y

P2Y

P5Y

-4000

22000

1154000

1192000

266000

769000

387000

1474000

1746000

965000

181000

-84492000

-79348000

7314000

5923000

4761000

1562000

1904000

1924000

1211000

1536000

1573000

1603000

33000

27000

21000

285000

288000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,759,840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total potential dilutive securities</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,784,380</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,068,905</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,438,256</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 14px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12px;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fixed assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">578</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accruals</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Asset retirement obligation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">124</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Research credit carryforwards</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Other</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,207</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,171</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,248</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,020</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,248</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,020</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 14px; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 12px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the year ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory income tax rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">21</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">28</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">35</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected income tax benefit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,080</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,878</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,157</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Meals and entertainment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-deductible penalties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant derivative liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Impact on the change in income tax rate</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,556</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">Change in estimate</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(178)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,228</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,703</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,123</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense (benefit)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of sales</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">202</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">158</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">372</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">333</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">371</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Work in process</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total inventory</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">530</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">494</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Enriched barium, non-current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials, non-current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total inventory, non-current</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">319</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 18pt; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Website development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Licenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">516</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">520</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patents and trademarks</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total Other Assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">972</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">976</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Accumulated Amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(810</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(778</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">198</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense on website development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense on licenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense on patents and trademarks</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total amortization expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price (a)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (b)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value (c)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2016</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,925,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.21</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.93</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted (d)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,150,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.61</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired/Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(509,904</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.55</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Voided</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,179,164</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.94</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,800</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.26</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2017</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,191</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.78</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.86</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">151</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted (d)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,125,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.47</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.75</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(561,541</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.77</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(82,810</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.61</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2018</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,759,840</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.69</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.75</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted (d)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,252,500</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.44</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(242,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.41</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(68,125</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.54</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(56,900</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.26</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.95</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.64</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.95</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,153,645</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.81</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.76</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Aggregate intrinsic value of options exercised (in thousands)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="15" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 51%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Year Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average fair value</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.31</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.34</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.45</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,252,500</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,125,000</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,150,000</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;">Exercise price</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.37</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.44</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.58</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.55</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.84</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.83%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.91%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.83%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.85%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.62%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.83%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">105%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94% </div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">101%</div></td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrants</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price (a)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2016</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230,087</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(230,087</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2017</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(250,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants Issued</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,830,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.76</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

2679000

2660000

2310000

420000

404000

372000

0.37

0.55

0.44

0.58

0.55

0.84

0.89

1.05

0.94

1.01

1.03

0.0183

0.0291

0.0183

0.0285

0.0162

0.0183

1000000

4000000

2153645

0.81

11000

3000

509904

100000

242000

561541

68125

2150000

1125000

1252500

0.31

0.34

0.45

263000

151000

49000

1000

2925059

3379191

3759840

4645315

1.21

0.78

0.69

0.64

1000

4645315

0.64

1252500

1125000

2150000

0.26

0.61

0.26

2.55

0.75

0.41

0.77

0.54

0.61

0.47

0.44

P5Y182D

P2Y

P3Y

1.0273

0.6

0.82

0.0274

0.0162

0.0255

P10Y

P5Y

P4Y

P5Y

P6Y277D

P6Y339D

P7Y313D

P7Y273D

P7Y346D

0.515

0.75

59065

55010619

59065

55017419

59065

56331147

59065

67388047

825000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;"></div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Basis of Presentation and Principles of Consolidation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation.</div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Cash Equivalents</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Investments</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Investments with original maturities greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months and remaining maturities less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are classified as “Short-term investments” and included in current assets. Investments with remaining maturities greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are classified as “Investments, non-current” and are included in noncurrent assets. These investments are held to maturity and carried at amortized cost.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Accounts Receivable</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Inventory</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Inventory is reported at the lower of cost or net realizable value. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out basis.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The cost of materials and production costs contained in inventory that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> usable due to the passage of time, and resulting loss of bio-effectiveness, are written off to cost of sales at the time it is determined that the product is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer usable.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Property and Equipment</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Fixed assets are capitalized and carried at cost less accumulated depreciation. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Depreciation is computed using the straight-line method over the following estimated useful lives:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt auto 0pt 45pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 87%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Production equipment (in years)</div> </td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">3</div></div> </td> <td style="vertical-align: top; width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 87%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Office equipment (in years)</div> </td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">2</div></div> </td> <td style="vertical-align: top; width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="vertical-align: top; width: 87%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Furniture and fixtures (in years)</div> </td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">2</div></div> </td> <td style="vertical-align: top; width: 3%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="vertical-align: top; width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recoverable and exceeds its fair value.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Prepaid Expenses and Other Assets</div> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Asset Retirement Obligation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The estimated fair value of the future retirement costs of the Company’s leased assets and the costs for the decontamination and reclamation of equipment located within the footprint leased asset are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Financial Instruments</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the carrying value of financial instruments which include U.S. Treasury Securities, certificates of deposit and restricted cash, approximated fair value.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Fair Value Measurement</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> uses quoted prices in active markets for identical assets or liabilities, Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> uses significant other observable inputs, and Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> financial assets or liabilities that are adjusted to fair value on a recurring basis.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assets or liabilities measured at fair-value on a recurring basis which were measured using Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div>), the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assets or liabilities measured at fair value on a nonrecurring basis during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. (In thousands)</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value at June 30, </div><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value at June 30, </div><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,600</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,600</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s cash and cash equivalent instruments are classified within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> of the fair value hierarchy because they are valued using quoted market prices.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Revenue Recognition</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company recognizes revenue based on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-step model for revenue recognition as prescribed by ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> <div style="display: inline; font-style: italic;">Revenue from Contracts with Customers</div>, as follows: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) identify the contract with the customer; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) identify the performance obligations in the contract; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) determine the transaction price; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) allocate the prices to the performance obligations; and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>) recognize revenue. The Company has some agreements that contain general commercial terms and product prices but do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contain an obligation to provide goods to the customer. Our performance obligation, which is established when the customer submits a purchase order and the Company accepts the order, is to deliver the product based on the purchase order received. The Company typically recognizes revenue at the time of shipment, at which time the title passes to the customer, and there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further performance obligations. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Shipping and Handling Costs</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in the transaction price.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Share-Based Compensation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options and stock warrants on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Company recognizes forfeitures as they occur.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Research and Development Costs </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Research and Development - Proprietary</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year recognized.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Research and Development - Collaborative Arrangement</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Research and development costs incurred and shared in connection with a collaborative research and development project are separately stated in the consolidated statement of operation under “Research and development: Collaboration arrangements, net of reimbursement.”</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Advertising and Marketing Costs</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. (In thousands)</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">For the Years Ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advertising and marketing costs expensed (including tradeshows)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">210</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">329</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">323</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">At June 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid marketing expenses deferred until event occurs</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Legal Contingencies</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe any probable legal proceedings or claims will have a material adverse effect on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company’s recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Income Taxes</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Income taxes are accounted for under the liability method. Under this method, the Company provides deferred income taxes for temporary differences that will result in taxable or deductible amounts in future years based on the reporting of certain costs in different periods for financial statement and income tax purposes. This method also requires the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that realization of such benefits is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not.</div> Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment of the change. In the event that the Company is assessed penalties and or interest, penalties will be charged to other operating expense and interest will be charged to interest expense in the period that they are assessed.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Income (Loss) Per Common Share</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company’s net loss position.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities that could be dilutive in the future are as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">9</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Preferred stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,065</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,080,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,645,315</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,759,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,191</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total potential dilutive securities</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,784,380</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,068,905</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,438,256</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Recent Accounting Pronouncements</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div>   Revenue Recognition, replacing guidance currently codified in Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> Revenue Recognition-Overall with various SEC Staff Accounting Bulletins providing interpretive guidance. The guidance establishes a new <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> step principle-based framework in an effort to significantly enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The standard became effective for the Company in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of its fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> The Company adopted the new standard in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and used the modified retrospective method. The adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the consolidated financial statements of the Company and did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> significantly change the timing of revenue recognition compared to the previous methodology. </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> Leases (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>including interim periods within those fiscal years. Early adoption is permitted. The modified retrospective transition approach is required. The ASU will be effective for the Company in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020</div> and the most significant effects of this ASU relate to the recognition of a new right-of-use asset and corresponding lease liability.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> Collaborative Arrangements (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">808</div>): Clarifying the Interaction Between Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">808</div> and Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606.</div> The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019, </div>with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Other accounting standards that have been issued or proposed by FASB that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require adoption until a future date are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to have a material impact on the consolidated financial statements upon adoption. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> discuss recent pronouncements that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</div></div></div>

250000

980918

11000000

980918

11000000

6800

82810

56900

6800

82810

56900

3000

1000

478000

479000

11000

7359000

7370000

2000

50000

15000

7680000

5030000

55000

82788000

-66442000

16401000

55000

83151000

-72604000

10602000

56000

84322000

-79348000

67000

92105000

-84492000

100000

27000

67042000

55159000

55016000

66147000

67331000

67333000

67357000

55017000

55056000

55100000

55463000

Weighted average exercise price per share. Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at June 30, 2019 and 2018 are costs associated with advance planning and design work on the Company's new production facility of $207,000. Weighted average exercise price per share. Weighted average remaining contractual life. Aggregate intrinsic value (in thousands). All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to five years. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000728387 2015-07-01 2016-06-30 0000728387 2015-12-01 2015-12-31 0000728387 2016-07-01 2017-06-30 0000728387 us-gaap:EmployeeStockOptionMember 2016-07-01 2017-06-30 0000728387 isr:PreferredStocksMember 2016-07-01 2017-06-30 0000728387 us-gaap:WarrantMember 2016-07-01 2017-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember isr:ElCaminoLosGatosOtherFacilitiesMember 2016-07-01 2017-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductAndServiceOtherMember 2016-07-01 2017-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember isr:ProstateBrachytherapyMember 2016-07-01 2017-06-30 0000728387 isr:GammatileLLCMember isr:CollaborativeDevelopmentAgreementMember 2016-07-01 2017-06-30 0000728387 us-gaap:ComputerSoftwareIntangibleAssetMember 2016-07-01 2017-06-30 0000728387 us-gaap:IntellectualPropertyMember 2016-07-01 2017-06-30 0000728387 us-gaap:LicensingAgreementsMember 2016-07-01 2017-06-30 0000728387 us-gaap:CostOfSalesMember 2016-07-01 2017-06-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2017-06-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2017-06-30 0000728387 us-gaap:SellingAndMarketingExpenseMember 2016-07-01 2017-06-30 0000728387 isr:RoyaltyAgreementForInventionAndPatentApplicationMember 2016-07-01 2017-06-30 0000728387 srt:MaximumMember 2016-07-01 2017-06-30 0000728387 srt:MinimumMember 2016-07-01 2017-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-07-01 2017-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2017-06-30 0000728387 us-gaap:CommonStockMember 2016-07-01 2017-06-30 0000728387 us-gaap:RetainedEarningsMember 2016-07-01 2017-06-30 0000728387 isr:AtTheMarketOfferingMember 2016-07-01 2017-06-30 0000728387 isr:RegisteredDirectOfferingMember 2016-07-01 2017-06-30 0000728387 isr:IrradiationServicesAgreementMember 2016-11-29 2016-11-29 0000728387 isr:ClassActionLawsuitRelatedToPressReleaseMember 2017-03-09 2017-03-09 0000728387 isr:ClassActionLawsuitReEquityPlanMember 2017-05-16 2017-05-16 0000728387 us-gaap:EmployeeStockOptionMember isr:The2017IncentivePlanMember 2017-06-01 2017-06-30 0000728387 2017-07-01 2017-09-30 0000728387 2017-07-01 2018-06-30 0000728387 us-gaap:EmployeeStockOptionMember 2017-07-01 2018-06-30 0000728387 isr:PreferredStocksMember 2017-07-01 2018-06-30 0000728387 us-gaap:WarrantMember 2017-07-01 2018-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember isr:ElCaminoLosGatosOtherFacilitiesMember 2017-07-01 2018-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductAndServiceOtherMember 2017-07-01 2018-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember isr:ProstateBrachytherapyMember 2017-07-01 2018-06-30 0000728387 isr:GammatileLLCMember isr:CollaborativeDevelopmentAgreementMember 2017-07-01 2018-06-30 0000728387 us-gaap:WarrantMember 2017-07-01 2018-06-30 0000728387 us-gaap:WarrantMember srt:MaximumMember 2017-07-01 2018-06-30 0000728387 us-gaap:WarrantMember srt:MinimumMember 2017-07-01 2018-06-30 0000728387 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-07-01 2018-06-30 0000728387 us-gaap:IntellectualPropertyMember 2017-07-01 2018-06-30 0000728387 us-gaap:LicensingAgreementsMember 2017-07-01 2018-06-30 0000728387 us-gaap:CostOfSalesMember 2017-07-01 2018-06-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2018-06-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2018-06-30 0000728387 us-gaap:SellingAndMarketingExpenseMember 2017-07-01 2018-06-30 0000728387 isr:RoyaltyAgreementForInventionAndPatentApplicationMember 2017-07-01 2018-06-30 0000728387 srt:MaximumMember 2017-07-01 2018-06-30 0000728387 srt:MinimumMember 2017-07-01 2018-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-07-01 2018-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2018-06-30 0000728387 us-gaap:CommonStockMember 2017-07-01 2018-06-30 0000728387 us-gaap:RetainedEarningsMember 2017-07-01 2018-06-30 0000728387 isr:AtTheMarketOfferingMember 2017-07-01 2018-06-30 0000728387 isr:RegisteredDirectOfferingMember 2017-07-01 2018-06-30 0000728387 2017-10-01 2017-12-31 0000728387 2018-01-01 2018-03-31 0000728387 2018-04-01 2018-06-30 0000728387 isr:SalesAgreementMember 2018-05-08 2018-06-30 0000728387 isr:SalesAgreementMember 2018-07-01 2018-07-31 0000728387 2018-07-01 2018-09-30 0000728387 2018-07-01 2019-06-30 0000728387 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000728387 isr:PreferredStocksMember 2018-07-01 2019-06-30 0000728387 us-gaap:WarrantMember 2018-07-01 2019-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember isr:ElCaminoLosGatosOtherFacilitiesMember 2018-07-01 2019-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductAndServiceOtherMember 2018-07-01 2019-06-30 0000728387 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember isr:ProstateBrachytherapyMember 2018-07-01 2019-06-30 0000728387 isr:GammatileLLCMember isr:CollaborativeDevelopmentAgreementMember 2018-07-01 2019-06-30 0000728387 us-gaap:WarrantMember 2018-07-01 2019-06-30 0000728387 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-07-01 2019-06-30 0000728387 us-gaap:IntellectualPropertyMember 2018-07-01 2019-06-30 0000728387 us-gaap:LicensingAgreementsMember 2018-07-01 2019-06-30 0000728387 us-gaap:CostOfSalesMember 2018-07-01 2019-06-30 0000728387 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2019-06-30 0000728387 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2019-06-30 0000728387 us-gaap:SellingAndMarketingExpenseMember 2018-07-01 2019-06-30 0000728387 isr:RoyaltyAgreementForInventionAndPatentApplicationMember 2018-07-01 2019-06-30 0000728387 us-gaap:EquipmentMember srt:MaximumMember 2018-07-01 2019-06-30 0000728387 us-gaap:EquipmentMember srt:MinimumMember 2018-07-01 2019-06-30 0000728387 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2018-07-01 2019-06-30 0000728387 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2018-07-01 2019-06-30 0000728387 us-gaap:OfficeEquipmentMember srt:MaximumMember 2018-07-01 2019-06-30 0000728387 us-gaap:OfficeEquipmentMember srt:MinimumMember 2018-07-01 2019-06-30 0000728387 isr:OtherMember 2018-07-01 2019-06-30 0000728387 srt:MaximumMember 2018-07-01 2019-06-30 0000728387 srt:MinimumMember 2018-07-01 2019-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2018-07-01 2019-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-07-01 2019-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2019-06-30 0000728387 us-gaap:CommonStockMember 2018-07-01 2019-06-30 0000728387 us-gaap:RetainedEarningsMember 2018-07-01 2019-06-30 0000728387 isr:AtTheMarketOfferingMember 2018-07-01 2019-06-30 0000728387 isr:RegisteredDirectOfferingMember 2018-07-01 2019-06-30 0000728387 us-gaap:PrivatePlacementMember 2018-07-11 2018-07-11 0000728387 2018-10-01 2018-12-31 0000728387 2019-01-01 2019-03-31 0000728387 2019-04-01 2019-06-30 0000728387 2016-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000728387 us-gaap:CommonStockMember 2016-06-30 0000728387 us-gaap:RetainedEarningsMember 2016-06-30 0000728387 isr:The2006DirectorPlanMember 2016-08-15 0000728387 2017-06-30 0000728387 isr:The2017IncentivePlanMember 2017-06-30 0000728387 srt:MaximumMember 2017-06-30 0000728387 srt:MinimumMember 2017-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2017-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000728387 us-gaap:CommonStockMember 2017-06-30 0000728387 us-gaap:RetainedEarningsMember 2017-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2017-12-31 0000728387 2018-06-30 0000728387 isr:GammatileLLCMember isr:CollaborativeDevelopmentAgreementMember 2018-06-30 0000728387 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000728387 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000728387 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000728387 us-gaap:WarrantMember 2018-06-30 0000728387 us-gaap:WarrantMember srt:MaximumMember 2018-06-30 0000728387 us-gaap:WarrantMember srt:MinimumMember 2018-06-30 0000728387 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-06-30 0000728387 us-gaap:IntellectualPropertyMember 2018-06-30 0000728387 us-gaap:LicensingAgreementsMember 2018-06-30 0000728387 isr:For91DaysToSixMonthsMember us-gaap:CertificatesOfDepositMember 2018-06-30 0000728387 isr:GreaterThan1YearMember us-gaap:CertificatesOfDepositMember 2018-06-30 0000728387 isr:SixMonthsTo1YearMember us-gaap:CertificatesOfDepositMember 2018-06-30 0000728387 isr:Under90DaysMember us-gaap:CertificatesOfDepositMember 2018-06-30 0000728387 us-gaap:ConstructionInProgressMember 2018-06-30 0000728387 us-gaap:EquipmentMember 2018-06-30 0000728387 us-gaap:LandMember 2018-06-30 0000728387 us-gaap:LeaseholdImprovementsMember 2018-06-30 0000728387 isr:OtherMember 2018-06-30 0000728387 isr:EnrichedBariumInventoryMember 2018-06-30 0000728387 isr:RawMaterialsMember 2018-06-30 0000728387 srt:MaximumMember 2018-06-30 0000728387 srt:MinimumMember 2018-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2018-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2018-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000728387 us-gaap:CommonStockMember 2018-06-30 0000728387 us-gaap:RetainedEarningsMember 2018-06-30 0000728387 isr:SalesAgreementMember 2018-06-30 0000728387 isr:WarrantsWithExercisePriceOf75CentsPerShareMember us-gaap:PrivatePlacementMember 2018-07-11 0000728387 isr:WarrantsWithExercisePriceOfPoint9375PerShareMember isr:HCWainwrightCoLLCMember us-gaap:PrivatePlacementMember 2018-07-11 0000728387 us-gaap:PrivatePlacementMember 2018-07-11 0000728387 2018-12-31 0000728387 us-gaap:SeriesBPreferredStockMember 2018-12-31 0000728387 2019-06-30 0000728387 isr:GammatileLLCMember isr:CollaborativeDevelopmentAgreementMember 2019-06-30 0000728387 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000728387 us-gaap:WarrantMember 2019-06-30 0000728387 us-gaap:WarrantMember srt:MaximumMember 2019-06-30 0000728387 us-gaap:WarrantMember srt:MinimumMember 2019-06-30 0000728387 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-06-30 0000728387 us-gaap:IntellectualPropertyMember 2019-06-30 0000728387 us-gaap:LicensingAgreementsMember 2019-06-30 0000728387 isr:PatentAndKnowHowRoyaltyLicenseAgreementMember 2019-06-30 0000728387 isr:RoyaltyAgreementForInventionAndPatentApplicationMember 2019-06-30 0000728387 isr:RoyaltyAgreementForInventionAndPatentApplicationMember isr:FormerEmployeeAndShareholderMember 2019-06-30 0000728387 us-gaap:ConstructionInProgressMember 2019-06-30 0000728387 us-gaap:EquipmentMember 2019-06-30 0000728387 us-gaap:LandMember 2019-06-30 0000728387 us-gaap:LeaseholdImprovementsMember 2019-06-30 0000728387 isr:OtherMember 2019-06-30 0000728387 isr:EnrichedBariumInventoryMember 2019-06-30 0000728387 isr:RawMaterialsMember 2019-06-30 0000728387 srt:MaximumMember 2019-06-30 0000728387 srt:MinimumMember 2019-06-30 0000728387 us-gaap:SeriesAPreferredStockMember 2019-06-30 0000728387 us-gaap:SeriesBPreferredStockMember 2019-06-30 0000728387 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-06-30 0000728387 us-gaap:SeriesCPreferredStockMember 2019-06-30 0000728387 us-gaap:SeriesDPreferredStockMember 2019-06-30 0000728387 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000728387 us-gaap:CommonStockMember 2019-06-30 0000728387 us-gaap:RetainedEarningsMember 2019-06-30 0000728387 us-gaap:ResearchMember 2019-06-30 0000728387 srt:MaximumMember us-gaap:SubsequentEventMember 2019-07-03 0000728387 2019-09-24

EX-101.SCH 11 isr-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statement of Changes in Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Short-term Investments link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Inventory link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Prepaid expenses and Other Current Assets link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Property & Equipment link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Restricted Cash link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Other Assets, Net link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Asset Retirement Obligation link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Distribution Agreements link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Concentrations of Credit and Other Risks link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17 - Quarterly Financial Data (Unaudited) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 19 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 3 - Short-term Investments (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 4 - Inventory (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Prepaid expenses and Other Current Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 6 - Property & Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 8 - Other Assets, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 9 - Asset Retirement Obligation (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 10 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 11 - Shareholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 12 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 15 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 17 - Quarterly Financial Data (Unaudited) (Tables) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 18 - Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair value (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Advertising and Marketing Costs (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 3 - Short-term Investments - Summary of Short- Term Investments (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 4 - Inventory - Current Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 4 - Inventory - Noncurrent Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 5 - Prepaid expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 6 - Property & Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 6 - Property & Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 7 - Restricted Cash (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 8 - Other Assets, Net - Other Assets, Net of Accumulated Amortization (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 8 - Other Assets, Net - Future Amortization (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 9 - Asset Retirement Obligation - Asset Retirement Obligation (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 10 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 10 - Share-based Compensation - Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 10 - Share-based Compensation - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 10 - Share-based Compensation - Summary of Stock Option (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 11 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 11 - Shareholders' Equity - Fair Value Assumption of Warrant (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 11 - Shareholders' Equity - Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 12 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 12 - Income Taxes - Deferred Tax Components (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 12 - Income Taxes - Reconciliation of Income Tax Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 15 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 15 - Commitments and Contingencies - Future Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 15 - Commitments and Contingencies - Royalty Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 16 - Concentrations of Credit and Other Risks (Details Textual) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 17 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 18 - Contracts With Customers (Details Textual) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 18 - Contracts With Customers - Concentration of Customers (Details) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 19 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 12 isr-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 isr-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 isr-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Expected income tax benefit Note 3 - Short-term Investments Risk-free rate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Note 4 - Inventory Note 5 - Prepaid expenses and Other Current Assets Note 6 - Property & Equipment Note 8 - Other Assets, Net Note 9 - Asset Retirement Obligation Note 10 - Share-based Compensation Income Tax Disclosure [Text Block] Note 11 - Shareholders' Equity Note 12 - Income Taxes Note 15 - Commitments and Contingencies Note 17 - Quarterly Financial Data (Unaudited) Volatility us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Note 18 - Contracts With Customers us-gaap_LiabilitiesCurrent Total current liabilities Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details) Note 2 - Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair value (Details) Note 2 - Summary of Significant Accounting Policies - Advertising and Marketing Costs (Details) Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) Expected term (in years) (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Accrued radioactive waste disposal us-gaap_OtherLiabilitiesCurrent Note 3 - Short-term Investments - Summary of Short- Term Investments (Details) Schedule of Other Assets [Table Text Block] Note 4 - Inventory - Current Inventory (Details) Note 4 - Inventory - Noncurrent Inventory (Details) Note 5 - Prepaid expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) Note 6 - Property & Equipment - Summary of Property and Equipment (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 8 - Other Assets, Net - Other Assets, Net of Accumulated Amortization (Details) Note 8 - Other Assets, Net - Future Amortization (Details) Note 9 - Asset Retirement Obligation - Asset Retirement Obligation (Details) Note 10 - Share-based Compensation - Assumptions (Details) us-gaap_LitigationSettlementAmountAwardedToOtherParty Litigation Settlement, Amount Awarded to Other Party Note 10 - Share-based Compensation - Share-based Compensation Expense (Details) Note 10 - Share-based Compensation - Summary of Stock Option (Details) Note 11 - Shareholders' Equity - Fair Value Assumption of Warrant (Details) Note 11 - Shareholders' Equity - Warrant Activity (Details) Note 12 - Income Taxes - Deferred Tax Components (Details) Note 12 - Income Taxes - Reconciliation of Income Tax Expenses (Details) Note 15 - Commitments and Contingencies - Future Minimum Lease Payments (Details) Note 15 - Commitments and Contingencies - Royalty Expenses (Details) Note 17 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) Note 18 - Contracts With Customers - Concentration of Customers (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] Vested and expected to vest, Life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Vested and expected to vest, Options (in shares) Vested and expected to vest, Price (in dollars per share) Vested and expected to vest, Value Exercisable, Price (in dollars per share) Exercisable, Life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Aggregate intrinsic value of options exercised (in thousands) Exercisable, Options (in shares) Balance, Life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Balance, Value Weighted average fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Warrants issued (in shares) The number of warrants issued under the agreement. Proceeds from maturity of certificates of deposit us-gaap_PaymentsToAcquireShortTermInvestments Purchases of and interest from certificates of deposit Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balance, Price (in dollars per share) Balance, Price (in dollars per share) Forfeited, Price (in dollars per share) Accounts payable and accrued expenses us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Expired, Price (in dollars per share) Financial Instrument [Axis] Granted, Price (in dollars per share) Exercised, Price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Balance, Options (in shares) Balance, Options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, Options (in shares) Proceeds from sale of equipment us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued vacation us-gaap_AccruedVacationCurrent Schedule of Change in Asset Retirement Obligation [Table Text Block] Options issued (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Licensing Agreements [Member] us-gaap_PaymentsToAcquireIntangibleAssets Additions to other assets us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Weighted average shares used in computing net loss per share: Product and Service, Other [Member] Restricted Assets Disclosure [Text Block] Current liabilities: us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] Other Assets Disclosure [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Other Current Assets [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Intellectual Property [Member] us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net loss applicable to common shareholders Computer Software, Intangible Asset [Member] Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Award Type [Domain] us-gaap_PreferredStockDividendsIncomeStatementImpact Preferred stock dividends us-gaap_RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents, Total Award Type [Axis] Net loss Net loss Net loss us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Less: Accumulated Amortization us-gaap_FiniteLivedIntangibleAssetsNet Other assets, net Finite-Lived Intangible Assets, Gross Share-based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Inventory [Axis] Inventory [Domain] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Property and equipment, gross CASH FLOWS FROM INVESTING ACTIVITIES: Accounts payable and accrued expenses us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit), Total Income tax expense (benefit) us-gaap_OperatingExpenses Total operating expenses Restricted cash Restricted cash General and administrative Cash and cash equivalents us-gaap_CashAndCashEquivalentsAtCarryingValue Cash and cash equivalents Accrued radioactive waste disposal us-gaap_AllocatedShareBasedCompensationExpense Share-based compensation Accretion of discount Accretion of asset retirement obligation Rental expense Royalty Expense Amendment Flag Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_GainLossOnSaleOfPropertyPlantEquipment (Gain) loss on equipment disposals us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets: Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Document Period End Date Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company us-gaap_DividendsPreferredStockCash Payment of dividend to preferred shareholders Document Information [Line Items] Document Information [Table] Entity Public Float Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Investments by Secondary Categorization [Domain] Investment Secondary Categorization [Axis] Concentration Risk, Percentage Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Share-based compensation us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Quarterly Financial Information [Text Block] Entity Central Index Key Entity Registrant Name Product Concentration Risk [Member] Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Amortization of Intangible Assets Concentration Risk Type [Axis] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss, Ending Balance Concentration Risk Type [Domain] Entity Common Stock, Shares Outstanding (in shares) Advertising and marketing costs expensed (including tradeshows) Revenue Benchmark [Member] Investments [Domain] us-gaap_IncreaseDecreaseInInventories Inventory Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Nature of Operations [Text Block] Issuance of common stock pursuant to exercise of warrants Issuance of common stock pursuant to exercise of warrants (in shares) Issuance of common stock pursuant to exercise of options (in shares) Exercised, Options (in shares) us-gaap_GainLossOnDispositionOfAssets Gain on equipment disposals EX-101.PRE 15 isr-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 16 chart1.jpg begin 644 chart1.jpg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end GRAPHIC 17 ex_158727img001.gif begin 644 ex_158727img001.gif M1TE&.#EA1 %? /< ,P 9@ F0 S _P K K,P K9@ KF0 K MS K_P!5 !5,P!59@!5F0!5S !5_P" " ,P" 9@" F0" S " _P"J "J M,P"J9@"JF0"JS "J_P#5 #5,P#59@#5F0#5S #5_P#_ #_,P#_9@#_F0#_ MS #__S, #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5 M,S-59C-5F3-5S#-5_S. #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8 &8 M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695 MS&95_V: &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5 M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD )D ,YD 9ID F9D MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF )F M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5 MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P ,P ,\P 9LP F
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end XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.2

Note 1 - Organization
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Nature of Operations [Text Block]

1.

Organization

Isoray, Inc. was incorporated in Minnesota in
1983.
On
July 28, 2005,
Isoray Medical, Inc. (Medical) became a wholly-owned subsidiary of Isoray, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. In
December 2018,
upon approval of a majority of shareholders, Isoray, Inc. was redomiciled to Delaware. Medical was formed under Delaware law on
June 15, 2004
and on
October 1, 2004
acquired
two
affiliated predecessor companies which began operations in
1998.
Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.

Isoray International LLC (International), a Washington limited liability company, was formed on
November 27, 2007
and is a wholly-owned subsidiary of Isoray, Inc. International has entered into various international distribution agreements.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R3.htm IDEA: XBRL DOCUMENT v3.19.2

Consolidated Balance Sheets (Parentheticals) - $ / shares

Jun. 30, 2019

Jun. 30, 2018

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 7,000,000 7,001,671

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 200,000,000 200,000,000

Common stock, shares issued (in shares) 67,388,047 56,331,147

Common stock, shares outstanding (in shares) 67,388,047 56,331,147

Series B Preferred Stock [Member]

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares issued (in shares) 59,065 59,065

Preferred stock, shares outstanding (in shares) 59,065 59,065

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R26.htm IDEA: XBRL DOCUMENT v3.19.2

Significant Accounting Policies (Policies)
12 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation.

Cash and Cash Equivalents, Policy [Policy Text Block]
Cash Equivalents

The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of
three
months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States.

Investment, Policy [Policy Text Block]
Investments

Investments with original maturities greater than
three
months and remaining maturities less than
one
year are classified as “Short-term investments” and included in current assets. Investments with remaining maturities greater than
one
year are classified as “Investments, non-current” and are included in noncurrent assets. These investments are held to maturity and carried at amortized cost.

Accounts Receivable [Policy Text Block]
Accounts Receivable

Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries.

Inventory, Policy [Policy Text Block]
Inventory

Inventory is reported at the lower of cost or net realizable value. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a
first
-in,
first
-out basis.

The cost of materials and production costs contained in inventory that are
not
usable due to the passage of time, and resulting loss of bio-effectiveness, are written off to cost of sales at the time it is determined that the product is
no
longer usable.

Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment

Fixed assets are capitalized and carried at cost less accumulated depreciation. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations.

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment (in years)

3

to

7

Office equipment (in years)

2

to

5

Furniture and fixtures (in years)

2

to

5

Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.

Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is
not
recoverable and exceeds its fair value.

Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment.

Other Assets [Policy Text Block]
Prepaid Expenses and Other Assets

Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value.

Asset Retirement Obligation [Policy Text Block]
Asset Retirement Obligation

The estimated fair value of the future retirement costs of the Company’s leased assets and the costs for the decontamination and reclamation of equipment located within the footprint leased asset are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets.

Fair Value of Financial Instruments, Policy [Policy Text Block]
Financial Instruments

The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and
not
recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At
June 30, 2019
and
2018,
the carrying value of financial instruments which include U.S. Treasury Securities, certificates of deposit and restricted cash, approximated fair value.

Fair Value Measurement, Policy [Policy Text Block]
Fair Value Measurement

When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level
1
uses quoted prices in active markets for identical assets or liabilities, Level
2
uses significant other observable inputs, and Level
3
uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. The Company has
no
financial assets or liabilities that are adjusted to fair value on a recurring basis.

At
June 30, 2019
and
2018,
there were
no
assets or liabilities measured at fair-value on a recurring basis which were measured using Level
3
inputs. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are
not
measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note
9
), the Company had
no
assets or liabilities measured at fair value on a nonrecurring basis during the
two
years ended
June 30, 2019.

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. (In thousands)

Fair value at June 30,
2019

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
5,326
$
5,326
$
-
$
-

Fair value at June 30,
2018

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
2,600
$
2,600
$
-
$
-

The Company’s cash and cash equivalent instruments are classified within Level
1
of the fair value hierarchy because they are valued using quoted market prices.

Revenue [Policy Text Block]
Revenue Recognition

The Company recognizes revenue based on the
five
-step model for revenue recognition as prescribed by ASC
606,

Revenue from Contracts with Customers
, as follows: (
1
) identify the contract with the customer; (
2
) identify the performance obligations in the contract; (
3
) determine the transaction price; (
4
) allocate the prices to the performance obligations; and (
5
) recognize revenue. The Company has some agreements that contain general commercial terms and product prices but do
not
contain an obligation to provide goods to the customer. Our performance obligation, which is established when the customer submits a purchase order and the Company accepts the order, is to deliver the product based on the purchase order received. The Company typically recognizes revenue at the time of shipment, at which time the title passes to the customer, and there are
no
further performance obligations. See Note
18.

Shipping and Handling Cost [Policy Text Block]
Shipping and Handling Costs

Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in the transaction price.

Share-based Payment Arrangement [Policy Text Block]
Share-Based Compensation

The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options and stock warrants on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Company recognizes forfeitures as they occur.

Research and Development Expense, Policy [Policy Text Block]
Research and Development Costs

Research and Development - Proprietary

Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and
not
treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year recognized.

Research and Development - Collaborative Arrangement

Research and development costs incurred and shared in connection with a collaborative research and development project are separately stated in the consolidated statement of operation under “Research and development: Collaboration arrangements, net of reimbursement.”

Advertising Cost [Policy Text Block]
Advertising and Marketing Costs

Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. (In thousands)

For the Years Ended June 30,

2019

2018

2017

Advertising and marketing costs expensed (including tradeshows)
$
210
$
329
$
323

At June 30,

201
9

201
8

Prepaid marketing expenses deferred until event occurs
$
9
$
9

Commitments and Contingencies, Policy [Policy Text Block]
Legal Contingencies

The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of
third
-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does
not
believe any probable legal proceedings or claims will have a material adverse effect on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company’s recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred.

Income Tax, Policy [Policy Text Block]
Income Taxes

Income taxes are accounted for under the liability method. Under this method, the Company provides deferred income taxes for temporary differences that will result in taxable or deductible amounts in future years based on the reporting of certain costs in different periods for financial statement and income tax purposes. This method also requires the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that realization of such benefits is more likely than
not.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment of the change. In the event that the Company is assessed penalties and or interest, penalties will be charged to other operating expense and interest will be charged to interest expense in the period that they are assessed.

Earnings Per Share, Policy [Policy Text Block]
Income (Loss) Per Common Share

Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does
not
include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company’s net loss position.

Securities that could be dilutive in the future are as follows:

June 30,

201
9

201
8

201
7

Preferred stock

59,065

59,065

59,065

Common stock warrants

6,080,000

250,000

-

Common stock options

4,645,315

3,759,840

3,379,191

Total potential dilutive securities

10,784,380

4,068,905

3,438,256

Use of Estimates, Policy [Policy Text Block]
Use of Estimates

The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.

New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements

In
May 2014,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.

2014
-
09
Revenue Recognition, replacing guidance currently codified in Subtopic
605
-
10
Revenue Recognition-Overall with various SEC Staff Accounting Bulletins providing interpretive guidance. The guidance establishes a new
five
step principle-based framework in an effort to significantly enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The standard became effective for the Company in the
first
quarter of its fiscal year
2019.
The Company adopted the new standard in the
first
quarter of fiscal year
2019
and used the modified retrospective method. The adoption of ASU
2014
-
09
did
not
have a material impact on the consolidated financial statements of the Company and did
not
significantly change the timing of revenue recognition compared to the previous methodology.

In
February 2016,
the FASB issued ASU
2016
-
02
Leases (Subtopic
842
), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for fiscal years beginning after
December 15, 2018,
including interim periods within those fiscal years. Early adoption is permitted. The modified retrospective transition approach is required. The ASU will be effective for the Company in the
first
quarter of fiscal year
2020
and the most significant effects of this ASU relate to the recognition of a new right-of-use asset and corresponding lease liability.

In
November 2018,
the FASB issued ASU
2018
-
18,
Collaborative Arrangements (Topic
808
): Clarifying the Interaction Between Topic
808
and Topic
606,
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic
606.
The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2019,
with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.

Other accounting standards that have been issued or proposed by FASB that do
not
require adoption until a future date are
not
expected to have a material impact on the consolidated financial statements upon adoption. The Company does
not
discuss recent pronouncements that are
not
anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

X

- Definition
Disclosure of the accounting policy for other assets.
+ References
No definition available.
+ Details

Name: isr_OtherAssetsPolicyTextBlock

Namespace Prefix: isr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.
+ References
No definition available.
+ Details

Name: isr_ShippingAndHandlingCost1PolicyTextBlock

Namespace Prefix: isr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for advertising cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_AssetRetirementObligationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment in financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534
+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R22.htm IDEA: XBRL DOCUMENT v3.19.2

Note 16 - Concentrations of Credit and Other Risks
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

16.

Concentrations of Credit and Other Risks

The Company’s financial instruments that were exposed to concentrations of credit risk consist primarily of cash and cash equivalents, U.S. Treasury securities, certificates of deposit, and accounts receivable.

The Company’s cash and cash equivalents were maintained with high-quality financial institutions at
June 30, 2019
and
2018,
respectively. At
June 30, 2019
and
2018,
respectively, all cash balances were guaranteed by the Federal Deposit Insurance Corporation (FDIC) and all cash equivalents consisted of U.S. Treasury securities.

The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. At both
June 30, 2019
and
2018,
the allowance was approximately
$26,000
.

Inventories

Most components used in the Company’s product are purchased from outside sources. Certain components are purchased from single suppliers. The failure of any such supplier to meet its commitment on schedule could have a material adverse effect on the Company’s business, operating results and financial condition. If a sole-source supplier were to go out of business or otherwise become unable to meet its supply commitments, the process of locating and qualifying alternate sources could require up to several months, during which time the Company’s production could be delayed. Such delays could have a material adverse effect on the Company’s business, operating results and financial condition. Sanctions placed on financial transactions with Russian banking institutions
may
interfere with the Company’s ability to transact business in Russia on a temporary or other basis resulting in an interruption of the Cesium-
131
supply which could have a temporary material adverse effect on the Company’s business, operating results and financial condition.

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R43.htm IDEA: XBRL DOCUMENT v3.19.2

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Antidilutive Securities (in shares) 10,784,380 4,068,905 3,438,256

Preferred Stocks [Member]

Antidilutive Securities (in shares) 59,065 59,065 59,065

Warrant [Member]

Antidilutive Securities (in shares) 6,080,000 250,000

Share-based Payment Arrangement, Option [Member]

Antidilutive Securities (in shares) 4,645,315 3,759,840 3,379,191

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=isr_PreferredStocksMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R47.htm IDEA: XBRL DOCUMENT v3.19.2

Note 5 - Prepaid expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Prepaid insurance $ 38 $ 24

Other prepaid expenses 154 241

Other current assets 27 29

Other receivables 86 41

Total prepaid expenses and other current assets $ 305 $ 335

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765
+ Details

Name: us-gaap_OtherPrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 24 R68.htm IDEA: XBRL DOCUMENT v3.19.2

Note 17 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 12 Months Ended

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Net revenue $ 1,924 $ 1,924 $ 1,904 $ 1,562 $ 1,603 $ 1,573 $ 1,536 $ 1,211

Gross profit 879 879 765 524 443 609 531 265 $ 3,047 $ 1,842 $ 838

Net loss $ (1,095) $ (1,127) $ (1,414) $ (1,508) $ (2,343) $ (1,332) $ (1,463) $ (1,546) $ (5,144) $ (6,700) $ (6,162)

Net loss per share – basic and diluted (in dollars per share) $ (0.02) $ (0.02) $ (0.02) $ (0.02) $ (0.04) $ (0.02) $ (0.03) $ (0.03) $ (0.08) $ (0.12) $ (0.11)

Shares used in basic and diluted per share calculation (in shares) 67,357 67,333 67,331 66,147 55,463 55,100 55,056 55,017 67,042 55,159 55,016

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 R64.htm IDEA: XBRL DOCUMENT v3.19.2

Note 15 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 12 Months Ended

May 16, 2017

Mar. 09, 2017

Nov. 29, 2016

Dec. 31, 2015

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Jul. 03, 2019

Royalty Expense $ 285,000 $ 285,000 $ 288,000

Purchase Agreement Period 1 year

Research and Development Expense, Total 1,474,000 1,746,000 965,000

Receivables, Net, Current, Total 1,154,000 1,192,000

Class Action Lawsuit Related to Press Release [Member]

Litigation Settlement, Amount Awarded to Other Party $ 3,537,500

Class Action Lawsuit re Equity Plan [Member]

Litigation Settlement, Amount Awarded to Other Party $ 195,000

Collaborative Development Agreement [Member] | GammaTile LLC [Member]

Research and Development Expense, Total 266,000 769,000 387,000

Receivables, Net, Current, Total $ 0 22,000

Maximum [Member] | Subsequent Event [Member]

Lease Agreement, Early Termination Penalty $ 40,000

Royalty Agreement for Invention and Patent Application [Member]

Percentage of Royalty Rate Payable 2.00%

Royalty Expense $ 33,000 $ 27,000 $ 21,000

Royalty Agreement for Invention and Patent Application [Member] | Former Employee and Shareholder [Member]

Percentage of Royalty, Exchanged for Interest in Predecessor Company 1.00%

Patent and Know-How Royalty License Agreement [Member]

Percentage of Royalty Rate Payable 1.00%

Irradiation Services Agreement [Member]

Irradiation Service Agreement, Term 5 years

Irradiation Service Agreement, Renewal Period 1 year

X

- Definition
The renewal period for Irradiation Service Agreement.
+ References
No definition available.
+ Details

Name: isr_IrradiationServiceAgreementRenewalPeriod

Namespace Prefix: isr_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The term of Irradiation Service Agreement.
+ References
No definition available.
+ Details

Name: isr_IrradiationServiceAgreementTerm

Namespace Prefix: isr_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The early termination penalty pursuant to the lease agreement.
+ References
No definition available.
+ Details

Name: isr_LeaseAgreementEarlyTerminationPenalty

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The percentage of royalty that exchanged for the interest in predecessor company.
+ References
No definition available.
+ Details

Name: isr_PercentageOfRoyaltyExchangedForInterestInPredecessorCompany

Namespace Prefix: isr_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The percentage of royalty to gross profit.
+ References
No definition available.
+ Details

Name: isr_PercentageOfRoyaltyRatePayable

Namespace Prefix: isr_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
This element represents the period of purchase for which the entity is enabled to purchase.
+ References
No definition available.
+ Details

Name: isr_PurchaseAgreementPeriod

Namespace Prefix: isr_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount awarded to other party in judgment or settlement of litigation.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_LitigationCaseAxis=isr_ClassActionLawsuitRelatedToPressReleaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=isr_ClassActionLawsuitReEquityPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=isr_CollaborativeDevelopmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=isr_GammatileLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=isr_RoyaltyAgreementForInventionAndPatentApplicationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=isr_FormerEmployeeAndShareholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=isr_PatentAndKnowHowRoyaltyLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=isr_IrradiationServicesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R60.htm IDEA: XBRL DOCUMENT v3.19.2

Note 11 - Shareholders' Equity - Warrant Activity (Details) - $ / shares
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Balance (in shares) 250,000 230,087

Balance (in dollars per share) ^[1] $ 0.54 $ 0.94

Warrants expired (in shares) (230,087)

Warrants expired (in dollars per share) ^[1] $ 0.94

Warrants issued (in shares) 5,830,000 500,000

Warrants issued (in dollars per share) ^[1] $ 0.76 $ 0.28

Warrants exercised (in shares) (250,000)

Warrants exercised (in dollars per share) ^[1] $ 0.01

Balance (in shares) 6,080,000 250,000

Balance (in dollars per share) ^[1] $ 0.75 $ 0.54

[1] Weighted average exercise price per share.

X

- Definition
The exercise price of warrants exercised during the period.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised

Namespace Prefix: isr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The exercise price of warrants expired during the period.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired

Namespace Prefix: isr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The exercise price of warrants issued during the period.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued

Namespace Prefix: isr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents for shares of warrants exercised during the period.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightExercised

Namespace Prefix: isr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Class of Warrant or Right, Expired in Period
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightExpired

Namespace Prefix: isr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of warrants issued under the agreement.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightIssuedForServices

Namespace Prefix: isr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 27 R56.htm IDEA: XBRL DOCUMENT v3.19.2

Note 10 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Share-based compensation $ 420 $ 404 $ 372

Cost of Sales [Member]

Share-based compensation 38 62 86

Research and Development Expense [Member]

Share-based compensation 84 92 60

Selling and Marketing Expense [Member]

Share-based compensation 96 92 86

General and Administrative Expense [Member]

Share-based compensation $ 202 $ 158 $ 140

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R52.htm IDEA: XBRL DOCUMENT v3.19.2

Note 8 - Other Assets, Net - Future Amortization (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Year ended June 30, 2020 $ 38

2021 23

2022 23

2023 23

2024 23

Thereafter 32

Other assets, net $ 162 $ 198

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 29 R71.htm IDEA: XBRL DOCUMENT v3.19.2

Note 19 - Subsequent Events (Details Textual)

Jul. 03, 2019

USD ($)

Maximum [Member] | Subsequent Event [Member]

Lease Agreement, Early Termination Penalty $ 40,000

X

- Definition
The early termination penalty pursuant to the lease agreement.
+ References
No definition available.
+ Details

Name: isr_LeaseAgreementEarlyTerminationPenalty

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.19.2

Note 12 - Income Taxes
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Income Tax Disclosure [Text Block]

12.

Income Taxes

Due to net losses, the Company did
not
record an income tax provision or benefit for the years ending
June 30, 2019,
2018
and
2017.

The significant deferred tax components using a federal income tax rate of
21%
for the years ended
June 30, 2019
and
2018
are as follows (in thousands):

As of June 30,

201
9

201
8

Fixed assets
$
204
$
197

Share-based compensation

578

480

Other accruals

27

38

Asset retirement obligation

130

124

Research credit carryforwards
96

-

Other
6

10

Net operating loss carryforwards

15,207

14,171

Total deferred tax assets

16,248

15,020

Valuation allowance

(16,248

)

(15,020

)

Total
$
-
$
-

As management of the Company cannot determine that it is more likely than
not
that the Company will realize the benefit of the net deferred tax asset, a valuation allowance equal to
100%
of the net deferred tax asset has been recorded at both
June 30, 2019
and
2018.

The Company has federal net operating loss carryforwards of approximately
$72.4
million on
June 30, 2019
that can be used to offset future regular taxable income. These net operating loss carryforwards expire at various times through the years
2025
to
2038.
The current year net operating loss carryforward does
not
have an expiration date.

The Company has a research credit carryforward of approximately
$0.1
million on
June 30, 2019
that expire at various times through the years
2037
to
2038.

On
December 22, 2017,
the United States enacted the Tax Cuts and Jobs Act (the "Act") resulting in significant modifications to existing law. The Company did
not
incur any income tax benefit or provision for the year ended
June 30, 2018
as a result of the changes to tax laws and tax rates under the Act. The Company’s net deferred tax asset was reduced by approximately
$9.5
million during the year ended
June 30, 2018,
which consisted primarily of the remeasurement of federal deferred tax assets and liabilities from
35%
to
21%.

The Company’s statutory rate reconciliation is as follows (in thousands):

For the year ended June 30,

201
9

201
8

201
7

U.S. federal statutory income tax rate

21

%

28

%

35

%

Expected income tax benefit
$
(1,080

)
$
(1,878

)
$
(2,157

)

Meals and entertainment

12

21

17

Non-deductible penalties

18

4

16

Warrant derivative liability

-

-

(9

)

Share-based compensation

-

-

10

Impact on the change in income tax rate
-

9,556

-

Change in estimate
(178)

Change in valuation allowance

1,228

(7,703

)

2,123

Income tax expense (benefit)
$
-
$
-
$
-

The Company has reviewed the tax positions taken and concluded that it does
not
have to book a liability for uncertain tax positions.

Currently, tax years
2017
-
2019
remain open for examination by United States taxing authorities. Net operating losses prior to
2017
could be adjusted during an examination of open years.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R14.htm IDEA: XBRL DOCUMENT v3.19.2

Note 8 - Other Assets, Net
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Other Assets Disclosure [Text Block]

8.

Other Assets, net

Other assets, net of accumulated amortization consisted of the following (in thousands):

June 30,

2019

2018

Website development
$
90
$
90

Licenses

516

520

Patents and trademarks

366

366

Total Other Assets

972

976

Less: Accumulated Amortization

(810

)

(778

)

$
162
$
198

Year Ended June 30,

201
9

201
8

201
7

Amortization expense on website development
$
14
$
14
$
12

Amortization expense on licenses

18

18

16

Amortization expense on patents and trademarks

18

18

17

Total amortization expense
$
50
$
50
$
45

Future amortization is expected to be as follows (in thousands):

Year ended June 30, 2020
$
38

2021

23

2022

23

2023

23

2024

23

Thereafter

32

$
162

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_OtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R10.htm IDEA: XBRL DOCUMENT v3.19.2

Note 4 - Inventory
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Inventory Disclosure [Text Block]

4.

Inventory

Inventory consisted of the following (in thousands):

June 30,

2019

2018

Raw materials
$
333
$
371

Work in process

166

96

Finished goods

31

27

Total inventory
$
530
$
494

June 30,

2019

2018

Enriched barium, non-current
$
117
$
276

Raw materials, non-current

38

43

Total inventory, non-current
$
155
$
319

Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will
not
be consumed within an operating cycle. On
August 25, 2017,
the Company entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC to begin utilizing our enriched barium-
130
carbonate inventory. The Company anticipates obtaining enough Cesium-
131
under this arrangement to obtain over
4,000
curies of Cesium-
131.
During the year ended
June 30, 2019
the Company obtained
1,166
curies under this agreement which has been used in production. At
June 30, 2019,
the Company estimates that the remaining enriched barium will result in
925
curies; approximately
90
of which will be obtained in the year ended
June 30, 2020
and
835
will be obtained after
June 30, 2020.
There is
no
assurance as to whether the agreement will be terminated before this full amount is obtained and other supply sources are used, nor is there assurance that the agreements with the
third
-party Cesium-
131
suppliers will be executed.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R33.htm IDEA: XBRL DOCUMENT v3.19.2

Note 9 - Asset Retirement Obligation (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Change in Asset Retirement Obligation [Table Text Block]

Year Ended June 30,

2019

2018

Beginning balance
$
590
$
561

Accretion of discount

31

29

Ending balance
$
621
$
590

X

- Definition
Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 30
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6393242&loc=d3e13201-110859
+ Details

Name: us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R37.htm IDEA: XBRL DOCUMENT v3.19.2

Note 15 - Commitments and Contingencies (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Year ending June 30,

Amount

2020

290

2021

241

$
531

Unrecorded Unconditional Purchase Obligations Disclosure [Table Text Block]

For the Year Ended June 30,

2019

2018

2017

Rental expense
$
285
$
285
$
288

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of unconditional purchase obligations that are not recognized as a liability on the balance sheet, including the nature and significant terms of an unconditional purchase obligation; the amount of the fixed and determinable portion of the obligation as of the date of the latest balance sheet presented in the aggregate and, if determinable, for each of the five succeeding fiscal years; the nature of any variable components of the obligation; the amount purchased under the obligation (for example, the take-or-pay or throughput contract) for the reporting period; and may include the amount of imputed interest necessary to reduce the obligation to present value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25287-109308
+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R57.htm IDEA: XBRL DOCUMENT v3.19.2

Note 10 - Share-based Compensation - Summary of Stock Option (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Jun. 30, 2016

Balance, Options (in shares) 3,759,840 3,379,191 2,925,059

Balance, Price (in dollars per share) ^[1] $ 0.69 $ 0.78 $ 1.21

Balance, Life (Year) ^[2] 7 years 346 days 7 years 273 days 7 years 313 days 6 years 339 days

Balance, Value ^[3] $ 1 $ 49 $ 151 $ 263

Granted, Options (in shares) ^[4] 1,252,500 1,125,000 2,150,000

Granted, Price (in dollars per share) ^[1],[4] $ 0.44 $ 0.47 $ 0.61

Expired, Options (in shares) (242,000) (100,000) (509,904)

Expired, Price (in dollars per share) ^[1] $ 0.41 $ 0.75 $ 2.55

Voided, Options (in shares) (1,179,164)

Voided, Price (in dollars per share) ^[1] $ 0.94

Exercised, Options (in shares) (56,900) (82,810) (6,800)

Exercised, Price (in dollars per share) ^[1] $ 0.26 $ 0.61 $ 0.26

Forfeited, Options (in shares) (68,125) (561,541)

Forfeited, Price (in dollars per share) ^[1] $ 0.54 $ 0.77

Balance, Options (in shares) 4,645,315 3,759,840 3,379,191 2,925,059

Balance, Price (in dollars per share) ^[1] $ 0.64 $ 0.69 $ 0.78 $ 1.21

Vested and expected to vest, Options (in shares) 4,645,315

Vested and expected to vest, Price (in dollars per share) ^[1] $ 0.64

Vested and expected to vest, Life (Year) ^[2] 7 years 346 days

Vested and expected to vest, Value ^[3] $ 1

Exercisable, Options (in shares) 2,153,645

Exercisable, Price (in dollars per share) ^[1] $ 0.81

Exercisable, Life (Year) ^[2] 6 years 277 days

Aggregate intrinsic value of options exercised (in thousands) $ 11 $ 3

[1] Weighted average exercise price per share.

[2] Weighted average remaining contractual life.

[3] Aggregate intrinsic value (in thousands).

[4] All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to five years.

X

- Definition
Number of options or other stock instruments for which the right to voided has lapsed under the terms of the plan agreements.
+ References
No definition available.
+ Details

Name: isr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVoided

Namespace Prefix: isr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were voided.
+ References
No definition available.
+ Details

Name: isr_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsVoidedInPeriodWeightedAverageExercisePrice

Namespace Prefix: isr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 36 R53.htm IDEA: XBRL DOCUMENT v3.19.2

Note 9 - Asset Retirement Obligation - Asset Retirement Obligation (Details) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Beginning balance $ 590 $ 561

Accretion of discount 31 29 $ 29

Ending balance $ 621 $ 590 $ 561

X

- Definition
The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849
+ Details

Name: us-gaap_AssetRetirementObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848
+ Details

Name: us-gaap_AssetRetirementObligationAccretionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 37 R70.htm IDEA: XBRL DOCUMENT v3.19.2

Note 18 - Contracts With Customers - Concentration of Customers (Details)
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Revenue Benchmark [Member] | Customer Concentration Risk [Member] | El Camino, Los Gatos, & Other Facilities [Member]

Concentration Risk, Percentage 22.10% 24.20% 22.90%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=isr_ElCaminoLosGatosOtherFacilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R15.htm IDEA: XBRL DOCUMENT v3.19.2

Note 9 - Asset Retirement Obligation
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Asset Retirement Obligation Disclosure [Text Block]

9.

Asset Retirement Obligation

The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. The ARO changed as follows (in thousands):

Year Ended June 30,

2019

2018

Beginning balance
$
590
$
561

Accretion of discount

31

29

Ending balance
$
621
$
590

X

- Definition
The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2175671
+ Details

Name: us-gaap_AssetRetirementObligationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R11.htm IDEA: XBRL DOCUMENT v3.19.2

Note 5 - Prepaid expenses and Other Current Assets
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Other Current Assets [Text Block]

5.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

June 30,

2019

2018

Prepaid insurance
$
38
$
24

Other prepaid expenses

154

241

Other current assets

27

29

Other receivables

86

41

Total prepaid expenses and other current assets $
305
$
335

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other current assets.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.19.2

Note 13 - 401(k) and Profit Sharing Plan
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Pension and Other Postretirement Benefits Disclosure [Text Block]

13.

401
(k) and Profit Sharing Plan

The Company has a
401
(k) plan, which commenced in fiscal year
2007,
covering all eligible full-time employees of the Company. Contributions to the
401
(k) plan are made by the participants to their individual accounts through payroll withholding. The
401
(k) plan also allows the Company to make contributions at the discretion of management. To date, the Company has
not
made any contributions to the
401
(k) plan.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R32.htm IDEA: XBRL DOCUMENT v3.19.2

Note 8 - Other Assets, Net (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Other Assets [Table Text Block]

June 30,

2019

2018

Website development
$
90
$
90

Licenses

516

520

Patents and trademarks

366

366

Total Other Assets

972

976

Less: Accumulated Amortization

(810

)

(778

)

$
162
$
198

Year Ended June 30,

201
9

201
8

201
7

Amortization expense on website development
$
14
$
14
$
12

Amortization expense on licenses

18

18

16

Amortization expense on patents and trademarks

18

18

17

Total amortization expense
$
50
$
50
$
45

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year ended June 30, 2020
$
38

2021

23

2022

23

2023

23

2024

23

Thereafter

32

$
162

X

- Definition
Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R36.htm IDEA: XBRL DOCUMENT v3.19.2

Note 12 - Income Taxes (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

As of June 30,

201
9

201
8

Fixed assets
$
204
$
197

Share-based compensation

578

480

Other accruals

27

38

Asset retirement obligation

130

124

Research credit carryforwards
96

-

Other
6

10

Net operating loss carryforwards

15,207

14,171

Total deferred tax assets

16,248

15,020

Valuation allowance

(16,248

)

(15,020

)

Total
$
-
$
-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

For the year ended June 30,

201
9

201
8

201
7

U.S. federal statutory income tax rate

21

%

28

%

35

%

Expected income tax benefit
$
(1,080

)
$
(1,878

)
$
(2,157

)

Meals and entertainment

12

21

17

Non-deductible penalties

18

4

16

Warrant derivative liability

-

-

(9

)

Share-based compensation

-

-

10

Impact on the change in income tax rate
-

9,556

-

Change in estimate
(178)

Change in valuation allowance

1,228

(7,703

)

2,123

Income tax expense (benefit)
$
-
$
-
$
-

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R6.htm IDEA: XBRL DOCUMENT v3.19.2

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (5,144) $ (6,700) $ (6,162)

Adjustments to reconcile net loss to net cash used by operating activities:

Allowance for doubtful accounts (4)

Depreciation expense 136 80 68

(Gain) loss on equipment disposals (24) (2)

Amortization of other assets 50 50 45

Change in fair value of warrant derivative liability (27)

Accretion of asset retirement obligation 31 29 29

Change in estimate of asset retirement obligation (48)

Share-based compensation 420 404 372

Share-based compensation for third party services 203

Changes in operating assets and liabilities:

Accounts receivable 38 (466) (184)

Inventory 128 23 89

Prepaid expenses and other current assets 30 (64) 100

Accounts payable and accrued expenses (708) 761 18

Accrued protocol expense 56 2 (47)

Accrued radioactive waste disposal 37 (88) (52)

Accrued payroll and related taxes (66) 17 66

Accrued vacation (33) 37 27

Net cash used by operating activities (5,049) (5,712) (5,712)

CASH FLOWS FROM INVESTING ACTIVITIES:

Additions to property and equipment (444) (337) (549)

Additions to other assets (14) (18) (124)

Proceeds from sale of equipment 34 6

Proceeds from maturity of certificates of deposit 5,550 6,268 2,296

Purchases of and interest from certificates of deposit (4,725) (4,054) (115)

Net cash provided by investing activities 401 1,859 1,514

CASH FLOWS FROM FINANCING ACTIVITIES:

Preferred dividends paid (11) (11) (11)

Proceeds from sales of common stock, pursuant to exercise of warrants, net 3

Proceeds from sales of common stock, pursuant to exercise of options 15 50 2

Net cash provided by (used in) financing activities 7,374 521 (9)

Net increase (decrease) in cash, cash equivalents, and restricted cash 2,726 (3,332) (4,207)

Cash, cash equivalents, and restricted cash beginning of year 2,781 6,113 10,320

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF YEAR 5,507 2,781 6,113

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:

Cash and cash equivalents 5,326 2,600 5,932

Restricted cash 181 181 181

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF YEAR 5,507 2,781 6,113

Non-cash investing and financing activities:

Warrants issued to placement agent of registered direct offering 163

Registered Direct Offering [Member]

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from sales of common stock 7,370

At the Market Offering [Member]

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from sales of common stock $ 479

X

- Definition
The amount of gain (loss) related to the change in ARO estimate.
+ References
No definition available.
+ Details

Name: isr_GainLossOnChangeInAROEstimate

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the amount of increase (decrease) in accrued payroll and related taxes.
+ References
No definition available.
+ Details

Name: isr_IncreaseDecreaseInAccruedPayrollAndRelatedTaxes

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in accrued protocol expense.
+ References
No definition available.
+ Details

Name: isr_IncreaseDecreaseInAccruedProtocolExpense

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in accrued vacation.
+ References
No definition available.
+ Details

Name: isr_IncreaseDecreaseInAccruedVacation

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of warrants issued in a non-cash financing activity
+ References
No definition available.
+ Details

Name: isr_NoncashFinancingActivitiesWarrantsIssued

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: isr_ReconciliatoinOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheetsAbstract

Namespace Prefix: isr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848
+ Details

Name: us-gaap_AssetRetirementObligationAccretionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in current liabilities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(5))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=isr_RegisteredDirectOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=isr_AtTheMarketOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R2.htm IDEA: XBRL DOCUMENT v3.19.2

Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Current assets:

Cash and cash equivalents $ 5,326 $ 2,600

Short-term investments (Note 3) 825

Accounts receivable, net 1,154 1,192

Inventory 530 494

Prepaid expenses and other current assets 305 335

Total current assets 7,315 5,446

Property and equipment, net 1,609 1,311

Restricted cash 181 181

Inventory, non-current 155 319

Other assets, net of accumulated amortization 162 198

Total assets 9,422 7,455

Current liabilities:

Accounts payable and accrued expenses 683 1,391

Accrued protocol expense 133 77

Accrued radioactive waste disposal 74 37

Accrued payroll and related taxes 89 155

Accrued vacation 142 175

Total current liabilities 1,121 1,835

Non-current liabilities:

Asset retirement obligation 621 590

Total liabilities 1,742 2,425

Commitments and contingencies (Note 15)

Shareholders' equity:

Preferred stock, $.001 par value; 7,000,000 and 7,001,671shares authorized: Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding

Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 and 56,331,147 shares issued and outstanding 67 56

Additional paid-in capital 92,105 84,322

Accumulated deficit (84,492) (79,348)

Total shareholders' equity 7,680 5,030

Total liabilities and shareholders' equity $ 9,422 $ 7,455

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for accrued payroll and related taxes.
+ References
No definition available.
+ Details

Name: isr_AccruedPayrollAndRelatedTaxesCurrent

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the amount of accrued protocol expense.
+ References
No definition available.
+ Details

Name: isr_AccruedProtocolExpense

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedVacationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849
+ Details

Name: us-gaap_AssetRetirementObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(d))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 46 0001437749-19-019176-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-19-019176-xbrl.zip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Ȝ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end XML 47 R27.htm IDEA: XBRL DOCUMENT v3.19.2

Note 2 - Summary of Significant Accounting Policies (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Estimated Useful Lives of Assets [Table Text Block]

Production equipment (in years)

3

to

7

Office equipment (in years)

2

to

5

Furniture and fixtures (in years)

2

to

5

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

Fair value at June 30,
2019

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
5,326
$
5,326
$
-
$
-

Fair value at June 30,
2018

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
2,600
$
2,600
$
-
$
-

Schedule of Other Operating Cost and Expense, by Component [Table Text Block]

For the Years Ended June 30,

2019

2018

2017

Advertising and marketing costs expensed (including tradeshows)
$
210
$
329
$
323

At June 30,

201
9

201
8

Prepaid marketing expenses deferred until event occurs
$
9
$
9

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

June 30,

201
9

201
8

201
7

Preferred stock

59,065

59,065

59,065

Common stock warrants

6,080,000

250,000

-

Common stock options

4,645,315

3,759,840

3,379,191

Total potential dilutive securities

10,784,380

4,068,905

3,438,256

X

- Definition
Describes the periods of time over which an entity anticipates to receive utility from its estimated useful lives of assets.
+ References
No definition available.
+ Details

Name: isr_ScheduleOfEstimatedUsefulLivesOfAssetsTableTextBlock

Namespace Prefix: isr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2C
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R23.htm IDEA: XBRL DOCUMENT v3.19.2

Note 17 - Quarterly Financial Data (Unaudited)
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Quarterly Financial Information [Text Block]

1
7
.

Quarterly Financial Data (unaudited)

The following table provides the selected quarterly financial data for fiscal years
2019
and
2018
(dollars and shares in thousands, except for per share amounts):

Quarters ended

September 30,

December 31,

March 31,

June 30,

201
8

201
8

201
9

201
9

Net revenue
$
1,562
$
1,904
$
1,924
$
1,924

Gross profit
$
524
$
765
$
879
$
879

Net loss
$
(1,508

)
$
(1,414

)
$
(1,127

)
$
(1,095

)

Net loss per share – basic and diluted
$
(0.02

)
$
(0.02

)
$
(0.02

)
$
(0.02

)

Shares used in basic and diluted per share calculation

66,147

67,331

67,333

67,357

Quarters ended

September 30,

December 31,

March 31,

June 30,

201
7

201
7

201
8

201
8

Net revenue
$
1,211
$
1,536
$
1,573
$
1,603

Gross profit/(loss)
$
265
$
531
$
609
$
443

Net loss
$
(1,546

)
$
(1,463

)
$
(1,332

)
$
(2,343

)

Net loss per share – basic and diluted
$
(0.03

)
$
(0.03

)
$
(0.02

)
$
(0.04

)

Shares used in basic and diluted per share calculation

55,017

55,056

55,100

55,463

1.

Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations
may
be different.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-URI http://asc.fasb.org/topic&trid=2126967
+ Details

Name: us-gaap_QuarterlyFinancialInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R42.htm IDEA: XBRL DOCUMENT v3.19.2

Note 2 - Summary of Significant Accounting Policies - Advertising and Marketing Costs (Details) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Advertising and marketing costs expensed (including tradeshows) $ 210 $ 329 $ 323

Prepaid marketing expenses deferred until event occurs $ 9 $ 9

X

- Definition
The total expense recognized in the period for promotion, public relations, and brand or product advertising.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_MarketingAndAdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(6)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidAdvertising

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 R46.htm IDEA: XBRL DOCUMENT v3.19.2

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Total inventory, non-current $ 155 $ 319

Enriched Barium Inventory [Member]

Total inventory, non-current 117 276

Raw Materials [Member]

Total inventory, non-current $ 38 $ 43

X

- Definition
Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(d))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=isr_EnrichedBariumInventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=isr_RawMaterialsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R65.htm IDEA: XBRL DOCUMENT v3.19.2

Note 15 - Commitments and Contingencies - Future Minimum Lease Payments (Details)
$ in Thousands

Jun. 30, 2019

USD ($)

2020 $ 290

2021 241

$ 531

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 53 R61.htm IDEA: XBRL DOCUMENT v3.19.2

Note 12 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Income Tax Expense (Benefit), Total $ 0 $ 0 $ 0

Deferred Tax Assets, Valuation Allowance, Percentage 100.00% 100.00%

Operating Loss Carryforwards, Total $ 72,400

Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability $ 9,500

Open Tax Year 2017 2018 2019

Research Tax Credit Carryforward [Member]

Tax Credit Carryforward, Amount $ 100

X

- Definition
The percentage of valuation allowance for deferred tax assets.
+ References
No definition available.
+ Details

Name: isr_DeferredTaxAssetsValuationAllowancePercentage

Namespace Prefix: isr_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Tax year that remains open to examination under enacted tax laws, in CCYY format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_OpenTaxYear

Namespace Prefix: us-gaap_

Data Type: us-types:gYearListItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R69.htm IDEA: XBRL DOCUMENT v3.19.2

Note 18 - Contracts With Customers (Details Textual)
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Return Policy, Restocking Fee, Percent 50.00%

Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]

Concentration Risk, Percentage 89.00% 86.00% 88.00%

Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]

Concentration Risk, Percentage 11.00% 14.00% 12.00%

X

- Definition
The restocking fee charged for allowed returns represented as a percent of the purchase price.
+ References
No definition available.
+ Details

Name: isr_ReturnPolicyRestockingFeePercent

Namespace Prefix: isr_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=isr_ProstateBrachytherapyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R59.htm IDEA: XBRL DOCUMENT v3.19.2

Note 11 - Shareholders' Equity - Fair Value Assumption of Warrant (Details) - $ / shares
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Jun. 30, 2016

Warrants issued (in shares) 5,830,000 500,000

Exercise price (in dollars per share) ^[1] $ 0.75 $ 0.54 $ 0.94

Warrant [Member]

Weighted average fair value (in dollars per share) $ 0.51 $ 0.41

Warrants issued (in shares) 5,830,000 500,000

Expected term (in years) (Year) 5 years 182 days

Risk-free rate 2.74%

Volatility 102.73%

Warrant [Member] | Minimum [Member]

Exercise price (in dollars per share) $ 0.75 $ 0.01

Expected term (in years) (Year) 2 years

Risk-free rate 1.62%

Volatility 60.00%

Warrant [Member] | Maximum [Member]

Exercise price (in dollars per share) $ 0.9375 $ 0.54

Expected term (in years) (Year) 3 years

Risk-free rate 2.55%

Volatility 82.00%

[1] Weighted average exercise price per share.

X

- Definition
The number of warrants issued under the agreement.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightIssuedForServices

Namespace Prefix: isr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The grant date fair value of warrants or rights issued for services.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightIssuedForServicesGrantDateFairValue

Namespace Prefix: isr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R55.htm IDEA: XBRL DOCUMENT v3.19.2

Note 10 - Share-based Compensation - Assumptions (Details) - $ / shares
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Weighted average fair value (in dollars per share) $ 0.31 $ 0.34 $ 0.45

Options issued (in shares) 1,252,500 1,125,000 2,150,000

Expected term (in years) (Year) 5 years 5 years

Minimum [Member]

Exercise price (in dollars per share) $ 0.37 $ 0.44 $ 0.55

Expected term (in years) (Year) 4 years

Risk-free rate 1.83% 1.83% 1.62%

Volatility 89.00% 94.00% 101.00%

Maximum [Member]

Exercise price (in dollars per share) $ 0.55 $ 0.58 $ 0.84

Expected term (in years) (Year) 5 years

Risk-free rate 2.91% 2.85% 1.83%

Volatility 105.00% 101.00% 103.00%

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R51.htm IDEA: XBRL DOCUMENT v3.19.2

Note 8 - Other Assets, Net - Other Assets, Net of Accumulated Amortization (Details) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Finite-Lived Intangible Assets, Gross $ 972 $ 976

Less: Accumulated Amortization (810) (778)

Other assets, net 162 198

Amortization of Intangible Assets 50 50 $ 45

Computer Software, Intangible Asset [Member]

Finite-Lived Intangible Assets, Gross 90 90

Amortization of Intangible Assets 14 14 12

Licensing Agreements [Member]

Finite-Lived Intangible Assets, Gross 516 520

Amortization of Intangible Assets 18 18 16

Intellectual Property [Member]

Finite-Lived Intangible Assets, Gross 366 366

Amortization of Intangible Assets $ 18 $ 18 $ 17

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R30.htm IDEA: XBRL DOCUMENT v3.19.2

Note 5 - Prepaid expenses and Other Current Assets (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

June 30,

2019

2018

Prepaid insurance
$
38
$
24

Other prepaid expenses

154

241

Other current assets

27

29

Other receivables

86

41

Total prepaid expenses and other current assets $
305
$
335

X

- Definition
Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R34.htm IDEA: XBRL DOCUMENT v3.19.2

Note 10 - Share-based Compensation (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

For the Year Ended June 30,

2019

2018

2017

Weighted average fair value

$0.31

$0.34

$0.45

Options issued

1,252,500

1,125,000

2,150,000

Exercise price
$0.37

to

$0.55

$0.44

to

$0.58

$0.55

to

$0.84

Expected term (in years)

5

5

4

to

5

Risk-free rate

1.83%

to

2.91%

1.83%

to

2.85%

1.62%

to

1.83%

Volatility

89%

-

105%

94%

-

101%

101%

-

103%

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

For the Year Ended June 30,

2019

2018

2017

Cost of sales
$
38
$
62
$
86

Research and development expense

84

92

60

Sales and marketing expense

96

92

86

General and administrative expense

202

158

140

Total share-based compensation
$
420
$
404
$
372

Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

Options

Outstanding

Price (a)

Life (b)

Value (c)

Balance at June 30, 2016

2,925,059
$
1.21

6.93
$
263

Granted (d)

2,150,000

.61

Expired/Forfeited

(509,904

)

2.55

Voided

(1,179,164

)

.94

Exercised

(6,800

)

.26

Balance at June 30, 2017

3,379,191
$
0.78

7.86
$
151

Granted (d)

1,125,000

.47

Expired

(100,000

)

.75

Forfeited

(561,541

)

.77

Exercised

(82,810

)

.61

Balance at June 30, 2018

3,759,840
$
0.69

7.75
$
49

Granted (d)

1,252,500

.44

Expired

(242,000

)

.41

Forfeited

(68,125

)

.54

Exercised

(56,900

)

.26

Balance at June 30, 2019

4,645,315
$
0.64

7.95
$
1

Vested and expected to vest at June 30, 2019

4,645,315
$
0.64

7.95
$
1

Exercisable at June 30, 2019

2,153,645
$
0.81

6.76
$
-

For the Year Ended June 30,

2019

2018

2017

Aggregate intrinsic value of options exercised (in thousands)
$
11
$
-
$
3

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R38.htm IDEA: XBRL DOCUMENT v3.19.2

Note 17 - Quarterly Financial Data (Unaudited) (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Quarterly Financial Information [Table Text Block]

Quarters ended

September 30,

December 31,

March 31,

June 30,

201
8

201
8

201
9

201
9

Net revenue
$
1,562
$
1,904
$
1,924
$
1,924

Gross profit
$
524
$
765
$
879
$
879

Net loss
$
(1,508

)
$
(1,414

)
$
(1,127

)
$
(1,095

)

Net loss per share – basic and diluted
$
(0.02

)
$
(0.02

)
$
(0.02

)
$
(0.02

)

Shares used in basic and diluted per share calculation

66,147

67,331

67,333

67,357

Quarters ended

September 30,

December 31,

March 31,

June 30,

201
7

201
7

201
8

201
8

Net revenue
$
1,211
$
1,536
$
1,573
$
1,603

Gross profit/(loss)
$
265
$
531
$
609
$
443

Net loss
$
(1,546

)
$
(1,463

)
$
(1,332

)
$
(2,343

)

Net loss per share – basic and diluted
$
(0.03

)
$
(0.03

)
$
(0.02

)
$
(0.04

)

Shares used in basic and diluted per share calculation

55,017

55,056

55,100

55,463

X

- Definition
Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306
+ Details

Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R17.htm IDEA: XBRL DOCUMENT v3.19.2

Note 11 - Shareholders' Equity
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

11.

Shareholders’ Equity

The authorized capital structure of the Company consists of
$.001
par value preferred stock and
$.001
par value common stock.

Common Stock

On
May 8, 2018,
the Company entered into a Sales Agreement with H.C. Wainwright & Co., LLC (“Wainwright”). The common stock sold in the Sales Agreement was distributed at the market prices prevailing at the time of sale. As of
June 30, 2018,
the Company had sold an aggregate of
980,918
shares under the Sales Agreement at an average price of approximately
$0.515
per common share for gross proceeds of approximately
$505,000.
Net proceeds from this raise totaled approximately
$478,000.

No
additional sales were made in
July 2018
and this offering was suspended on
July 9, 2018.

On
July 11, 2018,
the Company sold
11,000,000
shares of its common stock at a price of
$0.75
per share, for aggregate gross proceeds of
$8.25
million.

Additionally, the Company issued to the purchasers unregistered warrants to purchase up to
5,500,000
shares of common stock. The warrants have an exercise price of
$0.75
per share common stock, are exercisable commencing
six
months following the issuance date, and expire
five
and
one
-half years from the issuance date. The Company also issued warrants to purchase up to
330,000
shares of common stock of the Company, at an exercise price of
$0.9375,
to representatives of Wainwright, the placement agent for the registered direct offering, as part of its compensation. If exercised for cash, future exercises of these warrants will provide additional capital to the Company. The Company evaluated the warrants under ASC
815
, Derivatives and Hedging,
and ASC
480,

Distinguishing Liabilities from Equity.
Based on the guidance from ASC
815
and ASC
480,
the warrants meet the requirement for equity classification as they meet the definition of a derivative, are indexed to the Company's own stock and cannot be net cash settled. The fair value of the warrants with an exercise price of
$0.75
was estimated to be
$2.8
million and the fair value of the warrants with an exercise price of
$0.9375
was estimated to be
$0.2
million on the issuance date using a Black-Scholes valuation model. The assumptions used in the Black-Scholes valuation model are in the table below.

Preferred Stock

The Company’s Certificate of Incorporation authorize
7,000,000
shares of
$0.001
par value preferred stock available for issuance with such rights and preferences, including liquidation, dividend, conversion, and voting rights, as described below. In connection with redomiciling the Company to Delaware, Preferred Stock Series A, C and D designations were terminated. There were
no
shares issued under these Series. Series B is the remaining Series authorized at
June 30, 2019
and had
59,065
issued and outstanding shares at
June 30, 2019.

Series B

Series B preferred shares are entitled to a cumulative
15%
dividend annually on the stated par value per share. These shares are convertible into shares of common stock at the rate of
one
share of common stock for each share of Series B preferred stock, and are subject to automatic conversion into common stock upon the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of
1933
covering the offer and sale of common stock in which the gross proceeds to the Company are at least
$4,000,000.
Series B preferred shareholders have voting rights equal to the voting rights of common stock, except that the vote or written consent of a majority of the outstanding preferred shares is required for any changes to the Company’s Certificate of Incorporation, Bylaws or Certificate of Designation, or for any bankruptcy, insolvency, dissolution or liquidation of the Company. Upon liquidation of the Company, the Company’s assets are
first
distributed ratably to the Series B preferred shareholders and then to the holders of the Common Stock.

On
December 18, 2018,
the Board of Directors declared a dividend on the Series B Preferred Stock of all outstanding and cumulative dividends through
December 31, 2018.
The total dividends of
$11,000
were paid as of
December 31, 2018.
On
December 14, 2017
,
the Board of Directors declared a dividend on the Series B Preferred Stock of all outstanding and cumulative dividends through
December 31, 2017
.
The total dividends of
$11,000
were paid as of
December 31, 2017
.
At
June 30, 2019
and
2018,
there were
59,065
Series B preferred shares outstanding and cumulative dividends in arrears were
$5,000.

Warrants

During the year ended
June 30, 2019
the Company issued a total of
5,830,000
warrants in connection with the registered direct offering that was completed on
July 11, 2018.
The weighted average fair value of warrants issued and the key assumptions used in the Black-Scholes valuation model to calculate the fair value, are as follows:

Weighted average fair value

$0.51

Warrants issued

5,830,000

Exercise price
$0.75

to

$0.9375

Expected term (in years)

5.5

Risk-free rate

2.74%

Volatility

102.73%

During the year ended
June 30, 2018,
the Company issued warrants as share-based compensation for
third
party services, principally marketing. The weighted average fair value of warrants issued and the key assumptions used in the Black-Scholes valuation model to calculate the fair value, are as follows:

Weighted average fair value

$0.41

Warrants issued

500,000

Exercise price

$0.01

to

$0.54

Expected term (in years)

2

to

3

Risk-free rate

1.62%

to

2.55%

Volatility

60%

-

82%

The following table summarizes the activity of all stock warrants and weighted average exercise prices.

Warrants

Price (a)

Balance at June 30, 2016

230,087
$
0.94

Warrants expired

(230,087

)

0.94

Balance at June 30, 2017

-

-

Warrants issued

500,000

0.28

Warrants exercised

(250,000

)

0.01

Balance at June 30, 2018

250,000
$
0.54

Warrants Issued

5,830,000

0.76

Balance at June 30, 2019

6,080,000
$
0.75

(a)

Weighted average exercise price per share.

As of
June 30, 2019,
the Company had
6,080,000
common warrants outstanding exercisable on or before
January 11, 2024.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R13.htm IDEA: XBRL DOCUMENT v3.19.2

Note 7 - Restricted Cash
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Restricted Assets Disclosure [Text Block]

7.

Restricted Cash

The Washington Department of Health requires the Company to provide collateral for the decommissioning of its facility. To satisfy this requirement, the Company has a bank account with a balance of
$181,000.
The account is termed restricted cash and classified as a long-term asset as the Company does
not
anticipate decommissioning the facility until the end of the current lease. The current lease as extended in
July 2019
expires
April 30, 2026.
The cash will become unrestricted following the decommissioning of the facility and the release of the facility by the Washington Department of Health back to the landlord.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R29.htm IDEA: XBRL DOCUMENT v3.19.2

Note 4 - Inventory (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Inventory, Current [Table Text Block]

June 30,

2019

2018

Raw materials
$
333
$
371

Work in process

166

96

Finished goods

31

27

Total inventory
$
530
$
494

Schedule of Inventory, Noncurrent [Table Text Block]

June 30,

2019

2018

Enriched barium, non-current
$
117
$
276

Raw materials, non-current

38

43

Total inventory, non-current
$
155
$
319

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(d))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R25.htm IDEA: XBRL DOCUMENT v3.19.2

Note 19 - Subsequent Events
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Subsequent Events [Text Block]

19.

Subsequent Events

On
July 3, 2019
,
the Company entered into another modification of the production facility lease that extends the term to
April 20, 2026.
This lease modification maintains the current rental rate through
April 2020,
and provides for an
eighteen
month termination notice with an early termination penalty of up to
$40,000
which decreases each year.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R21.htm IDEA: XBRL DOCUMENT v3.19.2

Note 15 - Commitments and Contingencies
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

15.

Commitments and Contingencies

Royalty Agreement for Invention and Patent Application

A former employee and shareholder of the Company previously assigned his rights, title and interest in an invention to Isoray Products LLC (a predecessor company) in exchange for a royalty equal to
1%
of the Gross Profit, as defined, from the sale of “seeds” incorporating the technology. The patent and associated royalty obligations were transferred to the Company in connection with the merger transaction.

The Company must also pay a royalty of
2%
of Gross Sales, as defined, for any sub-assignments of the aforesaid patented process to any
third
parties. The royalty agreement remained in force until the expiration of the patents on the assigned technology. The patent expired in
April 2019
and
no
royalties were paid on sales after the expiration of the patent.

During fiscal years
2019,

2018
and
2017,
the Company recorded royalty expenses of
$33,000,

$27,000,
and
$21,000,
respectively.

Patent and Know-How Royalty License Agreement

The Company is the holder of an exclusive license to use certain “know-how” developed by
one
of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed sales. Because the licensor’s patent application was ultimately abandoned, only a
1%
“know-how” royalty based on Net Factory Sales Price, as defined in the agreement, remains applicable. To date, management believes that there have been
no
sales incorporating the “know-how” and therefore
no
royalty is due pursuant to the terms of the agreement. Management believes that the possibility of a negative outcome in this matter is remote.

The licensor of the “know-how” has disputed management’s contention that it is
not
using this “know-how.” On
September 25, 2007
and again on
October 31, 2007,
the Company participated in nonbinding mediation regarding this matter; however,
no
settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in
April 2008,
the parties failed to reach a settlement. The parties
may
demand binding arbitration at any time.

Irradiation Services Agreement

On
November 29, 2016,
Medical, a wholly owned subsidiary of IsoRay, entered into an Irradiation Services Agreement (MURR Agreement) with the Curators of the University of Missouri, a public corporation of the State of Missouri, on behalf of its University of Missouri Research Reactor (MURR). The MURR Agreement provides Medical with access to reactor space for the irradiation of natural or enriched barium to produce Ba-
131,
which is used by Medical to produce Cesium-
131
for use in its product. The MURR Agreement has a term of
five
years concluding
November 29, 2021
and will automatically renew for successive
twelve
-month periods unless terminated by either party, and can be terminated by either party upon
three
months written notice. The MURR Agreement does
not
require minimum orders or obligate Medical to future minimum payments. After a thorough review of the capacity and quality of production at the MURR facility, the Company determined to terminate its supply agreement with MURR and the last shipment of isotope from MURR was received in
January 2019.

Isotope Purchase Agreement

In
December 2015,
the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cesium-
131
manufactured by the Institute of Nuclear Materials. The purchase agreement provided the Company with
one
year’s supply of Cesium-
131.
The original agreement was due to expire on
March 31, 2017,
but in
December 2016
an addendum was signed extending it until
December 31, 2017.
On
October 23, 2017,
the Company, together with The Open Joint Stock Company, signed an addendum to the contract to include Cesium-
131
manufactured at RIAR and extending it until
December 31, 2018.
On
December 24, 2018,
an addendum was signed extending the term of the supply contract through
December 31, 2019
and modifying the volume of additional shipments of Cesium-
131.
Under the addendum, current pricing and volumes for Cesium-
131
purchases remained in place until
May 31, 2019.
On
July 11, 2019,
another addendum was signed extending the pricing terms until
August 4, 2019.
On
July 30, 2019,
a new supply contract was signed with The Open Joint Stock Company for a term of
August 2019
to
December 2020
as the Company had purchased the maximum amount of Cesium-
131
permitted under the prior agreement.

Operating Lease Agreements

The Company leases office and laboratory space under an operating lease. The lease
may
be terminated by either party with a
six
-month written notice. The lease terms require monthly lease payments and include a contractually permitted annual rent increase based on changes in the CPI index. Future minimum lease payments under this operating lease are as follows (in thousands):

Year ending June 30,

Amount

2020

290

2021

241

$
531

For the Year Ended June 30,

2019

2018

2017

Rental expense
$
285
$
285
$
288

In
July 2019,
the Company entered into another modification of the production facility lease that extends the term to
April 20, 2026,
maintains the current rental rate through
April 2020,
and provides for an
eighteen
-month termination notice with an early termination penalty of up to
$40,000
which decreases each year.

Research and Development - Collaborative Arrangement

On
March 13, 2017,
Medical entered into a Collaborative Development Agreement (CDA) with GammaTile, LLC, now known as GT Medical Technologies, Inc. (GT Med Tech), to further develop a brachytherapy medical device for the treatment of cancerous tumors in the brain and to seek regulatory approval for the new product. As the project manager, Medical incurs all costs in connection with the collaboration project which will be shared equally by both parties as of
November 8, 2016
when they informally began the collaboration. The arrangement is accounted for as a collaborative arrangement and related costs are incurred, shared, and separately stated in connection with a collaborative research and development project. These costs are reported on the financial statements under “Research and development: Collaboration arrangements, net of reimbursement.”

Gross costs incurred in connection with the collaboration agreement during fiscal years
2019,

2018
and
2017
were
$266,000,

$769,000
and
$387,000,
respectively. As of
June 30, 2019
and
2018,
the Company had a receivable balance related to this CDA of
$0
and
$22,000,
respectively.

The CDA with GT Med Tech terminated in
March 2018
but the Company continued to work collaboratively with GT Med Tech to obtain
510
(k) clearance from the FDA and on the design transfer to production without a formal agreement. Beginning in
April 2018
costs were
no
longer shared equally as had been done historically and GT Med Tech was responsible for more than
50%
of the costs. The Company stopped sharing costs with GT Med Tech related to the development of GammaTile™ in
December 2018
when the product entered a limited market release.

Class Action Lawsuit Related to Press Release

On
May 22, 2015,
the
first
of
three
lawsuits was filed against Isoray, Inc. and
two
of its officers – Dwight Babcock (the Company’s retired CEO) and Brien Ragle (former CFO who was later dismissed from the lawsuits) – related to a press release on
May 20, 2015
regarding a
May 19
online publication of the peer-reviewed article in the journal Brachytherapy titled “
Analysis of Stereotactic Radiation vs. Wedge Resection vs. Wedge Resection Plus Cesium-
131
Brachytherapy in Early-Stage Lung Cancer
” by Dr. Bhupesh Parashar, et al. The lawsuits were class actions alleging violations of the federal securities laws. By Order dated
August 17, 2015,
the
three
lawsuits were consolidated into
one
case – In re Isoray, Inc. Securities Litigation; Case
No.

4:15
-cv-
05046
-LRS, in the U.S. District Court for the Eastern District of Washington.

On
March 9, 2017,
the parties settled this matter and the court entered an order and final judgment that (i) dismissed with prejudice and released the claims asserted in the complaint against the defendants, including Isoray, and (ii) approved the payment of the
$3,537,500
settlement fund (paid by Isoray’s insurers), minus the payment of attorneys’ fees and costs to plaintiff’s counsel, to members of the settlement class. This lawsuit is now concluded.

Derivative Complaint related to Shareholder Value

On
September 29, 2016,
David M. Kitley, purportedly on behalf of Isoray, filed a derivative lawsuit in the United States District Court for the District of Minnesota under the case caption Kitley v. Isoray, Inc., Case
No.

0:16
-cv-
03297
-DTS. The complaint named as defendants current and former Isoray directors Dwight Babcock, Thomas LaVoy, Philip J. Vitale and Michael W. McCormick, alleging that they violated their fiduciary duties to Isoray in connection with a press release allegedly containing false and misleading statements concerning the results from a peer reviewed study of its Cesium-
131
isotope seeds for the treatment of non-small cell lung cancers, thereby artificially inflating the price of Isoray stock. The complaint sought unspecified damages, in an amount
not
presently determinable, among other forms of relief.

On
November 17, 2016,
Isoray moved to dismiss the complaint, arguing that plaintiff was
not
entitled to pursue his derivative claims due to his failure to serve a pre-suit demand on Isoray’s board. Rather than respond to the motion to dismiss, plaintiff filed an amended complaint on
January 23, 2017.
The amended complaint alleged the same derivative claims as the original, and added Isoray director Alan Hoffmann as a defendant. Plaintiff sought an award of damages and an order directing Isoray to undertake reforms of its corporate governance and internal procedures. Isoray moved to dismiss the amended complaint on
March 9, 2017.
Plaintiff responded on
April 20, 2017,
and Isoray replied on
May 17, 2017.
The court heard oral argument on the motion on
August 22, 2017,
and took the matter under advisement at that time. On
October 19, 2017,
the court granted Isoray’s motion to dismiss. The matter is now resolved.

Class Action Lawsuit re Equity Plans

On
January 31, 2017,
a putative class action complaint was filed against Isoray and certain current and former directors in the Superior Court of the State of Washington in and for Benton County under the case caption Griffith v. Isoray, Inc., Case
No.

17
-
2
-
00194
-
2.
The complaint alleged that Isoray’s board permitted certain employee compensation plans to be implemented without receiving the requisite percentage of votes by Isoray shareholders. On
May 16, 2017,
the parties executed a settlement for
$195,000
of the individual Plaintiffs’ claims. The action was dismissed on
July 10, 2017.

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R4.htm IDEA: XBRL DOCUMENT v3.19.2

Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Sales, net $ 7,314 $ 5,923 $ 4,761

Cost of sales 4,267 4,081 3,923

Gross profit 3,047 1,842 838

Research and development

Proprietary research and development 1,429 1,351 771

Collaboration arrangement, net of reimbursement (Note 15) 45 395 194

Total research and development 1,474 1,746 965

Sales and marketing 2,679 2,660 2,310

General and administrative 4,172 4,165 3,920

Change in estimate of asset retirement obligation (48)

Gain on equipment disposals (24) (2)

Total operating expenses 8,301 8,571 7,145

Operating loss (5,254) (6,729) (6,307)

Non-operating income:

Interest income 108 29 118

Change in fair value of warrant derivative liability 27

Other income 2

Non-operating income, net 110 29 145

Net loss (5,144) (6,700) (6,162)

Preferred stock dividends (11) (11) (11)

Net loss applicable to common shareholders $ (5,155) $ (6,711) $ (6,173)

Basic and diluted loss per share (in dollars per share) $ (0.08) $ (0.12) $ (0.11)

Weighted average shares used in computing net loss per share:

Basic and diluted (in shares) 67,042 55,159 55,016

X

- Definition
The amount of gain (loss) related to the change in ARO estimate.
+ References
No definition available.
+ Details

Name: isr_GainLossOnChangeInAROEstimate

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of research and development expense during the period related to the collaboration services, net of reimbursement.
+ References
No definition available.
+ Details

Name: isr_ResearchAndDevelopmentCollaborationServicesNetOfReimbursement

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of research and development expense during the period related to the proprietary research and development.
+ References
No definition available.
+ Details

Name: isr_ResearchAndDevelopmentProprietaryResearchAndDevelopment

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 67 R8.htm IDEA: XBRL DOCUMENT v3.19.2

Note 2 - Summary of Significant Accounting Policies
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

2.

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation.

Cash Equivalents

The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of
three
months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States.

Investments

Investments with original maturities greater than
three
months and remaining maturities less than
one
year are classified as “Short-term investments” and included in current assets. Investments with remaining maturities greater than
one
year are classified as “Investments, non-current” and are included in noncurrent assets. These investments are held to maturity and carried at amortized cost.

Accounts Receivable

Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries.

Inventory

Inventory is reported at the lower of cost or net realizable value. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a
first
-in,
first
-out basis.

The cost of materials and production costs contained in inventory that are
not
usable due to the passage of time, and resulting loss of bio-effectiveness, are written off to cost of sales at the time it is determined that the product is
no
longer usable.

Property and Equipment

Fixed assets are capitalized and carried at cost less accumulated depreciation. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations.

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment (in years)

3

to

7

Office equipment (in years)

2

to

5

Furniture and fixtures (in years)

2

to

5

Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.

Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is
not
recoverable and exceeds its fair value.

Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment.

Prepaid Expenses and Other Assets

Prepaid expenses and other assets, which include website development costs, trademarks, patents and licenses, are stated at cost, less accumulated amortization. For website development, costs incurred in the planning stage are expensed as incurred whereas costs associated with the application and infrastructure development, graphics development, and content development are capitalized. Amortization of website development costs is computed using the straight-line method over the estimated economic useful lives of the asset. Trademarks and patents include costs, primarily legal, incurred in obtaining them. Amortization of trademarks and patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of other assets and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value.

Asset Retirement Obligation

The estimated fair value of the future retirement costs of the Company’s leased assets and the costs for the decontamination and reclamation of equipment located within the footprint leased asset are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets.

Financial Instruments

The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and
not
recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At
June 30, 2019
and
2018,
the carrying value of financial instruments which include U.S. Treasury Securities, certificates of deposit and restricted cash, approximated fair value.

Fair Value Measurement

When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level
1
uses quoted prices in active markets for identical assets or liabilities, Level
2
uses significant other observable inputs, and Level
3
uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. The Company has
no
financial assets or liabilities that are adjusted to fair value on a recurring basis.

At
June 30, 2019
and
2018,
there were
no
assets or liabilities measured at fair-value on a recurring basis which were measured using Level
3
inputs. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are
not
measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note
9
), the Company had
no
assets or liabilities measured at fair value on a nonrecurring basis during the
two
years ended
June 30, 2019.

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. (In thousands)

Fair value at June 30,
2019

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
5,326
$
5,326
$
-
$
-

Fair value at June 30,
2018

Total

Level 1

Level 2

Level 3

Cash and cash equivalents
$
2,600
$
2,600
$
-
$
-

The Company’s cash and cash equivalent instruments are classified within Level
1
of the fair value hierarchy because they are valued using quoted market prices.

Revenue Recognition

The Company recognizes revenue based on the
five
-step model for revenue recognition as prescribed by ASC
606,

Revenue from Contracts with Customers
, as follows: (
1
) identify the contract with the customer; (
2
) identify the performance obligations in the contract; (
3
) determine the transaction price; (
4
) allocate the prices to the performance obligations; and (
5
) recognize revenue. The Company has some agreements that contain general commercial terms and product prices but do
not
contain an obligation to provide goods to the customer. Our performance obligation, which is established when the customer submits a purchase order and the Company accepts the order, is to deliver the product based on the purchase order received. The Company typically recognizes revenue at the time of shipment, at which time the title passes to the customer, and there are
no
further performance obligations. See Note
18.

Shipping and Handling Costs

Shipping and handling costs include charges associated with delivery of goods from the Company’s facilities to its customers and are reflected in cost of sales. The Company has elected to account for shipping and handling activities as a fulfillment cost. Shipping and handling costs paid to the Company by its customers are included in the transaction price.

Share-Based Compensation

The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options and stock warrants on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Company recognizes forfeitures as they occur.

Research and Development Costs

Research and Development - Proprietary

Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and
not
treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year recognized.

Research and Development - Collaborative Arrangement

Research and development costs incurred and shared in connection with a collaborative research and development project are separately stated in the consolidated statement of operation under “Research and development: Collaboration arrangements, net of reimbursement.”

Advertising and Marketing Costs

Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. (In thousands)

For the Years Ended June 30,

2019

2018

2017

Advertising and marketing costs expensed (including tradeshows)
$
210
$
329
$
323

At June 30,

201
9

201
8

Prepaid marketing expenses deferred until event occurs
$
9
$
9

Legal Contingencies

The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of
third
-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does
not
believe any probable legal proceedings or claims will have a material adverse effect on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company’s recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred.

Income Taxes

Income taxes are accounted for under the liability method. Under this method, the Company provides deferred income taxes for temporary differences that will result in taxable or deductible amounts in future years based on the reporting of certain costs in different periods for financial statement and income tax purposes. This method also requires the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that realization of such benefits is more likely than
not.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment of the change. In the event that the Company is assessed penalties and or interest, penalties will be charged to other operating expense and interest will be charged to interest expense in the period that they are assessed.

Income (Loss) Per Common Share

Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does
not
include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company’s net loss position.

Securities that could be dilutive in the future are as follows:

June 30,

201
9

201
8

201
7

Preferred stock

59,065

59,065

59,065

Common stock warrants

6,080,000

250,000

-

Common stock options

4,645,315

3,759,840

3,379,191

Total potential dilutive securities

10,784,380

4,068,905

3,438,256

Use of Estimates

The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.

Recent Accounting Pronouncements

In
May 2014,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.

2014
-
09
Revenue Recognition, replacing guidance currently codified in Subtopic
605
-
10
Revenue Recognition-Overall with various SEC Staff Accounting Bulletins providing interpretive guidance. The guidance establishes a new
five
step principle-based framework in an effort to significantly enhance comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. The standard became effective for the Company in the
first
quarter of its fiscal year
2019.
The Company adopted the new standard in the
first
quarter of fiscal year
2019
and used the modified retrospective method. The adoption of ASU
2014
-
09
did
not
have a material impact on the consolidated financial statements of the Company and did
not
significantly change the timing of revenue recognition compared to the previous methodology.

In
February 2016,
the FASB issued ASU
2016
-
02
Leases (Subtopic
842
), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for fiscal years beginning after
December 15, 2018,
including interim periods within those fiscal years. Early adoption is permitted. The modified retrospective transition approach is required. The ASU will be effective for the Company in the
first
quarter of fiscal year
2020
and the most significant effects of this ASU relate to the recognition of a new right-of-use asset and corresponding lease liability.

In
November 2018,
the FASB issued ASU
2018
-
18,
Collaborative Arrangements (Topic
808
): Clarifying the Interaction Between Topic
808
and Topic
606,
which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic
606.
The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2019,
with early adoption permitted. The Company is in the process of evaluating the impact the standard will have on its financial statements.

Other accounting standards that have been issued or proposed by FASB that do
not
require adoption until a future date are
not
expected to have a material impact on the consolidated financial statements upon adoption. The Company does
not
discuss recent pronouncements that are
not
anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 R67.htm IDEA: XBRL DOCUMENT v3.19.2

Note 16 - Concentrations of Credit and Other Risks (Details Textual) - USD ($)

Jun. 30, 2019

Jun. 30, 2018

Accounts Receivable, Allowance for Credit Loss, Ending Balance $ 26,000 $ 26,000

X

- Definition
Amount of allowance for credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 R63.htm IDEA: XBRL DOCUMENT v3.19.2

Note 12 - Income Taxes - Reconciliation of Income Tax Expenses (Details) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

U.S. federal statutory income tax rate 21.00% 28.00% 35.00%

Expected income tax benefit $ (1,080) $ (1,878) $ (2,157)

Meals and entertainment 12 21 17

Non-deductible penalties 18 4 16

Warrant derivative liability (9)

Share-based compensation 10

Impact on the change in income tax rate 9,556

Change in estimate (178)

Change in valuation allowance 1,228 (7,703) 2,123

Income tax expense (benefit) $ 0 $ 0 $ 0

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in estimate.
+ References
No definition available.
+ Details

Name: isr_IncomeTaxReconciliationChangeInEstimate

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Income Tax Reconciliation Change in Fair Value of Warrants.
+ References
No definition available.
+ Details

Name: isr_IncomeTaxReconciliationChangeInFairValueOfWarrants

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 71 R40.htm IDEA: XBRL DOCUMENT v3.19.2

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)
12 Months Ended

Jun. 30, 2019

Equipment [Member] | Minimum [Member]

Property, Plant and Equipment, Useful Life (Year) 3 years

Equipment [Member] | Maximum [Member]

Property, Plant and Equipment, Useful Life (Year) 7 years

Office Equipment [Member] | Minimum [Member]

Property, Plant and Equipment, Useful Life (Year) 2 years

Office Equipment [Member] | Maximum [Member]

Property, Plant and Equipment, Useful Life (Year) 5 years

Furniture and Fixtures [Member] | Minimum [Member]

Property, Plant and Equipment, Useful Life (Year) 2 years

Furniture and Fixtures [Member] | Maximum [Member]

Property, Plant and Equipment, Useful Life (Year) 5 years

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 187 375 1 true 65 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://isoray.com/20190630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://isoray.com/20190630/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://isoray.com/20190630/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://isoray.com/20190630/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statement of Changes in Shareholders' Equity Sheet http://isoray.com/20190630/role/statement-consolidated-statement-of-changes-in-shareholders-equity Consolidated Statement of Changes in Shareholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://isoray.com/20190630/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Organization Sheet http://isoray.com/20190630/role/statement-note-1-organization Note 1 - Organization Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Short-term Investments Sheet http://isoray.com/20190630/role/statement-note-3-shortterm-investments Note 3 - Short-term Investments Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Inventory Sheet http://isoray.com/20190630/role/statement-note-4-inventory Note 4 - Inventory Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Prepaid expenses and Other Current Assets Sheet http://isoray.com/20190630/role/statement-note-5-prepaid-expenses-and-other-current-assets Note 5 - Prepaid expenses and Other Current Assets Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Property & Equipment Sheet http://isoray.com/20190630/role/statement-note-6-property-equipment Note 6 - Property & Equipment Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Restricted Cash Sheet http://isoray.com/20190630/role/statement-note-7-restricted-cash Note 7 - Restricted Cash Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Other Assets, Net Sheet http://isoray.com/20190630/role/statement-note-8-other-assets-net Note 8 - Other Assets, Net Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Asset Retirement Obligation Sheet http://isoray.com/20190630/role/statement-note-9-asset-retirement-obligation Note 9 - Asset Retirement Obligation Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Share-based Compensation Sheet http://isoray.com/20190630/role/statement-note-10-sharebased-compensation Note 10 - Share-based Compensation Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Shareholders' Equity Sheet http://isoray.com/20190630/role/statement-note-11-shareholders-equity Note 11 - Shareholders' Equity Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Income Taxes Sheet http://isoray.com/20190630/role/statement-note-12-income-taxes Note 12 - Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Note 13 - 401(k) and Profit Sharing Plan Sheet http://isoray.com/20190630/role/statement-note-13-401k-and-profit-sharing-plan Note 13 - 401(k) and Profit Sharing Plan Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Distribution Agreements Sheet http://isoray.com/20190630/role/statement-note-14-distribution-agreements Note 14 - Distribution Agreements Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Commitments and Contingencies Sheet http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies Note 15 - Commitments and Contingencies Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Concentrations of Credit and Other Risks Sheet http://isoray.com/20190630/role/statement-note-16-concentrations-of-credit-and-other-risks Note 16 - Concentrations of Credit and Other Risks Notes 22 false false R23.htm 022 - Disclosure - Note 17 - Quarterly Financial Data (Unaudited) Sheet http://isoray.com/20190630/role/statement-note-17-quarterly-financial-data-unaudited Note 17 - Quarterly Financial Data (Unaudited) Notes 23 false false R24.htm 023 - Disclosure - Note 18 - Contracts With Customers Sheet http://isoray.com/20190630/role/statement-note-18-contracts-with-customers Note 18 - Contracts With Customers Notes 24 false false R25.htm 024 - Disclosure - Note 19 - Subsequent Events Sheet http://isoray.com/20190630/role/statement-note-19-subsequent-events Note 19 - Subsequent Events Notes 25 false false R26.htm 025 - Disclosure - Significant Accounting Policies (Policies) Sheet http://isoray.com/20190630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies 26 false false R27.htm 026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies 27 false false R28.htm 027 - Disclosure - Note 3 - Short-term Investments (Tables) Sheet http://isoray.com/20190630/role/statement-note-3-shortterm-investments-tables Note 3 - Short-term Investments (Tables) Tables http://isoray.com/20190630/role/statement-note-3-shortterm-investments 28 false false R29.htm 028 - Disclosure - Note 4 - Inventory (Tables) Sheet http://isoray.com/20190630/role/statement-note-4-inventory-tables Note 4 - Inventory (Tables) Tables http://isoray.com/20190630/role/statement-note-4-inventory 29 false false R30.htm 029 - Disclosure - Note 5 - Prepaid expenses and Other Current Assets (Tables) Sheet http://isoray.com/20190630/role/statement-note-5-prepaid-expenses-and-other-current-assets-tables Note 5 - Prepaid expenses and Other Current Assets (Tables) Tables http://isoray.com/20190630/role/statement-note-5-prepaid-expenses-and-other-current-assets 30 false false R31.htm 030 - Disclosure - Note 6 - Property & Equipment (Tables) Sheet http://isoray.com/20190630/role/statement-note-6-property-equipment-tables Note 6 - Property & Equipment (Tables) Tables http://isoray.com/20190630/role/statement-note-6-property-equipment 31 false false R32.htm 031 - Disclosure - Note 8 - Other Assets, Net (Tables) Sheet http://isoray.com/20190630/role/statement-note-8-other-assets-net-tables Note 8 - Other Assets, Net (Tables) Tables http://isoray.com/20190630/role/statement-note-8-other-assets-net 32 false false R33.htm 032 - Disclosure - Note 9 - Asset Retirement Obligation (Tables) Sheet http://isoray.com/20190630/role/statement-note-9-asset-retirement-obligation-tables Note 9 - Asset Retirement Obligation (Tables) Tables http://isoray.com/20190630/role/statement-note-9-asset-retirement-obligation 33 false false R34.htm 033 - Disclosure - Note 10 - Share-based Compensation (Tables) Sheet http://isoray.com/20190630/role/statement-note-10-sharebased-compensation-tables Note 10 - Share-based Compensation (Tables) Tables http://isoray.com/20190630/role/statement-note-10-sharebased-compensation 34 false false R35.htm 034 - Disclosure - Note 11 - Shareholders' Equity (Tables) Sheet http://isoray.com/20190630/role/statement-note-11-shareholders-equity-tables Note 11 - Shareholders' Equity (Tables) Tables http://isoray.com/20190630/role/statement-note-11-shareholders-equity 35 false false R36.htm 035 - Disclosure - Note 12 - Income Taxes (Tables) Sheet http://isoray.com/20190630/role/statement-note-12-income-taxes-tables Note 12 - Income Taxes (Tables) Tables http://isoray.com/20190630/role/statement-note-12-income-taxes 36 false false R37.htm 036 - Disclosure - Note 15 - Commitments and Contingencies (Tables) Sheet http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies-tables Note 15 - Commitments and Contingencies (Tables) Tables http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies 37 false false R38.htm 037 - Disclosure - Note 17 - Quarterly Financial Data (Unaudited) (Tables) Sheet http://isoray.com/20190630/role/statement-note-17-quarterly-financial-data-unaudited-tables Note 17 - Quarterly Financial Data (Unaudited) (Tables) Tables http://isoray.com/20190630/role/statement-note-17-quarterly-financial-data-unaudited 38 false false R39.htm 038 - Disclosure - Note 18 - Contracts With Customers (Tables) Sheet http://isoray.com/20190630/role/statement-note-18-contracts-with-customers-tables Note 18 - Contracts With Customers (Tables) Tables http://isoray.com/20190630/role/statement-note-18-contracts-with-customers 39 false false R40.htm 039 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details) Sheet http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-details Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details) Details 40 false false R41.htm 040 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair value (Details) Sheet http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-financial-assets-and-liabilities-measured-at-fair-value-details Note 2 - Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair value (Details) Details 41 false false R42.htm 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Advertising and Marketing Costs (Details) Sheet http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-advertising-and-marketing-costs-details Note 2 - Summary of Significant Accounting Policies - Advertising and Marketing Costs (Details) Details 42 false false R43.htm 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) Sheet http://isoray.com/20190630/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) Details 43 false false R44.htm 043 - Disclosure - Note 3 - Short-term Investments - Summary of Short- Term Investments (Details) Sheet http://isoray.com/20190630/role/statement-note-3-shortterm-investments-summary-of-short-term-investments-details Note 3 - Short-term Investments - Summary of Short- Term Investments (Details) Details 44 false false R45.htm 044 - Disclosure - Note 4 - Inventory - Current Inventory (Details) Sheet http://isoray.com/20190630/role/statement-note-4-inventory-current-inventory-details Note 4 - Inventory - Current Inventory (Details) Details 45 false false R46.htm 045 - Disclosure - Note 4 - Inventory - Noncurrent Inventory (Details) Sheet http://isoray.com/20190630/role/statement-note-4-inventory-noncurrent-inventory-details Note 4 - Inventory - Noncurrent Inventory (Details) Details 46 false false R47.htm 046 - Disclosure - Note 5 - Prepaid expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) Sheet http://isoray.com/20190630/role/statement-note-5-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details Note 5 - Prepaid expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) Details 47 false false R48.htm 047 - Disclosure - Note 6 - Property & Equipment (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-6-property-equipment-details-textual Note 6 - Property & Equipment (Details Textual) Details http://isoray.com/20190630/role/statement-note-6-property-equipment-tables 48 false false R49.htm 048 - Disclosure - Note 6 - Property & Equipment - Summary of Property and Equipment (Details) Sheet http://isoray.com/20190630/role/statement-note-6-property-equipment-summary-of-property-and-equipment-details Note 6 - Property & Equipment - Summary of Property and Equipment (Details) Details 49 false false R50.htm 049 - Disclosure - Note 7 - Restricted Cash (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-7-restricted-cash-details-textual Note 7 - Restricted Cash (Details Textual) Details http://isoray.com/20190630/role/statement-note-7-restricted-cash 50 false false R51.htm 050 - Disclosure - Note 8 - Other Assets, Net - Other Assets, Net of Accumulated Amortization (Details) Sheet http://isoray.com/20190630/role/statement-note-8-other-assets-net-other-assets-net-of-accumulated-amortization-details Note 8 - Other Assets, Net - Other Assets, Net of Accumulated Amortization (Details) Details 51 false false R52.htm 051 - Disclosure - Note 8 - Other Assets, Net - Future Amortization (Details) Sheet http://isoray.com/20190630/role/statement-note-8-other-assets-net-future-amortization-details Note 8 - Other Assets, Net - Future Amortization (Details) Details 52 false false R53.htm 052 - Disclosure - Note 9 - Asset Retirement Obligation - Asset Retirement Obligation (Details) Sheet http://isoray.com/20190630/role/statement-note-9-asset-retirement-obligation-asset-retirement-obligation-details Note 9 - Asset Retirement Obligation - Asset Retirement Obligation (Details) Details 53 false false R54.htm 053 - Disclosure - Note 10 - Share-based Compensation (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-10-sharebased-compensation-details-textual Note 10 - Share-based Compensation (Details Textual) Details http://isoray.com/20190630/role/statement-note-10-sharebased-compensation-tables 54 false false R55.htm 054 - Disclosure - Note 10 - Share-based Compensation - Assumptions (Details) Sheet http://isoray.com/20190630/role/statement-note-10-sharebased-compensation-assumptions-details Note 10 - Share-based Compensation - Assumptions (Details) Details 55 false false R56.htm 055 - Disclosure - Note 10 - Share-based Compensation - Share-based Compensation Expense (Details) Sheet http://isoray.com/20190630/role/statement-note-10-sharebased-compensation-sharebased-compensation-expense-details Note 10 - Share-based Compensation - Share-based Compensation Expense (Details) Details 56 false false R57.htm 056 - Disclosure - Note 10 - Share-based Compensation - Summary of Stock Option (Details) Sheet http://isoray.com/20190630/role/statement-note-10-sharebased-compensation-summary-of-stock-option-details Note 10 - Share-based Compensation - Summary of Stock Option (Details) Details 57 false false R58.htm 057 - Disclosure - Note 11 - Shareholders' Equity (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-11-shareholders-equity-details-textual Note 11 - Shareholders' Equity (Details Textual) Details http://isoray.com/20190630/role/statement-note-11-shareholders-equity-tables 58 false false R59.htm 058 - Disclosure - Note 11 - Shareholders' Equity - Fair Value Assumption of Warrant (Details) Sheet http://isoray.com/20190630/role/statement-note-11-shareholders-equity-fair-value-assumption-of-warrant-details Note 11 - Shareholders' Equity - Fair Value Assumption of Warrant (Details) Details 59 false false R60.htm 059 - Disclosure - Note 11 - Shareholders' Equity - Warrant Activity (Details) Sheet http://isoray.com/20190630/role/statement-note-11-shareholders-equity-warrant-activity-details Note 11 - Shareholders' Equity - Warrant Activity (Details) Details 60 false false R61.htm 060 - Disclosure - Note 12 - Income Taxes (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-12-income-taxes-details-textual Note 12 - Income Taxes (Details Textual) Details http://isoray.com/20190630/role/statement-note-12-income-taxes-tables 61 false false R62.htm 061 - Disclosure - Note 12 - Income Taxes - Deferred Tax Components (Details) Sheet http://isoray.com/20190630/role/statement-note-12-income-taxes-deferred-tax-components-details Note 12 - Income Taxes - Deferred Tax Components (Details) Details 62 false false R63.htm 062 - Disclosure - Note 12 - Income Taxes - Reconciliation of Income Tax Expenses (Details) Sheet http://isoray.com/20190630/role/statement-note-12-income-taxes-reconciliation-of-income-tax-expenses-details Note 12 - Income Taxes - Reconciliation of Income Tax Expenses (Details) Details 63 false false R64.htm 063 - Disclosure - Note 15 - Commitments and Contingencies (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies-details-textual Note 15 - Commitments and Contingencies (Details Textual) Details http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies-tables 64 false false R65.htm 064 - Disclosure - Note 15 - Commitments and Contingencies - Future Minimum Lease Payments (Details) Sheet http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies-future-minimum-lease-payments-details Note 15 - Commitments and Contingencies - Future Minimum Lease Payments (Details) Details 65 false false R66.htm 065 - Disclosure - Note 15 - Commitments and Contingencies - Royalty Expenses (Details) Sheet http://isoray.com/20190630/role/statement-note-15-commitments-and-contingencies-royalty-expenses-details Note 15 - Commitments and Contingencies - Royalty Expenses (Details) Details 66 false false R67.htm 066 - Disclosure - Note 16 - Concentrations of Credit and Other Risks (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-16-concentrations-of-credit-and-other-risks-details-textual Note 16 - Concentrations of Credit and Other Risks (Details Textual) Details http://isoray.com/20190630/role/statement-note-16-concentrations-of-credit-and-other-risks 67 false false R68.htm 067 - Disclosure - Note 17 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) Sheet http://isoray.com/20190630/role/statement-note-17-quarterly-financial-data-unaudited-selected-quarterly-financial-data-details Note 17 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) Details http://isoray.com/20190630/role/statement-note-17-quarterly-financial-data-unaudited-tables 68 false false R69.htm 068 - Disclosure - Note 18 - Contracts With Customers (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-18-contracts-with-customers-details-textual Note 18 - Contracts With Customers (Details Textual) Details http://isoray.com/20190630/role/statement-note-18-contracts-with-customers-tables 69 false false R70.htm 069 - Disclosure - Note 18 - Contracts With Customers - Concentration of Customers (Details) Sheet http://isoray.com/20190630/role/statement-note-18-contracts-with-customers-concentration-of-customers-details Note 18 - Contracts With Customers - Concentration of Customers (Details) Details 70 false false R71.htm 070 - Disclosure - Note 19 - Subsequent Events (Details Textual) Sheet http://isoray.com/20190630/role/statement-note-19-subsequent-events-details-textual Note 19 - Subsequent Events (Details Textual) Details http://isoray.com/20190630/role/statement-note-19-subsequent-events 71 false false All Reports Book All Reports isr-20190630.xml isr-20190630.xsd isr-20190630_cal.xml isr-20190630_def.xml isr-20190630_lab.xml isr-20190630_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 73 R44.htm IDEA: XBRL DOCUMENT v3.19.2

Note 3 - Short-term Investments - Summary of Short- Term Investments (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

CDARS $ 825

Certificates of Deposit [Member] | Under 90 Days [Member]

CDARS 825

Certificates of Deposit [Member] | For 91 Days to Six Months [Member]

CDARS

Certificates of Deposit [Member] | Six Months to 1 Year [Member]

CDARS

Certificates of Deposit [Member] | Greater than 1 Year [Member]

CDARS

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentSecondaryCategorizationAxis=isr_Under90DaysMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentSecondaryCategorizationAxis=isr_For91DaysToSixMonthsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentSecondaryCategorizationAxis=isr_SixMonthsTo1YearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentSecondaryCategorizationAxis=isr_GreaterThan1YearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R48.htm IDEA: XBRL DOCUMENT v3.19.2

Note 6 - Property & Equipment (Details Textual) - USD ($)
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Depreciation, Total $ 136,000 $ 80,000 $ 68,000

Other [Member]

Depreciation, Total 0

Construction in Progress [Member]

Capitalized Costs Related to Advance Planning and Design Work $ 207,000 $ 207,000

X

- Definition
The amount of costs capitalized related to advace planning and design work.
+ References
No definition available.
+ Details

Name: isr_CapitalizedCostsRelatedToAdvancePlanningAndDesignWork

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=isr_OtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R24.htm IDEA: XBRL DOCUMENT v3.19.2

Note 18 - Contracts With Customers
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

18.

Contracts with Customers

We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms, and in most cases, prices for the products that we offer. However, these agreements do
not
obligate us to provide goods to the customer and there is
no
consideration promised to us at the onset of these arrangements. For customers without separate agreements, we have a standard list price established for all products and our invoices contain standard terms and conditions that are applicable to those customers where a separate agreement is
not
controlling. Our performance obligations are established when a customer submits a purchase order or e-mail notification (in writing, electronically or verbally) for goods, and we accept the order. We identify performance obligations as the sale of our products and services as requested from our customers. We generally recognize revenue upon the satisfaction of these criteria when control of the product has been transferred to the customer at which time we have an unconditional right to receive payment. Our prices are fixed and are
not
affected by contingent events that could impact the transaction price. We do
not
offer price concessions and do
not
accept payment that is less than the price stated when we accept the purchase order, except in rare credit related circumstances. We do
not
have any material performance obligations where we are acting as an agent for another entity.

Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are
no
further performance obligations.

Sources of Revenue

We have identified the following revenues disaggregated by revenue source:

1.

Domestic – direct sales of products and services.

2.

International – direct sales of products and services.

During the fiscal years
2019,

2018
and
2017,
the Company had revenue from both sources. International revenues in all periods was immaterial. For the fiscal year
2019,
prostate brachytherapy comprised
89%
of our revenue while other revenue comprised
11%
compared to
86%
and
14%,
respectively, in the fiscal year
2018,
and
88%
and
12%,
respectively, in the fiscal year
2017.

Contract Balances

We incur obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate.

Warranty

Our general product warranties do
not
extend beyond an assurance that the product delivered will be consistent with stated specifications and do
not
include separate performance obligations.

Returns

Generally, we allow returns if
not
implanted and we are notified within a few weeks after satisfying our performance obligations of a return. Returns after shipment
may
result in a
50%
restocking fee.

Significant Judgments in the Application of the Guidance in ASC
606

There are
no
significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Commissions and Contract Costs

We expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do
not
incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement.

Practical Expedients

Our payment terms for sales direct to customers and distributors are substantially less than the
one
year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

Shipping and Handling Charges

Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of sales.

Taxes Collected from Customers

As our products are used in another service and are exempt, to this point we have
not
collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities.

Concentration of Customers

One group of customers, facilities or physician practices has revenues that aggregate to greater than
10%
of total Company sales. This group of facilities individually do
not
aggregate to more than
10%
of total Company sales. They are serviced by the same physician group,
one
of whom is our Medical Director:

Year ended June 30,

Facility

201
9

% of

total

revenue

201
8

% of

total

revenue

201
7

% of

total

revenue

El Camino, Los Gatos, & other facilities

22.1

%

24.2

%

22.9

%

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 76 R20.htm IDEA: XBRL DOCUMENT v3.19.2

Note 14 - Distribution Agreements
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Significant Agreements Disclosure [Text Block]

14.

Distribution Agreements

On
July 14, 2017,
the Company entered into an agreement with a new distributor in Russia that provides for the ability to sell the entire product line in the Russian Federation. The agreement has a
one
-year initial term with
two
additional
one
-year terms which automatically renew unless either party invokes their right to terminate earlier under the provisions of the agreement. The Company and the distributor for Italy and Switzerland executed the distribution agreement on
August 1, 2016.
The agreement has a
one
-year initial term with
two
additional
one
-year terms which automatically renew unless either party invoke their right to terminate earlier under the provisions of the agreement. The agreement expired on
August 1, 2019
and was
not
renewed. As the Company elected to
not
renew its CE mark in fiscal
2019,
distribution will be limited to those countries outside the European Union.

X

- Definition
The entire disclosure for distribution agreements.
+ References
No definition available.
+ Details

Name: isr_SignificantAgreementsDisclosureTextBlock

Namespace Prefix: isr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R28.htm IDEA: XBRL DOCUMENT v3.19.2

Note 3 - Short-term Investments (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Cost Method Investments [Table Text Block]

Under 90

91 days to

Six months to

Greater

days

six months

1 year

than 1 year

CDARS, as of June 30, 2018
$
825
$
-
$
-
$
-

X

- Definition
A tabular disclosure of (a) the aggregate carrying amount of all cost-method investments; (b) the aggregate carrying amount of cost-method investments that the investor did not evaluate for impairment for cost-method investments.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCostMethodInvestmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R9.htm IDEA: XBRL DOCUMENT v3.19.2

Note 3 - Short-term Investments
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Cost-method Investments, Description [Text Block]

3.

Short-Term Investments

The Company had
no
short-term investments at
June 30, 2019.
At
June 30, 2018
the Company had short-term investments consisting of Certificate of Deposit Account Registry Service (CDARS) accounts.

CDARS is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the
$250,000
limit to be fully insured by the Federal Deposit Insurance Corporation (FDIC). That institution utilizes the CDARS system to purchase certificates of deposit at other financial Institutions while keeping the investment at each institution fully insured by the Federal Deposit Insurance Corporation (FDIC).

Short-term investments held by the Company at
June 30, 2018
were as follows (in thousands):

Under 90

91 days to

Six months to

Greater

days

six months

1 year

than 1 year

CDARS, as of June 30, 2018
$
825
$
-
$
-
$
-

X

- Definition
The entire disclosure for investments accounted for under the cost-method. The carrying amount of such investments may be adjusted, for example, distributions in excess of cost (return of capital) or for other-than-temporary impairments. The cost method and lower-of-cost or market, an adaptation of the cost method, is generally followed for most investments in noncontrolled corporations, in some corporate joint ventures, and to a lesser extent in unconsolidated subsidiaries in which the entity does not have the ability to exercise significant influence.
+ References
No definition available.
+ Details

Name: us-gaap_CostMethodInvestmentsDescriptionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 79 R5.htm IDEA: XBRL DOCUMENT v3.19.2

Consolidated Statement of Changes in Shareholders' Equity - USD ($)
$ in Thousands

Preferred Stock [Member]

Series B Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Total

Balances (in shares) at Jun. 30, 2016 59,065 55,010,619

Balances at Jun. 30, 2016 $ 55 $ 82,788 $ (66,442) $ 16,401

Issuance of common stock pursuant to exercise of options (in shares) 6,800 6,800

Issuance of common stock pursuant to exercise of options 2 $ 2

Payment of dividend to preferred shareholders (11) (11)

Share-based compensation 372 372

Net loss (6,162) (6,162)

Balances (in shares) at Jun. 30, 2017 59,065 55,017,419

Balances at Jun. 30, 2017 $ 55 83,151 (72,604) $ 10,602

Issuance of common stock pursuant to exercise of options (in shares) 82,810 82,810

Issuance of common stock pursuant to exercise of options 50 $ 50

Payment of dividend to preferred shareholders (11) (11)

Share-based compensation 404 404

Net loss (6,700) (6,700)

Issuance of common stock pursuant to at the market offering, net (in shares) 980,918

Issuance of common stock $ 1 478 479

Issuance of common stock pursuant to exercise of warrants (in shares) 250,000

Issuance of common stock pursuant to exercise of warrants 3 3

Share-based compensation for third party services 203 203

Adoption of ASU 2016-09 44 (44)

Balances (in shares) at Jun. 30, 2018 59,065 56,331,147

Balances at Jun. 30, 2018 $ 56 84,322 (79,348) $ 5,030

Issuance of common stock pursuant to exercise of options (in shares) 56,900 56,900

Issuance of common stock pursuant to exercise of options 15 $ 15

Payment of dividend to preferred shareholders (11) (11)

Share-based compensation 420 420

Net loss (5,144) (5,144)

Issuance of common stock pursuant to at the market offering, net (in shares) 11,000,000

Issuance of common stock $ 11 7,359 7,370

Balances (in shares) at Jun. 30, 2019 59,065 67,388,047

Balances at Jun. 30, 2019 $ 67 $ 92,105 $ (84,492) $ 7,680

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation for third party services.
+ References
No definition available.
+ Details

Name: isr_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationThirdPartyServices

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in additional paid in capital for reclassification from retained earnings attributable to the adoption of ASU 2016-09.
+ References
No definition available.
+ Details

Name: isr_AdoptionOfASU201609ReclassificationFromRetainedEarningsToAdditionalPaidInCapital

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_DividendsPreferredStockCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 80 R1.htm IDEA: XBRL DOCUMENT v3.19.2

Document And Entity Information - USD ($)
12 Months Ended

Jun. 30, 2019

Sep. 24, 2019

Dec. 31, 2018

Document Information [Line Items]

Entity Registrant Name IsoRay, Inc.

Entity Central Index Key 0000728387

Trading Symbol isr

Current Fiscal Year End Date --06-30

Entity Filer Category Non-accelerated Filer

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Entity Emerging Growth Company false

Entity Small Business true

Entity Common Stock, Shares Outstanding (in shares) 67,388,047

Entity Public Float $ 20,081,002

Entity Shell Company false

Document Type 10-K

Document Period End Date Jun. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus FY

Amendment Flag false

Title of 12(b) Security Common Stock

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 81 R66.htm IDEA: XBRL DOCUMENT v3.19.2

Note 15 - Commitments and Contingencies - Royalty Expenses (Details) - USD ($)
$ in Thousands
12 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2017

Rental expense $ 285 $ 285 $ 288

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 82 R62.htm IDEA: XBRL DOCUMENT v3.19.2

Note 12 - Income Taxes - Deferred Tax Components (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Fixed assets $ 204 $ 197

Share-based compensation 578 480

Other accruals 27 38

Asset retirement obligation 130 124

Research credit carryforwards 96

Other 6 10

Net operating loss carryforwards 15,207 14,171

Total deferred tax assets 16,248 15,020

Valuation allowance (16,248) (15,020)

Total

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from asset retirement obligations. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 83 R49.htm IDEA: XBRL DOCUMENT v3.19.2

Note 6 - Property & Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Property and equipment, gross $ 8,979 $ 8,982

Less accumulated depreciation (7,370) (7,671)

Property and equipment, net 1,609 1,311

Land [Member]

Property and equipment, gross 366 366

Equipment [Member]

Property and equipment, gross 3,825 4,152

Leasehold Improvements [Member]

Property and equipment, gross 4,143 4,136

Other [Member]

Property and equipment, gross ^[1] $ 645 $ 328

[1] Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at June 30, 2019 and 2018 are costs associated with advance planning and design work on the Company's new production facility of $207,000.

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=isr_OtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 84 R41.htm IDEA: XBRL DOCUMENT v3.19.2

Note 2 - Summary of Significant Accounting Policies - Financial Assets and Liabilities Measured at Fair value (Details) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Cash and cash equivalents $ 5,326 $ 2,600

Fair Value, Inputs, Level 1 [Member]

Cash and cash equivalents 5,326 2,600

Fair Value, Inputs, Level 2 [Member]

Cash and cash equivalents

Fair Value, Inputs, Level 3 [Member]

Cash and cash equivalents

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 85 R45.htm IDEA: XBRL DOCUMENT v3.19.2

Note 4 - Inventory - Current Inventory (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Jun. 30, 2018

Raw materials $ 333 $ 371

Work in process 166 96

Finished goods 31 27

Total inventory $ 530 $ 494

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 87 R54.htm IDEA: XBRL DOCUMENT v3.19.2

Note 10 - Share-based Compensation (Details Textual) - USD ($)
1 Months Ended 12 Months Ended

Jun. 30, 2017

Jun. 30, 2019

Aug. 15, 2016

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 632,000

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 1 year 29 days

The 2006 Director Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 1,000,000

The 2017 Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 4,000,000

The 2017 Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=isr_The2006DirectorPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=isr_The2017IncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 88 R50.htm IDEA: XBRL DOCUMENT v3.19.2

Note 7 - Restricted Cash (Details Textual)

Jun. 30, 2019

USD ($)

Restricted Cash and Cash Equivalents, Total $ 181,000

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 89 R58.htm IDEA: XBRL DOCUMENT v3.19.2

Note 11 - Shareholders' Equity (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 12 Months Ended

Jul. 11, 2018

Jul. 31, 2018

Jun. 30, 2018

Jun. 30, 2019

Dec. 31, 2018

Dec. 31, 2017

Jun. 30, 2017

Jun. 30, 2016

Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001

Common Stock, Par or Stated Value Per Share 0.001 $ 0.001

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,830,000

Class of Warrant or Right, Exercise Price of Warrants or Rights ^[1] $ 0.54 $ 0.75 $ 0.94

Preferred Stock, Shares Authorized 7,001,671 7,000,000

Class of Warrant or Right, Outstanding 250,000 6,080,000 230,087

Series A Preferred Stock [Member]

Preferred Stock, Shares Issued, Total 0

Series B Preferred Stock [Member]

Preferred Stock, Shares Authorized 5,000,000 5,000,000

Preferred Stock, Shares Issued, Total 59,065 59,065

Preferred Stock, Dividend Rate, Percentage 15.00%

Convertible Preferred Stock, Shares Issued upon Conversion 1

Convertible Preferred Stock Terms of Forced Conversion $ 4,000,000

Cumulative Dividends $ 11,000 $ 11,000

Preferred Stock, Shares Outstanding, Ending Balance 59,065 59,065

Preferred Stock, Amount of Preferred Dividends in Arrears $ 5,000

Series C Preferred Stock [Member]

Preferred Stock, Shares Outstanding, Ending Balance 0

Series D Preferred Stock [Member]

Preferred Stock, Shares Issued, Total 0

Sales Agreement [Member]

Stock Issued During Period, Shares, New Issues 0 980,918

Shares Issued, Price Per Share $ 0.515

Proceeds from Issuance of Common Stock $ 505,000

Proceeds from Issuance of Common Stock, Net of Issuance Costs $ 478,000

Private Placement [Member]

Stock Issued During Period, Shares, New Issues 11,000,000

Shares Issued, Price Per Share $ 0.75

Proceeds from Issuance of Common Stock $ 8,250,000

Private Placement [Member] | Warrants With Exercise Price of $0.75 Per Share [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,500,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.75

Class of Warrant or Right, Estimated Fair Value of Warrants $ 2,800,000

Private Placement [Member] | Warrants With Exercise Price of $0.9375 Per Share [Member] | H.C. Wainwright & Co., LLC [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 330,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.9375

Class of Warrant or Right, Estimated Fair Value of Warrants $ 200,000

[1] Weighted average exercise price per share.

X

- Definition
Represents the fair value of the estimated future value of warrants at the time they can be exercised.
+ References
No definition available.
+ Details

Name: isr_ClassOfWarrantOrRightEstimatedFairValueOfWarrants

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Convertible Preferred Stock, Forced Conversion Term
+ References
No definition available.
+ Details

Name: isr_ConvertiblePreferredStockTermsOfForcedConversion

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, net of issuance costs.
+ References
No definition available.
+ Details

Name: isr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts

Namespace Prefix: isr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of cumulative cash dividends distributed to shareholders.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate amount of cumulative preferred dividends in arrears.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644
+ Details

Name: us-gaap_PreferredStockAmountOfPreferredDividendsInArrears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=isr_SalesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=isr_WarrantsWithExercisePriceOf75CentsPerShareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=isr_WarrantsWithExercisePriceOfPoint9375PerShareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=isr_HCWainwrightCoLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 90 R39.htm IDEA: XBRL DOCUMENT v3.19.2

Note 18 - Contracts With Customers (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

Year ended June 30,

Facility

201
9

% of

total

revenue

201
8

% of

total

revenue

201
7

% of

total

revenue

El Camino, Los Gatos, & other facilities

22.1

%

24.2

%

22.9

%

X

- Definition
Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592
+ Details

Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 91 R31.htm IDEA: XBRL DOCUMENT v3.19.2

Note 6 - Property & Equipment (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

June 30,

2019

2018

Land
$
366
$
366

Equipment

3,825

4,152

Leasehold improvements

4,143

4,136

Other
1

645

328

Property and equipment

8,979

8,982

Less accumulated depreciation

(7,370

)

(7,671

)

Property and equipment, net
$
1,609
$
1,311

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 92 R35.htm IDEA: XBRL DOCUMENT v3.19.2

Note 11 - Shareholders' Equity (Tables)
12 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]

Weighted average fair value

$0.51

Warrants issued

5,830,000

Exercise price
$0.75

to

$0.9375

Expected term (in years)

5.5

Risk-free rate

2.74%

Volatility

102.73%

Weighted average fair value

$0.41

Warrants issued

500,000

Exercise price

$0.01

to

$0.54

Expected term (in years)

2

to

3

Risk-free rate

1.62%

to

2.55%

Volatility

60%

-

82%

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Warrants

Price (a)

Balance at June 30, 2016

230,087
$
0.94

Warrants expired

(230,087

)

0.94

Balance at June 30, 2017

-

-

Warrants issued

500,000

0.28

Warrants exercised

(250,000

)

0.01

Balance at June 30, 2018

250,000
$
0.54

Warrants Issued

5,830,000

0.76

Balance at June 30, 2019

6,080,000
$
0.75

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of warrants and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
No definition available.
+ Details

Name: isr_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock

Namespace Prefix: isr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TableTextBlock

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 93 R16.htm IDEA: XBRL DOCUMENT v3.19.2

Note 10 - Share-based Compensation
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

10.

Share-Based Compensation

The Company currently provides share-based compensation under
one
equity incentive plan approved by the Board of Directors and the shareholders:

■
2017
Equity Incentive Plan (
2017
Incentive Plan).

The
2006
Director Plan allowed the Board of Directors to grant options to purchase up to
1,000,000
shares of common stock to directors of the Company. The plan expired on
August 16, 2016.

Options granted prior to fiscal
2017
were made pursuant to plans that have expired or were terminated.

The Company’s shareholders approved the
2017
Incentive Plan (
“2017
Plan”) in
June 2017.
The
2017
Plan allows the Board of Directors to grant up to
4,000,000
shares of common stock to directors, officers, employees and consultants in a combination of equity incentive forms including incentive stock options (ISO), non-qualified stock options (NQSO), stock appreciation right (SAR) or restricted shares (RSU) of common stock. Options granted under all of the Plans have a
ten
year maximum term, an exercise price equal to at least the fair market value of the Company’s common stock (based on the trading price on the NYSE American) on the date of the grant, and with varying vesting periods as determined by the Board.

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have
no
vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. The Company uses the Black-Scholes option valuation model because management believes the model is appropriate for the Company. However, management understands that because changes in the subjective input assumptions can materially affect the fair value estimate, this valuation model does
not
necessarily provide a reliable single measure of the fair value of its stock options. The risk-free interest rate is based on the U.S. treasury security rate with an equivalent term in effect as of the date of grant. The expected option lives and volatility assumptions are based on historical data of the Company.

The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows:

For the Year Ended June 30,

2019

2018

2017

Weighted average fair value

$0.31

$0.34

$0.45

Options issued

1,252,500

1,125,000

2,150,000

Exercise price
$0.37

to

$0.55

$0.44

to

$0.58

$0.55

to

$0.84

Expected term (in years)

5

5

4

to

5

Risk-free rate

1.83%

to

2.91%

1.83%

to

2.85%

1.62%

to

1.83%

Volatility

89%

-

105%

94%

-

101%

101%

-

103%

The following table presents the share-based compensation expense (in thousands):

For the Year Ended June 30,

2019

2018

2017

Cost of sales
$
38
$
62
$
86

Research and development expense

84

92

60

Sales and marketing expense

96

92

86

General and administrative expense

202

158

140

Total share-based compensation
$
420
$
404
$
372

The total value of the stock options awards is expensed ratably over the vesting period of the employees receiving the awards. As of
June 30, 2019,
total unrecognized compensation cost related to stock-based options and awards was
$632,000
and the weighted-average period over which it is expected to be recognized is approximately
1.08
years.

A summary of stock option information within the Company’s share-based compensation plans during the fiscal years is presented below:

Options

Outstanding

Price (a)

Life (b)

Value (c)

Balance at June 30, 2016

2,925,059
$
1.21

6.93
$
263

Granted (d)

2,150,000

.61

Expired/Forfeited

(509,904

)

2.55

Voided

(1,179,164

)

.94

Exercised

(6,800

)

.26

Balance at June 30, 2017

3,379,191
$
0.78

7.86
$
151

Granted (d)

1,125,000

.47

Expired

(100,000

)

.75

Forfeited

(561,541

)

.77

Exercised

(82,810

)

.61

Balance at June 30, 2018

3,759,840
$
0.69

7.75
$
49

Granted (d)

1,252,500

.44

Expired

(242,000

)

.41

Forfeited

(68,125

)

.54

Exercised

(56,900

)

.26

Balance at June 30, 2019

4,645,315
$
0.64

7.95
$
1

Vested and expected to vest at June 30, 2019

4,645,315
$
0.64

7.95
$
1

Exercisable at June 30, 2019

2,153,645
$
0.81

6.76
$
-

(a)

Weighted average exercise price per share.

(b)

Weighted average remaining contractual life.

(c)

Aggregate intrinsic value (in thousands).

(d)

All options granted had exercise prices equal to or greater than the ending closing market price of the Company’s common stock on the grant date. The options were granted to employees and management by the Compensation Committee and had vesting periods from immediate to
five
years.

For the Year Ended June 30,

2019

2018

2017

Aggregate intrinsic value of options exercised (in thousands)
$
11
$
-
$
3

The Company’s current policy is to issue new shares to satisfy option exercises.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 94 R12.htm IDEA: XBRL DOCUMENT v3.19.2

Note 6 - Property & Equipment
12 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

6.

Property & Equipment

Property & equipment consisted of the following (in thousands):

June 30,

2019

2018

Land
$
366
$
366

Equipment

3,825

4,152

Leasehold improvements

4,143

4,136

Other
1

645

328

Property and equipment

8,979

8,982

Less accumulated depreciation

(7,370

)

(7,671

)

Property and equipment, net
$
1,609
$
1,311

1.

Plant and equipment,
not
placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore,
no
depreciation expense has been recognized. Also included at
June 30, 2019
and
2018
are costs associated with advance planning and design work on the Company’s new production facility of
$207,000.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2019	Jun. 30, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	7,000,000	7,001,671
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	67,388,047	56,331,147
Common stock, shares outstanding (in shares)	67,388,047	56,331,147
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities (in shares)	10,784,380	4,068,905	3,438,256
Preferred Stocks [Member]
Antidilutive Securities (in shares)	59,065	59,065	59,065
Warrant [Member]
Antidilutive Securities (in shares)	6,080,000	250,000
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	4,645,315	3,759,840	3,379,191

Note 5 - Prepaid expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Prepaid insurance	$ 38	$ 24
Other prepaid expenses	154	241
Other current assets	27	29
Other receivables	86	41
Total prepaid expenses and other current assets	$ 305	$ 335

Note 17 - Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Net revenue	$ 1,924	$ 1,924	$ 1,904	$ 1,562	$ 1,603	$ 1,573	$ 1,536	$ 1,211
Gross profit	879	879	765	524	443	609	531	265	$ 3,047	$ 1,842	$ 838
Net loss	$ (1,095)	$ (1,127)	$ (1,414)	$ (1,508)	$ (2,343)	$ (1,332)	$ (1,463)	$ (1,546)	$ (5,144)	$ (6,700)	$ (6,162)
Net loss per share – basic and diluted (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.02)	$ (0.03)	$ (0.03)	$ (0.08)	$ (0.12)	$ (0.11)
Shares used in basic and diluted per share calculation (in shares)	67,357	67,333	67,331	66,147	55,463	55,100	55,056	55,017	67,042	55,159	55,016

Note 15 - Commitments and Contingencies (Details Textual) - USD ($)				1 Months Ended	12 Months Ended
	May 16, 2017	Mar. 09, 2017	Nov. 29, 2016	Dec. 31, 2015	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jul. 03, 2019
Royalty Expense					$ 285,000	$ 285,000	$ 288,000
Purchase Agreement Period				1 year
Research and Development Expense, Total					1,474,000	1,746,000	965,000
Receivables, Net, Current, Total					1,154,000	1,192,000
Class Action Lawsuit Related to Press Release [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 3,537,500
Class Action Lawsuit re Equity Plan [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 195,000
Collaborative Development Agreement [Member] \| GammaTile LLC [Member]
Research and Development Expense, Total					266,000	769,000	387,000
Receivables, Net, Current, Total					$ 0	22,000
Maximum [Member] \| Subsequent Event [Member]
Lease Agreement, Early Termination Penalty								$ 40,000
Royalty Agreement for Invention and Patent Application [Member]
Percentage of Royalty Rate Payable					2.00%
Royalty Expense					$ 33,000	$ 27,000	$ 21,000
Royalty Agreement for Invention and Patent Application [Member] \| Former Employee and Shareholder [Member]
Percentage of Royalty, Exchanged for Interest in Predecessor Company					1.00%
Patent and Know-How Royalty License Agreement [Member]
Percentage of Royalty Rate Payable					1.00%
Irradiation Services Agreement [Member]
Irradiation Service Agreement, Term			5 years
Irradiation Service Agreement, Renewal Period			1 year

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 5,326	$ 2,600
Short-term investments (Note 3)		825
Accounts receivable, net	1,154	1,192
Inventory	530	494
Prepaid expenses and other current assets	305	335
Total current assets	7,315	5,446
Property and equipment, net	1,609	1,311
Restricted cash	181	181
Inventory, non-current	155	319
Other assets, net of accumulated amortization	162	198
Total assets	9,422	7,455
Current liabilities:
Accounts payable and accrued expenses	683	1,391
Accrued protocol expense	133	77
Accrued radioactive waste disposal	74	37
Accrued payroll and related taxes	89	155
Accrued vacation	142	175
Total current liabilities	1,121	1,835
Non-current liabilities:
Asset retirement obligation	621	590
Total liabilities	1,742	2,425
Commitments and contingencies (Note 15)
Shareholders' equity:
Preferred stock, $.001 par value; 7,000,000 and 7,001,671shares authorized: Series B: 5,000,000 shares allocated; 59,065 shares issued and outstanding
Common stock, $.001 par value; 200,000,000 shares authorized; 67,388,047 and 56,331,147 shares issued and outstanding	67	56
Additional paid-in capital	92,105	84,322
Accumulated deficit	(84,492)	(79,348)
Total shareholders' equity	7,680	5,030
Total liabilities and shareholders' equity	$ 9,422	$ 7,455

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Total inventory, non-current	$ 155	$ 319
Enriched Barium Inventory [Member]
Total inventory, non-current	117	276
Raw Materials [Member]
Total inventory, non-current	$ 38	$ 43

Note 18 - Contracts With Customers (Details Textual)	12 Months Ended
Note 18 - Contracts With Customers (Details Textual)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Return Policy, Restocking Fee, Percent	50.00%
Prostate Brachytherapy [Member] \| Revenue Benchmark [Member] \| Product Concentration Risk [Member]
Concentration Risk, Percentage	89.00%	86.00%	88.00%
Product and Service, Other [Member] \| Revenue Benchmark [Member] \| Product Concentration Risk [Member]
Concentration Risk, Percentage	11.00%	14.00%	12.00%

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Jun. 30, 2019
Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Office Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	2 years
Office Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	2 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years

Note 3 - Short-term Investments - Summary of Short- Term Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
CDARS		$ 825
Certificates of Deposit [Member] \| Under 90 Days [Member]
CDARS		825
Certificates of Deposit [Member] \| For 91 Days to Six Months [Member]
CDARS
Certificates of Deposit [Member] \| Six Months to 1 Year [Member]
CDARS
Certificates of Deposit [Member] \| Greater than 1 Year [Member]
CDARS

Consolidated Statement of Changes in Shareholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2016	59,065	55,010,619
Balances at Jun. 30, 2016		$ 55	$ 82,788	$ (66,442)	$ 16,401
Issuance of common stock pursuant to exercise of options (in shares)		6,800			6,800
Issuance of common stock pursuant to exercise of options			2		$ 2
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			372		372
Net loss				(6,162)	(6,162)
Balances (in shares) at Jun. 30, 2017	59,065	55,017,419
Balances at Jun. 30, 2017		$ 55	83,151	(72,604)	$ 10,602
Issuance of common stock pursuant to exercise of options (in shares)		82,810			82,810
Issuance of common stock pursuant to exercise of options			50		$ 50
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			404		404
Net loss				(6,700)	(6,700)
Issuance of common stock pursuant to at the market offering, net (in shares)		980,918
Issuance of common stock		$ 1	478		479
Issuance of common stock pursuant to exercise of warrants (in shares)		250,000
Issuance of common stock pursuant to exercise of warrants			3		3
Share-based compensation for third party services			203		203
Adoption of ASU 2016-09			44	(44)
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56	84,322	(79,348)	$ 5,030
Issuance of common stock pursuant to exercise of options (in shares)		56,900			56,900
Issuance of common stock pursuant to exercise of options			15		$ 15
Payment of dividend to preferred shareholders			(11)		(11)
Share-based compensation			420		420
Net loss				(5,144)	(5,144)
Issuance of common stock pursuant to at the market offering, net (in shares)		11,000,000
Issuance of common stock		$ 11	7,359		7,370
Balances (in shares) at Jun. 30, 2019	59,065	67,388,047
Balances at Jun. 30, 2019		$ 67	$ 92,105	$ (84,492)	$ 7,680

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Jun. 30, 2019	Sep. 24, 2019	Dec. 31, 2018
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	0000728387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		67,388,047
Entity Public Float			$ 20,081,002
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock

Note 12 - Income Taxes - Deferred Tax Components (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Fixed assets	$ 204	$ 197
Share-based compensation	578	480
Other accruals	27	38
Asset retirement obligation	130	124
Research credit carryforwards	96
Other	6	10
Net operating loss carryforwards	15,207	14,171
Total deferred tax assets	16,248	15,020
Valuation allowance	(16,248)	(15,020)
Total

Note 4 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Raw materials	$ 333	$ 371
Work in process	166	96
Finished goods	31	27
Total inventory	$ 530	$ 494

Note 10 - Share-based Compensation (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2019	Aug. 15, 2016
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 632,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 29 days
The 2006 Director Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,000,000
The 2017 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,000,000
The 2017 Incentive Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years